

Reference Committee B

Report(s) of the Board of Trustees

- 09 Council on Legislation Sunset Review of 2014 House P
- 11 Safe and Effective Overdose Reversal Medications in Educational Settings
- 13 Prohibiting Covenants Not-to-Compete
- 14 Physician Assistant and Nurse Practitioner Movement Between Specialties
- 15 Augmented Intelligence Development, Deployment, and Use in Health Care
- 16 Support for Mental Health Courts
- 17 Drug Policy Reform
- 18 Supporting Harm Reduction
- 19 Attorneys' Retention of Confidential Medical Records and Controlled Medical Expert's Tax Returns After Case Adjudication

Resolutions

- 201 Research Correcting Political Misinformation and Disinformation on Scope of Practice
- 202 Use of Artificial Intelligence and Advanced Technology by Third Party Payors to Deny Health Insurance Claims
- 203 Medicaid Patient Accountability
- 204 Staffing Ratios in the Emergency Department
- 205 Medical-Legal Partnerships & Legal Aid Services
- 206 Indian Health Service Youth Regional Treatment Centers
- 207 Biosimilar Use Rates and Prevention of Pharmacy Benefit Manager Abuse
- 208 Improving Supplemental Nutrition Programs
- 209 Native American Voting Rights
- 210 Support for Physicians Pursuing Collective Bargaining and Unionization
- 211 Deceptive Hospital Badging 2.0
- 212 Advocacy Education Towards a Sustainable Medical Care System
- 213 Access to Covered Benefits with an Out of Network Ordering Physician
- 214 Support for Paid Sick Leave
- 215 American Indian and Alaska Native Language Revitalization and Elder Care
- 216 The AMA Supports H.R. 7225, the Bipartisan "Administrative Law Judges Competitive Service Restoration Act"
- 217 Protecting Access to IVF Treatment
- 218 Designation of Descendants of Enslaved Africans in America
- 219 Bundling for Maternity Care Services
- 220 Restorative Justice for the Treatment of Substance Use Disorders
- 221 Reforming Medicare Part B Drug Reimbursement to Promote Patient Affordability and Physician Practice Sustainability
- 222 Studying Avenues for Parity in Mental Health & Substance Use Coverage
- 223 Increase in Children's Hospital Graduate Medical Education Funding
- 224 Antidiscrimination Protections for LGBTQ+ Youth in Foster Care
- 225 Humanitarian Efforts to Resettle Refugees
- 226 Protecting Access to IVF Treatment
- 227 Medicare Reimbursement for Telemedicine
- 228 Waiver of Due Process Clauses
- 229 Opposition to Legalization of Psilocybin

- 230 Protecting Patients from Inappropriate Dentist and Dental Hygienist Scope of Practice Expansion
- 231 Supporting the Establishment of Rare Disease Advisory Councils
- 232 Medicare Advantage Part B Drug Coverage
- 233 Prohibiting Mandatory White Bagging
- 234 State Prescription Drug Affordability Boards - Study
- 235 Establish a Cyber-Security Relief Fund
- 236 Support of Physicians Pursuing Collective Bargaining and Unionization
- 237 Encouraging the Passage of the Preventive Health Savings Act (S.114)
- 238 AMA Supports Efforts to Fund Overdose Prevention Sites
- 239 Requiring stores that sell tobacco products to display NYS Quitline information
- 240 Expanding Visa Requirement Waivers for NY IMGs Working in Underserved Areas
- 241 Healthcare Cybersecurity Breaches
- 242 Cancer Care in Indian Health Services Facilities
- 243 Disaggregation of Demographic Data for Individuals of Federally Recognized Tribes
- 244 Graduate Medical Education Opportunities for American Indian and Alaska Native Communities

REPORT OF THE BOARD OF TRUSTEES

B of T Report 09-A-24

Subject: Council on Legislation Sunset Review of 2014 House Policies

Presented by: Willie Underwood, III, MD, MSc, MPH, Chair

Referred to: Reference Committee B

- 1 Policy G-600.110, “Sunset Mechanism for AMA Policy,” calls for the decennial review of
2 American Medical Association (AMA) policies to ensure that our AMA’s policy database is
3 current, coherent, and relevant. Policy G-600.010 reads as follows, laying out the parameters for
4 review and specifying the procedures to follow:
5
6 1. As the House of Delegates (HOD) adopts policies, a maximum ten-year time horizon shall
7 exist. A policy will typically sunset after 10 years unless action is taken by the HOD to retain
8 it. Any action of our AMA HOD that reaffirms or amends an existing policy position shall
9 reset the sunset “clock,” making the reaffirmed or amended policy viable for another 10 years.
10
11 2. In the implementation and ongoing operation of our AMA policy sunset mechanism, the
12 following procedures shall be followed: (a) Each year, the Speakers shall provide a list of
13 policies that are subject to review under the policy sunset mechanism; (b) Such policies shall
14 be assigned to the appropriate AMA councils for review; (c) Each AMA council that has been
15 asked to review policies shall develop and submit a report to the HOD identifying policies that
16 are scheduled to sunset; (d) For each policy under review, the reviewing council can
17 recommend one of the following actions: (i) retain the policy; (ii) sunset the policy; (iii) retain
18 part of the policy; or (iv) reconcile the policy with more recent and like policy; (e) For each
19 recommendation that it makes to retain a policy in any fashion, the reviewing council shall
20 provide a succinct, but cogent justification; or (f) The Speakers shall determine the best way
21 for the HOD to handle the sunset reports.
22
23 3. Nothing in this policy shall prohibit a report to the HOD or resolution to sunset a policy earlier
24 than its 10-year horizon if it is no longer relevant, has been superseded by a more current
25 policy, or has been accomplished.
26
27 4. The AMA councils and the HOD should conform to the following guidelines for sunset:
28 (a) when a policy is no longer relevant or necessary; (b) when a policy or directive has been
29 accomplished; or (c) when the policy or directive is part of an established AMA practice that is
30 transparent to the House and codified elsewhere such as the AMA Bylaws or the AMA HOD
31 Reference Manual: Procedures, Policies and Practices.
32
33 5. The most recent policy shall be deemed to supersede contradictory past AMA policies.
34
35 6. Sunset policies will be retained in the AMA historical archives.

1 RECOMMENDATION

2

3 The Board of Trustees recommends that the House of Delegates policies that are listed in the
 4 appendix to this report be acted upon in the manner indicated and the remainder of this report be
 5 filed.

APPENDIX – Recommended Actions

Policy Number	Title	Text	Recommendation
D-105.996	Impact of Pharmaceutical Advertising on Women's Health	<p>1. Our AMA urges the US Food and Drug Administration (FDA) to assure that all direct-to-consumer advertising of pharmaceuticals includes information regarding differing effects and risks between the sexes.</p> <p>2. Our AMA urges the FDA to assure that advertising of pharmaceuticals to health care professionals includes specifics outlining whether testing of drugs prescribed to both sexes has included sufficient numbers of women to assure safe use in this population and whether such testing has identified needs to modify dosages based on sex.</p> <p>(Res. 509, A-14)</p>	Retain – this policy remains relevant.
D-115.988	Medication Non-Adherence and Errors	<p>Our AMA will recommend the Centers for Medicare & Medicaid Services conduct a cost/benefit analysis and an analysis of the ability of seniors and people with disabilities to use blister packs in order to determine the feasibility of expanding coverage for timed calendar blister packs for prescription medications beyond residents of long term care facilities.</p> <p>(BOT Rep. 11, A-14)</p>	<p>Sunset this policy.</p> <p>The recommendation was communicated to the Centers for Medicare & Medicaid Services.</p>
D-120.944	Improvement of Electronic Prescription Software	<p>Our AMA will: (1) advocate for changing the national standards for controlled substance prescriptions so that prescriptions for controlled substances can be transmitted electronically directly to the pharmacy in a secure manner; and (2) work with pharmacies, vendors, and other appropriate entities to encourage the use of standards that would allow the transmission of short messages regarding</p>	<p>Retain this policy in part.</p> <p>Delete clause (1). Drug Enforcement Administration regulations allow the option of writing prescriptions for controlled substances electronically. The regulations also permit</p>

Policy Number	Title	Text	Recommendation
		<p>prescriptions so that both physicians and pharmacists could communicate directly with each other within the secure health records systems that they are already using.</p> <p>(Res. 209, A-14)</p>	<p>pharmacies to receive, dispense, and archive these electronic prescriptions.</p>
D-120.980	Regulation of Media-Based Drug Sales Without Good Faith Medical Examination	<p>Our AMA will develop and promote model federal legislation to eliminate the sale, without a legitimate prescription, of prescription drugs over the Internet, if such bills to establish national standards in this area are not forthcoming.</p> <p>(Sub. Res. 520, A-04; Reaffirmed: BOT Rep. 19, A-14)</p>	<p>Sunset this policy.</p> <p>This policy has been superseded by more recent AMA policy (H-120.956, Internet Prescribing).</p>
D-130.971	The Future of Emergency and Trauma Care	<p>Our AMA will: (1) expand the dialogue among relevant specialty societies to gather data and identify best practices for the staffing, delivery, and financing of emergency/trauma services, including mechanisms for the effective regionalization of care and use of information technology, teleradiology and other advanced technologies to improve the efficiency of care; (2) with the advice of specific specialty societies, advocate for the creation and funding of additional residency training positions in specialties that provide emergency and trauma care and for financial incentive programs, such as loan repayment programs, to attract physicians to these specialties; (3) continue to advocate for the following: a. Insurer payment to physicians who have delivered EMTALA-mandated, emergency care, regardless of in-network or out-of-network patient status, b. Financial support for providing EMTALA-mandated care to uninsured patients, c. Bonus payments to physicians who provide emergency/trauma services to patients from physician shortage areas, regardless of the site of service, d. Federal and state liability protections for physicians providing EMTALA-mandated care; (4) disseminate these</p>	<p>Retain – this policy remains relevant.</p>

Policy Number	Title	Text	Recommendation
		<p>recommendations immediately to all stakeholders including but not limited to Graduate Medical Education Program Directors for appropriate action/implementation; (5) support demonstration programs to evaluate the expansion of liability protections under the Federal Tort Claims Act for EMTALA-related care; (6) support the extension of the Federal Tort Claims Act (FTCA) to all Emergency Medical Treatment and Labor Act (EMTALA) mandated care if an evaluation of a demonstration program, as called for in AMA Policy D-130.971(5), shows evidence that physicians would benefit by such extension; and (7) if an evaluation of a demonstration program, as called for in AMA Policy D-130.971(5), shows evidence that physicians would benefit by extension of the FTCA, our AMA will conduct a legislative campaign, coordinated with national specialty societies, targeted toward extending FTCA protections to all EMTALA-mandated care, and the AMA will assign high priority to this effort.</p> <p>(BOT Rep. 14, I-06; Reaffirmation A-07; Reaffirmation A-08; BOT action in response to referred for decision Res. 204, A-11; Appended: Res. 221, I-11; Modified: CCB/CLRPD Rep. 2, A-14)</p>	
D-130.976	Implications of the November 2003 Emergency Medical Treatment and Labor Act (EMTALA) Final Rule	<p>Our AMA will: (1) ask the EMTALA Technical Advisory Group (TAG) and the Centers for Medicare and Medicaid Services (CMS) for assistance in ameliorating the differential economic and staffing burdens on certain categories of facilities, including but not limited to academic health centers, trauma centers, critical access hospitals, and safety net hospitals, which are likely to receive high volumes of patients as a result of the EMTALA regulations; (2) work with the EMTALA TAG and CMS to ensure that physicians staffing emergency departments and on-call</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		<p>emergency services be appropriately compensated for providing EMTALA mandated services; (3) with input from all interested Federation members, coordinate an effort to educate the membership about emergency department coverage issues and the efforts to resolve them; (4) seek to require all insurers, both public and private, to pay promptly and fairly all claims for services mandated by EMTALA for all plans they offer, or face fines and penalties comparable to those imposed on providers; and (5) seek to have CMS require all states participating in Medicaid, as a condition of continued participation, establish and adequately fund state Emergency Medical Services funds which physicians providing EMTALA-mandated services may bill, and from which those physicians shall receive prompt and fair compensation.</p> <p>(CME Rep. 3, A-05; Reaffirmation A-07; Reaffirmed in lieu of Res. 605, I-08; Modified: CCB/CLRPD Rep. 2, A-14)</p>	
D-160.991	Licensure and Liability for Senior Physician Volunteers	<p>Our AMA (1) and its Senior Physician Group will inform physicians about federal and state-based charitable immunity laws that protect physicians wishing to volunteer their services in free medical clinics and other venues; and (2) will work with organizations representing free clinics to promote opportunities for physicians who wish to volunteer.</p> <p>(BOT Rep. 17, A-04; Reaffirmed: CCB/CLRPD Rep. 1, A-14)</p>	Retain – this policy remains relevant.
D-175.985	The CMS Electronic Medical Records Initiative Should Not Be Used To Detect Alleged Fraud by Physicians	<p>1. Our AMA will (A) communicate its concerns about the plan recently announced by the Centers for Medicare and Medicaid Services (CMS), in which CMS is to use data from the electronic medical record incentive program in the pursuit of fraud, waste and abuse; and (B) seek active involvement in the drafting of all program directives for CMS's electronic medical record</p>	<p>Retain this policy in part.</p> <p>Delete clauses (1) - (4) and modify clause (7). Our AMA communicated these concerns to the Centers for Medicare & Medicaid Services.</p>

Policy Number	Title	Text	Recommendation
		<p>initiative, including all directives about potential data capture and subsequent audit processes.</p> <p>2. Our AMA will lead an effort in concert with the Centers for Medicare and Medicaid Services to establish specific guidance to be utilized by entities that audit documentation generated by an electronic health record.</p> <p>3. Such guidance will provide specific protocols used by Medicare and Medicaid auditors to allege a service is not reasonable and necessary based on the generation of an electronic health record.</p> <p>4. Our AMA will inform state and specialty societies about available AMA resources to assist physicians with audits of electronic health records and prominently feature on their website information about methods, resources, and technologies related to appeals of electronic health record audits and Medicare and Medicaid overpayment recoveries as a members-only benefit.</p> <p>51. Our AMA believes that the use of time-saving features, such as cloning, templates, macros, "pull forward technology", auto-population and identical language in EMRs, by itself is not an indication of inaccurate documentation or incorrect coding.</p> <p>62. Our AMA believes that audit results that imply incorrect coding must specifically indicate which portion of the chart language either does not accurately reflect the office visit or reflects unnecessary care.</p> <p>73. Our AMA will: (1) develop guidelines in conjunction with the Centers for Medicare & Medicaid Services to provide clear and direct guidance to physicians concerning the permissible use for coding and billing of electronic health record (EHR) clinical documentation tools, such as templates, macros, cutting and pasting, and cloning; and (2) study the impact of EHR clinical documentation tools and shortcuts on</p>	

Policy Number	Title	Text	Recommendation
		<p>patient safety, quality of care and safe harbor laws.</p> <p>(Res. 212, A-10; Appended: Res. 206, I-11; Appended: Res. 715, A-13; Reaffirmed: BOT Rep. 20, A-14)</p>	
D-215.995	Specialty Hospitals and Impact on Health Care	<p>Our AMA will: (1) oppose efforts to either temporarily or permanently extend the 18-month moratorium on physician referrals to specialty hospitals in which they have an ownership interest; (2) support changes in the inpatient and outpatient Medicare prospective payment systems to eliminate the need for cross-subsidization by more accurately reflecting the relative costs of hospital care; (3) support federal legislation and/or regulations that would fix the flawed methodology for allocating Medicare and Medicaid Disproportionate Share Hospital (DSH) payments to help ensure the financial viability of safety-net hospitals so they can continue to provide adequate access to health care for indigent patients; (4) encourage physicians who contemplate formation of a specialty hospital to consider the best health interests of the community they serve. Physicians should explore the opportunities to enter into joint ventures with existing community hospitals before proceeding with the formation of a physician-owned specialty hospital; and (5) oppose the enactment of federal certificate of need (CON) legislation and support state medical associations in their advocacy efforts to repeal current CON statutes and to oppose the reinstatement of CON legislation or its expansion to physician-owned ambulatory health care facilities.</p> <p>(BOT Rep. 15, I-04; Reaffirmation A-09; Modified: CCB/CLRPD Rep. 2, A-14)</p>	Retain – this policy remains relevant.
D-255.985	Conrad 30 - J-1 Visa Waivers	<p>1. Our AMA will: (A) lobby for the reauthorization of the Conrad 30 J-1 Visa Waiver Program; (B) advocate that the J-1 Visa waiver slots be increased from 30 to 50 per state; (C) advocate for</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		<p>expansion of the J-1 Visa Waiver Program to allow IMGs to serve on the faculty of medical schools and residency programs in geographic areas or specialties with workforce shortages; (D) publish on its website J-1 visa waiver (Conrad 30) statistics and information provided by state Conrad 30 administrators along with a frequently asked questions (FAQs) document about the Conrad 30 program; (E) advocate for solutions to expand the J-1 Visa Waiver Program to increase the overall number of waiver positions in the US in order to increase the number of IMGs who are willing to work in underserved areas to alleviate the physician workforce shortage; (F) work with the Educational Commission for Foreign Medical Graduates and other stakeholders to facilitate better communication and information sharing among Conrad 30 administrators, IMGs, US Citizenship and Immigration Services and the State Department; and (G) continue to communicate with the Conrad 30 administrators and IMGs members to share information and best practices in order to fully utilize and expand the Conrad 30 program.</p> <p>2. Our AMA will continue to monitor legislation and provide support for improvements to the J-1 Visa Waiver program.</p> <p>3. Our AMA will continue to promote its educational or other relevant resources to IMGs participating or considering participating in J-1 Visa waiver programs.</p> <p>4. As a benefit of membership, our AMA will provide advice and information on Federation and other resources (but not legal opinions or representation), as appropriate to IMGs in matters pertaining to work-related abuses.</p> <p>5. Our AMA encourages IMGs to consult with their state medical society and consider requesting that their state society ask for assistance by the AMA</p>	

Policy Number	Title	Text	Recommendation
		<p>Litigation Center, if it meets the Litigation Center's established case selection criteria.</p> <p>(Res. 233, A-06; Appended: CME Rep. 10, A-11; Appended: Res. 303, A-11; Reaffirmation I-11; Modified: BOT Rep. 5, I-12; Appended: BOT Rep. 27, A-13; Reaffirmation A-14)</p>	
D-255.993	J-1 Visas and Waivers	<p>1. Our AMA shall encourage HHS and other interested government agencies to continue sponsorship of the J-1 visa waiver program.</p> <p>2. If the USDA does not continue in its role as an interested government agency (IGA), the AMA encourage HHS to expand its J-1 visa waiver program.</p> <p>3. Our AMA will work with federal agencies to ensure better coordination of federal, state, and local agencies in monitoring the placement and enforcement of physicians' service requirements through the J-1 waiver and Conrad-30 programs with a report back at A-03.</p> <p>4. Our AMA will work towards regulation and/or legislation to allow physicians on H-1B <u>w</u> <u>a</u> <u>i</u> <u>v</u> <u>a</u> <u>w</u> <u>a</u> <u>i</u> <u>v</u> <u>e</u> <u>r</u> <u>s</u> <u>for</u> <u>their</u> <u>J-1</u> <u>visa</u> <u>waiver</u>, who are limited to serving in medically underserved areas, to continue to care for their patients who require hospitalization in the closest appropriate medical facility which may not be in the underserved area.</p> <p>5. Our AMA will work with state medical societies to study and report back on the feasibility of having support a national data repository of J-1 Visa Waiver statistics so that J-1 Visa Waiver unoffered positions can be transferred to states as needed to treat underserved communities and to monitor the success of this program.</p> <p>(BOT Rep. 11, I-02; Appended: Res. 324, A-11; Appended: Res. 904, I-11; Reaffirmation A-14)</p>	<p>Retain this policy in part.</p> <p>Delete clause (2) and modify clauses (3) – (5). In 2002 the USDA decided to discontinue its role as an IGA on behalf of foreign research scientists or physicians desiring a recommendation of a J-1 Visa waiver. Moreover, HHS has already expanded its J-1 visa waiver program.</p>

Policy Number	Title	Text	Recommendation
D-260.994	Point of Care Availability for Blood Glucose Testing	<p>Our AMA will work with the Food and Drug Administration and the Centers for Medicare & Medicaid Services to maintain the Clinical Laboratory Improvement Act exempt status of point-of-care glucose testing.</p> <p>(Res. 727, A-14)</p>	<p>Sunset this policy.</p> <p>Our AMA communicated support to the U.S. Food and Drug Administration and the Centers for Medicare & Medicaid services for Clinical Laboratory Improvement Amendments exempt status of point of care blood glucose testing.</p>
D-315.984	Ownership of Claims Data	<p>Our AMA will: (1) encourage physicians to include language designed to buttress rights associated with claims data ownership and access when contracting with health plan payers and other third parties; (2) continue to educate physicians on providing public and private health plan payers the "minimum necessary," as defined in the Health Insurance Portability and Accountability Act (HIPAA) of 1996 and regulations thereunder, protected health information necessary to achieve the purpose of a disclosure; (3) assist physicians wishing to register a complaint against health plan payers that have used claims data to form a database, or that have permitted access to or sale of the database or its contents without explicit patient and/or physician authorization, beyond the scope permitted by HIPAA with the Department of Health and Human Services Office of Civil Rights; (4) advocate to the Department of Health and Human Services, Office of the National Coordinator of Health Information Technology and/or other appropriate agencies for rules and regulations ensuring appropriate physician ownership and access rights to claims data, and appropriate protection of claims data held by various parties; and (5) continue to monitor federal and state activities impacting the exchange of physician-generated health information, including claims data.</p>	<p>Retain – this policy remains relevant.</p>

Policy Number	Title	Text	Recommendation
		(BOT Rep. 19, I-06; Modified: CCB/CLRPD Rep. 2, A-14)	
D-35.994	Scope of Practice Participants in Health Plans	<p>Our AMA Advocacy Resource Center will work at the invitation of AMA component societies to oppose legislative mandates on health care plans that may lead to inappropriate scope of practice expansion of non-physician providers.</p> <p>(Res. 923, I-04; Reaffirmed: BOT Rep. 19, A-14)</p>	Retain – this policy remains relevant.
D-375.997	Peer Reviewer Immunity	<p>Our AMA will: (1) recommend medical staffs adopt/implement staff by laws that are consistent with HCQIA and AMA policy by communicating the guidelines from AMA policy H-375.983 widely through appropriate media to the relevant organizations and institutions, including a direct mailing to all medical staff presidents in the United States, indicating that compliance is required to conform to HCQIA and related court decisions; (2) monitor legal and regulatory challenges to peer review immunity and non discoverability of peer review records/proceedings and continue to advocate for adherence to AMA policy, reporting challenges to peer review protections to the House of Delegates and produce an additional report with recommendations that will protect patients and physicians in the event of misdirected or negligent peer review at the local level while retaining peer review immunity for the process; and (3) continue to work to provide peer review protection under federal law.</p> <p>(BOT Rep.8, I-01; Reaffirmation A-05; Modified: CCB/CLRPD Rep. 2, A-14)</p>	Retain – this policy remains relevant.
D-40.995	The Implications of Health Care Personnel Delivery System	<p>Our AMA will continue to monitor the Health Care Personnel Delivery System (HCPDS) and initiate communication with the Selective Service System and other relevant governmental bodies to address questions and concerns related to the implementation of the HCPDS.</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		(CME Rep. 2, I-04; Reaffirmed: CMS Rep. 1, A-14)	
D-400.984	Transparency, Participation, and Accountability in CMS' Payment Determination Process	<p>1. Our AMA will urgently advocate for the Centers for Medicare and Medicaid Services (CMS) to improve its rate-setting processes by first publishing modifications to Medicare physician fees that result from CMS' misvalued codes initiative in the Medicare Physician Fee Schedule proposed rule instead of the final rule to afford adequate time for providers, professional medical societies and other stakeholders to review and comment on such changes before they take effect.</p> <p>2. Our AMA will demand that CMS be transparent in its processes and methodologies for establishing physician work values and allow adequate opportunity for public comment on its methodologies before changes in physician work values take effect.</p> <p>(Res. 220, A-14)</p>	Retain – this policy remains relevant.
D-406.998	National Provider Identification	<p>Our AMA will work closely in consultation with the Centers for Medicare and Medicaid Services to introduce safeguards and penalties surrounding the use of National Provider Identification to protect physicians' privacy, integrity, autonomy, and ability to care for patients.</p> <p>(Res. 717, I-04; Reaffirmed: CMS Rep. 1, A-14)</p>	Retain – this policy remains relevant.
D-435.978	Loss of Medical Staff Privileges for Lack of "Tail Coverage"	<p>Our AMA will: (1) Advocate for better disclosures by professional medical liability insurance carriers to their policyholders about the continuing financial health of the carrier; and advocate that carriers create and maintain a listing of alternate professional liability insurance carriers in good financial health which can provide physicians replacement tail or other coverage if the carrier becomes insolvent; and (2) Support model medical staff bylaw language stating: "Where continuous professional liability</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		<p>insurance coverage is a condition of medical staff membership, a temporary loss of professional liability insurance coverage (whether or not limited to "tail" coverage) is not grounds for immediate termination of medical staff membership. The Medical Executive Committee shall determine the length and other conditions of an individual waiver of the coverage requirement."</p> <p>(BOT Action in response to referred for decision Res. 537, A-04; Modified: CMS Rep. 1, A-14)</p>	
D-435.985	Use of Countersuits to Discourage Frivolous Lawsuits	<p>Our AMA will advise members of the option for countersuits against plaintiffs and attorneys who have filed frivolous lawsuits against physicians.</p> <p>(Sub. Res. 914, I-04; Reaffirmed: BOT Rep. 19, A-14)</p>	Retain – this policy remains relevant.
D-440.933	VA ACES Travel Policy	<p>Our AMA will send a letter to the Secretary of the Department of Veterans Affairs (VA) and any other appropriate entities noting that the Attendance and Cost Estimation System (ACES) system has become a barrier to VA physician attendance at medical and scientific meetings, and encourage the Secretary to adopt ACES system reforms that will allow VA employed physicians to attend medical and scientific conferences.</p> <p>(Res. 614, A-14)</p>	<p>Sunset this policy.</p> <p>Our AMA submitted a letter to the Department of Veterans Affairs advocating for ACES reforms to lower the barriers and make it easier for VA-employed physicians and researchers to attend medical and scientific conferences.</p>
D-440.934	Onerous Restrictions on Travel of Government Scientists	<p>Our AMA will pursue legislative or regulatory action to achieve <u>supports</u> easing of travel restrictions for federally-employed scientists who are attending academic or scientific conferences that are consistent with current HHS policies and procedures, to include a simplified approval process.</p> <p>(Res. 608, A-14)</p>	<p>Retain this policy in part.</p> <p>Our AMA has communicated to the federal government about easing and simplifying restrictions related to federally employed scientists attending academic and scientific conferences.</p>
D-450.959	Improvements to the Value-Based Modifier	<p>Our AMA will: (1) seek a delay in the Value-Based Modifier (VBM) penalty for smaller practices; and (2) continue to encourage selection of VBM quality</p>	<p>Sunset this policy.</p> <p>The Value-Based Modifier program was replaced by</p>

Policy Number	Title	Text	Recommendation
		<p>measures that are physician-defined, clinically meaningful, specialty-appropriate, realistic, and within reasonable control of the physician.</p> <p>(Sub. Res. 218, A-14)</p>	<p>the Merit-based Incentive Payment System (MIPS) under the Quality Payment Program.</p>
D-450.981	Protecting Patients Rights	<p>Our AMA will: (1) continue to advocate for the repeal of the flawed sustainable growth rate formula without compromising our AMA's principles for pay-for-performance; and (2) develop a media campaign and public education materials to teach patients and other stakeholders about the potential risks and liabilities of pay-for-performance programs, especially those that are not consistent with AMA policies, principles, and guidelines.</p> <p>(Modified: CCB/CLRPD Rep. 2, A-14)</p>	<p>Sunset this policy.</p> <p>The sustainable growth rate was repealed by the Medicare Access and CHIP Reauthorization Act.</p>
D-450.987	Support of Patient Safety Aspects of The Joint Commission	<p>Our AMA will continue to work with The Joint Commission on the development of standards which improve patient safety; and our AMA and The Joint Commission will then present these changes to the Centers for Medicare & Medicaid Services to effect an update of good health care policy and to delete outdated wasteful health care policy.</p> <p>(Res. 530, A-04; Modified: CMS Rep. 1, A-14)</p>	<p>Retain – this policy remains relevant.</p>
D-480.973	President's Council on Science and Technology Report	<p>Our AMA will analyze the President's Council on Science and Technology Report entitled "Better Health Care and Lower Costs: Accelerating Improvement through Systems Engineering" and respond as appropriate.</p> <p>(Res. 523, A-14)</p>	<p>Sunset this policy.</p> <p>Our AMA thoroughly analyzed the May 2014 President's Council on Science and Technology Report (PCAST) and has taken steps to implement the recommendations through testimony to an Office the National Coordinator Federal Advisory Committee, public comment on ONC's proposed 10-year health IT roadmap, and comment letters to the</p>

Policy Number	Title	Text	Recommendation
			Administration in support of the health IT framework outlined in the November 2014 Report to the President: Better Health Care and Lower Costs: Accelerating Improvement Through Systems Engineering.
D-60.968	Ensuring Access to Health Care, Mental Health Care, Legal and Social Services for Unaccompanied Minors and Other Recently Immigrated Children and Youth	Our AMA will work with medical societies and all clinicians to (i) work together with other child-serving sectors to ensure that new immigrant children receive timely and age-appropriate services that support their health and well-being, and (ii) secure federal, state, and other funding sources to support those services. (Res. 8, I-14)	Retain – this policy remains relevant.
D-80.997	Identify Theft	1. Our AMA will request that the Internal Revenue Service (IRS) adopt policies to ensure greater security protection for electronically filed federal income tax returns, including the universal use of PINs, or personal identification numbers. 2. Our AMA will request that the IRS and the Centers for Medicare & Medical Services promulgate regulations to prohibit the use of Social Security numbers (SSN) by insurers, health care vendors, state agencies other than the state taxing authority and non-financial businesses. (Res. 613, A-14)	Retain this policy in part. Delete clause 2. In 2023, the Centers for Medicare & Medicaid Services removed SSN-based health insurance claim numbers from Medicare cards and is now using Medicare Beneficiary Identifiers (MBIs) for Medicare transactions like billing, eligibility status, and claim status.
H-110.998	Cost of New Prescription Drugs	Our AMA urges the pharmaceutical industry to exercise reasonable restraint in the pricing of drugs. (Res. 112, I-89; Reaffirmed: Res. 520, A-99; Reaffirmed: CSAPH Rep. 1, A-09; Reaffirmed in lieu of Res. 229, I-14)	Sunset this policy. This policy has been superseded by more recent AMA policy (H-110.987, Pharmaceutical Costs ; H-110.988, Controlling the Skyrocketing Costs of Generic Prescription Drugs ;

Policy Number	Title	Text	Recommendation
			H-110.997, Cost of Prescription Drugs ; H-285.965, Managed Care Cost Containment Involving Prescription Drugs ; H-110.997, Cost of Prescription Drugs).
H-120.937	Methadone Should Not Be Designated as the Sole Preferred Analgesic	Our AMA recommends that methadone should not be designated as the sole preferred analgesic by any insurance payer, whether public or private. (Res. 117, A-14)	Sunset this policy. This policy has been superseded by more recent policy (H-185.931, Workforce and Coverage for Pain Management ; D-120.932, Inappropriate Use of CDC Guidelines for Prescribing Opioids).
H-120.948	Positive Verification of Contact Lens Prescriptions	Our AMA will support positive prescription verification for contact lenses and recommend that the federal government monitor the effects of the Fairness to Contact Lens Consumers Act (FCLCA) on the accuracy of prescriptions. (Res. 225, A-04; Reaffirmed: BOT Rep. 19, A-14)	Retain – this policy remains relevant.
H-160.907	Hospital Inpatient Admission Order and Certification	Our AMA: (1) supports the rescission of the requirement that a physician certify the estimated time the patient will need to remain in the hospital as a condition for payment for inpatient services; and (2) believes that upon admission of any patient to a hospital for inpatient services, the admitting/attending physician should have access to appropriate information--for example the Geometric Mean Length of Stay (GMLOS)--to help the physician plan appropriately for the services that will be required to care for that particular patient; and (3) will inform the Centers for Medicare & Medicaid Services as soon as possible of the AMA's policy calling for the rescission of the requirement that a physician certify the estimated time the patient will need to remain in the hospital, and take appropriate action to enact this policy.	Retain this policy in part. Delete clause (3). Our AMA communicated to the Centers for Medicare & Medicaid Services the AMA's policy calling for the rescission of the requirement that a physician certify the estimated time the patient will need to remain in the hospital.

Policy Number	Title	Text	Recommendation
		(Res. 227, I-13; BOT action in response to referred for decision Res. 227, I-13; Reaffirmation A-14)	
H-175.984	Health Care Fraud and Abuse Update	<p>AMA policy is that: (1) our AMA leadership intensify efforts to urge federal policy makers to apply traditional definitions of fraud and abuse which focus on intentional acts of misconduct and activities inconsistent with accepted medical practice;</p> <p>(2) our AMA continue to work with federal law enforcement officials to improve the ability to root out intentional schemes to defraud public programs;</p> <p>(3) our AMA work with federal policymakers to balance payment integrity objectives with reasonable documentation and other administrative requirements;</p> <p>(4) our AMA develop model compliance plans and educational materials to assist physicians in conforming to the latest laws and regulations; and</p> <p>(5) our AMA continue to work in a coalition of other health care organizations to lobby for restrictions on the use of the False Claims Act.</p> <p>(BOT Rep. 25, I-97; Reaffirmation A-99; Reaffirmation I-99; Reaffirmation I-00; Reaffirmed: BOT Rep. 6, A-10; Reaffirmed in lieu of Res. 223, A-14)</p>	Retain – this policy remains relevant.
H-185.949	Centers for Medicare and Medicaid Services Policy on Hospital Acquired Conditions - Present on Admission	<p>1. Our AMA will: (a) continue its strong opposition to non-payment for conditions outlined in the Hospital Acquired Condition -- Present on Admission (HAC-POA) policy that are not reasonably preventable through the application of evidence-based guidelines developed by appropriate medical specialty organizations based on non-biased, well-designed, prospective, randomized studies; (b) ask CMS or other appropriate bodies to monitor and evaluate practice changes made as a result of HAC-POA law, and associated outcomes, and report back on best practices; (c) educate physicians about</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		<p>the HAC-POA law and its implications for patient care, coding requirements and payment; (d) continue its education and advocacy of CMS, Members of Congress and the public about the unintended consequences of non-payment for hospital acquired conditions that may not in fact be preventable, and that adversely affect access to and quality of care; (e) oppose the use of payment and coverage decisions of governmental and commercial health insurance entities as determinative of the standard of care for medical practice and advocate that payment decisions by any third party payer not be considered in determining standards of care for medical practice; and (f) continue to study the effect of HAC-POA penalty programs on professional liability; potential institutional demands to control or micro-manage doctors' professional decision-making; and efforts to develop evidence-based information about which events may be truly preventable as opposed to those whose frequency can be reduced by appropriate intervention. 2. Our AMA will: (a) continue its efforts to advocate against expansion of the Hospital Acquired Conditions - Present on Admission policy to physicians; (b) communicate to the Administration how burdensome the HAC-POA policy is for physicians and the Medicare program; (c) work with federal agencies to further monitor the HAC-POA program evaluation, and offer constructive input on its content and design; and (d) maintain efforts with our hospital association colleagues, such as the American Hospital Association, to monitor HAC-POA policy and its impact.</p> <p>(BOT Rep. 17, A-08; Appended: BOT Rep. 2, I-10; Modified: CCB/CLRPD Rep. 2, A-14)</p>	

Policy Number	Title	Text	Recommendation
H-185.951	Home Anti-Coagulation Monitoring	<p>1. Our AMA encourages all third party payers to extend coverage and reimbursement for home monitors and supplies for home self-monitoring of anti-coagulation for all medically appropriate conditions.</p> <p>2. Our AMA (a) supports the appropriate use of home self-monitoring of oral anticoagulation therapy and (b) will continue to monitor safety and effectiveness data, in particular cost-effectiveness data, specific to the United States on home management of oral anticoagulation therapy.</p> <p>3. Our AMA will request a change in Centers for Medicare & Medicaid Services' regulations to allow a nurse, under physician supervision, to visit a patient who cannot travel, has no family who can reliably test, or is unable to test on his/her own to obtain and perform a protime/INR without restrictions.</p> <p>(Res. 825, I-05; Modified and Reaffirmed: CSAPH Rep. 9, A-07; Appended: Res. 709, A-14)</p>	Retain – this policy remains relevant.
H-225.995	Duplication in Hospital Liability and Physicians' Professional Liability Insurance	<p>Our AMA believes that (1) Each physician should be free to determine whether to carry liability coverage as well as the amount of such coverage. Likewise, it is the responsibility of the hospital governing board to determine the extent to which the hospital should protect its assets by purchasing liability insurance; and (2) Regardless of the type of insurance coverage or protection plan hospitals and physicians on the organized staff have, the AMA encourages medical staffs and hospitals to work toward the establishment of effective risk management programs.</p> <p>(Res. 60, A-80; Reaffirmed: CLRPD Rep. B, I-90; Reaffirmed: Sunset Report, I-00; Modified: Res. 813, I-02; Reaffirmation A-04; Modified: CMS Rep. 1, A-14)</p>	Retain – this policy remains relevant.
H-245.979	Opposition to Proposed Budget	The AMA opposes reductions in funding for WIC and Head Start and other	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
	Cuts in WIC and Head Start	<p>programs that significantly impact child and infant health and education.</p> <p>(Res. 246, I-94; Reaffirmed: BOT Rep. 29, A-04; Reaffirmed: BOT Rep. 19, A-14)</p>	
H-250.987	Duty-Free Medical Equipment and Supplies Donated to Foreign Countries	<p>Our AMA will seek, through the federal government, a process to allow for duty-free donations of medical equipment and supplies, which are intended to reach medically-underserved areas and not be used for profit, to foreign countries.</p> <p>(Res. 229, A-04; Reaffirmed: BOT Rep. 19, A-14)</p>	Retain – this policy remains relevant.
H-275.918	Pediatric Medical Orders Between States	<p>1. Our AMA supports legislation or regulation that allows physicians currently licensed and registered to practice medicine in any of the United States to duly execute conventional medical orders for their patients who are moving out of their state and into another state for use in any of the United States, for a transitional period of no more than sixty days. This would allow a child with special health care needs to attend early child care, daycare, nursery, preschool, and school safely in their new location while the family secures a new medical home, health insurance, and, when indicated, subspecialty care.</p> <p>2. Our AMA will work with interested states and specialties on legislation or regulations to allow temporary honoring of medical orders by an out-of-state physician, as long as the physician is registered and licensed to practice medicine in the United States.</p> <p>(BOT Rep. 16, A-14)</p>	Retain – this policy remains relevant.
H-330.974	Modification or Repeal of the Federal False Claims Act and Other Similar Statutes	<p>It is the policy of the AMA to expend those resources necessary to monitor situations where physicians are under investigation, to provide financial and legal assistance where it is determined these are necessary, and to lobby for modification or repeal of the Federal False Claims Act and similar federal statutes.</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		(Res. 152, A-90; Reaffirmation A-99; Reaffirmation I-99; Reaffirmation A-01; Reaffirmed: BOT Rep. 22, A-11; Reaffirmed in lieu of Res. 223, A-14)	
H-335.980	Payment For Copying Medical Records	<p>It is the policy of the AMA to seek legislation under which Medicare will be required to reimburse physicians and hospitals for the reasonable cost of copying medical records which are required for the purpose of postpayment audit. A reasonable charge will be paid by the patient or requesting entity for each copy (in any form) of the medical record provided.</p> <p>(Res. 161, I-90; Appended by Res. 819, A-98; Reaffirmation A-08; Reaffirmed in lieu of Res. 710, A-14)</p>	<p>Sunset this policy.</p> <p>This matter is covered under Code of Medical Ethics 3.3.1, Management of Medical Records, which allows for physicians to charge a reasonable fee for the cost of transferring a record.</p>
H-35.968	Averting a Collision Course Between New Federal Law and Existing State Scope of Practice Laws	<p>1. Our AMA will: (A) work to repeal new Public Health Service Act Section 2706, so-called provider "Non-Discrimination in Health Care," as enacted in PPACA, through active direct and grassroots lobbying of and formal AMA written communications and/or comment letters to the Secretary of Health and Human Services and Congressional leaders and the chairs and ranking members of the House Ways and Means and Energy and Commerce and Senate Finance Committees; and (B) promptly initiate a specific lobbying effort and grassroots campaign to repeal the provider portion of the Patient Protection and Affordable Care Act's "Non-Discrimination in Health Care" language, including direct collaboration with other interested components of organized medicine. 2. Our AMA will: (A) create and actively pursue legislative and regulatory opportunities to <u>advocate for the repeal of the so-called "Non-discrimination in Health Care" clause in Public Health Service Act Section 2706, as enacted in the Patient Protection and Affordable Care Act;</u> and (B) lead a specific lobbying effort and grassroots campaign in cooperation with members</p>	<p>Retain this policy in part.</p> <p>Delete part 1 and modify part 2. Our AMA has advocated for repeal of section 2706 of the Affordable Care Act and has successfully advocated to the Centers for Medicare & Medicaid Services to clarify, consistent with the statutory language in the ACA and with Medicare Advantage and Medicaid policies, that section 2706 does not go beyond existing Medicare or Medicaid rules regarding the scope of practice of particular types of non-physician practitioners, nor does it require health plans and issuers to contract with particular types of non-physician practitioners or cover all types of services.</p>

Policy Number	Title	Text	Recommendation
		<p>of the federation of medicine and other interested components of organized medicine to repeal the provider portion of PPACA's "Non-Discrimination in Health Care" language.</p> <p>(Res. 220, A-10; Appended: Res. 241, A-12; Appended: BOT Rep. 8, I-12; Modified: CCB/CLRPD Rep. 2, A-14)</p>	
H-350.962	Reauthorization of the Indian Health Care Improvement Act	<p>Our AMA supports reauthorization of the Indian Health Care Improvement Act.</p> <p>(Res. 221, A-07; Modified: CCB/CLRPD Rep. 2, A-14)</p>	<p>Sunset this policy.</p> <p>The Indian Health Care Improvement Act (IHCA) was made permanent in 2010 as part of the Patient Protection and Affordable Care Act.</p>
H-355.975	Opposition to the National Practitioner Data Bank	<ol style="list-style-type: none"> 1. Our AMA communicates to legislators the fundamental unfairness of the civil judicial system as it now exists, whereby a jury, rather than a forum of similarly educated peers, determines if a physician has violated the standards of care and such results are communicated to the National Practitioner Data Bank; and impresses on our national legislators that only when a physician has been disciplined by his/her state licensing agency should his/her name appear on the National Practitioner Data Bank. 2. Our AMA affirms its support for the Federation of State Medical Boards Action Data Bank and seeks to abolish the National Practitioner Data Bank. 3. Our AMA urges HHS to retain an independent consultant to (A) evaluate the utility and effectiveness of the National Practitioner Data Bank, (B) evaluate the confidentiality and security of the reporting, processing and distribution of Data Bank information, and (C) provide the findings and recommendations to the National Practitioner Data Bank Executive Committee and the General Accounting Office. 4. Our AMA will take appropriate steps to have Congress repeal Section 4752 (f) 	<p>Retain – this policy remains relevant.</p>

Policy Number	Title	Text	Recommendation
		<p>of OBRA 1990 requiring peer review organizations and private accreditation entities to report any negative action or finding to the Data Bank.</p> <p>5. Our AMA seeks to amend the Health Care Quality Improvement Act of 1986 to allow a physician, at the time the physician notifies the Data Bank of a dispute, to attach an explanation or statement to the disputed report;</p> <p>6. Our AMA opposes any legislative or administrative efforts to expand the Data Bank reporting requirements for physicians, such as the reporting of a physician who is dismissed from a malpractice suit without any payment made on his or her behalf, or to expand the entities permitted to query the Data Bank such as public and private third party payers for purposes of credentialing or reimbursement.</p> <p>7. Our AMA (A) urges HHS to work with the Federation of State Medical Boards to refine its National Practitioner Data Bank breakdown of drug violation reporting into several categories; (B) urges the HHS to analyze malpractice data gathered by the Physician Insurance Association of America and recommend to Congress that a threshold of at least \$30,000 for the reporting of malpractice payments be established as soon as possible; (C) will continue to work with HHS to allow physicians an expanded time period to verify the accuracy of information reported to the Data Bank prior to its release in response to queries; (D) will work with HHS and the Office of Management and Budget to reduce the amount of information required on the request for information disclosure form and to improve the design of the form to allow for more efficient processing of information; and (E) will continue to work with HHS to improve its mechanism to distribute revisions and clarifications of Data Bank policy and procedure.</p>	

Policy Number	Title	Text	Recommendation
		<p>8. Our AMA will review questions regarding reportability to the Data Bank and will provide periodic updates on this issue to the AMA House of Delegates.</p> <p>(CCB/CLRPD Rep. 3, A-14)</p>	
H-365.980	OSHA Regulations Pertaining to Physicians' Offices and Hospitals	<p>The AMA continues to review the data and rationale used to substantiate OSHA regulations pertaining to medical practice in physician offices and health care facilities. Where OSHA rules and regulations are found to be unnecessary or inappropriate, the AMA will work for their modification or repeal.</p> <p>(Sub. Res. 218, A-94; Reaffirmed: BOT Rep. 29, A-04; Reaffirmed: BOT Rep. 19, A-14)</p>	Retain – this policy remains relevant.
H-375.972	Lack of Federal Peer Review Confidentiality Protection	<p>Our AMA will seek to vigorously pursue enactment of federal legislation to prohibit discovery of records, information, and documents obtained during the course of professional review proceedings. Our AMA will immediately work with the Administration and Congress to enact legislation that is consistent with Policy H-375.972.</p> <p>(Res. 221, I-96; Reaffirmed: BOT Rep. 13, I-00; Reaffirmation A-01; Reaffirmed: BOT Rep. 8, I-01; Reaffirmed: CMS Rep. 6, I-02; Appended: Res. 925, I-03; Reaffirmation A-05; Reaffirmed: BOT Rep. 13, I-11; Modified: CCB/CLRPD Rep. 2, A-14)</p>	<p>Sunset this policy.</p> <p>This policy is superseded by more recent AMA policy (D-375.999, Confidentiality of Physician Peer Review; H-375.962, Legal Protections for Peer Review).</p>
H-40.967	Physician Participation in Department of Defense Reserve Components	<p>1. Our AMA endorses voluntary physician participation in the military reserve components' medical programs as a means of actively aiding national defense while preserving the right of the individual physician to practice his/her profession without interruption in peace time.</p> <p>2. Our AMA supports the U.S. Department of Defense by publicizing its needs for physicians in active duty military service and in the reserve components and guard, and encourages the active support and participation of</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		<p>physicians in active duty military service and in the reserves.</p> <p>3. Our AMA will (a) continue to work with all appropriate parties in developing and proposing a multi-faceted approach toward rejuvenation and improvement in recruitment and retention in the military reserves; (b) work to assure that retired military medical personnel become eligible for reserve status; (c) support enactment of federal laws to assist physicians in the transition from medical practice to active military service; (d) promote use of existing laws for selective service and retirement credits as models for development of practical equitable criteria to be applied; and (e) support improvements in professional utilization of military medical personnel during both active duty periods and "weekend drill."</p> <p>4. Our AMA supports the development of a statutory system of limitations on call-up, retention and recall of reservists in order to provide stability and predictability to reserve status and duty, with the basis for such a system to be defined statutorily using credits or "points" to prioritize options available to individual reservists as to call-up, retention, rotation and recall.</p> <p>(CCB/CLRPD Rep. 3, A-14)</p>	
H-406.989	Work of the Task Force on the Release of Physician Data	<p>1. Our AMA Council on Legislation will use the Release of Claims and Payment Data from Governmental Programs as a basis for draft model legislation. 2. Our AMA will create additional tools to assist physicians in dealing with the release of physician data. 3. Our AMA will continue to monitor the status of, and take appropriate action on, any legislative or regulatory opportunities regarding the appropriate release and use of physician data and its use in physician profiling programs. 4. Our AMA will monitor new and existing Web sites and programs that collect and use data on patient</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		<p>satisfaction and take appropriate action when safeguards are not in place to ensure the validity of the results. 5. Our AMA will continue and intensify its extensive efforts to educate employers, healthcare coalitions and the public about the potential risks and liabilities of pay-for-performance and public reporting programs that are not consistent with AMA policies, principles, and guidelines. 6. Our AMA: A) opposes the public reporting of individual physician performance data collected by certification and licensure boards for purposes of MOC and MOL; and B) supports the principle that individual physician performance data collected by certification and licensure boards should only be used for the purposes of helping physicians to improve their practice and patient care, unless specifically approved by the physician.</p> <p>(BOT Rep. 18, A-09; Reaffirmed: BOT action in response to referred for decision Res. 709, A-10, Res. 710, A-10, Res. 711, A-10 and BOT Rep. 17, A-10; Reaffirmed in lieu of Res. 808, I-10; Appended: Res. 327, A-11; Modified: CCB/CLRPD Rep. 2, A-14)</p>	
H-415.998	Preferred Provider Organizations	<p>The AMA: (1) opposes federal legislation that would preempt state regulation of PPOs; and (2) encourages state medical associations to support legislation that: (a) insures proper state regulation of PPOs, with particular attention to such practices as arbitrary determinations of medical necessity by carriers, "hold harmless" clauses, and predatory pricing concepts; and (b) requires independent, physician-directed peer review of the services provided by PPOs.</p> <p>(Sub. Res. 16, A-84; Reaffirmed by CLRPD Rep. 3 - I-94; Reaffirmed: BOT Rep. 29, A-04; Reaffirmed: BOT Rep. 19, A-14)</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
H-435.957	Uniform and Consistent Tort Reform	<p>Our AMA will not pursue federal medical liability reform legislation that would divide or diminish the voice of the House of Medicine.</p> <p>(Sub. Res. 910, I-03; Reaffirmed in lieu of Res. 216, A-04; Reaffirmed: BOT Rep. 19, A-14)</p>	Retain – this policy remains relevant.
H-435.963	Professional Liability Claims Reporting	<p>The AMA opposes the need for reporting on medical staff and other non-licensing board applications, including insurance company credentialing applications, (excepting professional liability insurance applications) any threatened, pending, or closed professional liability claims where the claim did not result in payment on behalf of that physician.</p> <p>(Sub. Res. 818, A-95; Modified: BOT Rep. 18, A-03; Reaffirmed: Res. 806, I-03; Reaffirmation A-04; Reaffirmed: BOT Rep. 19, A-14)</p>	Retain – this policy remains relevant.
H-435.968	Enterprise Liability	<p>The AMA: (1) affirms its position that effective medical liability reform based on California's MICRA model is integral to health system reform, and must be included in any comprehensive health system reform proposal that hopes to be effective in containing costs, providing access to health care services and promoting the quality and safety of health care services; (2) opposes any proposal that would mandate or impose enterprise liability concepts. Federal funding to evaluate the comparative advantages and disadvantages of enterprise liability may be best spent studying the operation, effect on liability costs and patient safety/injury prevention results of liability channeling systems that already exist and function as close analogs to the enterprise liability model (BOT Rep. I-93-53); and (3) supports strong patient safety initiatives and the investigation of alternative dispute resolution models, appropriate uses of practice parameters in medical liability litigation and other reform ideas that have the potential to decrease defensive</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		<p>medicine costs and more fairly and cost-effectively compensate persons injured in the course of receiving health care services.</p> <p>(BOT Rep. III, A-93; Reaffirmed: BOT Rep. 40, I-93; Reaffirmed: BOT Rep. 28, A-03; Reaffirmation A-04; Reaffirmed: BOT Rep. 19, A-14)</p>	
H-435.991	Professional Liability Countersuits	<p>Our AMA supports the principle that the "special injury" element required to win a malicious prosecution countersuit in some jurisdictions should be eliminated.</p> <p>(Res. 44, I-84; Reaffirmed: Sunset Report, I-98; Reaffirmed: Sub. Res. 914, I-04; Reaffirmed: BOT Rep. 19, A-14)</p>	Retain – this policy remains relevant.
H-440.876	Opposition to Criminalization of Medical Care Provided to Undocumented Immigrant Patients	<p>1. Our AMA: (a) opposes any policies, regulations or legislation that would criminalize or punish physicians and other health care providers for the act of giving medical care to patients who are undocumented immigrants; (b) opposes any policies, regulations, or legislation requiring physicians and other health care providers to collect and report data regarding an individual patient's legal resident status; and (c) opposes proof of citizenship as a condition of providing health care. 2. Our AMA will work with local and state medical societies to immediately, actively and publicly opposes any legislative proposals that would criminalize the provision of health care to undocumented residents.</p> <p>(Res. 920, I-06; Reaffirmed and Appended: Res. 140, A-07; Modified: CCB/CLRPD Rep. 2, A-14)</p>	<p>Retain this policy in part.</p> <p>Modify Part 2 by broadening the language and making it more consistent with Part 1.</p>
H-45.975	Proposed Change in Medical Requirements for 3rd Class Pilots' Licenses	<p>Our AMA will: (1) oppose efforts to substitute the third class medical certificate with a driver's license; and (2) write a letter encouraging the Federal Aviation Administration to retain the third class medical certification process.</p> <p>(Res. 228, A-14)</p>	<p>Sunset this policy.</p> <p>Legislation was enacted in 2016 (Public Law 114-190, the FAA Extension, Safety, and Security Act of 2016) that statutorily allows pilots of small, non-commercial planes to forgo the medical</p>

Policy Number	Title	Text	Recommendation
			certification process if the pilot and aircraft meet certain prescribed conditions under an FAA program called "BasicMed." A 2020 FAA study found no difference in accident risk between flights conducted by pilots operating under BasicMed and flights conducted by pilots holding third-class medical certificates.
H-478.987	Compliance with Meaningful Use Requirements as a Condition of Medical Licensure	<p>1. Our AMA stands on record as opposing any requirement that medical licensure be conditioned upon compliance with "Meaningful Use" requirements.</p> <p>2. Our AMA, working with state and specialty medical societies, will make efforts at all appropriate levels of government to secure the reversal of any requirements that medical licensure be conditioned upon compliance with meaningful use requirements.</p> <p>(Res. 232, A-14)</p>	<p>Sunset this policy.</p> <p>The Centers for Medicare & Medicaid Services renamed this EHR Incentive Program to the Medicare and Medicaid Promoting Interoperability Programs in April 2018. This policy has been superseded by more recent AMA policy (H-478.993, Implementing Electronic Medical Records).</p>
H-478.991	Federal EMR and Electronic Prescribing Incentive Program	<p>Our AMA: (1) will communicate to the federal government that the Electronic Medical Record (EMR) incentive program should be made compliant with AMA principles by removing penalties for non-compliance and by providing inflation-adjusted funds to cover all costs of implementation and maintenance of EMR systems; (2) supports the concept of electronic prescribing, as well as the offering of financial and other incentives for its adoption, but strongly discourages a funding structure that financially penalizes physicians that have not adopted such technology; and (3) will work with the Centers for Medicaid & Medicare Services and the Department of Defense to oppose programs that unfairly penalize or create disincentives, including e-prescribing limitations for physicians who provide care to military patients, and replace them with</p>	<p>Retain – this policy remains relevant.</p>

Policy Number	Title	Text	Recommendation
		<p>meaningful percentage requirements of e-prescriptions or exemptions of military patients in the percentages, where paper prescriptions are required.</p> <p>(Sub. Res. 202, A-09; Reaffirmation I-09; Reaffirmation A-10; Reaffirmation I-10; Reaffirmed in lieu of Res. 237, A-12; Reaffirmed in lieu of Res. 218, I-12; Reaffirmed in lieu of Res. 219, I-12; Reaffirmed in lieu of Res. 226, I-12; Reaffirmed in lieu of Res. 228, I-12; Reaffirmed in lieu of Res. 725, A-13; Appended: Res. 205, A-13; Reaffirmed in lieu of Res. 214, I-13; Reaffirmed in lieu of Res. 221, I-13; Reaffirmed in lieu of Res. 222, I-13; Reaffirmed in lieu of Res. 223, I-14)</p>	
H-55.991	Use of Heroin in Terminally Ill Cancer Patients With Severe Chronic Pain	<p>Our AMA remains opposed to legislation or any other action that would reschedule heroin from Schedule 1 to Schedule 2 of the Controlled Substances Act.</p> <p>(BOT Rep. TT, A-87; Reaffirmed: Sunset Report, I-97; Modified and Reaffirmed: CSAPH Rep. 3, A-07; Modified: CCB/CLRPD Rep. 2, A-14)</p>	Retain - this policy remains relevant.
H-60.940	Partner Co-Adoption	<p>Our AMA will support legislative and other efforts to allow the adoption of a child by the non-married partner who functions as a second parent or co-parent to that child. (Res. 204, A-04)</p> <p>(Res. 204, A-04; Modified: CSAPH Rep. 1, A-14)</p>	Retain – this policy remains relevant.
H-75.998	Opposition to HHS Regulations on Contraceptive Services for Minors	<p>(1) Our AMA continues to oppose regulations that require parental notification when prescription contraceptives are provided to minors through federally funded programs, since they create a breach of confidentiality in the physician-patient relationship. (2) The Association encourages physicians to provide comparable services on a confidential basis where legally permissible.</p> <p>(Sub. Res. 65, I-82; Reaffirmed: CLRPD Rep. A, I-92; Reaffirmed: BOT Rep. 28,</p>	Retain – this policy remains relevant.

Policy Number	Title	Text	Recommendation
		A-03; Reaffirmed: Res. 825, I-04; Reaffirmed: CMS Rep. 1, A-14)	
H-95.941	Restricting Prescriptions to Medicare Beneficiaries	<p>1. Our AMA will work with the Centers for Medicare & Medicaid Services and state medical societies as needed to preserve access to care and eliminate the burden of provisions in the Patient Protection and Affordable Care Act that require physicians to enroll in Medicare, Medicaid and other governmentally sponsored health insurance programs as a condition of referring, ordering or prescribing for patients enrolled in these programs.</p> <p>2. Our AMA supports federal legislation to eliminate the burden of provisions in the Patient Protection and Affordable Care Act that require physicians to enroll in Medicare, Medicaid and other governmentally sponsored health insurance programs as a condition of referring, ordering or prescribing for patients enrolled in these programs.</p> <p>(BOT Rep. 22, A-14)</p>	Retain – this policy remains relevant.

REPORT OF THE BOARD OF TRUSTEES

B of T Report 11-A-24

Subject: Safe and Effective Overdose Reversal Medications in Educational Settings

Presented by: Willie Underwood, III, MD, MSc, MPH, Chair

Referred to: Reference Committee B

1 INTRODUCTION

2
3 At the 2023 Annual Meeting of the American Medical Association (AMA) House of Delegates
4 (HOD), Resolution 217 entitled, “Increase Access to Safe and Effective Overdose Reversal
5 Medications in Educational Settings,” was adopted. This resolution called on the AMA to:

- 6
7 • Encourage states, communities, and educational settings, to adopt legislative and
8 regulatory policies that allow schools to make safe and effective overdose reversal
9 medications naloxone readily accessible to staff and teachers to prevent opioid overdose
10 deaths in educational settings;
11 • Encourage states, communities, and educational settings to remove barriers to students
12 carrying safe and effective overdose reversal medications; and
13 • Study and report back on issues regarding student access to safe and effective overdose
14 reversal medications.
15

16 The HOD adopted the resolution, which has been codified at Policy H-95.908, “Increase Access to
17 Safe and Effective Overdose Reversal Medications in Educational Settings.” In response to the
18 third resolve of the HOD action, this report provides background information, a discussion on
19 naloxone access in schools and other educational settings, relevant AMA advocacy initiatives, and
20 other updates.

21 22 BACKGROUND

23
24 More than 2,200 adolescents (ages 10-19) died of a drug-related overdose between July 2019-
25 December 2021, with nearly 84 percent of these deaths involving illicitly manufactured fentanyl.
26 An opioid of any type was involved in more than 91 percent of deaths, according to the Centers for
27 Disease Control and Prevention (CDC).¹ Naloxone was administered only 30 percent of the time,
28 according to the CDC.² Unintentional drug overdose deaths among young people (ages 15-19)
29 continued to remain high in 2022, according to the National Institute on Drug Abuse (NIDA).³
30 Two-thirds of those who died did not have any history of prior opioid use.⁴

31
32 Naloxone was created in the 1960s and subsequently began being used in emergency departments
33 and other hospital settings.⁵ Naloxone distribution in the community became more prevalent in the
34 1990s through harm reduction organizations.⁶ Naloxone is most commonly administered via
35 intramuscular injection or intranasal spray, and user preference may vary depending on familiarity
36 with a product and how to use it.⁷ With respect to availability in schools and other educational
37 settings, the nasal spray formulation is most commonly cited in school educational resources and

1 guidelines. It is important to emphasize, however, that the AMA does not endorse any specific
2 brand or generic formulation of naloxone or other U.S. Food and Drug Administration (FDA)-
3 approved opioid overdose reversal agents. While it is beyond the scope of this report to review the
4 several decades of life-saving benefits of naloxone, it is notable that AMA policy supports
5 continued development of and access to additional medications to reverse opioid-related overdoses.
6

7 Access to naloxone in the community has increased considerably in the past decade. From
8 2012-2017, naloxone prescriptions dispensed in the United States grew from 1,061 prescriptions to
9 nearly 270,000 prescriptions.⁸ Naloxone prescriptions dispensed increased to nearly 1.7 million
10 prescriptions in 2022. Based on our strong policy, the AMA continues to urge all physicians to
11 prescribe naloxone or other overdose reversal medications to patients at risk of overdose—and to
12 friends and family of those who might be in a position to save a life from overdose. The AMA also
13 continues to encourage physicians and physician offices to educate patients about the availability of
14 naloxone and other overdose reversal agents available over the counter, from pharmacists via a
15 standing order, or reversal agents that may be available through public health agencies. The
16 National Association of Counties details multiple strategies and examples to increase state- and
17 community-level distribution of naloxone.⁹
18

19 In addition to physicians' increasing efforts in prescribing naloxone, the AMA also recognizes the
20 longstanding role that harm reduction organizations have played in saving lives from overdose.
21 Harm reduction and other community-based organizations distributed more than 3.7 million doses
22 of naloxone between 2017–2020.¹⁰ From August 2021 to July 2023, national harm reduction
23 organization, Remedy Alliance For The People, sent 1,639,542 doses of generic injectable
24 naloxone to 196 harm reduction projects in 44 US states, DC, and Puerto Rico, of which
25 206,371 doses were provided at no-cost to 138 under-resourced harm reduction projects.¹¹
26 Naloxone has saved hundreds of thousands of lives in the United States, and the Board of Trustees
27 continues to strongly support all efforts to increase access to naloxone and other opioid overdose
28 reversal agents.
29

30 DISCUSSION

31

32 Increasing access to naloxone was one of the first recommendations of the AMA Substance Use
33 and Pain Care Task Force (Task Force),¹² which was first convened in 2014 and remains a vital
34 part of ensuring that organized medicine communicates emerging issues and policies to improve
35 outcomes and save lives. The Task Force's work, including providing input on and development of
36 AMA model state legislation¹³ to increase access to naloxone, has been part of every state now
37 having broad naloxone access laws.¹⁴
38

39 AMA model legislation also includes broad authority and immunities for high schools, universities,
40 and other educational settings to possess, distribute and administer naloxone to teachers, staff, and
41 students. As a result of AMA and other organizations' advocacy, approximately 30 states authorize
42 educational settings to administer naloxone, and it varies by state regarding whether that includes
43 elementary schools, high schools, or schools of higher education.¹⁵
44

45 Multiple school districts and universities already provide naloxone and overdose prevention and
46 education opportunities. While the total number continues to grow, representative examples can be
47 found in Southwest Virginia, where nearly all schools carry naloxone,¹⁶ and the state itself has
48 amended its laws to authorize the ability for schools and school employees to carry, administer, and
49 distribute naloxone.¹⁷ All schools in the Miami-Dade public school system carry naloxone,
50 although it is most commonly held by school public safety officials.¹⁸ One student remarked that
51 she carries naloxone in her purse because, "Our friends do not know that those pills are more than

1 likely to be fake [or] have enough fentanyl in it to kill you. And that is scary. I carry Narcan in my
2 school bag. If I am going to a party, I will put it in my purse. It is just a layer of protection. You
3 wear your seatbelt not because you are going get in a car accident. It is to keep yourself safe.”
4

5 Additional examples of schools, universities and other educational settings carrying naloxone:
6

- 7 • University of Pennsylvania Perelman School of Medicine—medical students are taught
8 how to recognize signs of overdose and administer naloxone on their first day of medical
9 school.¹⁹
- 10 • University of Southern California—a group of pharmacy students found that once they
11 started a naloxone education and distribution program, demand outpaced expectations.²⁰
- 12 • Vanderbilt University—makes naloxone and other harm reduction supplies available for
13 individuals as well as at public locations throughout campus.²¹
- 14 • Akron (Ohio) School District—voted to approve naloxone availability in schools in 2017.²²
- 15 • Columbia (NY) University—students who carry naloxone have saved lives from overdose
16 in the community²³ and in schools. Naloxone education events have occurred since 2018
17 and resulted in “more than 2,500 students, faculty, staff and community members on how
18 to recognize an overdose and administer treatment.”²⁴
- 19 • University of South Carolina—naloxone is accessible at the university fitness center,
20 school pharmacy and other locations.²⁵
- 21 • Montana—authorizing naloxone distribution and use in schools has been one part of the
22 state’s naloxone efforts, which distributed more than 26,000 naloxone kits to first
23 responders, law enforcement, schools, and others.²⁶
- 24 • Texas—schools now are required to carry naloxone, which has been administered multiple
25 times to save the life of a young person, according to news reports.²⁷

26
27 This short list above of high schools, universities, and other settings is a very brief snapshot
28 showcasing the fact that school districts recognize the value of having naloxone in educational
29 settings. Given the rapid adoption of efforts to increase access to naloxone in school-based settings,
30 data on the total number of educational settings with naloxone is not currently available. The Board
31 of Trustees strongly encourages these trends to continue.
32

33 The Board of Trustees also wants to continue to dispel myths about naloxone. The Board is aware
34 of ongoing myths that naloxone may increase risky drug use behaviors. Much like debunked and
35 dangerous myths of how use of seatbelts encourages risky driving; that the presence of fire
36 hydrants encourages arson; or “that HPV vaccination increases promiscuity or increases risky
37 sexual behavior,”²⁸ the presence and availability of naloxone has consistently been found to not
38 increase use of drugs or increase risk of overdose. For example, a 2023 study found that “Naloxone
39 access laws and pharmacy naloxone distribution were more consistently associated with decreases
40 rather than increases in lifetime heroin and [injection drug use] among adolescents.”²⁹ The study
41 authors make clear that “Our findings therefore do not support concerns that naloxone access
42 promotes high-risk adolescent substance use behaviors.” A smaller study of heroin users found “no
43 evidence of compensatory drug use following naloxone/overdose training.”³⁰ And a report from
44 2010 looking at multiple myths cited multiple studies disproving the link between naloxone
45 availability and increased drug use.³¹ The Board of Trustees further emphasizes that while the
46 Board does not support illicit drug use, it unequivocally supports efforts to save lives from
47 unintentional drug-related overdose, including dispelling myths and supporting widespread
48 availability of naloxone and other opioid overdose reversal agents. The limitations of naloxone,
49 however, should be recognized. NIDA advises that “People with physical dependence on opioids
50 may have withdrawal symptoms within minutes after they are given naloxone. Withdrawal

1 symptoms might include headaches, changes in blood pressure, rapid heart rate, sweating, nausea,
2 vomiting, and tremors.”³² NIDA aptly points out, however, that “The risk of death for someone
3 overdosing on opioids is worse than the risk of having a bad reaction to naloxone.” The Board of
4 Trustees agrees that death is a greater harm than withdrawal symptoms.

5
6 As noted in the 2023 AMA Overdose Epidemic Report, overdose and death related to illicitly
7 manufactured fentanyl, methamphetamine and cocaine increase; and xylazine and other toxic
8 synthetic adulterants present new challenges. Naloxone does not reverse an overdose related to
9 methamphetamine, cocaine or other toxic substances. Naloxone also does not work to counteract
10 overdose related to alcohol, benzodiazepines or xylazine, which may increase the sedative effects
11 of opioids, making the antagonist effects of naloxone appear not as rapid or sustaining.³³
12 Polysubstance use, moreover, may be intentional or unintentional as illicit substances may contain
13 multiple toxic adulterants, including illicitly manufactured fentanyl.³⁴ The CDC, SAMHSA, NIDA
14 and many other leading public health organizations, including the AMA, continue to counsel that in
15 addition to immediately calling 911, it is still advised to administer naloxone because it is likely an
16 opioid is present, and naloxone will not harm an individual. The Board of Trustees agrees and
17 further points out that if an individual’s overdose is related to multiple substances, administering
18 naloxone could help reduce respiratory depression. Again, the benefits of naloxone outweigh the
19 limitations.

20
21 The presence of fentanyl in the nation’s illicit drug supply also has raised the question of whether
22 additional doses of naloxone are necessary, greater dose strengths, or different opioid overdose
23 reversal medication (OORM) work more effectively than another. According to SAMHSA, the
24 evidence shows that:

- 25
- 26 • Giving more than one dose of naloxone and using higher dose products may not be
27 necessary when responding to a known fentanyl overdose.
 - 28 • An overdose may appear to need additional doses if other sedating drugs are present in the
29 person’s body, such as alcohol, benzodiazepines, or xylazine; however, rapidly giving
30 more naloxone or using a stronger, more concentrated OORM will not necessarily speed
31 up the reversal process.
- 32

33 In fact, SAMHSA reports that “Multiple studies have found that despite the presence of fentanyl,
34 more doses were not associated with improved outcomes.”³⁵ The Board of Trustees further
35 emphasizes that there are multiple OORM that have been approved by the FDA. The AMA does
36 not take a position on which OORM is more effective than another and—for the purposes of this
37 report—encourages states, communities, and educational settings, to adopt legislative and
38 regulatory policies that allow schools to make safe and effective overdose reversal medications
39 such as naloxone readily accessible to staff and teachers to prevent opioid overdose deaths in
40 educational settings. The Board of Trustees further encourages states, communities, and
41 educational settings to remove barriers to students carrying safe and effective overdose reversal
42 medications. The Board of Trustees wants to make clear that even when naloxone or other OORM
43 saves a life from overdose, it is essential to seek immediate medical attention.

44 AMA POLICY

45
46
47 The two most relevant AMA policies covering the areas of this report are (1) “Increasing
48 Availability of Naloxone and Other Safe and Effective Overdose Reversal Medications”
49 (Policy H-95.932); and (2) “Prevention of Drug-Related Overdose” (Policy D-95.987).
50 Adoption of H-95.932 has helped the AMA to support a broad array of naloxone access initiatives
51 for nearly a decade. As identified in H-95.932, these initiatives include:

1
2 ...legislative, regulatory, and national advocacy efforts to increase access to
3 affordable naloxone and other safe and effective overdose reversal medications,
4 including but not limited to collaborative practice agreements with pharmacists and
5 standing orders for pharmacies and, where permitted by law, community-based
6 organizations, law enforcement agencies, correctional settings, schools, and other
7 locations that do not restrict the route of administration for naloxone and other safe
8 and effective overdose reversal medications delivery.
9

10 Moreover, in accordance with AMA policy, specifically “Increasing Availability of Naloxone and
11 Other Safe and Effective Overdose Reversal Medications” (Policy H-95.932), AMA advocacy has
12 helped states enact broad liability protections “for physicians and other healthcare professionals
13 and others who are authorized to prescribe, dispense and/or administer naloxone and other safe and
14 effective overdose reversal medications pursuant to state law.” As part of our advocacy to support
15 broad access, in accordance with AMA policy entitled, “Increasing Availability of Naloxone and
16 Other Safe and Effective Overdose Reversal Medications” (Policy H-95.932), AMA continues “to
17 encourage individuals who are authorized to administer naloxone and other safe and effective
18 overdose reversal medications to receive appropriate education to enable them to do so
19 effectively.”
20

21 As noted briefly above, existing AMA policy entitled, “Increasing Availability of Naloxone and
22 Other Safe and Effective Overdose Reversal Medications” (Policy H-95.932), also allows for broad
23 support for “the widespread implementation of easily accessible naloxone and other safe and
24 effective overdose reversal medications rescue stations,” as well as “access to and use
25 of naloxone and other safe and effective overdose reversal medications in all public spaces
26 regardless of whether the individual holds a prescription.” This includes public schools and other
27 educational settings.
28

29 Given the broad nature of our existing AMA policy, which is amply reflected in the positive
30 developments to implement these policies throughout the United States, the Board of Trustees
31 concludes that AMA policy is sufficient and that additional new policy is not necessary. This report
32 also accomplishes the task set to the Board of Trustees to study and report back on issues regarding
33 student access to safe and effective overdose reversal medications.
34

35 RECOMMENDATIONS

36

37 The Board of Trustees recommends that the following be adopted, and that the remainder of the
38 report be filed:
39

- 40 1. Existing American Medical Association (AMA) policy entitled, “Increasing Availability of
41 Naloxone and Other Safe and Effective Overdose Reversal Medications” (Policy H-
42 95.932), be reaffirmed, and (Reaffirm HOD Policy)
43
- 44 2. The third resolve of Policy H-95.908, “Increase Access to Safe and Effective Overdose
45 Reversal Medications in Educational Settings” be rescinded and that the policy be updated
46 as noted. (Modify Current HOD Policy)

47 1. Our AMA will encourage states, communities, and educational settings to adopt
48 legislative and regulatory policies that allow schools to make safe and effective overdose
49 reversal medications readily accessible to staff and teachers to prevent opioid overdose
50 deaths in educational settings.

- 1 2. Our AMA will encourage states, communities, and educational settings to remove
- 2 barriers to students carrying safe and effective overdose reversal medications.
- 3 ~~3. Our AMA will study and report back on issues regarding student access to safe and~~
- 4 ~~effective overdose reversal medications.~~

Fiscal Note: Less than \$500.

REFERENCES

- ¹ Tanz LJ, Dinwiddie AT, Mattson CL, O'Donnell J, Davis NL. Drug Overdose Deaths Among Persons Aged 10–19 Years — United States, July 2019–December 2021. *MMWR Morb Mortal Wkly Rep* 2022;71:1576–1582. DOI: <http://dx.doi.org/10.15585/mmwr.mm7150a2>
- ² Tanz LJ, Dinwiddie AT, Mattson CL, O'Donnell J, Davis NL. Drug Overdose Deaths Among Persons Aged 10–19 Years — United States, July 2019–December 2021. *MMWR Morb Mortal Wkly Rep* 2022;71:1576–1582. DOI: <http://dx.doi.org/10.15585/mmwr.mm7150a2>
- ³ Unintentional Drug Overdose Death Rates Among US Youth Aged 15-19. National Institute on Drug Use. December 13, 2023. Available at <https://nida.nih.gov/research-topics/trends-statistics/infographics/unintentional-drug-overdose-death-rates-among-us-youth-aged-15-19>
- ⁴ Tanz LJ, Dinwiddie AT, Mattson CL, O'Donnell J, Davis NL. Drug Overdose Deaths Among Persons Aged 10–19 Years — United States, July 2019–December 2021. *MMWR Morb Mortal Wkly Rep* 2022;71:1576–1582. DOI: <http://dx.doi.org/10.15585/mmwr.mm7150a2>
- ⁵ Campbell ND. Naloxone as a technology of solidarity: history of opioid overdose prevention. *CMAJ*. 2019 Aug 26;191(34):E945-E946. doi: 10.1503/cmaj.190257. PMID: 31451527; PMCID: PMC6710079. Available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710079/>
- ⁶ The history of naloxone access in the United States. Remedy Alliance for the People. <https://remedyallianceftp.org/pages/history>
- ⁷ Marks, K.R., Oyler, D.R., Strickland, J.C. *et al.* Bystander preference for naloxone products: a field experiment. *Harm Reduct J* 20, 171 (2023). <https://doi.org/10.1186/s12954-023-00904-9>.
- ⁸ IQVIA Xponent limited to retail pharmacy dispensed prescriptions. Denition: USC 78312 Opioid Reversal Agents (naloxone). State-by-state data available at <https://end-overdose-epidemic.org/wp-content/uploads/2023/11/AMA-2023-overdose-report-IQVIA-data-naloxone-FINAL.pdf>
- ⁹ Naloxone to Reverse Opioid Overdose. National Association of Counties. July 17, 2023. Available at <https://www.naco.org/resource/osc-naloxone>
- ¹⁰ “Recommendations for Federal Partners and Health Departments Navigating Naloxone Supply.” NASTAD. July 2021. Available at <https://nastad.org/resources/recommendations-federal-partners-and-health-departments-navigating-naloxone-supply>
- ¹¹ Alliance For The People, R., Wheeler, E., Doe Simkins, M., & Dasgupta, N. (2023). Remedy Alliance For The People Annual Report 2023. <https://doi.org/10.17615/ymxe-6x08>
- ¹² The first set of recommendations were issued in 2015 and revised at several intervals. See, for example, the 2017 update here: <https://end-overdose-epidemic.org/wp-content/uploads/2020/06/AMA-Task-Force-to-Reduce-Opioid-Abuse-Overview-updated-June-2017.pdf>
- ¹³ The AMA Board of Trustees first approved model state legislation recommend by the AMA Council on Legislation in 2013. The model bill has been amended multiple times since then to strengthen access to naloxone and other forms of opioid-overdose reversal agents. In addition to the protections for school personnel, the model bill provides for liability protections to health care professionals prescribing naloxone as well as authorizing third-party prescriptions and standing orders to allow persons without a prescription to obtain naloxone from a pharmacy. It also includes broad Good Samaritan protections that provide extensive protections for civil and criminal penalties, including parole violations. Medical societies interested in broadening their state laws should contact the AMA Advocacy Resource Center.
- ¹⁴ Legal Interventions to Reduce Overdose Mortality: Naloxone Access Laws. The Network for Public Health Law. As of August 1, 2023. Available at <https://www.networkforphl.org/wp-content/uploads/2023/11/Naloxone-Access-Laws-50-State-Survey-2023.pdf>
- ¹⁵ See, for a general discussion of examples of state laws, “States Split on Whether to Stock Overdose Drugs in Schools.” *Governing*. KFF Health News. Oct. 6, 2023. Available at <https://www.governing.com/health/states-split-on-whether-to-stock-overdose-drugs-in-schools>
- ¹⁶ ‘List of Southwest Virginia schools that carry Narcan/Naloxone.’ *WDBJ*. February 15, 2024. Available at <https://www.wdbj7.com/2024/02/15/list-southwest-virginia-schools-that-carry-narcan-naloxone/>.
- ¹⁷ See, § 54.1-3408. Professional use by practitioners. <https://law.lis.virginia.gov/vacode/title54.1/chapter34/section54.1-3408/>
- ¹⁸ “All Miami-Dade public schools now stock overdose reversal drugs.” *WLRN*. November 3, 2023. Available at <https://www.wlrn.org/education/2023-11-03/miami-schools-naloxone-narcan-overdose-reversal-drugs>

- ¹⁹ “Narcan bootcamp, then the white coat.” University of Penn Medicine News. December 8, 2023. <https://www.pennmedicine.org/news/publications-and-special-projects/penn-medicine-magazine/fall-winter-2023/first-year-medical-students-learn-lifesaving-skills-on-day-one>
- ²⁰ Brown M, Tran C, Dadiomov D. Lowering barriers to naloxone access through a student-led harm reduction program. *J Am Pharm Assoc* (2003). 2023 Jan-Feb;63(1):349-355. doi: 10.1016/j.japh.2022.10.030. Epub 2022 Nov 4. PMID: 36443177.
- ²¹ Vanderbilt Recovery Support provides resources for campus community. October 11, 2023. <https://news.vanderbilt.edu/2023/10/11/vanderbilt-recovery-support-provides-resources-for-campus-community/>
- ²² Naloxone in Schools Policy Brief. Ohio Department of Health. September 30, 2020. Available at https://takecharge.ohio.gov/static/healthcare-professionals-toolkit/naloxone-resource-information/naloxone-in-schools_policy-brief.pdf
- ²³ Opioid Avengers: Columbia Students Save Four Lives With Naloxone. Carla Cantor. Columbia News. February 21, 2020. Available at <https://news.columbia.edu/news/opioid-overdose-students-save-lives-naloxone>
- ²⁴ Opioid Avengers: Columbia Students Save Four Lives With Naloxone. Carla Cantor. Columbia News. February 21, 2020. Available at <https://news.columbia.edu/news/opioid-overdose-students-save-lives-naloxone>
- ²⁵ “USC offers Narcan at fitness center, makes emergency resource more accessible.” The Daily Gamecock. September 4, 2023. Available at <https://www.dailygamecock.com/article/2023/09/usc-offers-narcan-at-fitness-center-makes-emergency-resource-more-accessible-news-bassett>
- ²⁶ Opioid Education and Naloxone Distribution Program. Montana Department of Public Health and Human Services. June 20, 2023. <https://content.govdelivery.com/accounts/MTDPHHS/bulletins/360ffbf>
- ²⁷ “Texas now requires your kid’s school to have Narcan: Here’s how it works.” November 9, 2023. <https://www.click2houston.com/news/local/2023/11/09/texas-now-requires-your-kids-school-to-have-narcan-heres-how-it-works/>
- ²⁸ Taumberger N, Joura EA, Arbyn M, Kyrgiou M, Sehoul J, Gultekin M. Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee. *Int J Gynecol Cancer*. 2022 Jul 12;32(10):1316–20. doi: 10.1136/ijgc-2022-003685. Epub ahead of print. PMID: 35820716; PMCID: PMC9554067.
- ²⁹ Emilie Bruzelius, Magdalena Cerdá, Corey S. Davis, Victoria Jent, Katherine Wheeler-Martin, Christine M. Mauro, Stephen Crystal, Katherine M. Keyes, Hillary Samples, Deborah S. Hasin, Silvia S. Martins, Naloxone expansion is not associated with increases in adolescent heroin use and injection drug use: Evidence from 44 US states, *International Journal of Drug Policy*, Volume 114, 2023, 103980, ISSN 0955-3959, <https://doi.org/10.1016/j.drugpo.2023.103980>. <https://www.sciencedirect.com/science/article/pii/S0955395923000294>
- ³⁰ Jones JD, Campbell A, Metz VE, Comer SD. No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. *Addict Behav*. 2017 Aug;71:104-106. doi: 10.1016/j.addbeh.2017.03.008. Epub 2017 Mar 9. PMID: 28325710; PMCID: PMC5449215.
- ³¹ Bazazi AR, Zaller ND, Fu JJ, Rich JD. Preventing opiate overdose deaths: examining objections to take-home naloxone. *J Health Care Poor Underserved*. 2010 Nov;21(4):1108-13. doi: 10.1353/hpu.2010.0935. PMID: 21099064; PMCID: PMC3008773.
- ³² NIDA. 2022, January 11. Naloxone DrugFacts. Retrieved from https://nida.nih.gov/publications/drugfacts/naloxone_on_March_14_2024.
- ³³ Substance Abuse and Mental Health Services Administration. SAMHSA Overdose Prevention and Response Toolkit. Publication No. PEP23-03-00-001. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2023. Available at <https://store.samhsa.gov/sites/default/files/overdose-prevention-response-kit-pep23-03-00-001.pdf>
- ³⁴ Polysubstance Use Facts. National Center for Injury Control and Prevention, Division of Drug Overdose Prevention. U.S. Centers for Disease Control and Prevention. Page last reviewed February 23, 2022. Available at <https://www.cdc.gov/stopoverdose/polysubstance-use/index.html>
- ³⁵ Substance Abuse and Mental Health Services Administration. SAMHSA Overdose Prevention and Response Toolkit. Publication No. PEP23-03-00-001. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2023. Available at <https://store.samhsa.gov/sites/default/files/overdose-prevention-response-kit-pep23-03-00-001.pdf>

REPORT 13 OF THE BOARD OF TRUSTEES (A-24)
Prohibiting Covenants Not-to-Compete (Resolution 237-A-23, Resolve 3)
Reference Committee B

EXECUTIVE SUMMARY

At the 2023 Annual Meeting, the American Medical Association (AMA) House of Delegates (HOD) adopted Resolution 237 entitled, “Prohibiting Covenants Not-to-Compete in Physician Contracts.” Resolution 237 was introduced by California, American Academy of Family Physicians, American Association of Neurological Surgeons, American College of Surgeons, Congress of Neurological Surgeons, and The Society of Thoracic Surgeons.

Resolve 3 of Resolution 237 (Resolve 3) directs that our AMA study and report back on current physician employment contract terms and trends with recommendations to address balancing legitimate business interests of physician employers while also protecting physician employment mobility and advancement, competition, and patient access to care – such recommendations to include the appropriate regulation or restriction of (1) covenants not to compete in physician contracts with independent physician groups that include time, scope, and geographic restrictions; and (2) de facto non-compete restrictions that allow employers to recoup recruiting incentives upon contract termination.

The term “non-compete” in the report refers to an agreement between an employer and an employed physician that prohibits the physician from working within a certain geographic area and for a period of time after the physician’s employment ends.

This report discusses physicians’ recurring concerns about the effect that non-competes have on both physicians and patients. The report also highlights the reasons why an independent physician group may think it necessary to use a reasonable non-compete to protect legitimate business interests (LBIs).

As directed by Resolve 3, this report describes many ways that non-competes can be regulated, restricted, or modified to achieve the purposes of Resolve 3. The report ends with a recommendation that would be new HOD policy. The recommendation calls on the AMA to continue assisting interested state medical associations in developing fair and reasonable strategies regarding restrictive covenants between physician employers and physician employees including regularly updating the AMA’s state restrictive covenant legislative template.

Following the instructions of the HOD, this report addresses only Resolve 3. As such, this report does not consider non-competes generally, nor does it adjust any AMA policy positions regarding the pros and cons of non-competes as they may exist between physician practices and physician employees.

REPORT OF THE BOARD OF TRUSTEES

B of T Report 13-A-24

Subject: Prohibiting Covenants Not-to-Compete
(Resolution 237-A-23, Resolve 3)

Presented by: Willie Underwood III, MD, MSc, MPH, Chair

Referred to: Reference Committee B

1 INTRODUCTION

2
3 At the 2023 Annual Meeting, the American Medical Association (AMA) House of Delegates
4 (HOD) adopted Resolution 237 entitled, “Prohibiting Covenants Not-to-Compete in Physician
5 Contracts.” Resolution 237 was introduced by California, American Academy of Family
6 Physicians, American Association of Neurological Surgeons, American College of Surgeons,
7 Congress of Neurological Surgeons, and The Society of Thoracic Surgeons. Resolution 237 stated
8 the following:
9

10 RESOLVED, That our American Medical Association support policies,
11 regulations, and legislation that prohibits covenants not-to-compete for all
12 physicians in clinical practice who hold employment contracts with for-profit or
13 non-profit hospital, hospital system, or staffing company employers (New HOD
14 Policy); and be it further
15

16 RESOLVED, That our AMA oppose the use of restrictive covenants not-to-
17 compete as a contingency of employment for any physician-in-training, regardless
18 of the ACGME accreditation status of the residency/fellowship training program
19 (New HOD Policy); and be it further
20

21 RESOLVED, That our AMA study and report back on current physician
22 employment contract terms and trends with recommendations to address balancing
23 legitimate business interests of physician employers while also protecting
24 physician employment mobility and advancement, competition, and patient access
25 to care - such recommendations to include the appropriate regulation or restriction
26 of 1) Covenants not to compete in physician contracts with independent physician
27 groups that include time, scope, and geographic restrictions; and 2) De facto non-
28 compete restrictions that allow employers to recoup recruiting incentives upon
29 contract termination. (Directive to Take Action)
30

31 As directed by the HOD, this report addresses only Resolve 3 of Resolution 237 (Resolve 3). As
32 such, this report does not consider non-competes generally, nor does it adjust any AMA policy
33 positions regarding the pros and cons of non-competes as they may exist between physician
34 practices and physician employees.
35

36 In this report, “non-compete” is defined as “a contractual term between a physician employer, e.g.,
37 a hospital, and a physician employee that prohibits the employee from working within a certain

1 geographic area and period of time after the physician’s employment ends.” For example, a
2 restrictive covenant may prohibit the physician from practicing medicine within 10 miles of the
3 location where he or she treated patients for two years after employment has ended.

4
5 BACKGROUND

6
7 Adoption of Resolution 237 made a significant change to the AMA’s policy on non-compete
8 clauses (a/k/a covenants not-to-compete or non-competes). Prior to Resolution 237, the AMA was
9 primarily guided by *Ethical Opinion 11.2.3.1, Restrictive Covenants (Ethical Opinion 11.2.3.1)*,
10 which states that physicians should not enter into unreasonable non-competes.¹

11
12 Pursuant to Resolution 237, AMA policy now requires the AMA to “support policies, regulations,
13 and legislation that prohibits covenants not-to-compete for all physicians in clinical practice who
14 hold employment contracts with for-profit or non-profit hospital, hospital system, or staffing
15 company employers.” Resolution 237 does not supplant *Ethical Opinion 11.2.3.1*, which opposes
16 the use of unreasonable physician non-competes. Thus, while Resolution 237 prohibits covenants
17 not-to-compete for all physicians in clinical practice who hold employment contracts with for-
18 profit or non-profit hospital, hospital system, or staffing company employers, *Ethical Opinion*
19 *11.2.3.1* applies in other contexts, and thus opposes the use of unreasonable non-competes between
20 physician employers and physician employees.

21
22 Resolve 3 appears to recognize the negative impact that non-competes – even those used by
23 physician employers – may have on physicians and patients. Specifically, Resolve 3 asks the AMA
24 to make recommendations concerning the appropriate regulation or restriction of non-competes in
25 physician contracts with independent physician groups that include time, scope, and geographic
26 restrictions. What follows is a brief discussion regarding how non-competes may harm patients and
27 physicians.

28
29 *Non-competes Harm Patients*

30
31 Enforcement of non-competes often harms patients by ending patient-physician relationships, e.g.,
32 if a non-compete forces a physician out of a community or otherwise makes the physician
33 geographically inaccessible to patients. Patients may be particularly at risk when the non-compete
34 severs long-standing patient-physician relationships where the physician has been taking care of
35 patients with chronic illnesses. Similarly, a non-compete can thwart a patient’s choice of physician.

36
37 Non-competes may hinder patients’ ability to timely access care. For example, depending on the
38 geographic area, there may be a few physicians, general practitioners, or specialists available to
39 serve the patient population. Even if several physicians practice in the community, forcing a
40 physician to leave the area may reduce the number of available physicians. Although a replacement
41 physician may ultimately be recruited to the area, recruitment can be a lengthy process. In the
42 meantime, the absence of the physician subject to the non-compete may frustrate timely patient
43 access to physician services – assuming the community’s remaining physicians have the capacity to
44 take on new patients.

45
46 Non-competes may also harm patients by compromising physician autonomy. For example, most
47 physician employment agreements allow the employer (and the physician) to end the agreement at
48 any time, so long as the other party is given advance notice. (This is typically referred to as
49 “without cause” termination). A physician who knows that an employer can end their employment
50 at any time, which will in turn trigger a non-compete, may be very reluctant to engage in patient
51 advocacy, and speak up about matters negatively affecting patient care, clinical decision-making,

1 etc.

2
3 *Non-competes Harm Physicians*

4
5 Non-competes can also harm employed physicians by locking them into untenable working
6 conditions or responsibilities that are detrimental to physicians' mental and/or physical health,
7 thereby contributing to the physician burnout epidemic. A physician who is practicing medicine in
8 demoralizing working conditions may feel an urgent need to find a job with a better working
9 environment and where the employer listens to its physicians' concerns and fosters a workplace
10 that is more conducive to the practice of medicine. If a competing employer in the community
11 offers the physician such an opportunity, a non-compete would bar the physician from accepting
12 the new position. The physician might solve this issue if he or she were willing to work for an
13 employer outside the non-compete's geographic restrictions. Doing so, however, could not only
14 force the physician to leave the area, but require the physician to uproot his or her family from a
15 community where the family has established significant roots. As a practical matter, working
16 outside of the non-compete's geographic restriction may then be completely out of the question.
17 Thus, the physician will simply have no option but to stay in a demoralizing employment situation
18 that continues to put the physician's mental and physical health at risk and increasingly subjects the
19 physician to burnout.

20
21 Based on all of the above, we understand that employed physicians have a strong case for wanting
22 the AMA to adopt policy calling for a complete ban on non-competes. However, while Resolve 3
23 requires the AMA to support a ban on non-competes in employment contracts with for-profit or
24 non-profit hospitals, hospital systems, or staffing company employers, Resolve 3 does not call on
25 the AMA to do the same with respect to non-competes between independent physician groups and
26 their physicians. Rather, Resolve 3 asks the AMA to study and report back with recommendations
27 to address balancing legitimate business interests (LBIs) of physician employers while also
28 protecting physician employment mobility and advancement, competition, and patient access to
29 care. Thus Resolve 3 appears to recognize that physician employers may feel the need to use
30 reasonable non-competes to protect LBIs. The next paragraph discusses those interests.

31
32 *Employer's Reasons for Requiring Restrictive Covenants*

33
34 Physician employers may feel that reasonable non-competes are essential to protect LBIs, which
35 may take several forms. For example, an independent physician group may train the physician,
36 make referral sources and contacts available to the physician, give the physician access to patients
37 and patient lists, market the physician in the community, and provide the physician with
38 proprietary practice information to help the physician build up his or her practice. Physician
39 employers may want to use non-competes to prohibit a physician from leaving and then opening up
40 their own practice "down the hall," in the same building, or even across the street – after receiving
41 the benefit of information, training, patient contacts, and other resources provided by the
42 independent physician group. Non-competes may give the physician employer the freedom and
43 security to invest significant resources in the employed physician's success, without the employer
44 having to worry that the physician will later leave after the physician has developed a significant
45 patient base, taking those patients with him or her.

46
47 DISCUSSION

48
49 There are two recent, major developments or trends relating to physician employment contract
50 terms relating to the potential balancing of the physician employer and their employed physicians
51 and patient access. These developments are: (1) the Federal Trade Commission's (FTC) proposed

1 rule on non-competes and (2) the ongoing enactment of state legislation dealing with non-
 2 competes. Because the FTC’s proposed rule bans physician non-competes, except with respect to
 3 501(c)(3) organizations under the U.S. Internal Revenue Code (which includes at least some
 4 hospitals and health systems), the proposed rule is not a source of recommendations about how
 5 physician contracting, regulation, or restrictions to non-competes might modify non-competes
 6 themselves to achieve the balance described in Resolve 3. The proposed rule does not prohibit the
 7 use of reasonable confidentiality provisions to protect trade secrets and other confidential
 8 information or repayment agreements. These types of provisions might, if taken together, be a
 9 possible means of achieving the kind of balance described by Resolve 3.

10
 11 *Recommendations Concerning Possible Modifications to Traditional Non-competes*

12
 13 State legislatures continue to consider bills that address non-competes, and most states have
 14 enacted statutes that are applicable to non-competes between physician employers and physician
 15 employees. These laws, as well as court decisions, provide the basis of how non-competes between
 16 physician employers and physician employees might be regulated. In states where one or more of
 17 these laws do not apply, the following recommendations could also be considered in contract
 18 negotiations between physician employers and their employees as a means of trying to achieve the
 19 balance described in Resolve 3.

- 20
 21 • **Bases of termination.** Rather than having the non-compete apply regardless of the reason for
 22 employment termination, the non-compete might be modified so that it is enforceable only if:
 23 (1) the physician terminated his or her employment without cause; (2) the physician’s license
 24 to practice medicine, or prescribe or dispense controlled substances, is currently revoked; or (3)
 25 the physician is currently excluded from participating in Medicare, Medicaid, or any other
 26 governmental program providing compensation for services rendered to patients.
 27
 28 • **Duration.** A non-compete could be drafted so that it has a short duration. It is not unusual for
 29 physician non-competes to last two years. But, following the direction of several state laws, the
 30 duration could be reduced to one year, or even six months. For example, Connecticut limits the
 31 duration of a physician non-compete to no more than one year.² In a frequently cited Arizona
 32 Supreme Court case, the court affirmed a lower court’s ruling that six months, rather than three
 33 years, was sufficient to protect the legitimate business interests of a physician practice with
 34 respect to competition from a formerly employed pulmonologist.³
 35
 36 • **Scope of services.** A non-compete should apply only to services that the employed physician
 37 provided to the physician employer, and not, for example, broadly restrict the physician from
 38 “practicing medicine.” For example, a Louisiana court ruled that a non-compete was too broad
 39 because it prohibited the physician employee from engaging in the practice of medicine, rather
 40 than being limited to the pain management services that he provided.⁴ On the other hand, the
 41 Illinois Supreme Court upheld a ruling holding that a non-compete prohibiting a physician
 42 from practicing medicine was not too broad.⁵
 43
 44 • **Working for competitors.** A non-compete could be structured so that it prohibits the departing
 45 physician from working for a competitor, rather than prohibiting the physician from working
 46 for any employer in the relevant geographic area.⁶
 47
 48 • **Tying the geographic scope of the non-compete to a single location.** A non-compete should
 49 be written so that it is tied to the specific location where the physician provided the majority of
 50 his or her services, sometimes referred to in state law as the “primary practice site.” A non-

1 compete should not include any geographic area where the physician employer has offices—
2 since the employer may have several offices in a state or states.⁷

- 3
- 4 • **Reasonable buy-out provision.** A non-compete could be drafted so that the departing
5 physician could buy his or her way out of the non-compete.⁸ The amount of the buyout should
6 be reasonable based on a predetermined formula to eliminate ambiguity concerning how the
7 buyout amount will be calculated. However, in some cases, even if there is no dispute
8 concerning the buyout’s reasonableness, a departing physician may not be able to buy his or
9 her way out of a non-compete because the amount of the buyout is more than the physician can
10 pay.
 - 11
 - 12 • **Carve out for specific types of patients.** Some state statutes that do permit the use of non-
13 competes allow the departing physician to continue to see patients with specific types of
14 conditions. For example, the Texas statute permits the physician to still treat patients with an
15 acute illness.⁹ The Colorado statute may also serve as an example here. Although the Colorado
16 law prohibits non-competes in physician employment agreements, it does permit punitive
17 damages related to competition. However, punitive damages are not recoverable if the formerly
18 employed physician is treating a patient with a rare disorder.¹⁰

19

20 *Use of Contractual Provisions that are not Non-competes*

21

22 There are other kinds of post-employment restrictions that may represent other ways of attempting
23 to achieve the balance described in Resolve 3. A physician employer may, however, be concerned
24 that these alternatives do not sufficiently protect its LBI. This section describes some of these other
25 options, which may be used in combination with one another.

26

27 Trade Secrets

28

29 A contract clause obligating the departing physician not to disclose the employer’s trade secrets is
30 one way that the physician employer could protect its LBI. All states have laws protecting trade
31 secrets and most states have adopted the Uniform Trade Secrets Act¹¹ (UTSA) in various forms.
32 The UTSA defines “trade secret” as information, including a formula, pattern, compilation,
33 program, device, method, technique, or process, that: (1) derives independent economic value,
34 actual or potential, from not being generally known to, and not being readily ascertainable by
35 proper means by, other persons who can obtain economic value from its disclosure or use and
36 (2) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy.

37

38 The UTSA includes a civil cause of action for trade secret misappropriation, which refers to
39 disclosure or use of a trade secret by a former employee without express or implied consent.
40 Moreover, the courts have held that trade secrets include patient lists, medical records, and
41 superbills containing patient addresses, medical diagnoses and treatment codes, and patient
42 insurance information.¹² AMA policy states, however, that billing records and associated medical
43 records should not be treated as proprietary or as trade secrets.¹³

44

45 Confidentiality Clauses

46

47 Physician employers may also use confidentiality agreements to protect legitimate business
48 interests. Confidential information includes, but is not limited to, trade secrets. Some state laws
49 define “confidential information.” For example, the Georgia non-compete statute defines
50 “confidential information” in part to mean data and information:

1 Relating to the business of the employer, regardless of whether the data or
2 information constitutes a trade secret...disclosed to the employee, that has value to
3 the employer; is not generally known to the employer's competitors; competitors
4 of the employer; and includes trade secrets, methods of operation, names of
5 customers, price lists, financial information and projections, route books, personnel
6 data, and similar information...¹⁴
7

8 The employer should require that, upon termination of the physician's employment, that the
9 departing physician promptly return any confidential information in the physician's possession or
10 control to the physician employer, including but not limited to, information on electronic devices.
11 Further, the physician employer should consider requiring the employee to agree to a provision
12 prohibiting a physician from taking any property, patient lists, or records of the employer with him
13 or her upon the termination or expiration of the employment agreement.¹⁵
14

15 Protecting Trade Secrets and Confidential Information Through Non-disclosure Agreements

16

17 A physician employer can take steps to protect both confidential and trade secrets information by
18 requiring the employee to sign a non-disclosure agreement (NDA) that applies after the physician
19 leaves the employer. An NDA needs to be (1) clear about the information that is protected and (2)
20 specifically tailored to protect that information. Courts may refuse to enforce NDAs that are too
21 broad, e.g., they apply to information that is not considered to be confidential.
22

23 In some circumstances an NDA may be so broad that it can function as a de facto non-compete.
24 One example of an NDA functioning as a de facto non-compete is found in *Brown v. TGS Mgmt.*
25 *Co., LLC*. In this case, "confidential information" included any information that was "usable in" or
26 "relates to" the securities industry. A California court refused to enforce the NDA because it
27 defined confidential information "so broadly as to prevent [the employee] from ever working again
28 in securities trading" and thus, operated as a de facto non-compete. As a result, the court concluded
29 that it could not be enforced under California law.¹⁶
30

31 While NDAs do not restrict the mobility of physician employees as much as non-competes,
32 physician employers may be concerned that an NDA is not sufficient to protect its trade secrets and
33 other confidential information. It may be challenging for the physician employer to detect a breach
34 of an NDA in comparison with a non-compete. Further, there can be significant litigation
35 concerning just what damage the breach has caused the employer. Issues with detection and
36 establishing damage amounts are likely to make enforcement of NDAs more expensive than
37 enforcement of non-competes. However, in lieu of having to prove damage amounts, the physician
38 employer might, to the extent permitted by state law, be able to include in the employment contract
39 a clause entitling the employer to liquidated damages if the physician breaches an NDA, although
40 the amount of liquidated damages could itself be subject to litigation.
41

42 Non-solicitation Agreements

43

44 Most states that prohibit non-competes do not disallow the use of non-solicitation agreements
45 (NSA). For example, the Minnesota non-compete statute does not prohibit an NDA, an agreement
46 designed to protect trade secrets or confidential information, an NSA, or an agreement restricting
47 the ability to use client or contact lists or solicit customers of the employer.¹⁷ NSAs can apply to
48 the physician employer's patients, employees, or both. An NSA should, however, entitle the
49 physician to notify patients whom they have seen and who wish to continue care with them of their
50 new location and be advised they may sign a records release to have their records transferred to
51 their physician of choice.

1 As in the case of NDA, it is likely that an employer will find it more difficult, and thus more
2 expensive, to detect the breach of an NSA and prove damages, as opposed to a non-compete.
3 Proving a breach of an NSA may be particularly challenging because employees may want to work
4 for, and patients may decide to continue their relationship with, the departing physician on their
5 own initiative without any solicitation from the physician. Again, as in the case of breach of an
6 NDA, the physician employer might, to the extent permitted by state law, include a liquidated
7 damages provision in its employment agreement with the physician to remedy a breach of an NSA,
8 which, as noted above, may also be the subject of litigation.

9 10 Repayment Agreements

11
12 Using a repayment agreement can be another way to attempt to achieve the balance described in
13 Resolve 3. The main concern here most likely has to do with what costs are covered by the
14 agreement. Fortunately, some state non-compete statutes address this issue. For example, the New
15 Mexico non-compete law, which bans non-competes in physician employee contracts, states that
16 during an initial employment period of less than three years, the physician employer can require
17 the departing physician to repay all or a portion of: (1) a loan; (2) relocation expenses; (3) a
18 signing bonus or other remuneration to induce the health care practitioner to relocate or establish a
19 health care practice in a specified geographic area; or (4) recruiting, education, and training
20 expenses.¹⁸ The West Virginia non-compete statute, on the other hand, states that a physician
21 employer may require an employed physician to repay all or a portion of: (1) a loan; (2) location
22 expenses; (3) a signing bonus; (4) remuneration to induce the physician to relocate or establish a
23 physician practice in a specific geographic area; or (5) recruiting, education, and training expenses.
24 (The West Virginia statute does permit the use of physician non-competes lasting no more than
25 one year). Unlike the New Mexico statute, the repayment obligation appears to have no time
26 limit.¹⁹

27
28 A physician employer must take care that the repayment agreement is fair and is not inflated by
29 costs that do not reflect actual financial benefits conferred on the employed physician. Notably, the
30 FTC's proposed non-compete rule states that a repayment agreement may function as a de facto
31 non-compete if the repayment obligation is not reasonably related to the costs the employer
32 incurred for training the worker.²⁰ The abuse of repayment agreements has come under fire from
33 other quarters as a means of preventing employees from leaving their jobs through debt, and are
34 being used as a work-around in states where non-competes are banned.²¹ If a physician employer is
35 considering how to structure a repayment agreement and what types of costs ought to be covered,
36 the cost categories listed in the New Mexico and the West Virginia laws may be useful guides,
37 keeping in mind that the cost amounts must also be reasonable.

38 39 *AMA Educational and Advocacy Resources*

40
41 The AMA has many educational and advocacy resources concerning non-competes. For example,
42 the Advocacy Resource Center (ARC) has, pursuant to prior AMA policy, developed a
43 comprehensive analysis of all state non-compete laws that apply to physicians entitled "Legislative
44 Template: Covenants not-to-Compete in Physician Contracts." Those interested in this advocacy
45 resource may obtain it by contacting the ARC at [https://www.ama-assn.org/system/files/rc-](https://www.ama-assn.org/system/files/rc-legislative-template.pdf)
46 [legislative-template.pdf](https://www.ama-assn.org/system/files/rc-legislative-template.pdf). The AMA Career Planning Resource webpage also has a wealth of
47 information discussing physician employment issues, which includes information and tips regarding
48 restrictive covenants. The AMA Career Planning Resource webpage may be accessed at
49 [https://www.ama-assn.org/residents-students/career-planning-resource/understanding-employment-](https://www.ama-assn.org/residents-students/career-planning-resource/understanding-employment-contracts)
50 [contracts](https://www.ama-assn.org/residents-students/career-planning-resource/understanding-employment-contracts).

1 RELEVANT AMA POLICY

2
3 The following AMA policy is relevant to this Board Report:

4
5 • **Code of Medical Ethics 11.2.3.1 Restrictive Covenants**

6
7 Competition among physicians is ethically justifiable when it is based on such factors as
8 quality of services, skill, experience, conveniences offered to patients, fees, or credit terms.

9
10 Covenants-not-to-compete restrict competition, can disrupt continuity of care, and may limit
11 access to care.

12
13 Physicians should not enter into covenants that:

14
15 (a) Unreasonably restrict the right of a physician to practice medicine for a specified period of
16 time or in a specified geographic area on termination of a contractual relationship; and

17
18 (b) Do not make reasonable accommodation for patients' choice of physician.

19
20 Physicians in training should not be asked to sign covenants not to compete as a condition of
21 entry into any residency or fellowship program.

22
23 AMA Principles of Medical Ethics: III, IV, VI, VII

24
25 • **Restrictive Covenants of Large Health Care Systems D-383.978**

26
27 Our AMA, through its Organized Medical Staff Section, will educate medical students,
28 physicians-in-training, and physicians entering into employment contracts with large health
29 care system employers on the dangers of aggressive restrictive covenants, including but not
30 limited to the impact on patient choice and access to care.

31
32 • **Restrictive Covenants in Physician Contracts H-383.987**

33
34 Our AMA will provide guidance, consultation, and model legislation concerning the
35 application of restrictive covenants to physicians upon request of state medical associations and
36 national medical specialty societies.

37
38 • **Prohibiting Covenants Not-To-Compete in Physician Contracts H-265.988**

39
40 (1) Our American Medical Association support policies, regulations, and legislation that
41 prohibits covenants not-to-compete for all physicians in clinical practice who hold employment
42 contracts with for-profit or non-profit hospital, hospital system, or staffing company
43 employers.

44
45 (2) Our AMA will oppose the use of restrictive covenants not-to-compete as a contingency of
46 employment for any physician-in-training, regardless of the ACGME accreditation status of the
47 residency/fellowship training program.

48
49 (3) Our AMA will study and report back on current physician employment contract terms and
50 trends with recommendations to address balancing legitimate business interests of physician

1 employers while also protecting physician employment mobility and advancement,
2 competition, and patient access to care - such recommendations to include the appropriate
3 regulation or restriction of a) Covenants not to compete in physician contracts with
4 independent physician groups that include time, scope, and geographic restrictions; and b) De
5 facto non-compete restrictions that allow employers to recoup recruiting incentives upon
6 contract termination.

7
8 • **Covenants Not to Compete D-265.988**
9

10 Our AMA will create a state restrictive covenant legislative template to assist state medical
11 associations, national medical specialty societies and physician members as they navigate the
12 intricacies of restrictive covenant policy at the state level.

13
14 **RECOMMENDATIONS**
15

16 The Board of Trustees recommends that the following policy be adopted, and the remainder of the
17 report be filed:

- 18
19 1. That the American Medical Association (AMA) continue to assist interested state
20 medical associations in developing fair and reasonable strategies regarding restrictive
21 covenants between physician employers and physician employees including regularly
22 updating the AMA's state restrictive covenant legislative template. (New HOD Policy)

Fiscal Note: Less than \$500

REFERENCES

- ¹ See <https://policysearch.ama-assn.org/policyfinder/detail/%2211.2.3.1%20Restrictive%20Covenants%22?uri=%2FAMADoc%2FEthics.xml-E-11.2.3.1.xml>
- ² Conn. Gen. Stat. § 20-14p
- ³ *Valley Medical Specialists v. Farber*, 982 P.2d 1277, 1281 (Ariz. 1999)
- ⁴ *Paradigm Health Sys., L.L.C. v. Faust*, 218 So. 3d 1068, 1071 (La.App. 1 Cir. 2017)
- ⁵ *Mohanty v. St. John Heart Clinic, S.C.*, 225 Ill. 2d 52, 77 (2006)
- ⁶ See e.g., NV Rev Stat § 613.195(6)(a) and (b)
- ⁷ See e.g., Conn. Gen. Stat. section 20-14p and W. Va. Code § 47-11E-2
- ⁸ For statutory examples, see IN Code § 25-22.5-5.5 and TX Bus & Com Code § 15.50
- ⁹ Tex. Bus. & Com. Code § 15.50
- ¹⁰ C.R.S. 8-2-113
- ¹¹ See <https://www.uniformlaws.org/committees/community-home/librarydocuments?communitykey=3a2538fb-e030-4e2d-a9e2-90373dc05792&LibraryFolderKey=&DefaultView=&5a583082-7c67-452b-9777-e4bdf7e1c729=eyJsaWJ5YXJ5ZmFkLTRjOGItODk3Yi1jYWE2ZjA4N2U4ZWmifQ%3D%3D>
- ¹² See e.g., *Total Care Physicians, P.A. v. O'Hara*, 798 A.2d 1043, 1054 (Del. Super. Ct. 2001)
- ¹³ Physician Access to Their Medical and Billing Records D-315.971
- ¹⁴ O.C.G.A. § 13-8-51
- ¹⁵ See e.g., W.Va. Code § 47-11E-3
- ¹⁶ *Brown v. TGS Mgmt. Co., LLC*, 57 Cal. App. 5th 303, 306, 319 (Cal. Ct. App. 2020); FTC Proposed Non-compete Rule, 88 F.R. 3482, 3509 (January 19, 2023) <https://www.govinfo.gov/content/pkg/FR-2023-01-19/pdf/2023-00414.pdf>
- ¹⁷ Minn. Stat. § 181.988
- ¹⁸ N.M. Stat. Ann. § 24-11-3
- ¹⁹ W.Va. Code § 47-11E-3
- ²⁰ FTC Proposed Non-compete Rule, 88 F.R. 3482, 3535 (January 19, 2023) <https://www.govinfo.gov/content/pkg/FR-2023-01-19/pdf/2023-00414.pdf>
- ²¹ See e.g., Harris, Jonathan, The New Non-compete: The Training Repayment Agreement Provision (TRAP) as a Scheme to Retain Workers through Debt (November 9, 2022). Northwestern University Law Review Of Note, Nov. 9, 2022, Loyola Law School, Los Angeles Legal Studies Research Paper No. 2022-15, Available at SSRN: <https://ssrn.com/abstract=4273728>

EXECUTIVE SUMMARY

While physicians receive extensive training in a chosen specialty during their medical residency, nurse practitioners and physician assistants do not specialize in a comparable way. Both nurse practitioners and physician assistants must graduate from an accredited program and pass a certification examination for licensure in most states. While didactic education and clinical training differs between the two professions, the education of both nurse practitioners and physician assistants is broadly focused, especially compared to that of a physician. Any focus on a specific specialty in formal training is limited. While some nurse practitioners and physician assistants may “specialize” by gaining certifications in a certain area, these additional certifications are earned by acquiring experience “on-the-job,” are optional upon completion of their formal training, and are separate from the initial certifications typically attained upon graduation.

Nurse practitioner programs do prepare students to provide care to a particular population as determined by the population focus selected by the students. Students choose one of six population foci—for example, family/individual, pediatrics, or psychiatric/mental health—to emphasize in their training. The chosen population focus typically determines the certification a nurse practitioner attains following graduation. As such, nurse practitioner programs vary based on the nurse practitioner’s chosen population foci and the primary certification they plan to attain. Importantly, however, the education around the population focus does not rise to the level of specialty training. Specialty training represents a “much more focused area of preparation and practice than does the APRN role/population focus level.”¹¹

On the other hand, physician assistant programs intentionally train physician assistants as “generalists,” not specialists. The physician assistant curriculum is largely the same for all physician assistant students. However, physician assistants can obtain Certificates of Added Qualifications (CAQs) post-graduation in certain specialties such as cardiovascular and thoracic surgery or emergency medicine. These CAQs are optional and require physician assistants to acquire work hours in the relevant specialty. Of note, CAQs are separate from the PA-C certification, which is the single certification offered to physician assistants who have graduated from an accredited program and passed the Physician Assistant National Certifying Examination.

A nurse practitioner or physician assistant’s certification is not always aligned with the specialty or setting in which they practice during their career. In fact, both can move between specialties throughout their career often with little to no additional education or training. Available data shows that an increasing number of nurse practitioners and physician assistants are practicing in specialties outside of primary care. However, there is no publicly available data on how often nurse practitioners change specialties and very little such data on physician assistants. Nevertheless, the flexibility to move between specialties is often touted as a “selling point” for prospective students.

This Board Report provides a summary of the underlying education and training of nurse practitioners and physician assistants, as well as an overview of initial certifications and optional specialty certifications available to each profession. The report also examines existing workforce studies and data on specialties and practice settings of nurse practitioners and physician assistants and the alignment of such to the certification of the respective nurse practitioner or physician assistant.

REPORT OF THE BOARD OF TRUSTEES

B of T Report 14-A-24

Subject: Physician Assistant and Nurse Practitioner Movement Between Specialties

Presented by: Willie Underwood, III, MD, MSc, MPH, Chair

Referred to: Reference Committee B

1 INTRODUCTION

2

3 At the 2023 Annual Meeting, the American Medical Association (AMA) House of Delegates
4 (HOD) adopted Resolution 239 entitled, “Physician Assistant and Nurse Practitioner Movement
5 Between Specialties.” This resolution asked the AMA to study the movement of nonphysician
6 health care professionals between specialties.

7

8 *Procedural History*

9

10 Resolution 239 was introduced by the Arizona delegation and asked:

11

12 That our American Medical Association Board of Trustees study and report back
13 at the 2023 Interim meeting on the economic impact to primary care and other
14 lower tier income medical specialties of specialty switching by Advanced
15 Practice Providers (Directive to Take Action); and

16

17 That our AMA Board of Trustees study and report back at the 2023 Interim
18 meeting about possible options on how APP’s can best be obligated to stay in a
19 specialty tract that is tied to the specialty area of their supervising physician in
20 much the same way their supervisory physicians are tied to their own specialty,
21 with an intent for the study to look at how the house of medicine can create
22 functional barriers that begin to make specialty switching by Advanced Practice
23 Providers appropriately demanding. (Directive to Take Action)

24

25 Similar in intent, Resolution 262 was introduced by the Private Practice Physicians Section and
26 asked:

27

28 That our American Medical Association create a national task force that will
29 make recommendations for the best process for advanced practice providers
30 (APPs) to develop specialty designations or an associated apprenticeship process
31 that is parallel to the specialties of the physicians that supervise them (Directive
32 to Take Action);

33

34 That our American Medical Association study and report back at Interim 2023 on
35 the economic impact to medical practices of specialty switching by advanced
36 practice providers (Directive to Take Action); and

1 That our American Medical Association study and report back at the 2023
2 Interim Meeting about possible options on how advanced practice providers can
3 best be obligated to stay in a specialty tract (Directive to Take Action).
4

5 Testimony on both of these Resolutions was limited. The Reference Committee heard that the
6 AMA does not have the authority or purview over post-graduate clinical training requirements of
7 nonphysicians and that the AMA has extensive resources detailing the education and training of
8 nurse practitioners and physician assistants. However, the Reference Committee also heard
9 testimony indicating that a growing number of nonphysicians are moving between specialties, and
10 that this is a concern for physicians.
11

12 Seeking to meet the underlying concerns raised in Resolutions 239 and 262, the Reference
13 Committee recommended that Resolution 239 be adopted with an amendment, and that the
14 amended Resolution 239 be adopted in lieu of Resolution 262. The HOD agreed and ultimately
15 adopted amended Resolution 239, which reads as follows:
16

17 That our American Medical Association study the movement of nonphysician
18 health care professionals such as physician assistants and nurse practitioners
19 between specialties.
20

21 This Board of Trustees Report aims to address this directive. It examines the educational
22 preparation of nurse practitioners and physician assistants and evaluates their ability to move
23 between specialties.
24

25 BACKGROUND

26

27 The implications of specialty switching by nurse practitioners and physician assistants are best
28 understood when one considers the underlying education, training, and certification of each
29 profession.
30

31 *Nurse Practitioner Education and Training*

32

33 Nurse practitioners are one type of Advanced Practice Registered Nurse (APRN). While the focus
34 of this board report is on nurse practitioner and physician assistant certification, the foundational
35 documents for nurse practitioner education include APRNs in four types of “roles:” nurse
36 practitioners, clinical nurse specialists, certified nurse midwives, and certified registered nurse
37 anesthetists (CRNAs). Each type of APRN has its own accreditation and certifying bodies. For
38 example, CRNA programs are accredited by the Council on Accreditation of Nurse Anesthesia
39 Education Programs (COA) and CRNAs can obtain certification from the National Board of
40 Certification and Recertification for Nurse Anesthetists (NBCRNA). By contrast, the Commission
41 on Collegiate Nursing Education (CCNE) and the Accreditation Commission for Education in
42 Nursing (ACEN) both accredit nurse practitioner programs, and nurse practitioners may be
43 certified by one of several different certifying bodies.
44

45 APRN education and training is based on foundational documents that were drafted and agreed to
46 by leaders in the nursing profession:
47

- 48 • Two American Association of Colleges of Nursing (AACN) “Essentials” documents: *The*
49 *Essentials of Master’s Education in Nursing (2011)* and *The Essentials of Doctoral*
50 *Education for Advanced Nursing Practice (2006)* (together, the *AACN Essentials*).

- 1 • The National Task Force on Quality Nurse Practitioner Education’s *2016 Criteria for*
2 *Evaluation of Nurse Practitioner Programs (NTF Standards)*.
- 3 • The Consensus Model for APRN Regulation: Licensure, Accreditation, Certification &
4 Education (APRN Consensus Model).

5
6 Taken together, these documents provide the framework for the curriculum and accreditation of
7 nurse practitioner graduate education programs.

8
9 What is referred to as the “APRN Consensus Model” also provides a model for APRN regulation
10 and certification. The APRN Consensus Model is the basis for the four distinct roles of APRNs and
11 the six-population foci that are foundational to APRN education and training:

- 12
- 13 • Family/individual across the lifespan;
- 14 • Adult-gerontology;
- 15 • Pediatrics;
- 16 • Neonatal;
- 17 • Women’s health/gender-related; and
- 18 • Psychiatric/mental health.

19
20 A nurse practitioner’s specific educational experience will depend on their chosen population
21 focus, and so will their certification. The APRN Consensus Model states that, “[e]ducation,
22 certification, and licensure of an individual must be congruent in terms of role and population
23 foci.”ⁱⁱ As such, distinct certifications—which are generally required for licensure—were created
24 for each population focus, and in some cases for primary care as distinct from acute care. Each
25 certification is aligned with a different educational track. In short, it is expected that a nurse
26 practitioner’s education and training will be based on the certification they plan to attain after
27 graduation. Consequentially, nurse practitioner programs vary slightly based on the nurse
28 practitioner’s chosen population foci and the certification they plan to attain. Each certification has
29 a somewhat different educational pathway, but all nurse practitioners must meet the same core
30 academic requirements. The APRN Consensus Model provides the required “APRN core” courses
31 included in the curriculum for all nurse practitioners (and all APRNs):

- 32
- 33 • Physiology/pathophysiology;
- 34 • Health assessment; and
- 35 • Pharmacology.ⁱⁱⁱ

36
37 Specialty training, by contrast, represents a “much more focused area of preparation and practice
38 than does the APRN role/population focus level.”^{iv}

39
40 Across all population foci, nurse practitioner clinical training requirements are largely not
41 standardized, in sharp contrast to physician clerkships and residencies. Nurse practitioners only
42 undergo 500-750 hours of clinical training. This results in evident experience gaps. For example,
43 even though some of the nurse practitioner certifications broadly span patient populations,
44 including across the lifespan from children to geriatric patients, studies on nurse practitioner
45 education have documented that family nurse practitioners (FNPs) often receive minimal training
46 across patient populations.

47
48 Notably, a study in the *Journal of Nursing Regulation* surveyed recent FNP graduates on how often
49 they performed basic tasks like prescribing medications, obtaining a health history, ordering

1 diagnostic tests, and developing differential diagnoses during their entire training.^v The survey also
2 examined these tasks across patient populations, providing a window into how the FNP education
3 and training prepares students for practice. The results were shocking. For example, only
4 61.5 percent of FNPs reported they prescribed medications to an adult patient more than 10 times,
5 15 percent said they only prescribed medications to an adult patient one to two times.^{vi} The
6 numbers were even lower for pediatric and geriatric patients. Only 44.6 percent and 56.3 percent of
7 FNP students surveyed said they prescribed medications more than 10 times to a pediatric patient
8 and geriatric patient respectively, with 5.5 percent and 4.0 percent of FNP students indicating they
9 *never* prescribed medications to pediatric or geriatric patients respectively during their clinical
10 training.^{vii} This study demonstrates the lack of standardization in nurse practitioner training
11 programs. Yet, FNPs often practice across patient populations and increasingly in specialties
12 outside primary care.

13

14 *Nurse Practitioner Certification*

15

16 For initial certification of nurse practitioners, two major certifying bodies exist: the American
17 Academy of Nurse Practitioners Certification Board (AANPCB) and the American Nurses
18 Credentialing Center (ANCC).^{viii} Each certifying body administers their own examination and
19 offers their own certifications. Both AANPCB and ANCC require nurse practitioners to renew their
20 certification every five years. Most states require certification for licensure as a nurse practitioner,
21 and certification exams are generally aligned with population foci.

22

23 The AANPCB offers three initial certifications: Family Nurse Practitioner (FNP), Adult-
24 Gerontology Primary Care Nurse Practitioner (A-GNP), and Psychiatric Mental Health Nurse
25 Practitioner (PMHNP).^{ix} AANPCB's FNP examination is an online examination with 150 multiple
26 choice questions, which must be completed in three-hours. In 2021 the pass rate was 84 percent.
27 AANPCB has retired a couple of certifications, including the Adult Nurse Practitioner (retired in
28 2017) and Gerontology Nurse Practitioner (retired in 2012). Nurse practitioners who obtained these
29 retired certifications can maintain the credential as long as they continue to renew their certification
30 by completing the required clinical practice hours and continuing education.

31

32 ANCC offers four certifications for nurse practitioners: Family Nurse Practitioner (FNP-BC),
33 Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP-BC), Adult-Gerontology Acute
34 Care Nurse Practitioner (AGACNP-BC), and Psychiatric Mental Health Nurse Practitioner
35 (PMHNP-BC). ANCC's FNP-BC certifying examination includes 150-200 questions that vary in
36 format from multiple choice, drop and drag, and multiple response. The average pass rate in
37 2021 was 87 percent. ANCC also offers certifications for registered nurses, as well as micro-
38 credentials in certain sub-specialties. ANCC has also retired several certifications, including Acute
39 Care Nurse Practitioner, Adult Nurse Practitioner, Adult-Psychiatric Mental Health Nurse
40 Practitioner, Emergency Nurse Practitioner, Gerontological Nurse Practitioner, Pediatric Primary
41 Care Nurse Practitioner, and School Nurse Practitioner. Like the retired certifications offered by
42 AANPCB, nurse practitioners may renew these ANCC retired certifications to maintain their
43 credential.^x

	American Academy of Nurse Practitioners Certification Board (AANPCB)	American Nurses Credentialing Center (ANCC)
Current certifications	Family Nurse Practitioner (FNP) Adult-Gerontology Primary Care Nurse Practitioner (A-GNP) Psychiatric Mental Health Nurse Practitioner (PMHNP)	Family Nurse Practitioner (FNP-BC) Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP-BC) Adult-Gerontology Acute Care Nurse Practitioner (AGACNP-BC) Psychiatric Mental Health Nurse Practitioner (PMHNP-BC)
Retired certifications	Adult NP (retired) Gerontology NP (retired)	Acute Care NP (retired) Adult NP (retired) Adult-Psychiatric Mental Health NP (retired) Emergency NP (retired) Gerontological NP (retired) Pediatric Primary Care NP (retired) School NP (retired)

1 While AANPCB and ANCC are the largest certifying bodies for nurse practitioners, other smaller
 2 certification bodies exist, including the American Association of Critical-Care Nurses (AACN),
 3 National Certification Corporation (NCC), Pediatric Certification Board (PNCB), Certification
 4 Board for Urological Nurses & Associates (CBUNA), and Hospice & Palliative Credentialing
 5 Center (HPCC).

6

7 *Nurse Practitioner Specialties*

8

9 Under the APRN Consensus Model, advanced practice registered nurses are licensed at the level of
 10 the population focus—not at the specialty level.^{xi} Advanced practice registered nurses cannot be
 11 licensed solely within a specialty area.^{xii} Regarding specialties, the APRN Consensus Model notes
 12 that specialties are optional but must be congruent with and build on the individual’s established
 13 role and population foci.

14

15 Nurse practitioners may pursue optional certification in various specialties/subspecialties after
 16 initial certification in their role and population focus. An array of certifying boards issue
 17 “specialty” certifications for nurse practitioners—typically these certifications are based on hours
 18 of practice experience in a specialty and passage of an exam. Customarily, the certifying boards are
 19 specific to nursing and specific to a single specialty. For example, the Orthopaedic Nurses
 20 Certification Board certifies nurse practitioners in the orthopaedic specialty (ONP-C) and the
 21 Dermatology Nurses Association certifies dermatology nurse practitioners (DCNPs). However,
 22 AANPCB offers an Emergency Nurse Practitioner (ENP) certification for certified FNPs with
 23 specialty education and practice in emergency care.

24

25 Note that specialty certification is generally not required for practice within a given specialty—
 26 indeed, work within a specific specialty is required to earn specialty certification.

27

28 *Nurse Practitioner Workforce*

29

30 Nurse practitioners are not required to practice within the specialty in which they are certified, and
 31 so there is great misalignment between nurse practitioner certification and the setting or specialty
 32 in which they practice. The APRN Consensus Model attempts to align the nurse practitioner
 33 curriculum with the certification a nurse practitioner can attain after graduation, however, a nurse

1 practitioner’s certification is not always congruent with the specialty or setting in which the nurse
 2 practitioner practices during their career. Myriad data sources confirm this misalignment. For
 3 example, the American Association of Nurse Practitioners (AANP) claims that 88 percent of nurse
 4 practitioners are certified in primary care, but also reports that only 70.3 percent of nurse
 5 practitioners deliver primary care. The most recent Health Resources and Services Administration
 6 (HRSA) workforce data suggests a greater disparity, reflecting that only 24 percent of nurse
 7 practitioners deliver primary care.^{xiii}

8
 9 HRSA’s findings are consistent with several state-level workforce studies, including the following:

- 10
 11 • A study from the Oregon Center for Nursing examined the number of nurse practitioners
 12 practicing in primary compared to specialty care in Oregon. Looking at practice setting and
 13 area of practice, data from the survey revealed that only one-third of nurse practitioners
 14 practice in primary care and about 22 percent provided a combination of primary and
 15 specialty care. Of those nurse practitioners providing both primary and specialty care,
 16 about 62 percent spent less than half of their time focusing on primary care.^{xiv} The study
 17 found that the gap between nurse practitioners providing primary care versus specialty care
 18 is widening over time, with a greater number of nurse practitioners providing specialty care
 19 and fewer nurse practitioners providing primary care. It concluded that certification alone
 20 is not enough to determine one’s area of practice.
- 21 • Adding to this body of evidence is *A Profile of New York State Nurse Practitioners, 2017*,
 22 a workforce report in which only about *one-third* of actively practicing nurse practitioners
 23 were considered primary care nurse practitioners based on their specialty certification and
 24 practice setting, even though a vast majority of nurse practitioners in the state report a
 25 primary care specialty certification. To indicate, 87 percent of nurse practitioners reported
 26 a certification in primary care (36.8 percent in family health, 23.2 percent in adult health,
 27 8.1 percent in pediatrics).^{xv}
- 28 • A *2023 South Dakota Workforce Study* had similar findings.^{xvi} Based on data gathered
 29 from nurse license renewal applications, including nurses who renewed their license,
 30 reactivated an inactive license, or reinstated a lapsed license, 80.9 percent indicated they
 31 were licensed and certified as family nurse practitioners yet only 24.9 percent identified
 32 “family health” as their primary area of specialty, 5.1 percent chose “primary care”, and
 33 6 percent chose adult health.^{xvii} Other notable specialties selected include “other”
 34 (11.6 percent), psychiatric/mental health/substance abuse (8.2 percent), acute/critical care
 35 (7.3 percent), cardiology (4.2 percent), and emergency/trauma (3.5 percent).^{xviii}

36
 37 Studies also elucidate lack of congruence between nurse practitioners’ certification and their
 38 practice in acute care settings.^{xix} As noted earlier, some certifications distinguish between primary
 39 and acute care—and this distinction is ostensibly reflected in the nurse practitioner’s educational
 40 track. Yet, many nurse practitioners are certified in primary care work in an acute care practice
 41 specialty or setting.

42
 43 A study published in *Nursing Outlook* using data from HRSA’s 2018 National Sample Survey of
 44 Registered Nurses found that among nurse practitioners working in acute care settings, only
 45 44.5 percent held a certification in acute care, while 55.5 percent held only a primary care
 46 certification (13.7 percent held both acute care and primary care certifications). Notably, only about
 47 half of nurse practitioners working in acute care reported that they feel prepared to be an
 48 independent practitioner.^{xx}

1 Below are findings by clinical specialty area in which the respondents worked:

	Acute Care Certified (N = 8,256)	Primary Care Certified (N = 10,297)
Total	44.5%	55.5%
Clinical Specialty		
General medical surgical	27.5%	37.6%
Critical care	23.5%	25.3%
Chronic Care	30.0%	10.6%
Neurological	6.4%	7.0%
Oncology	5.0%	9.2%
Other	7.6%	10.3%

*from Nursing Outlook $p < .01$

2 These findings were consistent with other studies examining the misalignment between nurse
 3 practitioners' credentials and their practice setting. For example, using data from the AANP
 4 National Nurse Practitioner Sample Survey, researchers found that of the 366 nurse practitioners
 5 who responded they were a hospitalist caring for adult patients (i.e., in an acute care setting),
 6 74.7 percent were certified in primary care—with a full 75 percent indicating “on-the-job training”
 7 as their qualification to be a nurse practitioner hospitalist.^{xxi}

8
 9 Similarly, while emergency departments are for acute-life or limb threatening emergencies and
 10 providing care to critically ill patients, most nurse practitioners working in emergency departments
 11 are certified as an FNP. In fact, while there is a separate specialty certification for emergency nurse
 12 practitioners (ENPs), only FNPs are eligible for such certification—not acute care nurse
 13 practitioners, even though emergency departments are acute care settings. Moreover, 90 percent of
 14 nurse practitioners practicing in emergency departments do not have the ENP additional specialty
 15 certification.^{xxii}

16
 17 Altogether, education and certification are not determinative of where a nurse practitioner will
 18 practice—workforce studies show that nurse practitioners commonly practice in clinical settings or
 19 specialties that are misaligned with, their education, training, and credentials.

20
 21 *Specialty Switching by Nurse Practitioners*
 22

23 Nurse practitioners may switch specialties throughout their career with few limitations, with the
 24 primary limitation being that, per the APRN Consensus Model, a nurse practitioner's specialty
 25 must align with the population focus of the nurse practitioner's training, as well as their
 26 certification. For some nurse practitioners this provides broad latitude in mid-career changes. For
 27 example, FNPs are trained to provide primary care across the lifespan and so would qualify for a
 28 broad range of specialties. By contrast, an adult-gerontology primary care nurse practitioner (AG-
 29 PCNP) might be more limited. For example, an AG-PCNP would likely have to complete
 30 additional training to care for children, or to care for adult or geriatric patients outside primary
 31 care.^{xxiii}

32
 33 *Physician Assistant Education and Training*
 34

35 Physician assistant programs are accredited by the Accreditation Review Commission on
 36 Education for the Physician Assistant (ARC-PA) and are two-to-three years in length. Physician

1 assistant programs provide a generalist education rather than focus on a particular specialty.^{xxiv} Per
2 the standards, program curriculum must include, “applied medical, behavioral and social sciences;
3 patient assessment and clinical medicine; *supervised clinical practice*; and health policy and
4 professional practice issues.”^{xxv} Upon completion of the program graduates are awarded a master’s
5 degree and become eligible to sit for the physician assistant certification examination.

6 7 *Physician Assistant Certification*

8
9 A single body certifies physician assistants: the National Commission on Certification of Physician
10 Assistants (NCCPA). Certification is available to physician assistants who graduate from an ARC-
11 PA accredited program and pass the Physician Assistant National Certifying Examination.
12 Physician assistants are eligible to take the examination up to six-years after graduation and those
13 who pass are awarded the PA-C credential. To maintain certification, physician assistants must
14 complete a minimum number of hours of continuing medical education (CME) and pass the
15 Physician Assistant National Recertifying Examination (PANRE) every 10 years. Most states
16 require completion of a minimum number of hours of CME, current certification by NCCPA, or
17 both as a condition of licensure or for licensure renewal.

18
19 The single certification for physician assistants is consistent with the approach for physician
20 assistant education and training—to provide a generalist education without a focus on specialty.
21 This is evident in both the didactic curriculum and clinical training of physician assistants. For
22 example, the 2,000 hours of clinical practice required of physician assistants includes rotations in
23 various specialties, including emergency medicine, obstetrics and gynecology, psychiatry, family
24 medicine, and internal medicine. Standards also include requirements that these clinical rotations
25 must include specific types of encounters. For example, physician assistant students must treat
26 patients requiring chronic, acute, emergent, and preventive care and must also provide care in a
27 variety of settings, including the emergency department, outpatient, and inpatient facilities. There
28 is no path for specialized focus in the physician assistant educational program.

29
30 In addition to the PA-C certification, NCCPA also offers optional specialty Certificates of Added
31 Qualification (CAQs) to physician assistants in 10 specialties, including:

- 32
33
- 34 • Cardiovascular & Thoracic Surgery;
 - 35 • Dermatology;
 - 36 • Emergency Medicine;
 - 37 • Hospital Medicine;
 - 38 • Nephrology;
 - 39 • Obstetrics and Gynecology;
 - 40 • Orthopaedic Surgery;
 - 41 • Palliative Medicine and Hospice Care;
 - 42 • Pediatrics; and
 - 43 • Psychiatry.^{xxvi}

44 A physician assistant who has acquired a CAQ is considered “board certified.” The specific
45 requirements vary by specialty but generally require the following: (1) completion of specialty-
46 specific CME, (2) attestation that the physician assistant has completed a certain number of hours
47 of experience in the specialty, (3) attestation that the physician assistant has the knowledge and
48 skills relevant to practice in the specialty, including the knowledge and skills to perform the
49 procedures relevant to the specialty, and/or that the physician assistant understands how and when

1 the knowledge and skills should be applied for appropriate patient management or how and when
2 the procedures should be performed, and (4) achieve a passing score on a specialty examination
3 (online or in person).

4
5 CAQs often rely heavily on attestations and may not actually require the physician assistant to
6 complete relevant procedures. Consider as an example the requirements to attain a CAQ in
7 emergency medicine:

- 8
- 9 • Self-attest to completing 75 credits of Category 1 CME focused on emergency medicine;
10 25 of which must be earned within two-years of the date of the application for the specialty
11 examination and the remaining earned within six years before this date.
 - 12 • Complete a comprehensive emergency medicine course that reflects the guidelines set forth
13 in the most current version of Model of the Clinical Practice of Emergency Medicine, and
14 complete the following courses:
 - 15 ○ Pediatric Advanced Life Support or Advanced Pediatric Life Support
 - 16 ○ Advanced Trauma Life Support
 - 17 ○ Airway course
 - 18 • Self-attest to completing 3,000 hours of experience working as a physician assistant in
19 emergency medicine within at least six-years.
 - 20 • Obtain attestation from a physician, lead/senior physician assistant, or physician/physician
21 assistant post graduate program director who works in emergency medicine and is familiar
22 with the physician assistant's practice and experience. The attestation must affirm that the
23 physician assistant, "*has performed* the procedures and patient management relevant to the
24 practice setting and/or *understands* how and when the procedures *should* be
25 performed...the PA may not have experience with each procedure, but he or she must be
26 knowledgeable of the basics of the procedures, in what situation the procedures should be
27 done, and the associated management of patients."^{xxvii}
 - 28 • Pass an examination which consists of 120 multiple choice questions, which can be taken
29 at a test center or online.
- 30

31 CAQs are wholly optional for physician assistants and are generally not required for physician
32 assistants to practice. Indeed, before earning and in order to earn a CAQ in the first instance, a
33 physician assistant must practice in a chosen specialty.

34 *Physician Assistant Workforce*

35
36
37 According to the NCCPA 2022 statistical profile of board-certified physician assistants, only 23.1
38 percent of physician assistants work in primary care, which includes "family medicine/general
39 practice, internal medicine general, and pediatrics general." When asked to identify their primary
40 area of practice, the most physician assistants reported working in the five specialties:

- 41
- 42 • Surgical subspecialties (18.6 percent);
 - 43 • Family medicine/general practice (17.1 percent);
 - 44 • Emergency medicine (11.2 percent);
 - 45 • Other (10.6 percent; *note that the most frequent responses include: urgent care,
46 interventional radiology, sleep medicine, aesthetics, trauma surgery, wound care, and
47 transplant surgery); and
 - 48 • Internal medicine subspecialties (9.9 percent).

1 Most physician assistants practice in hospital settings (41.7 percent) with office-based private
2 practice a close second (37.1 percent). Urgent care (5.6 percent) and federal government
3 facility/hospital/unit (4.7 percent) are a distant fourth and fifth.

4
5 While most physician assistants hold one clinical position (84.9 percent), 11.3 percent of physician
6 assistants hold two or more clinical positions, with emergency medicine (25.6 percent) being the
7 most common secondary specialty area of these physician assistants.

8 9 *Specialty Switching by Physician Assistants*

10
11 Since physician assistants are trained as “generalists,” they face very few barriers to specialty
12 switching. Indeed, more than half have changed specialties at least once during their career with
13 over 20 percent indicating they have changed specialties two to three times.^{xxviii} This can be done
14 without any additional education, formal training, or certification.

15 16 AMA POLICY

17
18 The AMA has extensive policy supporting physician-led team-based care, including policy on
19 appropriate physician supervision of nurse practitioners and physician assistants:

- 20
21
- 22 • Policy H-160.949, “Practicing Medicine by Non-Physicians;”
 - 23 • Policy H-160-906, “Models /Guidelines for Medical Health Care Teams;”
 - 24 • Policy H-160.950, “Guidelines for Integrated Practice of Physician and Nurse
25 Practitioner;”
 - 26 • Policy H-360.987, “Principles Guiding AMA Policy Regarding Supervision of Medical
27 Care Delivered by Advanced Practice Nurses in Integrated Practice;”
 - 28 • Policy H-35.989, “Physician Assistants;” and
 - 29 • Policy D-35.985 “Support for Physician Led, Team Based Care.”

30 The AMA also has policy directing our AMA to educate the public on the difference in the
31 education and training of physicians and non-physicians. Specifically:

- 32
- 33 • Policy H-160.949, “Practicing Medicine by Non-Physicians;”
 - 34 • Policy H-450.955, “Education of the General Public on the Role of Physician and Non-
35 Physician Health Care Providers;” and
 - 36 • Policy H-275.943, “Public Education about Physician Qualifications.”

37 38 DISCUSSION

39
40 The nurse practitioner and physician assistant professions both began with an emphasis on
41 providing primary care to patients to help address the primary care workforce shortages. Over time,
42 however, both nurse practitioners and physician assistants are increasingly choosing to practice in
43 specialties instead of primary care and may switch specialties multiple times during their career.
44 The idea of specialty switching by nurse practitioners and physician assistants is not a new
45 phenomenon and such flexibility in specialization is often touted by both professions as a positive
46 attribute to prospective students.

47
48 The underlying education and clinical training of both nurse practitioners and physician assistants
49 is founded upon a generalist approach. With limited exceptions, there is no focus on specialty care.

1 While state licensure requires graduation from an accredited program and certification by a
2 designated body, physician assistant certification and most nurse practitioner certifications are
3 extremely broad, allowing wide latitude in the patient population, specialty or setting in which they
4 can practice.

5
6 Moreover, there are little-to-no guardrails limiting the specialties in which nurse practitioners and
7 physician assistants may work. In fact, many studies show a misalignment between nurse
8 practitioner education, training, and certification and the specialty or setting in which they practice,
9 such that some nurse practitioners find themselves in the position of caring for a patient population
10 or level of acuity in which they have received no formal education or training. For both
11 professions, on-the-job training post-graduation is a common means to gain the requisite
12 knowledge in the specialty and practice setting in which they practice. This reinforces the
13 importance of physician-led team-based care.

14
15 While studies demonstrate the increased number of nurse practitioners and physician assistants
16 practicing in specialties as opposed to primary care, there is no publicly available data on specialty
17 switching by nurse practitioners. There are also no studies on the impact of specialty switching on
18 the cost and quality of care provided by nurse practitioners and physician assistants. Moreover,
19 there are no studies on the additional workload placed on physicians and other health care
20 professionals who must provide on-the-job training to nurse practitioners or physician assistants
21 who have switched specialties and/or are practicing in a specialty in which they have no formal
22 education, training, or certification. Moreover, there are no studies looking at the impact of
23 specialty switching in these professions on physician burnout, nor are there studies that look at the
24 impact on physician's time away from providing direct patient care. These gaps in literature are
25 ripe for analysis, particularly by those conducting research on the health care workforce. State
26 nursing and medical boards could also capture this information as part of a survey conducted at the
27 time of licensure renewals by nurse practitioners and physician assistants.

28 29 RECOMMENDATIONS

30
31 The Board of Trustees recommends that the following policy be adopted, and the remainder of the
32 report be filed:

- 33
34 1. That the American Medical Association (AMA) support workforce research, including
35 surveys by state medical and nursing boards, that specifically focus on gathering
36 information on nurse practitioners and physician assistants practicing in specialty care,
37 their certification(s), alignment of their certification to their specialty, and whether they
38 have switched specialties during their career. (New HOD Policy)
- 39 2. That the AMA support research that evaluates the impact of specialty switching by nurse
40 practitioners and physician assistants on the cost and quality of patient care. (New HOD
41 Policy)
- 42 3. That the AMA encourage hospitals and other health care entities employing nurse
43 practitioners to ensure that the nurse practitioner's certification aligns with the specialty in
44 which they will practice. (New HOD Policy)
- 45 4. That the AMA continue educating policymakers and lawmakers on the education, training,
46 and certification of nurse practitioners and physician assistants, including the concept of
47 specialty switching. (New HOD Policy)

Fiscal Note: Less than \$500.

REFERENCES

- ⁱ Consensus Model for APRN Regulation: Licensure, Accreditation, Certification & Education (July 7, 2008) pg. 12.
- ⁱⁱ *Id.* at 6.
- ⁱⁱⁱ *Id.* at 11.
- ^{iv} *Id.* at 12.
- ^v McNelis AM, Dreifuerst T, Beebe S, et al. Types, Frequency, and Depth of Direct Patient Care Experiences of Family Nurse Practitioner Students in the United States, *Journal of Nursing Regulation*, 2021; 12(1), 19-27.
- ^{vi} *Id.* at 25.
- ^{vii} *Id.*
- ^{viii} Other certifying bodies include: the American Association of Critical-Care Nurses (offers certification to RNs and APRNs),
- ^{ix} PMHNP is a new certification which will be available from AANPCB in January 2024.
- ^x <https://www.nursingworld.org/certification/aprn-consensus-model/> (last visited on Jan. 23, 2024).
- ^{xi} *Supra* note 1 at 13.
- ^{xii} *Id.* at 6
- ^{xiii} Health Resources and Services Administration. (2018). NCHWA Nursing Workforce Dashboard based on data form the 2018 National Sample Survey of Registered Nurses, which include Nurse Practitioners. <https://data.hrsa.gov/topics/health-workforce/nursing-workforce-dashboards>
- ^{xiv} Oregon Center for Nursing. Primary Care Workforce Crisis Looming in Oregon: Nurse Practitioners Vital to Filling the Gap, But Not Enough to Go Around. Portland, OR, Oregon Center for Nursing. 2020.
- ^{xv} Martiniano R, Wang S, Moore J. A Profile of New York State Nurse Practitioners, 2017. Center for Health Workforce Studies, School of Public Health, SUNY Albany. Oct. 2017.
- ^{xvi} South Dakota Center for Nursing Workforce. South Dakota Nursing Workforce: 2023 Supply and Employment Characteristics. April 8, 2023.
- ^{xvii} *Id.*
- ^{xviii} *Id.*
- ^{xix} Hoyt A, O'Reilly-Jacob M, & Souris-Kraemer M. (2022, May/June). Certification alignment of nurse practitioners in acute care. *Nursing Outlook*, 70(3), 417-428.
- ^{xx} *Id.*
- ^{xxi} Kaplan L, Klein T. Characteristics and perceptions of the US nurse practitioner hospitalist workforce. *Journal of the American Association of Nurse Practitioners* 33(12):p 1173-1179, December 2021.
- ^{xxii} Lavin RP, Veenema TG, Sasnett L, Schneider-Firestone S, et al. Analysis of Nurse Practitioners' Educational Preparation, Credentialing, and Scope of Practice in U.S. Emergency Departments, *Journal of Nursing Regulation*, Jan. 2022.
- ^{xxiii} Type of Nurse Practitioner Specialties, <https://www.nursingworld.org/practice-policy/workforce/what-is-nursing/types-of-nurse-practitioner-specialties/>. accessed Feb. 19, 2024.
- ^{xxiv} Dunker A, Krofah E, Isasi F. The Role of Physician Assistants in Health Care Delivery (Washington, D.C.: National Governor's Association Center for Best Practices, September 22, 2014).
- ^{xxv} ARC-PA *Accreditation Standards for Physician Assistant Education*, Fifth Edition, Effective Sept. 1, 2020.
- ^{xxvi} NCCPA. Specialty Certificates of Added Qualifications (CAQs). <https://www.nccpa.net/specialty-certificates/>
- ^{xxvii} *Id.* <https://www.nccpa.net/specialty-certificates/#emergency-medicine>
- ^{xxviii} NCCPA Statistical Profile of Board Certified PAs, Annual Report. 2022, p. 38.

REPORT 15 OF THE BOARD OF TRUSTEES (A-24)
Augmented Intelligence Development, Deployment, and Use in Health Care
(Resolution 247-A-23) (Resolution 206-I-23)
(Reference Committee B)

EXECUTIVE SUMMARY

At the June 2023 Annual Meeting, the American Medical Association (AMA) House of Delegates (HOD) adopted policy [H-480-935](#), “Assessing the Potentially Dangerous Intersection Between AI and Misinformation.” This policy calls on the AMA to “study and develop recommendations on the benefits and unforeseen consequences to the medical profession of large language models (LLM) such as, generative pretrained transformers (GPTs), and other augmented intelligence-generated medical advice or content, and that our AMA propose appropriate state and federal regulations with a report back at A-24.” This policy reflects the intense interest and activity in augmented intelligence (AI) prompted by the arrival of OpenAI’s ChatGPT and other LLMs/generative AI.

Additionally, at the November 2023 Interim Meeting, the AMA HOD referred Resolution 206-I-23, “The Influence of Large Language Models (LLMs) on Health Policy Formation and Scope of Practice.” Resolution 206-I-23 asked, “that our American Medical Association encourage physicians to educate our patients, the public, and policymakers about the benefits and risks of facing LLMs including GPTs for advice on health policy, information on health care issues influencing the legislative and regulatory process, and for information on scope of practice that may influence decisions by patients and policymakers.”

Generative AI is a type of AI that can recognize, summarize, translate, predict, and generate text and other content based on knowledge gained from large datasets. There has been increasing discussion about clinical applications of generative AI, including use as clinical decision support to provide differential diagnoses, early detection and intervention, and to assist in treatment planning. Generative AI tools are also being developed to assist with administrative functions, such as generating office notes, responding to documentation requests, and generating patient messages. While generative AI tools show tremendous promise to make a significant contribution to health care, there are a number of risks and limitations to consider when using these tools in a clinical setting or for direct patient care.

As the number of AI-enabled health care tools and systems continues to grow, these technologies must be designed, developed, and deployed in a manner that is ethical, equitable, responsible, and transparent. With a lagging effort towards adoption of national governance policies or oversight of AI, it is critical that the AMA and the physician community engage in the development of policies to help inform patient and physician education, help guide development of these tools in a way that best meets both patient and physician needs, and advocate for governance policies to help ensure that risks arising from AI are mitigated to the greatest extent possible.

This report highlights the AMA’s recognition of the issues raised at both the A-23 and I-23 HOD meetings, introduces and explains major themes of the report’s recommendations, and provides background information on the evolution of AI policy in health care and the direction that policy appears to be headed.

REPORT OF THE BOARD OF TRUSTEES

B of T Report 15-A-24

Subject: Augmented Intelligence Development, Deployment, and Use in Health Care
(Res. 247-A-23) Assessing the Potentially Dangerous Intersection Between AI
and Misinformation
(Res. 206-I-23) The Influence of Large Language Models (LLMs) on Health
Policy Formation and Scope of Practice

Presented by: Willie Underwood, III, MD, MSc, MPH, Chair

Referred to: Reference Committee B

1 INTRODUCTION

2
3 At the 2023 Annual Meeting, the American Medical Association (AMA) House of Delegates
4 (HOD) adopted policy [H-480-935](#), “Assessing the Potentially Dangerous Intersection Between AI
5 and Misinformation.” This policy calls on the AMA to “study and develop recommendations on
6 the benefits and unforeseen consequences to the medical profession of large language models
7 (LLM) such as, generative pretrained transformers (GPTs), and other augmented intelligence-
8 generated medical advice or content, and that our AMA propose appropriate state and federal
9 regulations with a report back at A-24.” This policy reflects the intense interest and activity in
10 augmented intelligence (AI) prompted by the arrival of OpenAI’s ChatGPT and other
11 LLMs/generative AI.

12
13 Additionally, at the 2023 Interim Meeting, the AMA HOD referred Resolution 206-I-23, “The
14 Influence of Large Language Models (LLMs) on Health Policy Formation and Scope of
15 Practice.” Resolution 206-I-23 asked, “that our American Medical Association encourage
16 physicians to educate our patients, the public, and policymakers about the benefits and risks of
17 facing LLMs including GPTs for advice on health policy, information on health care issues
18 influencing the legislative and regulatory process, and for information on scope of practice that
19 may influence decisions by patients and policymakers.”

20
21 Testimony on Resolution 206-I-23 highlighted the importance of physician understanding of
22 LLMs and the ability to weigh the benefits and risks of these tools as the excitement and
23 eagerness to implement them in everyday practice increases. Testimony emphasized that our
24 AMA is currently in the process of fulfilling the directive in Policy H-480-935 (adopted at A-23)
25 that directs our AMA to study and develop recommendations on the benefits and unforeseen
26 consequences to the medical profession of LLMs, such as GPTs, and other augmented
27 intelligence-generated medical advice or content. The HOD referred Resolution 206 so that the
28 issues raised in this resolution could be considered along with the issues in Policy H-480.935.

29
30 BACKGROUND

31
32 The issue of AI first presented itself as an area of potential interest to AMA physicians and
33 medical students that necessitated creation of AMA policy in 2018. At that time, physicians and
34 medical students primarily considered AI-enabled technologies within the context of medical

1 device and clinical decision support (CDS), although administrative applications of AI began to
2 grow exponentially and started to gain traction in the hospital, health system, and insurer space.
3 Since the development of the AMA’s foundational AI policy in 2018 and subsequent policy on
4 coverage and payment for AI in 2019, the number of AI-enabled medical devices approved by the
5 U.S. Food and Drug Administration (FDA) has grown to nearly 700. In 2022, the concept of
6 “generative AI” and what it can do became better understood to the public. Generative AI is a
7 broad term used to describe any type of artificial intelligence that can be used to create new text,
8 images, video, audio, code, or synthetic data. Generative AI and LLMs have rapidly transformed
9 the use cases and policy considerations for AI within health care, necessitating updated AMA
10 policy that reflects the rapidly evolving state of the technologies.

11
12 AMA policy adopted in [2018](#) and [2019](#) enabled the AMA to be a strong advocate on behalf of
13 patients and physicians and has been the bedrock of AMA’s advocacy on AI in the form of
14 lobbying key congressional committees, participating in expert panel discussions, creating
15 educational resources, and working with our Federation colleagues at the federal and state levels.
16 However, as AI has rapidly developed beyond AI-enabled medical devices and into
17 LLMs/generative AI, new policy and guidance are needed to ensure that they are designed,
18 developed, and deployed in a manner that is ethical, equitable, responsible, and transparent.

19
20 As an initial step, in November 2023, the AMA Board of Trustees approved a set of [advocacy](#)
21 [principles](#) developed by the Council on Legislation (COL) that serve as the framework of this
22 Board report. The main topics addressed in the principles include AI oversight, disclosure
23 requirements, liability, data privacy and security, and payor use of AI. In addition to the COL,
24 these principles have been vetted among multiple AMA business units, and AMA staff has
25 worked with several medical specialty societies that have an expertise in AI and has received
26 additional guidance and input from outside experts that have further refined these principles.
27 These principles build upon and are supplemental to the AMA’s existing AI policy, especially
28 Policy [H-480.940](#), “Augmented Intelligence in Health Care,” Policy [H-480.939](#), “Augmented
29 Intelligence in Health Care,” and Policy [D-480.956](#), “Use of Augmented Intelligence for Prior
30 Authorization,” as well as the [AMA’s Privacy Principles](#). The Board recommends adoption of
31 these principles as AMA policy to guide our AMA’s advocacy and educational efforts on
32 LLM/generative AI issues.

33
34 This report highlights the AMA’s recognition of the issues raised at both the A-23 and I-23 HOD
35 meetings, introduces and explains major themes of the report’s recommendations, and provides
36 background information on the evolution of AI policy in health care and the direction that policy
37 appears to be headed.

38 39 CURRENT STATUS OF OVERSIGHT OF AUGMENTED INTELLIGENCE-ENABLED 40 TECHNOLOGIES

41
42 There is currently no whole-of-government strategy for oversight and regulation of AI. The U.S.
43 Department of Health and Human Services (HHS) did establish an AI Office in March 2021 and
44 developed a general strategy to promote the use of trustworthy AI, but has not produced a
45 department-wide plan for the oversight of AI. While many other federal departments and agencies
46 also have some authority to regulate health care AI, many regulatory gaps exist. To address the
47 lack of a national strategy and national governance policies directing the development and
48 deployment of AI, the federal government has largely defaulted to public “agreements”
49 representing promises by large AI developers and technology companies to be good actors in
50 their development of AI-enabled technologies.

1 In December 2023, the Biden Administration released a reasonably comprehensive [executive](#)
2 [order](#) on the “Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence.”
3 While the executive order does not create new statutory or regulatory requirements, it does serve
4 to direct federal departments and agencies to take action to provide guidance, complete studies,
5 identify opportunities, etc. on AI across several sectors, including HHS. The AMA was pleased to
6 see close alignment between the executive order’s direction and AMA principles. However,
7 executive orders do not represent binding policy, so the regulatory status quo remains unchanged
8 at present.

9
10 The Biden Administration had also previously released a “[Blueprint for an AI Bill of Rights](#)”
11 setting forth five principles that should guide the design, use, and deployment of AI. Those
12 include recommendations for creating safe and effective systems; algorithmic discrimination
13 protections; data privacy; notice and explanation; and human alternatives, considerations, and
14 fallback. Like executive orders, this blueprint does not create new or binding policy and it does
15 not appear there have been new efforts by federal departments and agencies to take action to
16 ensure that AI aligns with these principles.

17
18 There have been few, but notable, additional actions by federal agencies that may serve to impact
19 patient and physician interaction with AI-enabled technologies. In 2022, the Centers for Medicare
20 & Medicaid Services (CMS) and HHS Office for Civil Rights (OCR) introduced a sweeping
21 liability proposal within its Section 1557 Non-Discrimination in Health Programs and Activities
22 proposed rule. The proposal, if finalized, would create liability for physicians if they “rely” on a
23 clinical algorithm that results in discriminatory harm to a patient. In the proposal, “clinical
24 algorithm” is defined to include AI. The AMA submitted detailed [comments](#) opposing this
25 section of the proposed rule. CMS and OCR have yet to finalize the rule.

26
27 In addition, the Office of the National Coordinator for Health Information Technology (ONC)
28 proposed and finalized, with some modifications, policies that will require electronic health record
29 (EHR) technology developers to make certain information about AI used in EHRs available to
30 physicians and other users. ONC refers to these AI tools as Predictive Decision Support
31 Interventions (Predictive DSI). Starting in 2025, EHR developers that supply Predictive DSIs as
32 part of the developer’s EHR offering must disclose specific attributes and inform users if patient
33 demographic, social determinants of health, or health assessment data are used in the Predictive
34 DSI. EHRs will be subject to regulatory requirements regarding the design, development,
35 training, and evaluation of Predictive DSIs along with mandated risk management practices.
36 ONC’s stated goal is to ensure that physicians understand how these tools work, how data are
37 used, the potential for bias, and any known limitations.

38 39 FDA APPROVED AI-ENABLED MEDICAL DEVICES

40
41 The FDA continues to rapidly approve AI-enabled medical devices. While FDA approval and
42 clearance of algorithmic-based devices dates back to 1995, clearance and approval of these
43 devices has rapidly accelerated in the last several years. As of October 2023, 692 devices that
44 FDA classifies as Artificial Intelligence/Machine Learning (AI/ML) devices have been approved
45 for marketing. The overwhelming number of these devices are classified as radiology devices and
46 this category of devices has seen the steadiest increases in the number of applications for FDA
47 approval. However, the number of applications is increasing in several specialties, including
48 cardiology, neurology, hematology, gastroenterology, urology, anesthesiology, otolaryngology,
49 ophthalmology, and pathology. A significant number of cleared or approved devices are
50 considered diagnostic in nature and many currently support screening or triage functions.

1 In 2017, the FDA announced that they were evaluating a potentially new regulatory approach
2 towards Software as a Medical Device, which would include AI/ML technologies. The so-called
3 Pre-Certification program, or “Pre-Cert,” progressed to an initial pilot program involving nine
4 manufacturer applicants. The program proposed to pre-certify manufacturers of software-based
5 medical devices. Devices developed by pre-certified manufacturers would be subject to varying
6 levels of FDA review based on risk to patients, including potentially being exempt from review if
7 the risk is low. However, the Pre-Cert program has been tabled and the pilot dismantled for the
8 time being, leaving FDA to utilize traditional review pathways for AI-enabled medical devices. In
9 the absence of new regulatory strategies tailored to SaMD and AI/ML, FDA has issued some
10 proposed guidance for developers of these devices but has not yet moved forward with additional
11 guidance for important, physician-facing topics, such as transparency and labeling requirements.
12 While transparency was listed as one of five major FDA priorities in this area, the Agency does
13 not have current plans to move forward on additional guidance at this time. This leaves a critical
14 gap in the oversight of AI-enabled medical devices.

15 *Data Privacy and Cybersecurity Considerations in Health Care AI*

16
17
18 The integration of AI into health care signifies a transformative era, greatly enhancing patient
19 care and operational efficiency. However, this advancement also introduces considerable
20 challenges, particularly in data privacy and cybersecurity. As health care facilities, technology
21 vendors, clinicians, and users increasingly adopt AI, it is vital to focus on protecting patient and
22 user data and securing AI systems against cyber threats. Handling vast amounts of sensitive data
23 raises critical questions about privacy and security. Survey data has shown that 9 out of 10
24 patients believe privacy is a right and nearly 75 percent of people are concerned about protecting
25 the privacy of their health data.ⁱ Addressing these concerns necessitates a multifaceted approach
26 that includes advanced data privacy techniques, data use transparency, robust cybersecurity
27 strategies, and compliance with regulatory standards.

28
29 Ensuring the protection of patient data in the context of AI requires sophisticated privacy
30 techniques. Key methods such as anonymization and pseudonymization can remove or replace
31 personal identifiers in data sets and significantly reduce the risk of re-identification. Additionally,
32 implementing a robust data management system empowers patients by providing clear ways to
33 grant, deny, or revoke consent for the use of their data, enhancing patient trust and ensuring
34 compliance with global data protection regulations such as the General Data Protection
35 Regulation and the Health Insurance Portability and Accountability Act (HIPAA). Moreover, the
36 collection of data should be kept to a minimum. By collecting only the data necessary for the
37 intended purpose, AI systems can mitigate the risks associated with data breaches and misuse.

38
39 Cybersecurity plays a crucial role in health care, especially in the context of the increasing
40 digitalization of medical records, patient data, and health care services. The health care sector is a
41 prime target for cyber-attacks due to the sensitivity and value of the data it handles, including
42 personal health information (PHI), financial data, and intellectual property related to medical
43 research. The integration of technology in health care has undoubtedly brought significant
44 benefits such as improved patient care, streamlined operations, and enhanced data analytics.
45 However, it also introduces vulnerabilities. These include potential unauthorized access, data
46 breaches, and disruptions to health care services, which can have dire consequences for patient
47 privacy and safety. In 2017, 83 percent of surveyed physicians had already experienced a
48 cyberattack and 85 percent stated that they want to share electronic PHI but were concerned about
49 the data security necessary to protect it.ⁱⁱ This risk is amplified by the recent increased use of
50 interconnected devices and systems, such as EHRs, telemedicine platforms, and mobile health
51 applications.

1 The attack on Change Healthcare in February 2024 is a stark reminder of the critical importance
2 of cybersecurity in health care. Change Healthcare, a division of UnitedHealth Group, was struck
3 by a ransomware attack that significantly disrupted the largest health care payment and operations
4 system in the United States. This incident led to widespread disruptions, affecting thousands of
5 medical practices, hospitals, pharmacies, and others. The attack was attributed to ransomware.
6 Despite efforts to recover from this attack, the impact on health care operations was profound,
7 including the disruption of claims processing, payments, and electronic prescriptions leading to
8 financial strain on physicians and delays in patient care. The health care sector's reliance on
9 interconnected digital systems for patient records, billing, and payments, means that the impact of
10 a cyberattack can be both immediate and widespread, affecting patient care and operational
11 continuity.

12
13 The implications of cybersecurity in health care AI are multifaceted. AI in health care,
14 encompassing machine learning algorithms, predictive analytics, and robotic process automation,
15 hold immense potential for diagnostic accuracy, personalized medicine, and operational
16 efficiency. However, the deployment of AI in health care settings creates unique cybersecurity
17 challenges. AI systems require large datasets to train and operate effectively, increasing the risk
18 of large-scale data breaches. Additionally, the complexity of AI algorithms can make them
19 opaque and vulnerable to manipulation, such as adversarial attacks that can lead to misdiagnoses
20 or inappropriate treatment recommendations. AI-driven health care solutions often rely on
21 continuous data exchange across networks, escalating the risk of cyber-attacks that can
22 compromise both the integrity and availability of critical health care services.

23
24 Model stealing attack represents a significant cybersecurity threat in the realm of AI, where a
25 malicious actor systematically queries an AI system to understand its behavior and subsequently
26 replicates its functionality. This form of intellectual property theft is particularly alarming due to
27 the substantial resources and time required to develop sophisticated AI models. An example of
28 this issue involves a health care organization that has invested heavily in an AI model designed to
29 predict patient health outcomes based on a wide range of variables. If a malicious entity were to
30 engage in model stealing by extensively querying this predictive model, it could essentially
31 duplicate the original model's predictive capabilities along with capitalizing on sensitive health
32 care information and physicians, users, or the entity's intellectual property. Absent strong
33 protections against input manipulation and malicious attacks, AI can become a new conduit for
34 bad actors to compromise health care organizations and harm patients. This not only undermines
35 the original investment but also poses a direct threat to the competitive advantage of the
36 innovating organization.

37
38 Moreover, the risk extends beyond intellectual property theft to encompass serious privacy
39 concerns. This is exemplified by incidents where generative AI models, trained on vast datasets,
40 inadvertently reveal sensitive information contained within their training data in response to
41 certain prompts. In the health care sector, where models are often trained on highly sensitive
42 patient data, including personally identifiable information, the unauthorized extraction of this data
43 can lead to significant breaches of patient confidentiality. The dual threat of intellectual property
44 theft and data privacy breaches underscores the critical need for robust cybersecurity measures in
45 safeguarding AI models, particularly those developed and utilized within the health care industry,
46 to maintain the integrity of both their intellectual property and the confidentiality of the sensitive
47 data they handle.

48
49 While there are new federal policies to increase data transparency when AI is used in conjunction
50 with health information technology, such as those issued by ONC, these new policies only cover

1 the certified EHR developer and stop short of holding AI developers accountable for robust data
2 governance or data security and privacy practices.ⁱⁱⁱ

3 4 GENERATIVE AI

5
6 The broad introduction of generative AI into the public sphere in 2022 saw a paradigm shift in
7 how physicians contemplated AI. Open-source LLM Chat GPT presented a new, easily accessible
8 AI-enabled technology with significant capabilities to generate new content and provide readily
9 available access to information from a huge number of sources. Generative AI tools have
10 significant potential to relieve physician administrative burdens by helping to address actions
11 such as in-box management, patient messages and prior authorization requests. They also show
12 promise in providing clinical decision support. These generative AI tools, however, can also pose
13 significant risk, particularly for clinical applications. They are largely unregulated, as there is no
14 current regulatory structure for generative AI clinical decision support tools unless they meet the
15 definition of a medical device regulated by the FDA. The U.S. Federal Trade Commission (FTC)
16 has limited authority to regulate data privacy issues that may be associated with generative AI
17 tools. The FTC can also regulate activities considered to be an unfair, deceptive, or abusive
18 business practice and can enforce laws for consumer protection. CMS has some authority to
19 regulate use of AI by entities receiving funds from Medicare and Medicaid, including use by
20 Medicare Advantage plans. OCR has some additional authorities to regulate data privacy and
21 nondiscrimination. CMS and OCR have already put forth a very concerning proposal regarding
22 physician liability for clinical algorithms, which the AMA has vigorously opposed.

23
24 While some federal agencies may have oversight and authorities to regulate some aspects of AI,
25 there are many regulatory gaps. These regulatory gaps are particularly significant when
26 considering generative AI, as tools like ChatGPT and others currently fall well outside the
27 definition of a regulated medical device. While generative AI use for clinical applications is
28 relatively limited right now, it is expected to grow and patients and physicians will need
29 assurances that it is providing safe, correct, non-discriminatory answers to the full extent possible,
30 whether through regulation or generally accepted standards for design, development, and
31 deployment.

32 33 USE OF AI BY PAYORS

34
35 There have been numerous reports recently regarding the use of what has been termed
36 “automated decision-making tools” by payors to process claims. However, numerous reports
37 regarding the use of these tools show a growing tendency toward inappropriate denials of care or
38 other limitations on coverage. Reporting by ProPublica claims that tools used by Cigna denied
39 300,000 claims in two months, with claims receiving an average of 1.2 seconds of review.^{iv} Two
40 class action lawsuits were filed during 2023, charging both United Health Care and Humana with
41 inappropriate claims denials resulting from use of the nHPredict AI model, a product of United
42 Health Care subsidiary NaviHealth. Plaintiffs in those suits claim the AI model wrongfully denied
43 care to elderly and disabled patients enrolled in Medicare Advantage (MA) plans with both
44 companies. Plaintiffs also claim that payors used the model despite knowing that 90 percent of
45 the tool’s denials were faulty.

46
47 There is growing concern among patients and physicians about what they perceive as increasing
48 and inappropriate denials of care resulting from the use of these automated decision-making tools.
49 In his recent Executive Order on AI, President Biden addressed this issue as an area of concern,
50 directing the HHS to identify guidance and resources for the use of predictive and generative AI

1 in many areas, including benefits administration, stating that it must take into account
2 considerations such as appropriate human oversight of the application of the output from AI.

3
4 There are currently no statutory and only limited regulatory requirements addressing the use of AI
5 and other automated decision-making tools by payors. States are beginning to look more closely
6 at this issue given the significant negative reporting in recent months and are a likely place for
7 near-term action on this issue. Congress has also shown increasing concern and has convened
8 hearings for testimony on the issue; however, there has been no further Congressional action or
9 legislation to pursue further limitations on use of these algorithms. Additionally, CMS has not
10 taken broad regulatory action to limit the use of these algorithms by entities administering
11 Medicare and Medicaid benefits.

12 13 AMA POLICY

14
15 The AMA has existing policies, [H-480.940](#) and [H-480.939](#) both titled “Augmented Intelligence in
16 Health Care,” which stem from a 2018 and 2019 Board report and cover an array of areas related
17 to the consequences and benefits of AI use in the physician’s practice. In pertinent part to this
18 discussion, AMA Policy H-480.940 seeks to “promote development of thoughtfully designed,
19 high-quality, clinically validated health care AI, encourage education for patients, physicians,
20 medical students, other health care professionals, and health administrators to promote greater
21 understanding of the promise and limitations of health care AI, and explore the legal implications
22 of health care AI, such as issues of liability or intellectual property, and advocate for appropriate
23 professional and governmental oversight for safe, effective, and equitable use of and access to
24 health care AI.” This policy reflects not only the significance of attribution on the part of the
25 developer, but furthermore emphasizes that physicians and other end users also play a role in
26 understanding the technology and the risks involved with its use.

27
28 AMA Policy H.480.939 also addresses key aspects of accountability and liability by stating that
29 “oversight and regulation of health care AI systems must be based on risk of harm and benefit
30 accounting for a host of factors, including but not limited to: intended and reasonably expected
31 use(s); evidence of safety, efficacy, and equity including addressing bias; AI system methods;
32 level of automation; transparency; and, conditions of deployment.” Furthermore, this policy
33 asserts that “liability and incentives should be aligned so that the individual(s) or entity(ies) best
34 positioned to know the AI system risks and best positioned to avert or mitigate harm do so
35 through design, development, validation, and implementation. Specifically, developers of
36 autonomous AI systems with clinical applications (screening, diagnosis, treatment) are in the best
37 position to manage issues of liability arising directly from system failure or misdiagnosis and
38 must accept this liability with measures such as maintaining appropriate medical liability
39 insurance and in their agreements with users.”

40
41 AMA Policy [D-480.956](#) supports “greater regulatory oversight of the use of augmented
42 intelligence for review of patient claims and prior authorization requests, including whether
43 insurers are using a thorough and fair process that: (1) is based on accurate and up-to-date clinical
44 criteria derived from national medical specialty society guidelines and peer reviewed clinical
45 literature; (2) includes reviews by doctors and other health care professionals who are not
46 incentivized to deny care and with expertise for the service under review; and (3) requires such
47 reviews include human examination of patient records prior to a care denial.”

1 DISCUSSION

2
3 As the number of AI-enabled health care tools and systems continues to grow, these technologies
4 must be designed, developed, and deployed in a manner that is ethical, equitable, responsible, and
5 transparent. With a lagging effort towards adoption of national governance policies or oversight
6 of AI, it is critical that the physician community engage in development of policies to help drive
7 advocacy, inform patient and physician education, and guide engagement with these new
8 technologies. It is also important that the physician community help guide development of these
9 tools in a way that best meets both patient and physician needs, and help define their own
10 organization's risk tolerance, particularly where AI impacts direct patient care. AI has significant
11 potential to advance clinical care, reduce administrative burdens, and improve clinician well-
12 being. This may only be accomplished by ensuring that physicians engage only with AI that
13 satisfies rigorous, clearly defined standards to meet the goals of the quadruple aim:^v advance
14 health equity, prioritize patient safety, and limit risks to both patients and physicians.

15
16 *Oversight of Health Care Augmented Intelligence*

17
18 There is currently no national policy or governance structure in place to guide the development
19 and adoption of non-device AI. As discussed above, the FDA regulates AI-enabled medical
20 devices, but many types of AI-enabled technologies fall outside the scope of FDA oversight^{vi}.
21 This potentially includes AI that may have clinical applications, such as some generative AI
22 technologies serving clinical decision support functions. While the FTC and OCR have oversight
23 over some aspects of AI, their authorities are limited and not adequate to ensure appropriate
24 development and deployment of AI generally, and specifically in the health care space. Likewise,
25 ONC's enforcement is limited and focused on EHR developers' use and integration of AI within
26 their federally certified EHRs. While this is a major first step in requiring AI transparency, it is
27 still the EHR developer that is regulated with few requirements on the AI developer itself.
28 Encouragement of a whole-of-government approach to implement governance policies will help
29 to ensure that risks to consumers and patients arising from AI are mitigated to the greatest extent
30 possible.

31
32 In addition to the government, health care institutions, practices, and professional societies share
33 some responsibility for appropriate oversight and governance of AI-enabled systems and
34 technologies. Beyond government oversight or regulation, purchasers and users of these
35 technologies should have appropriate and sufficient policies in place to ensure they are acting in
36 accordance with the current standard of care. Similarly, clinical experts are best positioned to
37 determine whether AI applications are high quality, appropriate, and whether the AI tools are
38 valid from a clinical perspective. Clinical experts can best validate the clinical knowledge,
39 clinical pathways, and standards of care used in the design of AI-enabled tools and can monitor
40 the technology for clinical validity as it evolves over time.

41
42 *Transparency in Use of Augmented Intelligence-Enabled Systems and Technologies*

43
44 As implementation of AI-enabled tools and systems increases, it is essential that use of AI in
45 health care be transparent to both patients and physicians. Transparency requirements should be
46 tailored in a way that best suits the needs of the end users. Care must be taken to preserve the
47 integrity of data sets used in health care such that individual choice and data privacy are balanced
48 with preserving algorithms that remain as pristine as possible to avoid exacerbating health care
49 inequities. Disclosure should contribute to patient and physician knowledge without increasing
50 administrative burden. When AI is utilized in health care decision-making, that use should be
51 disclosed and documented to limit risks to, and mitigate inequities for, both patients and

1 physicians, and to allow each to understand how decisions impacting patient care or access to
2 care are made. While transparency does not necessarily ensure AI-enabled tools are accurate,
3 secure, or fair, it is difficult to establish trust if certain characteristics are hidden.
4

5 Heightened attention to transparency and additional transparency requirements serve several
6 purposes. They help to both ensure that the best possible decisions are made about a patient's
7 health care and help patients and physicians identify critical decision points and possible points of
8 error. They can also serve as mechanisms to help shield physicians from liability so that potential
9 issues related to use of AI-enabled technologies can be isolated and accountability apportioned
10 appropriately.
11

12 There are currently few federal requirements for transparency regarding AI. The FDA requires
13 product labeling to provide certain information to physicians and other users, but requirements for
14 device labeling are generally considered to be less stringent and have more leeway than drug
15 product labeling. While FDA has stated that transparency is a key priority for the agency to
16 address, they have not taken any additional action to update the labeling requirements for AI-
17 enabled medical devices or put into place additional transparency requirements for AI-enabled
18 devices. As discussed above, ONC also has new transparency requirements applicable to the use
19 of AI within EHRs; however, again, those requirements are limited to AI within an EHR or other
20 applications integrated and made available through the EHR. They will not apply to AI-enabled
21 tools accessible through the Internet, cellular phones, etc. It is clear that there is an urgent need
22 for additional federal action to ensure AI transparency.
23

24 *Required Disclosures by Health Care Augmented Intelligence-Enabled Systems and Technologies* 25

26 Along with significant opportunity to improve patient care, all new technologies in health care
27 will likely present certain risks and limitations that physicians must carefully navigate during the
28 early stages of clinical implementation of these new systems and tools. AI-enabled tools are no
29 different and are perhaps more challenging than other advances as they present novel and
30 complex questions and risks. To best mitigate these risks, it is critical that physicians understand
31 AI-driven technologies and have access to certain information about the AI tool or system being
32 considered, including how it was trained and validated, so that they can assess the quality,
33 performance, equity, and utility of the tool to the best of their ability. This information may also
34 establish a set of baseline metrics for comparing AI tools. Transparency and explainability
35 regarding the design, development, and deployment processes should be mandated by law where
36 feasible, including potential sources of inequity in problem formulation, inputs, and
37 implementation. Additionally, sufficient detail should be disclosed to allow physicians to
38 determine whether a given AI-enabled tool would reasonably apply to the individual patient they
39 are treating.
40

41 Physicians should be aware and understand that, where they utilize AI-enabled tools and systems
42 without transparency provided by the AI developer, their risks of liability for reliance on that AI
43 will likely increase. The need for full transparency is greatest where AI-enabled systems have
44 greater impact on direct patient care, such as by AI-enabled medical devices, clinical decision
45 support, and interaction with AI-driven chatbots. Transparency needs may be somewhat lower
46 where AI is utilized for primarily administrative, practice-management functions.
47 While some of this information may be provided in labeling for FDA cleared and approved
48 medical devices, the labeling requirements for such devices have not been specifically tailored to
49 clearly convey information about these new types of devices. Updated guidance for FDA-
50 regulated medical devices is needed to provide this critical information. Congress should consider
51 actions to ensure appropriate authorities exist to require appropriate information to be provided to

1 users of AI so that they can best evaluate the technology to determine reported performance,
2 intended use, intended population, and appropriateness for the task. Developers and vendors
3 should consider voluntarily providing this information about their products, and physicians and
4 other purchasers should consider this information when selecting the AI tools they use.

5 6 *Generative AI*

7
8 Generative AI is a type of AI that can recognize, summarize, translate, predict, and generate text
9 and other content based on knowledge gained from large datasets. Generative AI tools are finding
10 an increasing number of uses in health care, including assistance with administrative functions,
11 such as generating office notes, responding to documentation requests, and generating patient
12 messages. Additionally, there has been increasing discussion about clinical applications of
13 generative AI, including use as clinical decision support to provide differential diagnoses, early
14 detection and intervention, and to assist in treatment planning. While generative AI tools show
15 tremendous promise to make a significant contribution to health care, there are a number of risks
16 and limitations to consider when using these tools in a clinical setting or for direct patient care.
17 These risks are especially important to consider for clinical applications that may impact clinical
18 decision-making and treatment planning where risks to patients are higher.

19
20 Given that there are no regulations or generally accepted standards or frameworks to govern the
21 design, development, and deployment of generative AI, consideration and mitigation of the
22 significant risks is paramount. To manage risk, health care organizations should develop and
23 adopt appropriate policies that anticipate and minimize negative impacts. Physicians who consider
24 utilizing a generative AI-based tool in their practice should ensure that all practice staff are
25 educated on the risks and limitations, including patient privacy concerns, and should have
26 appropriate governance policies in place for its use prior to adoption. Also, as raised in
27 Resolution 206-I-23, physicians should be encouraged to educate their patients about the benefits
28 and risks of using AI-based tools, such as LLMs, for information about health care conditions,
29 treatment options, or the type of health care professionals who have the education, training, and
30 qualifications to treat a particular condition. Patients and physicians should be aware that chatbots
31 powered by LLMs/generative AI could provide inaccurate, misleading, or unreliable information
32 and recommendations. This principle is incorporated in the recommendations in this report and
33 current AMA Policy [H-480.940](#), “Augmented Intelligence in Health Care.”

34 35 *Liability*

36
37 The question of physician liability for use of AI-enabled technologies presents novel and complex
38 legal questions and poses risks to the successful clinical integration of AI-enabled technologies. It
39 is also one of the most serious concerns for physicians when considering integration of AI into
40 their practice. Concerns also arise for employed physicians who feel they may have no choice but
41 to utilize the AI, should hospitals or health systems mandate its use or utilize an EHR system that
42 incorporates AI-based applications as standard.

43
44 The challenge for physicians regarding questions of liability for use of AI is that there is not yet
45 any clear legal standard for determining liability. While there are clear standards for general
46 medical malpractice and for medical device liability, AI presents novel and potentially complex
47 legal questions. When AI has suggested a diagnosis, the question of how appropriate it is for a
48 physician to rely on that result is yet to be determined and will likely continue to evolve as AI
49 improves. Ultimately the “standard of care” will help guide physician liability. It is expected that,
50 as it improves over time, AI will be incorporated into what is likely to be specialty-specific
51 standards of care. However, until that occurs, AI-transparency is of critical importance and

1 physicians will need to be diligent in ensuring that they engage with AI tools where performance
2 has been validated in their practice setting.

3
4 As AI continues to evolve, there may ultimately be questions regarding liability when physicians
5 fail to use AI and rely only on their professional judgment. Again, this question may ultimately
6 turn on what evolves to be considered the standard of care.

7
8 It should be noted that, when using AI, physicians will still be subject to general legal theories
9 regarding medical liability. Negligent selection of an AI tool, including using tools outside their
10 intended use or intended population, or choosing a tool where there is no evidence of clinical
11 validation, could be decisions that expose a physician to a liability claim.

12 13 *Data Privacy and Augmented Intelligence*

14
15 Data privacy is highly relevant to AI development, implementation, and use. The AMA is deeply
16 invested in ensuring individual patient rights and protections from discrimination remain intact,
17 that these assurances are guaranteed, and that the responsibility rests with the data holders. AI
18 development, training, and use requires assembling large collections of health data. AI machine
19 learning is data hungry; it requires massive amounts of data to function properly. Increasingly,
20 more electronic health records are interoperable across the health care system and, therefore, are
21 accessible by AI trained or deployed in medical settings. AI developers may enter into legal
22 arrangements (e.g., business associate agreements) that bring them under the Health Insurance
23 Portability and Accountability Act (HIPAA) Privacy and Security Rules. While some uses of AI
24 in health care, such as research, are not allowed by HIPAA absent patient authorization, the
25 applicability of other HIPAA privacy protections to AI use is not as clear and HIPAA cannot
26 protect patients from the “black box” nature of AI which makes the use of data opaque. AI system
27 outputs may also include inferences that reveal personal data or previously confidential details
28 about individuals. This can result in a lack of accountability and trust and exacerbate data privacy
29 concerns. Often, AI developers and implementers are themselves unaware of exactly how their
30 products use information to make recommendations.

31
32 It is unlikely that physicians or patients will have any clear insight into a generative AI tool’s
33 conformance to state or federal data privacy laws. LLMs are trained on data scraped from the web
34 and other digital sources, including one well-documented instance where HIPAA privacy
35 protections were violated.^{vii} Few, if any, controls are available to help users protect the data they
36 voluntarily enter in a chatbot query. For instance, there are often no mechanisms in place for
37 users to request data deletion or ensure that their inputs are not stored or used for future model
38 training. While tools designed for medical use should align with HIPAA, many “HIPAA-
39 compliant” generative tools rely on antiquated notions of deidentification, i.e., stripping data of
40 personal information. With today’s advances in computing power, data can easily be reidentified.
41 Rather than aiming to make LLMs compliant with HIPAA, all health care AI-powered generative
42 tools should be designed from the ground up with data privacy in mind.

43
44 [The AMA’s Privacy Principles](#) were designed to provide individuals with rights and protections
45 and shift the responsibility for privacy to third-party data holders. While the Principles are
46 broadly applicable to all AI developers, e.g., entities should only collect the minimum amount of
47 information needed for a particular purpose, the unique nature of LLMs and generative AI
48 warrant special emphasis on entity responsibility and user education.

1 *Augmented Intelligence Cybersecurity*

2
3 Data privacy relies on strong data security measures. There is growing concern that cyber
4 criminals will use AI to attack health care organizations. AI poses new threats to health IT
5 operations. AI-operated ransomware and AI-operated malware can be targeted to infiltrate health
6 IT systems and automatically exploit vulnerabilities. Attackers using ChatGPT can craft
7 convincing or authentic emails and use phishing techniques that entice people to click on links—
8 giving them access to the entire electronic health record system.

9
10 AI is particularly sensitive to the quality of data. Data poisoning is the introduction of “bad” data
11 into an AI training set, affecting the model’s output. AI requires large sets of data to build logic
12 and patterns used in clinical decision-making. Protecting this source data is critical. Threat actors
13 could also introduce input data that compromises the overall function of the AI tool. Failure to
14 secure and validate these inputs, and corresponding data, can contaminate AI models—resulting
15 in patient harm.

16
17 Because stringent privacy protections and higher data quality standards might slow model
18 development, there could be a tendency to forgo essential data privacy and security precautions.
19 However, strengthening AI systems against cybersecurity threats is crucial to their reliability,
20 resiliency, and safety.

21
22 *Payor Use of Augmented Intelligence in Automated Decision-Making*

23
24 Payors and health plans are increasingly using AI and algorithm-based decision-making in an
25 automated fashion to determine coverage limits, make claim determinations, and engage in
26 benefit design. Payors should leverage automated decision-making systems that improve or
27 enhance efficiencies in coverage and payment automation, facilitate administrative simplification,
28 and reduce workflow burdens. While the use of these systems can create efficiencies such as
29 speeding up prior authorization and cutting down on paperwork, there is concern these systems
30 are not being designed or supervised effectively—creating access barriers for patients and
31 limiting essential benefits.

32
33 Increasingly, evidence indicates that payors are using automated decision-making systems to
34 deny care more rapidly, often with little or no human review. This manifests in the form of
35 increased denials, stricter coverage limitations, and constrained benefit offerings. For example, a
36 payor allowed an automated system to cut off insurance payments for Medicare Advantage
37 patients struggling to recover from severe diseases, forcing them to forgo care or pay out of
38 pocket. In some instances, payors instantly reject claims on medical grounds without opening or
39 reviewing the patient’s medical record. There is also a lack of transparency in the development of
40 automated decision-making systems. Rather than payors making determinations based on
41 individualized patient care needs, reports show that decisions are based on algorithms developed
42 using average or “similar patients” pulled from a database. Models that rely on generalized,
43 historical data can also perpetuate biases leading to discriminatory practices or less inclusive
44 coverage.^{viii,ix,x,xi}

45
46 While AI can be used inappropriately by payors with severe detrimental outcomes to patients, it
47 can also serve to reduce administrative burdens on physicians, providing the ability to more easily
48 submit prior authorization and documentation requests in standardized forms that require less
49 physician and staff time. Given the significant burden placed on physicians and administrative
50 staff by prior authorization requests, AI could provide much needed relief and help to increase
51 professional satisfaction among health care professionals. With clear guidelines, AI-enabled

1 decision-making systems may also be appropriate for use in some lower-risk, less complex care
2 decisions.

3
4 While payor use of AI in well-defined situations with clear guidelines has the potential to reduce
5 burdens and benefit physician practices, new regulatory or legislative action is necessary to
6 ensure that automated decision-making systems do not reduce needed care, nor systematically
7 withhold care from specific groups. Steps should be taken to ensure that these systems do not
8 override clinical judgment. Patients and physicians should be informed and empowered to
9 question a payor's automated decision-making. There should be stronger regulatory oversight,
10 transparency, and audits when payors use these systems for coverage, claim determinations, and
11 benefit design. [See Policy [D-480.956](#), "Use of Augmented Intelligence for Prior Authorization;"
12 Policy [H-320.939](#), "Prior Authorization and Utilization Management Reform"]

13 14 CONCLUSION

15
16 As the number of AI-enabled health care tools and systems continue to grow, these technologies
17 must be designed, developed, and deployed in a manner that is ethical, equitable, responsible, and
18 transparent. In line with AMA Policy [H-480-935](#) and Resolution 206-I-23, this report highlights
19 some of the potential benefits and risks to the medical profession and patients of LLMs (e.g.,
20 GPTs) and other AI-generated medical decision-making tools, and recommends adoption of
21 policy to help inform patient and physician education and guide engagement with this new
22 technology, as well as position the AMA to advocate for governance policies that help to ensure
23 that risks arising from AI are mitigated to the greatest extent possible.

24 25 RECOMMENDATION

26
27 The Board of Trustees recommends that the following be adopted in lieu of Resolution 206-I-23
28 and that the remainder of the report be filed:

29 30 **AUGMENTED INTELLIGENCE DEVELOPMENT, DEPLOYMENT, AND USE IN** 31 **HEALTH CARE**

32 33 General Governance

- 34
- 35 • Health care AI must be designed, developed, and deployed in a manner which is ethical,
36 equitable, responsible, and transparent.
 - 37 • Use of AI in health care delivery requires clear national governance policies to regulate
38 its adoption and utilization, ensuring patient safety, and mitigating inequities.
39 Development of national governance policies should include interdepartmental and
40 interagency collaboration.
 - 41 • Compliance with national governance policies is necessary to develop AI in an ethical
42 and responsible manner to ensure patient safety, quality, and continued access to care.
43 Voluntary agreements or voluntary compliance is not sufficient.
 - 44 • Health care AI requires a risk-based approach where the level of scrutiny, validation, and
45 oversight should be proportionate to the potential overall of disparate harm and
46 consequences the AI system might introduce. [See also Augmented Intelligence in Health
47 Care [H-480.939](#) at (1)]
 - 48 • Clinical decisions influenced by AI must be made with specified human intervention
49 points during the decision-making process. As the potential for patient harm increases,
50 the point in time when a physician should utilize their clinical judgment to interpret or act
51 on an AI recommendation should occur earlier in the care plan.

- 1 • Health care practices and institutions should not utilize AI systems or technologies that
2 introduce overall or disparate risk that is beyond their capabilities to mitigate.
3 Implementation and utilization of AI should avoid exacerbating clinician burden and
4 should be designed and deployed in harmony with the clinical workflow.
- 5 • Medical specialty societies, clinical experts, and informaticists are best positioned and
6 should identify the most appropriate uses of AI-enabled technologies relevant to their
7 clinical expertise and set the standards for AI use in their specific domain. [See
8 Augmented Intelligence in Health Care [H-480.940](#) at (2)]
9

10 When to Disclose: Transparency in Use of Augmented Intelligence-Enabled Systems and 11 Technologies 12

- 13 • When AI is used in a manner which directly impacts patient care, access to care, or
14 medical decision making, that use of AI should be disclosed and documented to both
15 physicians and/or patients in a culturally and linguistically appropriate manner. The
16 opportunity for a patient or their caregiver to request additional review from a licensed
17 clinician should be made available upon request.
- 18 • When AI is used in a manner which directly impacts patient care, access to care, medical
19 decision making, or the medical record, that use of AI should be documented in the
20 medical record.
- 21 • AI tools or systems cannot augment, create, or otherwise generate records,
22 communications, or other content on behalf of a physician without that physician's
23 consent and final review.
- 24 • When health care content is generated by generative AI, including by large language
25 models, it should be clearly disclosed within the content that was generated by an AI-
26 enabled technology.
- 27 • When AI or other algorithmic-based systems or programs are utilized in ways that impact
28 patient access to care, such as by payors to make claims determinations or set coverage
29 limitations, use of those systems or programs must be disclosed to impacted parties.
- 30 • The use of AI-enabled technologies by hospitals, health systems, physician practices, or
31 other entities, where patients engage directly with AI should be clearly disclosed to
32 patients at the beginning of the encounter or interaction with the AI-enabled technology.
33

34 What to Disclose: Required Disclosures by Health Care Augmented Intelligence-Enabled 35 Systems and Technologies 36

- 37 • When AI-enabled systems and technologies are utilized in health care, the following
38 information should be disclosed by the AI developer to allow the purchaser and/or user
39 (physician) to appropriately evaluate the system or technology prior to purchase or
40 utilization:
 - 41 ○ Regulatory approval status
 - 42 ○ Applicable consensus standards and clinical guidelines utilized in design,
43 development, deployment, and continued use of the technology
 - 44 ○ Clear description of problem formulation and intended use accompanied by clear
45 and detailed instructions for use
 - 46 ○ Intended population and intended practice setting
 - 47 ○ Clear description of any limitations or risks for use, including possible disparate
48 impact
 - 49 ○ Description of how impacted populations were engaged during the AI lifecycle
 - 50 ○ Detailed information regarding data used to train the model:
 - 51 ■ Data provenance

- 1 ▪ Data size and completeness
- 2 ▪ Data timeframes
- 3 ▪ Data diversity
- 4 ▪ Data labeling accuracy
- 5 ○ Validation Data/Information and evidence of:
- 6 ▪ Clinical expert validation in intended population and practice setting and
- 7 intended clinical outcomes
- 8 ▪ Constraint to evidence-based outcomes and mitigation of “hallucination”
- 9 or other output error
- 10 ▪ Algorithmic validation
- 11 ▪ External validation processes for ongoing evaluation of the model
- 12 performance, e.g., accounting for AI model drift and degradation
- 13 ▪ Comprehensiveness of data and steps taken to mitigate biased outcomes
- 14 ▪ Other relevant performance characteristics, including but not limited to
- 15 performance characteristics at peer institutions/similar practice settings
- 16 ▪ Post-market surveillance activities aimed at ensuring continued safety,
- 17 performance, and equity
- 18 ○ Data Use Policy
- 19 ▪ Privacy
- 20 ▪ Security
- 21 ▪ Special considerations for protected populations or groups put at
- 22 increased risk
- 23 ○ Information regarding maintenance of the algorithm, including any use of active
- 24 patient data for ongoing training
- 25 ○ Disclosures regarding the composition of design and development team,
- 26 including diversity and conflicts of interest, and points of physician involvement
- 27 and review
- 28
- 29 • Purchasers and/or users (physicians) should carefully consider whether or not to engage
- 30 with AI-enabled health care technologies if this information is not disclosed by the
- 31 developer. As the risk of AI being incorrect increases risks to patients (such as with
- 32 clinical applications of AI that impact medical decision making), disclosure of this
- 33 information becomes increasingly important. [See also Augmented Intelligence in Health
- 34 Care [H-480.939](#)]
- 35

36 Generative Augmented Intelligence

- 37
- 38 • Generative AI should: (a) only be used where appropriate policies are in place within the
- 39 practice or other health care organization to govern its use and help mitigate associated
- 40 risks; and (b) follow applicable state and federal laws and regulations (e.g., HIPAA-
- 41 compliant Business Associate Agreement).
- 42 • Appropriate governance policies should be developed by health care organizations and
- 43 account for and mitigate risks of:
- 44 ○ Incorrect or falsified responses; lack of ability to readily verify the accuracy of
- 45 responses or the sources used to generate the response
- 46 ○ Training data set limitations that could result in responses that are out of date or
- 47 otherwise incomplete or inaccurate for all patients or specific populations
- 48 ○ Lack of regulatory or clinical oversight to ensure performance of the tool
- 49 ○ Bias, discrimination, promotion of stereotypes, and disparate impacts on access
- 50 or outcomes
- 51 ○ Data privacy

- 1 ○ Cybersecurity
- 2 ○ Physician liability associated with the use of generative AI tools
- 3 • Health care organizations should work with their AI and other health information
- 4 technology (health IT) system developers to implement rigorous data validation and
- 5 verification protocols to ensure that only accurate, comprehensive, and bias managed
- 6 datasets inform generative AI models, thereby safeguarding equitable patient care and
- 7 medical outcomes. [See Augmented Intelligence in Health Care [H-480.940](#) at (3)(d)]
- 8 • Use of generative AI should incorporate physician and staff education about the
- 9 appropriate use, risks, and benefits of engaging with generative AI. Additionally,
- 10 physicians should engage with generative AI tools only when adequate information
- 11 regarding the product is provided to physicians and other users by the developers of those
- 12 tools.
- 13 • Clinicians should be aware of the risks of patients engaging with generative AI products
- 14 that produce inaccurate or harmful medical information (e.g., patients asking chatbots
- 15 about symptoms) and should be prepared to counsel patients on the limitations of AI-
- 16 driven medical advice.
- 17 • Governance policies should prohibit the use of confidential, regulated, or proprietary
- 18 information as prompts for generative AI to generate content.
- 19 • Data and prompts contributed by users should primarily be used by developers to
- 20 improve the user experience and AI tool quality and not simply increase the AI tool's
- 21 market value or revenue generating potential.
- 22

23 Physician Liability for Use of Augmented Intelligence-Enabled Technologies

- 24
- 25 • Current AMA policy states that liability and incentives should be aligned so that the
- 26 individual(s) or entity(ies) best positioned to know the AI system risks and best
- 27 positioned to avert or mitigate harm do so through design, development, validation, and
- 28 implementation. [See Augmented Intelligence in Health Care [H-480.939](#)]
- 29 ○ Where a mandated use of AI systems prevents mitigation of risk and harm, the
- 30 individual or entity issuing the mandate must be assigned all applicable liability.
- 31 ○ Developers of autonomous AI systems with clinical applications (screening,
- 32 diagnosis, treatment) are in the best position to manage issues of liability arising
- 33 directly from system failure or misdiagnosis and must accept this liability with
- 34 measures such as maintaining appropriate medical liability insurance and in their
- 35 agreements with users.
- 36 ○ Health care AI systems that are subject to non-disclosure agreements concerning
- 37 flaws, malfunctions, or patient harm (referred to as gag clauses) must not be
- 38 covered or paid and the party initiating or enforcing the gag clause assumes
- 39 liability for any harm.
- 40 • When physicians do not know or have reason to know that there are concerns about the
- 41 quality and safety of an AI-enabled technology, they should not be held liable for the
- 42 performance of the technology in question.
- 43

44 Data Privacy and Augmented Intelligence

- 45
- 46 • Entity Responsibility:
- 47 ○ Entities should make information available about the intended use of generative
- 48 AI in health care and identify the purpose of its use. Individuals should know
- 49 how their data will be used or reused, and the potential risks and benefits.

- 1 ○ Individuals should have the right to opt-out, update, or forget use of their data in
2 generative AI tools. These rights should encompass AI training data and
3 disclosure to other users of the tool.
- 4 ○ Generative AI tools should not reverse engineer, reconstruct, or reidentify an
5 individual’s originally identifiable data or use identifiable data for nonpermitted
6 uses, e.g., when data are permitted to conduct quality and safety evaluations.
7 Preventive measures should include both legal frameworks and data model
8 protections, e.g., secure enclaves, federated learning, and differential privacy.
9
- 10 • User Education:
 - 11 ○ Users should be provided with training specifically on generative AI. Education
12 should address:
 - 13 ▪ legal, ethical, and equity considerations;
 - 14 ▪ risks such as data breaches and re-identification;
 - 15 ▪ potential pitfalls of inputting sensitive and personal data; and
 - 16 ▪ the importance of transparency with patients regarding the use of
17 generative AI and their data.

18 [See [H-480.940](#), Augmented Intelligence in Health Care, at (4) and (5)]

20 Augmented Intelligence Cybersecurity

- 21
- 22 • AI systems must have strong protections against input manipulation and malicious
23 attacks.
- 24 • Entities developing or deploying health care AI should regularly monitor for anomalies or
25 performance deviations, comparing AI outputs against known and normal behavior.
- 26 • Independent of an entity’s legal responsibility to notify a health care provider or
27 organization of a data breach, that entity should also act diligently in identifying and
28 notifying the individuals themselves of breaches that impact their personal information.
- 29 • Users should be provided education on AI cybersecurity fundamentals, including specific
30 cybersecurity risks that AI systems can face, evolving tactics of AI cyber attackers, and
31 the user’s role in mitigating threats and reporting suspicious AI behavior or outputs.
32

33 Payor Use of Augmented Intelligence and Automated Decision-Making Systems

- 34
- 35 • Use of automated decision-making systems that determine coverage limits, make claim
36 determinations, and engage in benefit design should be publicly reported, based on easily
37 accessible evidence-based clinical guidelines (as opposed to proprietary payor criteria),
38 and disclosed to both patients and their physician in a way that is easy to understand.
- 39 • Payors should only use automated decision-making systems to improve or enhance
40 efficiencies in coverage and payment automation, facilitate administrative simplification,
41 and reduce workflow burdens. Automated decision-making systems should never create
42 or exacerbate overall or disparate access barriers to needed benefits by increasing denials,
43 coverage limitations, or limiting benefit offerings. Use of automated decision-making
44 systems should not replace the individualized assessment of a patient’s specific medical
45 and social circumstances and payors’ use of such systems should allow for flexibility to
46 override automated decisions. Payors should always make determinations based on
47 particular patient care needs and not base decisions on algorithms developed on “similar”
48 or “like” patients.
- 49 • Payors using automated decision-making systems should disclose information about any
50 algorithm training and reference data, including where data were sourced and attributes
51 about individuals contained within the training data set (e.g., age, race, gender). Payors

- 1 should provide clear evidence that their systems do not discriminate, increase inequities,
2 and that protections are in place to mitigate bias.
- 3 • Payors using automated decision-making systems should identify and cite peer-reviewed
4 studies assessing the system’s accuracy measured against the outcomes of patients and
5 the validity of the system’s predictions.
 - 6 • Any automated decision-making system recommendation that indicates limitations or
7 denials of care, at both the initial review and appeal levels, should be automatically
8 referred for review to a physician (a) possessing a current and valid non-restricted license
9 to practice medicine in the state in which the proposed services would be provided if
10 authorized and (b) be of the same specialty as the physician who typically manages the
11 medical condition or disease or provides the health care service involved in the request
12 prior to issuance of any final determination. Prior to issuing an adverse determination, the
13 treating physician must have the opportunity to discuss the medical necessity of the care
14 directly with the physician who will be responsible for determining if the care is
15 authorized.
 - 16 • Individuals impacted by a payor’s automated decision-making system, including patients
17 and their physicians, must have access to all relevant information (including the coverage
18 criteria, results that led to the coverage determination, and clinical guidelines used).
 - 19 • Payors using automated decision-making systems should be required to engage in regular
20 system audits to ensure use of the system is not increasing overall or disparate claims
21 denials or coverage limitations, or otherwise decreasing access to care. Payors using
22 automated decision-making systems should make statistics regarding systems’ approval,
23 denial, and appeal rates available on their website (or another publicly available website)
24 in a readily accessible format with patient population demographics to report and
25 contextualize equity implications of automated decisions. Insurance regulators should
26 consider requiring reporting of payor use of automated decision-making systems so that
27 they can be monitored for negative and disparate impacts on access to care. Payor use of
28 automated decision-making systems must conform to all relevant state and federal laws.
29 (New HOD Policy)

Fiscal Note: Less than \$500.

REFERENCES

ⁱ <https://www.ama-assn.org/system/files/ama-patient-data-privacy-survey-results.pdf>.

ⁱⁱ <https://www.ama-assn.org/sites/ama-assn.org/files/corp/media-browser/public/government/advocacy/medical-cybersecurity-findings.pdf>.

ⁱⁱⁱ https://www.healthit.gov/sites/default/files/page/2024-01/DSI_HTI1%20Final%20Rule%20Presentation_508.pdf.

^{iv} <https://www.propublica.org/article/cigna-health-insurance-denials-pxdx-congress-investigation#:~:text=The%20letter%20follows%20an%20investigation.PXDX%20system%2C%20spending%20an%20average.>

^v AI systems should enhance the patient experience of care and outcomes, improve population health, reduce overall costs for the health care system while increasing value, and support the professional satisfaction of physicians and the health care team.

^{vi} For example, the 21st Century Cures Act includes several exemptions to FDA’s oversight, such as software intended for administrative support of a health care facility, maintaining or encouraging a healthy lifestyle (and is unrelated to the diagnosis, cure, mitigation, prevention, or treatment of a disease or condition), is intended to be used as electronic patient records, is intended for transferring, storing, converting formats, or displaying data or results, and otherwise does not meet the definition of a medical device under the Federal Food, Drug, and Cosmetic Act.

^{vii} Feathers, T., et al. “Facebook is receiving sensitive medical information from hospital websites. The Markup. June 16, 2022.” <https://themarkup.org/pixel-hunt/2022/06/16/facebook-is-receiving-sensitive-medical-information-from-hospital-websites>.

^{viii} Obermeyer, Ziad, et al. “Dissecting racial bias in an algorithm used to manage the health of populations.” *Science* 366.6464 (2019): 447-453. <https://www.science.org/doi/10.1126/science.aax2342>.

^{ix} Ross, C., Herman, B. (2023) “Medicare Advantage Plans’ Use of Artificial Intelligence Leads to More Denials.” <https://www.statnews.com/2023/03/13/medicare-advantage-plans-denial-artificial-intelligence/> (Accessed September 14, 2023).

^x Rucker, P., Miller, M., Armstrong, D. (2023). “Cigna and Its Algorithm Deny Some Claims for Genetic Testing, ProPublica Finds.” <https://www.propublica.org/article/cigna-pxdx-medical-health-insurance-rejection-claims> (Accessed September 14, 2023).

^{xi} Ross, C., Herman, B. (2023). “Medicare Advantage Algorithms Lead to Coverage Denials, With Big Implications for Patients.” <https://www.statnews.com/2023/07/11/medicare-advantage-algorithm-navihealth-unitedhealth-insurance-coverage/> (Accessed September 14, 2023).

REPORT OF THE BOARD OF TRUSTEES

B of T Report 16-A-24

Subject: Support for Mental Health Courts
Presented by: Willie Underwood, III, MD, MSc, MPH, Chair
Referred to: Reference Committee B

1 INTRODUCTION

2

3 At the 2023 Annual Meeting of the American Medical Association (AMA) House of Delegates
4 (HOD), Resolution 202 entitled, “Support for Mental Health Courts,” was introduced by the
5 Medical Student Section and called on the AMA to amend existing policy – Policy H-100.955
6 entitled, “Support for Drug Courts” – as follows:

7

8 Our AMA: (1) supports the establishment and use of mental health drug courts,
9 including drug courts and sobriety courts, as an effective method of intervention within
10 a comprehensive system of community-based supports and services for individuals
11 with mental illness involved in the justice system ~~addictive disease who are convicted~~
12 ~~of nonviolent crimes;~~ (2) encourages legislators to establish mental health drug courts
13 at the state and local level in the United States; and (3) encourages mental health drug
14 courts to rely upon evidence-based models of care for those who the judge or court
15 determine would benefit from intervention rather than incarceration.

16

17 There was robust discussion of this resolution, including widespread support for increasing access
18 to evidence-based care for individuals with a mental illness or substance use disorder (SUD) who
19 were involved with the justice system. Multiple questions were raised, however, regarding terms
20 of art that may be in use in legal settings compared to medical settings; the potential of unintended
21 consequences; and the different uses of such courts. Ultimately, the HOD referred this resolution
22 to the Board of Trustees for study. In response, this report provides background information;
23 discusses the different courts; presents AMA policy; and makes recommendations.

24

25 BACKGROUND

26

27 There are more than 4,000 courts in the United States that provide some measure of alternative to
28 incarceration when there is evidence of a mental illness, SUD, or other health condition impacting
29 an individual and/or family.¹ There are at least 39 states with a diversion program that addresses
30 substance use, and at least 24 that directly address mental health and illness needs.² A fact sheet
31 from the Obama Administration noted that, “Since 1989, drug courts have been established or are
32 being planned in all 50 States, the District of Columbia, the Northern Mariana Islands, Puerto Rico,
33 Guam, and in nearly 90 Tribal locations.”³ The AMA has long been a supporter of these programs.⁴

34

35 These programs go by many names, including “treatment court,” “adult drug court,” “DWI court,”
36 “family treatment court,” “juvenile treatment court,” “tribal healing to wellness court,” or “veterans
37 treatment court.” Other names used to describe programs that seek alternatives to incarceration are
38 “opioid intervention court,” “opiate treatment court,” “heroin court,” “treatment pathway

1 program,” “overdose avoidance and recovery program,” and “heroin overdose prevention and
2 education initiative.”⁵ The U.S. Department of Justice (DOJ) broadly describes these programs as
3 “pretrial diversion programs” to which the U.S. Attorney has discretion to “divert” if there are
4 “substance abuse or mental health challenges.”⁶

5
6 Given the many different types of programs that are designed to provide mental health or SUD
7 services as an alternative to incarceration, for the purposes of this report, any program that
8 addresses substance use or mental health in a justice-involved or justice-related setting or program
9 will be denoted as a “diversion program.” A recent issue brief from the National Conference of
10 State Legislatures (NCSL)⁷ further explains that “Pretrial diversion programs are post-arrest
11 interventions that occur at some point prior to final entry of judgment. Programs can take place
12 before charges are filed, before first appearance or before adjudication.”

13
14 Public health and public justice and law enforcement officials generally agree on the considerable
15 need to treat mental illness and SUDs. Data reported by the U.S. Substance Abuse and Mental
16 Health Services Administration (SAMHSA) show much greater prevalence of mental illness and
17 SUDs in jails and prisons compared to the general population. It is estimated that:⁸

- 18
- 19 • 18 percent of the general population has a mental illness; 44 percent of those in jail and
20 37 percent of those in prison have a mental illness;
- 21 • 11 percent of 18–25-year-olds, and 6 percent of those over 25 years old have a SUD; and
- 22 • 63 percent of people in jail and 58 percent in prison have a SUD.

23
24 In terms of sheer numbers, “1.2 million individuals living with mental illness sit in jail and prison
25 each year.”⁹ Making matters more challenging, more than 60 percent of individuals with a history
26 of mental illness do not receive treatment while incarcerated, and more than 50 percent of
27 individuals receiving medication for mental health conditions stop taking them upon being
28 incarcerated.¹⁰ The National Institutes on Drug Abuse says that estimates for SUD prevalence in
29 jails and prisons have been as high as 65 percent.¹¹

30 31 DISCUSSION

32 33 *Are Diversion Programs an Effective Method of Intervention for Individuals with Mental Illness or* 34 *Substance Use Disorder Involved with the Justice System?*

35
36 The first issue to address is whether diversion programs are an effective method of intervention for
37 individuals with a mental illness or SUD involved with the justice system. If so, what elements of a
38 diversion program demonstrate efficacy? For the purposes of this report, at least two metrics for
39 “efficacy” can be viewed as to whether individuals receive and continue to engage in treatment, as
40 well as whether they become re-incarcerated. While it is beyond the scope of this report to evaluate
41 the 4,000+ programs in existence in the United States, there are innumerable examples of programs
42 reporting that individuals enrolled in diversion programs not only start and continue treatment but
43 are also less likely to return to jail or prison or be re-arrested. Proponents of diversion programs
44 cite multiple economic and other benefits, including that they can connect hundreds of thousands of
45 individuals to medications for opioid use disorder (OUD).

46
47 A sample of meta-analyses also show general positivity, but identify challenges that come with
48 evaluating such programs:

- 1 • A 2012 meta-analysis found that adult drug courts are effective “in reducing
2 recidivism...[and] The evidence assessing DWI courts’ effectiveness is very promising but
3 more experimental evaluations are needed. Juvenile drug courts typically produce small
4 reductions in recidivism.”¹²
- 5 • A 2013 meta-review broadly found benefits of juvenile justice diversion programs.¹³
- 6 • A 2016 review of juvenile justice programs found, “There is no evidence that juvenile drug
7 courts are more or less effective than traditional court processing in terms of reducing
8 juveniles’ recidivism and drug use, but there is also no evidence of harm. The quality of
9 the body of evidence is very low, however, so we have little confidence in these null
10 findings.”¹⁴
- 11 • A 2016 guide from the National Drug Court Institute cited multiple studies showing that,
12 “Use of all three [MOUD] medications is associated with significantly reduced use of
13 unauthorized opioids among probationers, parolees, and other persons with opioid use
14 disorders involved in the criminal justice system.”¹⁵
- 15 • A 2017 review of mental health courts (MHC) found that, “Overall, a small effect of MHC
16 participation on recidivism was noted, compared with traditional criminal processing.
17 Findings suggest the need for research to identify additional sources of variability in the
18 effectiveness of MHCs.”¹⁶
- 19 • A 2019 systematic review of drug courts found that, “Treatment accessed via community-
20 based diversion is effective at reducing drug use in Class A drug-using offenders. Evidence
21 of a reduction in offending amongst this group as a result of diversion is uncertain. Poor
22 methodological quality and data largely limited to US methamphetamine users limits
23 available evidence.”¹⁷
- 24 • A 2020 literature review of mental health courts found that, while research generally
25 supports MHCs’ positive effects to reduce recidivism, there are inconsistencies with
26 overall study designs, data collection, lack of adequate controls and other methodological
27 faults.¹⁸
- 28 • Another 2020 meta-analysis found that, “diversion programs for low-level drug offenders
29 are likely to be cost-effective, generating savings in the criminal justice system while only
30 moderately increasing healthcare costs. Such programs can reduce incarceration and its
31 associated costs and avert overdose deaths and improve quality of life for PWID [people
32 who inject drugs], PWUD [people who use drugs], and the broader population (through
33 reduced HIV and HCV transmission).”¹⁹

34
35 Considering individual programs reporting broad benefits²⁰ and meta-analyses showing benefits as
36 well as raising questions about how broad those benefits might be, it seems prudent to call for
37 additional research as well as mechanisms to identify best practices. For example, some programs
38 to treat OUD might prohibit use of medications for opioid use disorder (MOUD) or rely on non-
39 evidence-based approaches. The Board of Trustees notes, however, that what works in one
40 jurisdiction may not work in another—and given the evidence that points to the overall benefits and
41 lack of harm, we believe that the AMA should continue to support these programs. To guide
42 programs, we highlight that professional medical organizations have published multiple guidelines
43 and treatment considerations for diversion programs and care for individuals involved with the
44 justice system, including the American Society of Addiction Medicine,²¹ American Psychiatric
45 Association,²² and Providers Clinical Support System.²³

46
47 There are many potential elements of “a comprehensive system of community-based supports and
48 services.” This includes benefits provided by “wraparound services,” such as community-based
49 interagency cooperation, care coordination, child and/or family teams, unified plans of care,
50 evidence-based systems of care, and other areas.²⁴ Additional guidance can be found in recent

1 SAMHSA grants for diversion programs in three jurisdictions.²⁵ These grants identify multiple
2 types of services that may be useful in a diversion program, including motivational interviewing;
3 crisis intervention training; psychiatric/psychosocial rehabilitation; dialectical behavior therapy;
4 community-based treatment; case management; comprehensive psychiatric services, including
5 psychotherapy and supportive counseling; substance use and detoxification treatment; housing and
6 employment support, including skills training; screening, assessment, referral, and treatment to
7 individuals at risk of entering the criminal justice system; and links between individuals and other
8 community resources. While not all diversion programs will have all these elements, the Board of
9 Trustees believes that the AMA should support development of diversion programs that include
10 broad-based community support that include these types of resources.

11
12 *Should Diversion Programs be Available to Both Nonviolent and Violent Offenders?*

13
14 The second issue is whether diversion programs should be available to both nonviolent and violent
15 offenders. It is first important to distinguish that *access to a diversion program* is related to—but
16 different from than *access to evidence-based treatment* for a mental illness or SUD within the
17 justice system. In 2022, the DOJ issued guidance making it clear that the Americans with
18 Disabilities Act (ADA) protects individuals with an OUD to continue treatment for an OUD while
19 incarcerated, including protecting continuity of care with MOUD.²⁶ The AMA has advocated in
20 multiple legal, legislative, and other forums that individuals involved with the justice system have a
21 medical—and constitutional right—to continue OUD while incarcerated. This advocacy is
22 highlighted in seminal cases: *Smith v. Aroostook County*²⁷ and *Pesce v. Coppinger*.²⁸ By extension,
23 an individual also likely has statutory and constitutional rights to MOUD—or other evidence-based
24 care—in a diversion program, but as the DOJ points out, there may be nuances if “the individual is
25 currently engaged in illegal drug use.”²⁹ The National Institute on Drug Abuse (NIDA) explains
26 that:

27
28 The chronic nature of addiction means that for some people relapse, or a return to
29 drug use after an attempt to stop, can be part of the process, but newer treatments
30 are designed to help with relapse prevention. Relapse rates for drug use are similar
31 to rates for other chronic medical illnesses. If people stop following their medical
32 treatment plan, they are likely to relapse.³⁰

33
34 The Board of Trustees believes that AMA support for individuals being able to stay in treatment
35 even if they engaged in illegal drug use is a natural extension of existing AMA policy to not punish
36 people because they have a SUD.

37
38 With respect to whether diversion programs should be available to non-violent and violent
39 offenders, given the evidence showing benefits of these programs—even if limited in some cases—
40 the AMA should continue to support access to evidence-based care, including MOUD, for non-
41 violent offenders. Notably, no change in policy is needed to meet this result. Whether to support
42 and advocate for diversion programs to be available to individuals charged or convicted of violent
43 offenses, however, raises multiple issues.

44
45 The first issue is whether those charged or convicted of a violent offense are legally eligible for a
46 diversion program. The U.S. Government Accountability Office (GAO) reports that, “adult drug
47 courts funded by DOJ grants are prohibited by law from using grant funding to include individuals
48 with prior or current violent offenses in their programs.”³¹ The GAO pointed out, however, that, “a
49 few adult drug courts told us that they admit violent offenders, by ensuring that they do not use
50 federal funding to serve these clients.” The GAO, which interviewed representatives from 44 adult
51 drug courts from a mix of rural, suburban, urban, and tribal adult drug courts, highlighted that some

1 violent offenders and those convicted of drug-related crimes would benefit from drug court
2 services. State law also commonly excludes individuals charged or convicted of a violent offense—
3 or having been convicted within a certain time period in the past.

4
5 The National Association of Drug Court Professionals counsels that, “Evidence does not support
6 blanket disqualification from treatment court for persons with a history of violent crimes. Instead,
7 persons charged with offenses involving violence, or who have a history of such offenses, should
8 be evaluated on a case-by-case basis to determine if they can be safely supervised in treatment
9 court.”³² The Board of Trustees agrees. Just as AMA policy does not discriminate against an
10 individual’s right to receive treatment based on external factors, the AMA should not discriminate
11 against access to evidence-based care for SUD and mental illness based on carceral status or
12 judicial supervision. As noted above, the provision of evidence-based care for mental illness and
13 SUDs has strong constitutional protections. And as discussed below, current AMA policy strongly
14 supports evidence-based care for individuals with a mental illness or SUD in jails and prisons.

15
16 Saying that the AMA should not oppose participation in a diversion program does not mean,
17 however, that there should not be comprehensive considerations about which individuals would
18 benefit most from participation in a diversion program. Such considerations, moreover, should
19 include whether an individual’s participation constitutes a threat to public safety. Thankfully, there
20 are robust eligibility criteria to help judicial and health care professionals make those
21 determinations. This guidance can help ensure “equitable access, services, and outcomes for all
22 sociodemographic and sociocultural groups,” including “guidance for treatment courts to monitor
23 and rectify unwarranted cultural disparities.”³³ The eligibility guidance, moreover, can help
24 diversion programs remove inappropriate restrictions and exclusions, ensure evidence-based care,
25 connect individuals to complementary services, as well as avoid conflicts of interest. And just as
26 important, the Board of Trustees agrees that:

27
28 All persons meeting evidence-based eligibility criteria for treatment court receive
29 the same opportunity to participate and succeed in the program regardless of their
30 sociodemographic characteristics or sociocultural identity, including but not
31 limited to their race, ethnicity, sex, gender identity, sexual orientation, age,
32 socioeconomic status, national origin, native language, religion, cultural practices,
33 and physical, medical, or other conditions.³⁴

34 35 AMA POLICY

36
37 A bedrock of AMA advocacy is found in Policy H-430-987, “Medications for Opioid Use Disorder
38 in Correctional Facilities,” which provides, “Our AMA endorses: (a) the medical treatment model
39 of employing medications for opioid use disorder (OUD) as the standard of care for persons with
40 OUD who are incarcerated.” This policy also calls for the AMA to advocate for

41
42 . . . legislation, standards, policies, and funding that require correctional facilities
43 to increase access to evidence-based treatment of OUD, including initiation and
44 continuation of medications for OUD, in conjunction with psychosocial treatment
45 when desired by the person with OUD, in correctional facilities within the United
46 States and that this apply to all individuals who are incarcerated, including
47 individuals who are pregnant, postpartum, or parenting.

1 The Board of Trustees recommends that diversion programs be held to the same standards.

2
3 The AMA also supports “veterans courts” as “a method of intervention for veterans who commit
4 criminal offenses that may be related to a neurological or psychiatric disorder.” (Policy H-510-979,
5 “Support for Veterans Courts”). If AMA policy supports broad access to veterans’ courts as a
6 matter of policy, the Board of Trustees does not see any reason why such policy should not also
7 apply to other types of diversion programs. Similarly, AMA policy calling to support “justice
8 reinvestment initiatives ... and assessing individuals for substance use disorders and mental health
9 issues, expanding jail diversion and jail alternative programs, and increasing access to reentry and
10 treatment programs,” does not distinguish between nonviolent and violent offenses.
11 (Policy H-94-931, “AMA Support for Justice Reinvestment Initiatives”).
12

13 Finally, AMA Ethics Policy recognizes that, “Although convicted criminals have fewer rights and
14 protections than other citizens, being convicted of a crime does not deprive an offender of all
15 protections under the law.” (Policy E-9.7.2, “Court-Initiated Medical Treatment in Criminal
16 Cases”). This policy also counsels for physicians to, “Treat patients based on sound medical
17 diagnoses, not court-defined behaviors. While a court has the authority to identify criminal
18 behavior, a court does not have the ability to make a medical diagnosis or to determine the type of
19 treatment that will be administered.” (Policy E-9.7.2, “Court-Initiated Medical Treatment in
20 Criminal Cases”). Thus, while the justice system may have guidance about which individuals are
21 eligible for a diversion program, the physician’s role is not to raise barriers to such care.
22

23 RECOMMENDATIONS

24
25 The Board of Trustees recommends that existing policy – Policy H-100.955, entitled, “Support for
26 Drug Courts” – be amended by addition and deletion in lieu of Resolution 202 as follows:
27

28 Support for Diversion Programs, Including Drug Courts, Mental Health Courts, Veterans 29 Courts, Sobriety Courts, and Similar Programs

30
31 Our AMA:

- 32
33 (1) supports the establishment and use of diversion and treatment programs ~~drug~~
34 ~~courts, including drug courts, mental health courts, veterans courts, sobriety courts,~~
35 and other types of similar programs, as an effective method of intervention within a
36 comprehensive system of community-based supports and services for individuals
37 with a mental illness or substance use disorder involved in the justice system
38 ~~addictive disease who are convicted of nonviolent crimes;~~
39 (2) encourages legislators and court systems to establish diversion and treatment
40 programs ~~drug courts~~ at the state and local level in the United States; ~~and~~
41 (3) encourages diversion and treatment programs ~~drug courts~~ to rely upon evidence-based
42 models of care, including medications for opioid use disorder, for those who the judge or
43 court determine would benefit from intervention, including treatment, rather than
44 incarceration; and
45 (4) supports individuals enrolled in diversion or treatment programs not be removed from a
46 program solely because of evidence showing that an individual used illegal drugs while
47 enrolled. (Modify HOD Policy)

Fiscal Note: Less than \$500.

REFERENCES

- ¹ All Rise, formerly known as the National Association of Drug Court Professionals. <https://allrise.org/about/treatment-courts/>
- ² Pretrial Diversion. National Conference of State Legislatures. September 2017. Available at <https://www.ncsl.org/civil-and-criminal-justice/pretrial-diversion>
- ³ Drug Courts: A Smart Approach to Criminal Justice. Office of National Drug Control Policy. May 2011. Available at https://obamawhitehouse.archives.gov/sites/default/files/ondcp/Fact_Sheets/drug_courts_fact_sheet_5-31-11.pdf
- ⁴ See, for example, letter from AMA Executive Vice President and CEO, James L. Madara, MD, to the National Governors Association, American Medical Association comments on “Reducing Prescription Drug Abuse: Lessons Learned, from an NGA Policy Academy.” December 17, 2013. Available at <https://searchlf.ama-assn.org/letter/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2Fnga-recommendations-lessons-learned.pdf>
- ⁵ Lucas, David; Arnold, Aaron. Center for Court Innovation. July 2019. Available at https://www.cossup.org/Content/Documents/Articles/Court_Responses_To_The_Opioid_Epidemic_Happening_Now.pdf
- ⁶ “Pretrial Diversion Program.” Justice Manual. Title 9. U.S. Department of Justice. Updated February 2023. Available at <https://www.justice.gov/jm/jm-9-22000-pretrial-diversion-program>
- ⁷ The Legislative Primer Series for Front-End Justice: Deflection and Diversion. National Conference of State Legislatures. August 2023. Available at <https://documents.ncsl.org/wwwncsl/Criminal-Justice/Deflection-Diversion-f02.pdf>
- ⁸ About Criminal and Juvenile Justice. U.S. Substance Abuse and Mental Health Services Administration. Last Updated March 2, 2022. Available at <https://www.samhsa.gov/criminal-juvenile-justice>
- ⁹ Access to Mental Health Care and Incarceration. Mental Health America. Available at <https://www.mhanational.org/issues/access-mental-health-care-and-incarceration> Last accessed February 23, 2024
- ¹⁰ Mental Health Treatment While Incarcerated. National Alliance on Mental Illness. Available at <https://www.nami.org/Advocacy/Policy-Priorities/Improving-Health/Mental-Health-Treatment-While-Incarcerated>
- ¹¹ Criminal Justice Drug Facts. National Institutes on Drug Abuse. Last updated June 2020. Available at <https://nida.nih.gov/publications/drugfacts/criminal-justice>
- ¹² Ojmarh Mitchell, David B. Wilson, Amy Eggers, Doris L. MacKenzie, Assessing the effectiveness of drug courts on recidivism: A meta-analytic review of traditional and non-traditional drug courts, Journal of Criminal Justice, Volume 40, Issue 1, 2012, Pages 60-71, <https://doi.org/10.1016/j.jcrimjus.2011.11.009>. <https://www.sciencedirect.com/science/article/pii/S0047235211001255>
- ¹³ The Effect of Youth Diversion Programs on Recidivism. A Meta-Analytic Review. Criminal Justice and Behavior. Vol. 40. No. 5. May 2013. Available at http://users.soc.umn.edu/~uggen/Wilson_CJB_13.pdf
- ¹⁴ Meta-Analysis of Research on the Effectiveness of Juvenile Drug Courts. Emily E. Tanner-Smith, PhD Mark W. Lipsey, PhD. David B. Wilson, PhD. Peabody Research Institute at Vanderbilt University. Available at <https://www.ojp.gov/pdffiles1/ojdp/grants/250439.pdf>
- ¹⁵ Drug Court Practitioner Fact Sheet. Medication-Assisted Treatment for Opioid Use Disorders in Drug Courts. National Drug Court Institute. August 2016. Vol. XI, No. 2. Available at https://allrise.org/wp-content/uploads/2022/07/mat_fact_sheet-1.pdf
- ¹⁶ Lowder EM, Rade CB, Desmarais SL. Effectiveness of Mental Health Courts in Reducing Recidivism: A Meta-Analysis. Psychiatr Serv. 2018 Jan 1;69(1):15-22. doi: 10.1176/appi.ps.201700107. Epub 2017 Aug 15. PMID: 28806894.
- ¹⁷ Hayhurst, K. P., Leitner, M., Davies, L., Millar, T., Jones, A., Flentje, R., Hickman, M., Fazel, S., Mayet, S., King, C., Senior, J., Lennox, C., Gold, R., Buck, D., & Shaw, J. (2019). The effectiveness of diversion programmes for offenders using Class A drugs: A systematic review and meta-analysis. Drugs: Education, Prevention & Policy, 26(2), 113–124. <https://doi.org/10.1080/09687637.2017.1398715>
- ¹⁸ Otto, H. D. (2020). A review of literature on mental health court goals, effectiveness, and future implications. Illinois Criminal Justice Information Authority.

¹⁹ Bernard CL, Rao IJ, Robison KK, Brandeau ML. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis. *PLoS Med.* 2020 Oct 13;17(10):e1003239. doi: 10.1371/journal.pmed.1003239. PMID: 33048929; PMCID: PMC7553283.

²⁰ For example, a study supported by the U.S. Department of Justice, National Institute of Justice evaluating the Multnomah County Drug Court in Oregon showed that participating offenders were rearrested less frequently than offenders going through traditional court. Drug court participants cost local taxpayers \$5,071 less on average over a 30-month period than those processed through traditional court. Overall, the drug courts saved Multnomah County more than \$1.5 million per year or approximately \$5,000 on average for each of the program participants in the study.

²¹ Drug Court Resources. American Society of Addiction Medicine. Available at <https://www.asam.org/quality-care/clinical-guidelines/clinical-resources/drug-court-resources>

²² Examining Mental Health Courts. American Psychiatric Association. Available at <https://www.psychiatry.org/news-room/apa-blogs/examining-mental-health-courts>

²³ Drug Court/Treatment Court. Providers Clinical Support System. Available at <https://pcssnow.org/topics/drug-court-treatment-court/>

²⁴ “Wraparound Process.” Literature review. Washington, D.C. Office of Juvenile Justice and Delinquency Prevention. https://www.ojjdp.gov/mpg/litreviews/Wraparound_Process.pdf Last updated April 2014.

²⁵ Law Enforcement and Behavioral Health Partnerships for Early Diversion. U.S. Substance Abuse and Mental Health Services Administration. Last Updated January 30, 2024. Available at <https://www.samhsa.gov/criminal-juvenile-justice/grants-grantees/early-diversion>

²⁶ The Americans with Disabilities Act and the Opioid Crisis: Combating Discrimination Against People in Treatment or Recovery. U.S. Department of Justice. Civil Rights Division. April 5, 2022. Available at https://archive.ada.gov/opioid_guidance.pdf

²⁷ See, generally, *Smith v. Aroostook County*. ACLU of Maine. <https://www.aclumaine.org/en/cases/smith-v-arostook-county>

²⁸ See, generally, *Pesce v. Coppinger*. ACLU of Massachusetts. <https://www.aclum.org/en/cases/pesce-v-coppinger>

²⁹ The Americans with Disabilities Act and the Opioid Crisis: Combating Discrimination Against People in Treatment or Recovery. U.S. Department of Justice. Civil Rights Division. April 5, 2022. Available at https://archive.ada.gov/opioid_guidance.pdf

³⁰ NIDA. 2023, September 25. Treatment and Recovery. Retrieved from <https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery-on-February-24-2024>.

³¹ Factors Related to Eligibility and Acceptance of Offers to Participate in DOJ Funded Adult Drug Courts. U.S. Government Accountability Office. February 2023. Available at <https://www.gao.gov/assets/gao-23-105272.pdf>

³² “Adult Treatment Court Best Practice Standards.” All Rise. 2023. https://allrise.org/wp-content/uploads/2023/12/All-Rise-Adult-Treatment-Court-Best-Practice-Standards-2nd-Ed.-I-VI_final.pdf

³³ “Adult Treatment Court Best Practice Standards.” All Rise. 2023. https://allrise.org/wp-content/uploads/2023/12/All-Rise-Adult-Treatment-Court-Best-Practice-Standards-2nd-Ed.-I-VI_final.pdf

³⁴ “Adult Treatment Court Best Practice Standards.” All Rise. 2023. https://allrise.org/wp-content/uploads/2023/12/All-Rise-Adult-Treatment-Court-Best-Practice-Standards-2nd-Ed.-I-VI_final.pdf

REPORT OF THE BOARD OF TRUSTEES

B of T Report 17-A-24

Subject: Drug Policy Reform

Presented by: Willie Underwood, III, MD, MSc, MPH, Chair

Referred to: Reference Committee B

1 INTRODUCTION

2
3 At the 2023 Annual Meeting of the American Medical Association (AMA) House of Delegates (HOD),
4 Resolution 203 entitled, “Drug Policy Reform,” was introduced by the Medical Student Section and
5 called on the AMA to:

- 6
7 • Advocate for federal and state reclassification of drug possession offenses as civil
8 infractions and the corresponding reduction of sentences and penalties for individuals
9 currently incarcerated, monitored, or penalized for previous drug-related felonies;
- 10 • Support federal and state efforts to expunge criminal records for drug possession
11 upon completion of a sentence or penalty at no cost to the individual; and
- 12 • Support federal and state efforts to eliminate incarceration-based penalties for
13 persons under parole, probation, pre-trial, or other criminal supervision for drug
14 possession.

15
16 Ultimately, Resolution 203 was referred to the Board of Trustees for study. Some of the primary reasons
17 for referral included the need for more background information on criminal penalties for drug possession;
18 the need to review the role of expungement for those convicted of drug-related crimes for drug
19 possession; and the need to identify the AMA’s unique role concerning other issues relating to drug
20 possession. This report also provides background information; discusses relevant policy and public health
21 considerations; presents AMA policy; and makes recommendations.

22 23 BACKGROUND

24
25 The National Center for Drug Abuse Statistics (NCDAS) reports that, “1.16 million Americans are
26 arrested annually for drug related offenses” and that, “227,655 Americans are arrested annually for the
27 possession of heroin, cocaine, and derivative products.” At the same time, NCDAS reports that, “40,446
28 Americans are arrested annually for the possession of synthetic drugs.”¹ A 2022 report from the Pew
29 Charitable Trusts found that between 2009-2019, “87 percent [of] drug arrests were for possession; the
30 rest were for sale or manufacturing.”² In the federal prison system, more than 44 percent of individuals
31 were incarcerated because of a drug-related offense.³

32
33 Incarceration rates for drug-related offenses, however, are decreasing. While the figures vary by state,
34 between 2009-2019, “The prison population in the 39 states with available data dropped by approximately
35 117,000 individuals from 2009 to 2019. The decrease in the number of people in prison for drug offenses
36 accounted for 61% of this total decline. Similarly, prison admissions fell by more than 131,000 from
37 2009 to 2019, with the drop in drug-related admissions accounting for 38 percent of the total.”⁴

38 There are significant racial disparities for those incarcerated for a drug-related offense. While use and
39 dependence rates between groups only vary by 1-2 percent, Black people are far more likely to be arrested

1 and incarcerated.⁵ These disparities have existed for decades,⁶ and they unfortunately continue. Research
2 from 2000 showed that Black individuals made up more than 60 percent of those sent to state prisons for
3 a drug-related offense⁷. The same study reported that, “Nationwide, black men are sent to state prison on
4 drug charges at 13 times the rate of white men.” More recent data show that, “prison admissions for Black
5 individuals for drug offenses decreased by 59 percent between 2009 and 2019, accounting for a quarter
6 (26 percent) of the total drop in admissions over that span.”⁸ Despite these decreases, disparities remain.
7 According to the Pew Charitable Trusts, “Black people made up 28 percent of admissions and 36 percent
8 of the population in prison for drug convictions in 2019, which are two and three times, respectively, their
9 share of the general population.”

10
11 The data also show differences in the prison population when race and gender are both considered.
12 Between 2009-2019, there was a “4 percent increase in admissions of White individuals for drug
13 offenses...[and] a 32 percent increase in the number of White females entering prison with drug
14 convictions. By comparison, admissions for drug offenses fell 71 percent for Black females and 4 percent
15 for White males.”⁹

16
17 Regarding youth-related drug offenses, between 2011-2020, there were an estimated 42,280 juvenile
18 arrests.¹⁰ Juvenile arrests for drug offenses decreased 72 percent between 2016-2020.¹¹ According to the
19 U.S. Office of Juvenile Justice and Delinquency Prevention, “the peak year for juvenile drug abuse
20 violation arrest rates was 1997 ... [and] overall from 1980 to 2020, the drug abuse violation arrest rate for
21 youth ages 15-17 decreased 64 percent , compared with a 21 percent decrease for young adults ages
22 18-20 and a 7 percent increase for young adults ages 21-24.”¹²

23 24 *Civil Infractions, Misdemeanors, and Felonies*

25
26 It is beyond the scope of this report to go into extensive detail about the wide variability and extensive
27 nuances in federal or state criminal codes concerning drug possession.¹³ A brief overview, however, may
28 be useful to underscore that the AMA’s unique role for this report is to focus on public health rather than
29 criminal law.

30
31 In general, a misdemeanor means any crime that does not amount to a felony.¹⁴ Misdemeanors generally
32 are those criminal offenses that carry punishments by incarceration of a year or less.¹⁵ A felony typically
33 denotes a crime more serious than a misdemeanor that subjects an individual to incarceration.¹⁶
34 Punishments for a felony typically are incarceration for periods of one year or more.¹⁷ An “infraction” can
35 have different meanings depending on the state, but it generally refers to a criminal act that is less serious
36 and carries less severe penalties than a misdemeanor, such a speeding ticket or parking meter violation.¹⁸
37 Criminal codes also distinguish “simple possession”¹⁹ from possession with intent to sell or distribute.²⁰

38
39 To prove a statutory crime, it is required to show both that an individual committed a criminal act, and in
40 so doing, acted with the state of mind requisite to constitute the crime in question.²¹ For simple drug
41 possession, the prosecutor must prove, generally, that the illicit substance was knowingly and/or
42 intentionally in the accused individual’s possession. Simple possession crimes differ from those with
43 intent to sell, manufacture or deliver in that simple possession typically is limited to personal use or
44 control whereas the crime of possession with intent to sell, manufacture or deliver requires proving both
45 possession/control of an illicit substance and that the individual had the intent to sell, manufacture or
46 deliver the substance. To prove intent to sell, manufacture or deliver, additional facts would be required,
47 which could come from undercover law enforcement or other witness testimony, exchange of money,
48 possession of manufacturing equipment, video surveillance, customer lists or other factual elements that
49 show more than just an intent limited to personal use or control.

50 There are a limited number of states that have decriminalized certain drug-related offenses. In 2020,
51 Oregon voters passed Ballot Measure 110, which among other things, effectively decriminalized
52 possession of certain amounts of Schedule I Controlled Substances, including cocaine, heroin, psilocybin,

1 and methamphetamine. Possession of amounts greater than the law authorized, as well as possession for
2 non-prescribed Schedule II-IV Controlled Substances, would subject an individual to a “Class E”
3 violation. Violators would be subject to a fine or agree to undertake a screening in lieu of a fine.²² Since
4 the measure went into effect, more than 7,600 individuals have received a Class E violation with
5 methamphetamine (55 percent) and Schedule II Controlled Substances (26 percent) the top reasons for
6 violations.²³ In response to multiple factors, including considerable public concern about reported
7 increases in public drug use, mortality and crime, the Oregon Legislature effectively ended
8 decriminalization of illegal drugs for personal use with passage of House Bill 4002, which the governor
9 said she will sign.²⁴ HB 4002 passed with wide, bipartisan margins in both the Oregon House and
10 Senate.²⁵

11
12 Additional state actions have occurred regarding psychedelics and other substances. For example,
13 legislative efforts surrounding Schedule I psychedelics are increasing. More than two dozen states have
14 considered or enacted measures to further study psychedelics, regulate their use, and establish pilot
15 treatment programs. For example, certain psychedelics were decriminalized in Washington, D.C. in
16 2021²⁶ and Colorado in 2022.²⁷ In 2021, drug possession was decriminalized in Washington state as a
17 result of a state supreme court decision in *State v. Blake*, which found the state’s drug possession statute
18 unconstitutional because it lacked an intent requirement.²⁸ The Washington Legislature re-criminalized
19 drug possession (as a misdemeanor) several months later in a special session.²⁹ The Washington law also
20 included provisions for diversion programs as an alternative to incarceration. The 2024 state legislative
21 sessions are actively considering many similar proposals.³⁰

22 23 *Expungement*

24
25 The Board of Trustees explained in [Board of Trustees Report 17-A-22](#) that it is important to recognize
26 that expungement, destruction, and sealing are legal processes.³¹ An expungement process may involve
27 multiple steps where the result is to remove a record of arrest and/or conviction from the official state or
28 federal record. The idea is that post-expungement, the record never existed. While an expungement may
29 “erase” a record, “sealing” hides the record from public view. More specifically, when “sealed,” the
30 record can be accessed under certain circumstances.³² Finally, “destruction” of a record generally means
31 to physically destroy it. When a record is “destroyed,” there is no record remaining whatsoever.³³ It is
32 important to note that specific definitions may vary by state.

33
34 Under federal law, the record of a conviction for drug possession may be able to be expunged depending
35 on the circumstances. An individual must qualify for expungement and undertake the process to formally
36 seek expungement. There are different requirements for those 21 years of age and older and those
37 younger than 21. The record of the underlying expungement also offers protection against future adverse
38 use, but it is retained by the U.S. Department of Justice.³⁴

39
40 At the state level, eligibility, and procedures for expungement of drug possession crimes vary
41 considerably.³⁵ State laws often are non-specific to controlled substances. In other words, eligibility and
42 procedures would be dependent on multiple factors, including whether a drug possession crime was a
43 misdemeanor or felony, and whether there were additional circumstances, including whether there were
44 other crimes committed and whether they were violent or nonviolent. Other states have waiting periods
45 after a sentence has been served, but these also are dependent on other factors that may be present,
46 including whether the drug possession crime was a first offense. States typically have different processes
47 and qualifications for minors.³⁶ In contrast, 24 states have specific procedures when the state has
48 decriminalized cannabis for medical and/or adult use.³⁷

1 DISCUSSION

2
3 *Reclassification of Drug Possession Offenses as Civil Infractions*
4

5 Proponents of decriminalizing drug possession cite multiple potential benefits, including saving money
6 from incarceration, focusing resources on treatment and social services, and other benefits such as
7 reducing the stigma surrounding drug use and having a substance use disorder.³⁸ Being incarcerated does
8 not often lead to treatment for a substance use disorder. The Pew Charitable Trusts reported data showing
9 that “1.1 million people with past-year illicit drug dependence or misuse reported being arrested and
10 booked in the past year...[but] 1 in 13—85,199—reported receiving drug treatment while in jail or prison.
11 Further, the drug- or alcohol-related mortality rate in jails increased from 9 in 100,000 in 2009 to 26 in
12 100,000 in 2019.”³⁹ Proponents also point to collateral consequences of having a criminal record for drug
13 possession, including denial of public benefits, losing custody of children, loss of voting rights, inability
14 to secure loans or financial aid, to name a few negative effects.⁴⁰ A meta-analysis of drug
15 decriminalization policies in 2020 focused on “evaluating effects of drug decriminalization or legal
16 regulation on drug availability, use or related health and social harms globally.”⁴¹ The analysis concluded
17 there was “a need for a broadening of the metrics used to assess the impacts of drug decriminalization and
18 legal regulation.”
19

20 Except for cannabis, there are few tangible examples in the United States on which to evaluate the
21 potential public health and collateral benefits of reclassifying drug possession offenses as civil infractions.
22 The Board of Trustees notes that our AMA Council on Science and Public Health has issued two previous
23 reports detailing the continued public health dangers associated with cannabis. Oregon, Colorado, and
24 Washington, D.C. are the only states to specifically decriminalize illicit substances, while multiple others
25 have enacted measures to direct law enforcement to treat possession of, for example, certain psychedelics,
26 as a “low priority.”⁴² In Oregon, the language of Ballot Measure 110 based part of its argument on the
27 premise that, “People suffering from addiction are more effectively treated with health care services than
28 with criminal punishments. A health care approach includes a health assessment to figure out the needs of
29 people who are suffering from addiction, and it includes connecting them to the services they need.” The
30 reality of Ballot Measure 110’s effects, however, demonstrate widespread challenges with connecting
31 individuals to screening, treatment, or recovery.
32

33 Three main studies of the effects of Oregon Ballot Measure 110 show that it generally failed to reduce
34 overdose-related fatality, and that it did not connect individuals to screening, treatment, or recovery. One
35 study found that Ballot Measure 110 “caused 182 additional unintentional drug overdose deaths to occur
36 in Oregon in 2021. This represents a 23 percent increase over the number of unintentional drug overdose
37 deaths predicted if Oregon had not decriminalized drugs.”⁴³ A separate study, however, found that there
38 was no significant change in death rates.⁴⁴ Perhaps most concerning is that Ballot Measure 110’s promise
39 of increased connections to treatment and increased access to evidence-based care has not been realized.
40 A state audit of Ballot Measure 110 discussed the widespread hopes for the ballot measure to improve
41 access to care for substance use disorders, reduce health inequities, and other laudable goals. The reality,
42 unfortunately, has been hampered by widespread challenges, including inefficient “program governance,”
43 “silos and fragmentation in the delivery of mental health and substance use disorder treatment,” poor
44 “stakeholder collaboration,” poor data collection and reporting structures, and a lack of coordination
45 between public health, public safety, and other agencies.⁴⁵
46

47 The Board of Trustees understands that the original intent of Oregon Ballot Measure 110 included an
48 effort to increase access to treatment, but there is a clear lack of evidence demonstrating public health
49 benefits or increases in access to evidence-based mental health or substance use disorder services in the
50 state. The available research, furthermore, does not clearly demonstrate tangible benefits on a wider scale.
51 The Board of Trustees observes that drug-related overdoses in Oregon have increased from 1,147 deaths
52 reported for the 12-month period between October 2020 and October 2021 to 1,683 deaths reported for

1 the 12-month period between October 2022 and October 2023.⁴⁶ The Board of Trustees believes that it is
2 premature to recommend decriminalizing drug possession offenses as a public health benefit in the
3 absence of evidence demonstrating public health benefits.

4
5 *Expungement of Criminal Records for Drug Possession upon Completion of a Sentence*

6
7 As noted above, there are ongoing collateral consequences experienced by individuals convicted of drug
8 possession (or other) crimes. The Board of Trustees emphasized these consequences as part of Board of
9 Trustees Report 17-A-22, “Expungement, Destruction, And Sealing Of Criminal Records For Legal
10 Offenses Related To Cannabis Use Or Possession.” That report recommended support for expungement
11 of cannabis-related offenses when those offenses were no longer illegal (because of newly enacted state
12 laws). As the Board stated in BOT Report 17-A-22,

13
14 Even if a record is expunged or sealed, however, that may not address collateral
15 consequences of the arrest or conviction, e.g., potential professional licensing sanctions,
16 adverse employment actions, and qualification for government benefits, including loans
17 and housing. These collateral consequences can also suppress the local tax base by
18 locking people into unemployment or lower paying jobs and increase taxpayer costs due
19 to increasing likelihood of further involvement in the criminal legal system.⁴⁷

20
21 The Board of Trustees supports reducing barriers to address these social determinants of health, including
22 supporting federal and state efforts to expunge criminal records for drug possession upon completion of a
23 sentence or penalty. Given that individuals released from jail or prison may have limited financial means,
24 we also support that the expungement process consider an individual’s financial hardship.

25
26 *Incarceration-based Penalties for Persons under Parole, Probation, Pre-trial, or other Criminal*
27 *Supervision for Drug Possession.*

28
29 As with different state laws and policies concerning what constitutes a drug possession felony or
30 misdemeanor, there is likely even greater state variation in what constitutes a violation of parole,
31 probation, pre-trial, or other supervisory agreement with an individual charged or convicted of drug
32 possession. While drug possession while on parole might trigger an automatic revocation in some
33 jurisdictions, in others there would be discretion. This is why some commentators argue for the “need to
34 critically examine the revocation process for probationers and parolees who transgress the terms and
35 conditions of their community supervision.”⁴⁸ Other commentators cite drug use or drug possession as a
36 common reason for parole, probation or other supervisory violations.⁴⁹ The Board of Trustees notes that
37 AMA advocacy and policy focus primarily on helping ensure individuals involved with the justice system
38 have access to evidence-based care. We certainly encourage discretion by court officers but do not believe
39 that the AMA has the unique expertise or experience to make categorical determinations about judicial
40 discretion.

41
42 Your Board – in a separate board report under consideration at this meeting, Board of Trustees Report 16
43 – explains why diversion programs should not automatically exclude individuals because they may have
44 previously used illicit substances. Similarly, we argue that individuals should not be removed from a
45 diversion program solely because they used an illicit substance. The National Institute of Drug Abuse
46 explains that “The chronic nature of addiction means that for some people relapse, or a return to drug use
47 after an attempt to stop, can be part of the process, but newer treatments are designed to help with relapse
48 prevention. Relapse rates for drug use are similar to rates for other chronic medical illnesses. If people
49 stop following their medical treatment plan, they are likely to relapse.”⁵⁰ AMA support for individuals
50 being able to continue parole or probation even if they engaged in illegal drug use is a natural extension
51 of AMA policy to not punish people because they have a substance use disorder.

1 AMA POLICY

2
3 AMA policy includes “support [for] legislation that promotes the use of non-financial release options for
4 individuals charged with nonviolent crimes.” (Policy H-80-993, “Ending Money Bail to Decrease Burden
5 on Lower Income Communities”). AMA policy also supports a broad range of elements for individuals
6 who are incarcerated, including, “...(a) linkage of those incarcerated to community clinics upon release in
7 order to accelerate access to comprehensive health care, including mental health and substance use
8 disorder services, and improve health outcomes among this vulnerable patient population, as well as
9 adequate funding; (b) the collaboration of correctional health workers and community health care
10 providers for those transitioning from a correctional institution to the community; (c) the provision of
11 longitudinal care from state supported social workers, to perform foundational check-ins that not only
12 assess mental health but also develop lifestyle plans with newly released people; and (d) collaboration
13 with community-based organizations and integrated models of care that support formerly incarcerated
14 people with regard to their health care, safety, and social determinant of health needs, including
15 employment, education, and housing.” (Policy H-430-986, “Health Care While Incarcerated”). Whether
16 these elements could be achieved through decriminalization of drug possession crimes is not clear,
17 however, which is why your Board supports additional research to inform future decision making.

18
19 AMA policy also supports “automatic expungement, sealing, and similar efforts regarding an arrest or
20 conviction for a cannabis-related offense for use or possession that would be legal or decriminalized
21 under subsequent state legalization or decriminalization of adult use or medicinal cannabis.”
22 (Policy H-95.910, “Expungement, Destruction, and Sealing of Criminal Records for Legal Offenses
23 Related to Cannabis Use or Possession”). AMA’s cannabis-related expungement policy also extends to
24 protections for minors and for “ending conditions such as parole, probation, or other court-required
25 supervision because of a cannabis-related offense for use or possession that would be legal or
26 decriminalized under subsequent state legalization or decriminalization of adult use or medicinal
27 cannabis.” (Policy H-430.986, “Health Care While Incarcerated”). Finally, AMA policy also calls for
28 “fairness in the expungement and sealing of records.” (Policy H-60.916, “Youth Incarceration in Adult
29 Facilities”). These policies highlight issues of fairness with respect to expungement as well as support for
30 the principle that drug use or possession—by itself—should not be a cause for additional criminal
31 penalty.

32
33 RECOMMENDATIONS

34
35 The Board of Trustees recommends that the following recommendations be adopted in lieu of Resolution
36 203 and the remainder of the report be filed:

- 37
38 1. That the American Medical Association (AMA) will continue to monitor the legal and public
39 health effects of state and federal policies to reclassify criminal offenses for drug possession for
40 personal use; (New HOD Policy)
- 41 2. That the AMA will support federal and state efforts to expunge, at no cost to the individual,
42 criminal records for drug possession for personal use upon completion of a sentence or penalty;
43 (New HOD Policy) and
- 44 3. That the AMA support programs that provide comprehensive substance use disorder treatment
45 and social support to people who use or possess illicit drugs for personal use as an alternative to
46 incarceration-based penalties for persons under parole, probation, pre-trial, or other civic,
47 criminal, or judicial supervision. (New HOD Policy)

Fiscal Note: Less than \$500.

REFERENCES

- ¹ Drug Related Crime Statistics. National Center for Drug Abuse Statistics. Updated 2024. Available at <https://drugabusestatistics.org/drug-related-crime-statistics/>
- ² Drug Arrests Stayed High Even as Imprisonment Fell From 2009 to 2019. Pew Charitable Trusts. February 2022. Available at <https://www.pewtrusts.org/-/media/assets/2022/02/drug-arrests-stayed-high-even-as-imprisonment-fell-from-2009-to-2019.pdf>
- ³ Offenses. Federal Bureau of Prisons. Data updated weekly. Accessed February 29, 2024. https://www.bop.gov/about/statistics/statistics_inmate_offenses.jsp
- ⁴ Drug Arrests Stayed High Even as Imprisonment Fell From 2009 to 2019. Pew Charitable Trusts. February 2022. Available at <https://www.pewtrusts.org/-/media/assets/2022/02/drug-arrests-stayed-high-even-as-imprisonment-fell-from-2009-to-2019.pdf>
- ⁵ Ojmarrh Mitchell & Michael S. Caudy (2015) Examining Racial Disparities in Drug Arrests, Justice Quarterly, 32:2, 288-313, DOI: 10.1080/07418825.2012.761721
- ⁶ Langan, Patrick A. The Racial Disparity in U.S. Drug Arrests. Bureau of Justice Statistics. October 1, 1995. <https://bjs.ojp.gov/content/pub/pdf/r dusda.pdf>
- ⁷ Punishment and Prejudice: Racial Disparities in the War on Drugs. Human Rights Watch. <https://www.hrw.org/legacy/campaigns/drugs/war/key-facts.htm>
- ⁸ Drug Arrests Stayed High Even as Imprisonment Fell From 2009 to 2019. Pew Charitable Trusts. February 2022. Available at <https://www.pewtrusts.org/-/media/assets/2022/02/drug-arrests-stayed-high-even-as-imprisonment-fell-from-2009-to-2019.pdf>
- ⁹ Drug Arrests Stayed High Even as Imprisonment Fell From 2009 to 2019. Pew Charitable Trusts. February 2022. Available at <https://www.pewtrusts.org/-/media/assets/2022/02/drug-arrests-stayed-high-even-as-imprisonment-fell-from-2009-to-2019.pdf>
- ¹⁰ OJJDP Statistical Briefing Book. Online. Available: <https://ojjdp.ojp.gov/statistical-briefing-book/crime/faqs/QA05101>. Released on 7/8/2022.
- ¹¹ OJJDP Statistical Briefing Book. Online. Available: <https://ojjdp.ojp.gov/statistical-briefing-book/crime/faqs/QA05101>. Released on 7/8/2022.
- ¹² OJJDP Statistical Briefing Book. Online. Available: <https://ojjdp.ojp.gov/statistical-briefing-book/crime/faqs/qa5308>. Released on July 08, 2022.
- ¹³ Drug Possession Laws: 50-State Survey. Justia. Last reviewed September 2023. Available at <https://www.justia.com/criminal/offenses/drug-crimes/drug-possession-laws-50-state-survey/>
- ¹⁴ Misdemeanor. Definition & Legal Meaning. The Law Dictionary. <https://thelawdictionary.org/misdemeanor/>
- ¹⁵ What Happens in a Misdemeanor Case. U.S. Attorneys Office. Northern District of Illinois. <https://www.justice.gov/usao-ndil/programs/vwa-misdemeanor> Updated July 24, 2015.
- ¹⁶ Felony. Definition & Legal Meaning. The Law Dictionary. <https://thelawdictionary.org/felony/>
- ¹⁷ What Happens in a Felony Case. U.S. Attorneys Office. Northern District of Illinois. <https://www.justice.gov/usao-ndil/programs/vwa-felony> Last Updated July 24, 2015.
- ¹⁸ Infraction. Legal Information Institute. Cornell Law School. <https://www.law.cornell.edu/wex/infraction>
- ¹⁹ 21 U.S.C. § 844 - Penalties for simple possession. <https://www.govinfo.gov/content/pkg/USCODE-2011-title21/pdf/USCODE-2011-title21-chap13-subchapI-partD-sec844.pdf>
- ²⁰ See, for example, Code of Virginia § 18.2-248. Manufacturing, selling, giving, distributing, or possessing with intent to manufacture, sell, give, or distribute a controlled substance or an imitation controlled substance prohibited; penalties. Available at <https://law.lis.virginia.gov/vacode/title18.2/chapter7/section18.2-248/>
- ²¹ See, generally, “criminal law.” Legal Information Institute. Cornell Law School. Available at https://www.law.cornell.edu/wex/criminal_law
- ²² See, Oregon Judicial Department. ORS 153.062. Class E violation proceedings. Available at https://oregon.public.law/statutes/ors_153.062
- ²³ Class E Violations Through 1/31/2024. Oregon Judicial Department. Available at <https://www.courts.oregon.gov/about/Documents/BM110Statistics.pdf>
- ²⁴ “Oregon Senate votes to end drug decriminalization.” Oregon Public Broadcasting, March 4, 2024. Available at <https://www.opb.org/article/2024/03/04/oregon-senate-votes-to-end-drug-decriminalization/>
- ²⁵ Oregon Legislative Information. Oregon State Legislature. HB 4002 Enrolled. 2024 Regular Session. Available at <https://olis.oregonlegislature.gov/liz/2024R1/Measures/Overview/HB4002>
- ²⁶ “Magic Mushrooms Are Decriminalized in DC as of Today. Ayahuasca, too.” The Washingtonian. March 15, 2021. Available at <https://www.washingtonian.com/2021/03/15/magic-mushrooms-are-decriminalized-in-dc-as-of-today/>

- ²⁷ “Colorado Voted to Decriminalize ‘Magic Mushrooms’—What Happens Next?” University of Colorado. November 15, 2022. Available at <https://news.cuanschutz.edu/medicine/colorado-magic-mushrooms-psilocybin>
- ²⁸ *State v. Blake*, 197 Wn.2d 170, 481 P.3d 521 (2021)
- ²⁹ “Washington governor signs new law keeping drug possession illegal.” CNN. May 17, 2023. Available at <https://www.cnn.com/2023/05/17/us/washington-drug-possession-law/index.html>
- ³⁰ Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic Drug Legislative Reform and Legalization in the US. *JAMA Psychiatry*. 2023 Jan 1;80(1):77-83. doi: 10.1001/jamapsychiatry.2022.4101. PMID: 36477830; PMCID: PMC10069558.
- ³¹ “Expungement, Destruction, and Sealing of Criminal Records for Legal Offenses Related to Cannabis Use or Possession.” Board of Trustees Report 17-A-22. Pages 87-91. Available at <https://www.ama-assn.org/system/files/a22-bot-reports.pdf>
- ³² “Restoration of Rights.” National Association of Criminal Defense Lawyers. “Expungement results in deletion of any record that an arrest or criminal conviction ever occurred. A sealed record is removed from general review; the record still exists and can be reviewed under limited circumstances.” Last accessed February 14, 2022. Available at <https://nacdl.org/Landing/RestorationofRightsandStatusAfterConviction>
- ³³ “What is expungement?” American Bar Association. November 20, 2018. Available at https://www.americanbar.org/groups/public_education/publications/teaching-legal-docs/what-is-expungement/
- ³⁴ 18 U.S.C. § 3607. Special probation and expungement procedures for drug possessors. Available at <https://www.govinfo.gov/app/details/USCODE-2022-title18/USCODE-2022-title18-partII-chap229-subchapA-sec3607>
- ³⁵ Record Clearing by Offense. National Conference of State Legislatures. Updated August 14, 2020. Available at <https://www.ncsl.org/civil-and-criminal-justice/record-clearing-by-offense>
- ³⁶ Automatic Expungement of Juvenile Records. National Conference of State Legislatures. Updated January 4, 2024. Available at <https://www.ncsl.org/civil-and-criminal-justice/automatic-expungement-of-juvenile-records>
- ³⁷ “50-State Comparison: Marijuana: Marijuana Legalization, Decriminalization, Expungement, and Clemency.” Restoration of Rights Project. Updated January 2023. Available at <https://ccresourcecenter.org/state-restoration-profiles/50-state-comparison-marijuana-legalization-expungement/>
- ³⁸ “Decriminalize Drugs, Invest in Health Services.” Drug Policy Alliance. Available at <https://drugpolicy.org/issue/decriminalize-drugs-invest-in-health-services/>
- ³⁹ Drug Arrests Stayed High Even as Imprisonment Fell From 2009 to 2019. Pew Charitable Trusts. February 2022. Available at <https://www.pewtrusts.org/-/media/assets/2022/02/drug-arrests-stayed-high-even-as-imprisonment-fell-from-2009-to-2019.pdf>
- ⁴⁰ “Fifty Years Ago Today, president Nixon Declared the War on Drugs.” Vera Institute on Justice. June 17, 2021. Available at <https://www.vera.org/news/fifty-years-ago-today-president-nixon-declared-the-war-on-drugs>
- ⁴¹ Scheim AI, Maghsoudi N, Marshall Z, Churchill S, Ziegler C, Werb D. Impact evaluations of drug decriminalisation and legal regulation on drug use, health and social harms: a systematic review. *BMJ Open*. 2020 Sep 21;10(9):e035148. doi: 10.1136/bmjopen-2019-035148. PMID: 32958480; PMCID: PMC7507857.
- ⁴² Psychedelic Legalization & Decriminalization Tracker. *Psychedelic Alpha*. Last Updated November 29, 2023. Available at <https://psychedelicalpha.com/data/psychedelic-laws>
- ⁴³ Noah Spencer, Does drug decriminalization increase unintentional drug overdose deaths?: Early evidence from Oregon Measure 110 ? *Journal of Health Economics*, Volume 91, 2023, 102798, ISSN 0167-6296, <https://doi.org/10.1016/j.jhealeco.2023.102798>. (<https://www.sciencedirect.com/science/article/pii/S0167629623000759>)
- ⁴⁴ Joshi S, Rivera BD, Cerdá M, et al. One-Year Association of Drug Possession Law Change With Fatal Drug Overdose in Oregon and Washington. *JAMA Psychiatry*. 2023;80(12):1277–1283. doi:10.1001/jamapsychiatry.2023.3416
- ⁴⁵ Too Early to Tell: The Challenging Implementation of Measure 110 Has Increased Risks, but the Effectiveness of the Program Has Yet to Be Determined. Oregon Health Authority. January 2023. Available at <https://sos.oregon.gov/audits/Documents/2023-03.pdf>
- ⁴⁶ Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2024. Last accessed March 13, 2024.
- ⁴⁷ “Expungement, Destruction, And Sealing Of Criminal Records For Legal Offenses Related To Cannabis Use Or Possession.” Board of Trustees Report 17-A-22.
- ⁴⁸ “Probation and Parole Officers and Discretionary Decision-Making: Responses to Technical and Criminal Violations.” Federal Probation. Volume 71, Number 1. Available at https://www.uscourts.gov/sites/default/files/71_1_2_0.pdf

⁴⁹ “Revoked: How Probation and Parole Feed Mass Incarceration in the United States.” Human Rights Watch. July 31, 2020. Available at <https://www.hrw.org/report/2020/07/31/revoked/how-probation-and-parole-feed-mass-incarceration-united-states>

⁵⁰ NIDA. 2023, September 25. Treatment and Recovery. Retrieved from <https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery-on-February-24>, 2024.

REPORT OF THE BOARD OF TRUSTEES

B of T Report 18-A-24

Subject: Supporting Harm Reduction

Presented by: Willie Underwood, III, MD, MSc, MPH, Chair

Referred to: Reference Committee B

1 INTRODUCTION

2
3 At the June 2023 Annual Meeting, the American Medical Association (AMA) House of Delegates
4 (HOD), Resolution 204 entitled, “Supporting Harm Reduction,” was introduced by the Medical Student
5 Section and called on the AMA to:

- 6
7 • Advocate for the removal of buprenorphine from the misdemeanor crime of
8 possession of a narcotic;
9 • Support any efforts to decriminalize the possession of non-prescribed
10 buprenorphine; and
11 • Amend the 4th and 6th resolves of Policy D-95.987 by addition and deletion to
12 read as follows:

13 4. Our AMA will advocate for and encourage state and county medical
14 societies to advocate for harm reduction policies that provide civil and
15 criminal immunity for the possession, distribution, and use of “drug
16 paraphernalia” designed for harm reduction from drug use, including but
17 not limited to drug contamination testing, safer smoking, and injection
18 drug preparation, use and disposal supplies.

19
20 6. Our AMA will advocate for ~~supports efforts to~~ increased access to and
21 decriminalization of fentanyl test strip, ~~and~~ other drug checking supplies,
22 and safer smoking kits for purposes of harm reduction.

23
24 The HOD discussed the strong evidence base supporting buprenorphine as a treatment for opioid use
25 disorder (OUD), the uncertainty surrounding the facts of buprenorphine “diversion,” and the significant
26 concerns about the meaning and practice of “safer smoking.” Ultimately, the HOD referred the resolution
27 to the Board of Trustees for study. In response, this board report provides background information;
28 discusses the different issues raised by the resolution; presents AMA policy; and makes policy
29 recommendations.

30
31 BACKGROUND

32
33 *Buprenorphine*

34
35 Buprenorphine is a Schedule III Controlled Substance that the U.S. Drug Enforcement Administration
36 (DEA) defines as a narcotic for purposes of drug scheduling.¹ The U.S. Food and Drug Administration
37 (FDA) first approved buprenorphine-containing products in 2002 for the treatment of OUD.

1 Buprenorphine for OUD may be prescribed as a “mono-product,” and some manufacturers combine it
2 with naloxone (“combination product”) to treat OUD. It may be available as a tablet, sublingual film,
3 transdermal film, or injection.
4

5 There is widespread evidence that supports buprenorphine as an evidence-based medication to treat
6 OUD.² Researchers and clinicians commonly promote statements such as, “opioid agonist therapy (OAT)
7 with methadone or buprenorphine is the gold-standard treatment for OUD.”³ The U.S. Substance Abuse
8 and Mental Health Services Administration (SAMHSA) provides multiple resources about
9 buprenorphine, including clinical and safety information, treating pregnant and postpartum individuals,
10 potential for misuse, and safety considerations.⁴ Because of its evidence-base, AMA advocacy has for
11 years called for removing all barriers to buprenorphine for the treatment of OUD—including prior
12 authorization reforms,⁵ the x-waiver,⁶ telehealth restrictions,⁷ and dosage caps.⁸
13

14 While prescriptions dispensed for medications to treat opioid use disorder (MOUD) have marginally
15 increased in the past five years from 14.54 million to 16.05 million,⁹ there remain millions of Americans
16 who misuse illicit substances, prescription opioids and/or have untreated substance use disorder.¹⁰ More
17 than 78 million illicit fentanyl-containing pills and 12,000 pounds of fentanyl powder were seized by the
18 U.S. Drug Enforcement Administration (DEA) in 2023.¹¹ The U.S. Centers for Disease Control and
19 Prevention (CDC) advise that, “Powdered fentanyl looks just like many other drugs. It is commonly
20 mixed with drugs like heroin, cocaine, and methamphetamine and made into pills that are made to
21 resemble other prescription opioids.”¹²
22

23 *“Safer Smoking”* 24

25 As a threshold matter, and discussed briefly below, the AMA does not support the concept of “safer
26 smoking.” The issue of “safer smoking” in relation to the nation’s drug-related overdose and death
27 epidemic, however, is a harm reduction concept that seeks to reduce the spread of infectious disease as
28 well as support changes to injection drug use. The types of safer smoking supplies are often, “specific for
29 each type of drug used, but generally includes a heat resistant pipe or foil, protective mouthpiece, tamp,
30 screen, and lip protectant, all of which reduce heat-related injuries and infection risk.”¹³ In addition to
31 reducing injection drug use, proponents of safer smoking supplies also point to, “Smoking supplies
32 distributed by harm reduction programs [that] are clean and safer than improvised items like aluminum
33 cans, plastic tubes, steel wool, and light bulbs that can break easily or release toxic fumes.”¹⁴ These
34 supplies are typically considered illicit drug paraphernalia, and “Nearly all states penalize the possession
35 and distribution of glass pipes and other devices used for smoking or inhaling illegal drugs.”¹⁵
36

37 In addition to state law prohibitions against safer smoking supplies, federal law defines a wide variety of
38 materials as illegal drug paraphernalia, including,
39

- 40 (1) metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes with or without screens,
- 41 permanent screens, hashish heads, or punctured metal bowls; (2) water pipes; (3)
- 42 carburetion tubes and devices; (4) smoking and carburetion masks; (5) roach clips:
- 43 meaning objects used to hold burning material, such as a marijuana cigarette, that has
- 44 become too small or too short to be held in the hand; (6) miniature spoons with level
- 45 capacities of one-tenth cubic centimeter or less; (7) chamber pipes; (8) carburetor pipes;
- 46 (9) electric pipes; (10) air-driven pipes; (11) chillums; (12) bongs; (13) ice pipes or
- 47 chillers; (14) wired cigarette papers; or (15) cocaine freebase kits.¹⁶
48

49 Every state—except Alaska—has a drug paraphernalia law.¹⁷ While state laws vary considerably, one
50 distinction is that needles and syringes may still be considered drug paraphernalia, but they are allowed

1 for personal use in most states. Penalties for individuals convicted of possession or use of other drug
2 paraphernalia can range from misdemeanors to felonies.¹⁸

3 4 DISCUSSION

5 6 *Decriminalization of Non-prescribed Possession and Use of Buprenorphine*

7
8 While penalties vary, possession of non-prescribed buprenorphine—like other non-prescribed controlled
9 substances—is generally considered a violation of state and/or federal law and can subject an individual
10 to monetary penalties and/or imprisonment depending on the circumstances.¹⁹ One of the key questions
11 for this board report, however, is whether the benefits of using non-prescribed buprenorphine in certain
12 circumstances outweigh the risks. The National Institute on Drug Abuse (NIDA) reports that, “most data
13 suggest that the majority of buprenorphine and methadone misuse (use without a prescription) is for the
14 purpose of controlling withdrawal and cravings for other opioids and not to get high.”²⁰ NIDA also points
15 out low rates of diversion risk, illicit use, and emergency department visits related to buprenorphine.
16 Research comparing buprenorphine-involved deaths compared to opioid-involved deaths during the
17 COVID-19 pandemic found that, “actions to facilitate access to buprenorphine-based treatment for opioid
18 use disorder during the COVID-19 pandemic were not associated with an increased proportion of
19 overdose deaths involving buprenorphine; efforts are needed to expand more equitable and culturally
20 competent access to and provision of buprenorphine-based treatment.”²¹ The AMA has argued that
21 individuals’ lack of access to buprenorphine is due to multiple factors, including stigma, and inadequate
22 networks of addiction medicine physicians, psychiatrists, primary care and other physicians willing to
23 prescribe buprenorphine. Access to buprenorphine is particularly problematic for racial and ethnic
24 minorities.²² The AMA and the AMA Substance Use and Pain Care Task Force has long urged that all
25 efforts be taken to increase access to buprenorphine and other medications for opioid use disorder
26 (MOUD). Decriminalization, however, is an issue of first impression for the AMA.

27
28 Decriminalization of possession of non-prescribed buprenorphine for personal use already is occurring in
29 the United States. Vermont became the first state in 2021 to specifically decriminalize possession of
30 224 milligrams of non-prescribed buprenorphine for personal use.²³ Initially enacted as a two-year pilot,
31 after positive reviews that the bill helped increase access to buprenorphine among people who use drugs
32 (PWUD) and also increase access to other forms of treatment, the Vermont Legislature made the
33 exemption permanent in 2023.²⁴ Rhode Island also decriminalized buprenorphine in 2021 by amending its
34 criminal code.²⁵ Another state example is when Oregon, in 2020, effectively decriminalized a wide range
35 of drugs for personal use, including Schedule III Controlled Substances.²⁶ It is not clear whether this has
36 increased access to buprenorphine in Oregon, but a report from the Oregon Judicial Department did not
37 cite “buprenorphine” for any of the new “Class E” violations.²⁷

38
39 Multiple studies have found the mortality risk of buprenorphine is low. This includes retrospective
40 mortality reviews showing how buprenorphine-involved mortality was commonly part of polysubstance
41 use.²⁸ In a study of Medicare beneficiaries, “Buprenorphine treatment after nonfatal opioid-involved
42 overdose was associated with a 62% reduction in the risk of opioid-involved overdose death.”²⁹ A review
43 of COVID-19-era opioid-involved overdose deaths found that “buprenorphine was involved in
44 2.6 percent of opioid-involved overdose deaths during July 2019 to June 2021”—a rate that “did not
45 increase” even as rates of overdose overall increased.³⁰ Commentators suggest that while there are some
46 risks to using non-prescribed buprenorphine, there are many benefits, including overcoming barriers that,
47 “extend across socioeconomic, bureaucratic, and stigmatizing lines and include unemployment, insurance
48 status, buprenorphine waiting lists, and most importantly, knowledge and physical access to providers
49 who can and want to prescribe buprenorphine.”³¹ The Board of Trustees acknowledges that use of
50 nonprescribed buprenorphine carries risks, but views the available evidence as mitigating in support of

1 doing all that is necessary to reduce health inequities and save lives from an opioid-related overdose,
2 including decriminalizing the personal possession and use of nonprescribed buprenorphine.

3
4 *“Safer Smoking” as a Harm Reduction Measure*

5
6 The AMA has supported a broad range of what are generally considered “harm reduction” measures. This
7 includes support for laws and other policies encouraging prescribing, distribution, and use of naloxone
8 and other opioid-overdose reversal agents. The AMA also supports broad Good Samaritan protections to
9 provide civil and criminal protections for individuals at the scene of an overdose event. The AMA further
10 supports the same protections for individuals who overdose. AMA policy also supports harm reduction
11 centers (also called overdose prevention sites), as well as the ability for syringe services programs (SSPs)
12 to provide sterile needles and syringes to help stem the spread of blood borne infectious disease. While
13 there will always be detractors and stigma, these harm reduction measures have been well-studied and
14 have been shown to help reduce mortality and improve health outcomes. It is beyond the scope of this
15 report to detail all the research for these measures, but it is important to highlight that each (to different
16 degrees) has largely overcome stigma in the medical community. The Board of Trustees acknowledges
17 that stigma remains a considerable barrier for SSPs and harm reduction centers.

18
19 Injection drug use continues to be a major public health issue. A Centers for Disease Control and
20 Prevention (CDC) study found that nearly 3.7 million people in the United States injected drugs in
21 2018—a 5-fold increase from 2011.³² The study also found that more than 42 percent of overdose deaths
22 were from injections. Another CDC report found that, “During 2013–2017, reported methamphetamine,
23 injection drug, and heroin use increased substantially among women and heterosexual men with [primary
24 and secondary] syphilis.”³³ Injection drug use may also result in the spread of skin and groin infections,
25 Hepatitis C, bacterial endocarditis, osteomyelitis, and other preventable health conditions.³⁴ Prevention of
26 the spread of blood-borne infectious disease is one of many reasons the AMA strongly supports broad
27 access to sterile needle and SSPs.

28
29 AMA support for SSPs, however, has been based on the strong evidence-base for SSPs. We raise the
30 question, therefore, whether the evidence supports increased use of safer smoking supplies (as defined
31 above), including decriminalization of such supplies. A 2023 descriptive review of 550 PWUDs found
32 that there was limited access but high interest in obtaining safer smoking supplies for heroin, crack
33 cocaine, and methamphetamine.³⁵ The authors were clear about the study limitations but highlighted other
34 research suggesting that obtaining safer smoking supplies could reduce injection drug use. A recently
35 published meta-review of global practices reported that, “Ten studies found that when people who use
36 drugs were provided with safer smoking materials, they engaged in fewer risky drug use behaviors (e.g.,
37 pipe sharing, using broken pipes) and showed improved health outcomes.”³⁶ The authors concluded that,
38 “safer smoking practices are essential forms of harm reduction,” but that “Additional research is also
39 needed to evaluate the efficacy of and access to safer smoking services, particularly in the U.S. and other
40 similar countries, where such practices are being implemented but have not been empirically studied in
41 the literature.” We agree that more research is necessary.

42
43 It is also important to emphasize that additional research into the potential benefits of any harm reduction
44 measure in no way condones or supports the use of illicit drugs or other substances whether through
45 injection, inhalation, or other routes of administration. The Board of Trustees notes that while reductions
46 in injection drug use should be considered positive, it is deeply concerning that it may be accompanied by
47 increases in smoking illicit fentanyl.³⁷ We agree with comments from addiction psychiatrists such as, “I
48 do not know that we are at a place where we can say, ‘Hey, maybe you should smoke it instead,’” and “It
49 would be hard for me to feel confident in recommending that to somebody.”³⁸ Further, it must be stressed
50 that there is no such thing as “safer smoking” of fentanyl, cannabis, tobacco or illicit substances, and also
51 stressed that smoking fentanyl carries significant risks, including overdose and death.³⁹ Similarly, the

1 Board of Trustees believes that while there may be some evidence showing reduced harms associated
2 with smoking fentanyl and certain safer smoking supplies as compared to injection use, there is a clear
3 need for much more research before the AMA spends its resources and puts its public health and science
4 credibility on the line.

5
6 *Decriminalization of Fentanyl Test Strips*
7

8 This resolution also calls for the AMA to support the decriminalization of fentanyl test strips. It is critical
9 to note that this ask is redundant as AMA policy already effectively accomplishes this. Specifically, our
10 policy states that, “Our AMA will: advocate for the removal of fentanyl test strips (FTS) and other testing
11 strips, devices or testing equipment used in identifying or analyzing whether a substance contains fentanyl
12 or other adulterants from the legal definition of drug paraphernalia.” (Policy D-95.987, “Prevention of
13 Drug-Related Overdose”) The AMA has advocated for this at the state and federal levels⁴⁰ and
14 encourages all medical societies to support legislation to implement this important policy. In this regard,
15 we appreciate the opportunity to highlight AMA advocacy and conclude that existing policy (and
16 subsequent advocacy measures) already meet the intent and purpose of the resolution.
17

18 **AMA POLICY**
19

20 Extending AMA policy to support decriminalization of non-prescribed buprenorphine for personal use
21 would become part of a broad and growing policy base supporting increased access to buprenorphine and
22 other MOUD. Policies in this family include:
23

- 24 • Policy H-420.970, “Treatment Versus Criminalization - Physician Role in Drug Addiction During
25 Pregnancy;”
- 26 • Policy H-95.956, “Harm Reduction Through Addiction Treatment;”
- 27 • Policy H-430.987, “Medications for Opioid Use Disorder in Correctional Facilities;”
- 28 • Policy H-290.962, “Medicaid Substance Use Disorder Coverage;”
- 29 • Policy H-320.941, “Eliminate Fail First Policy in Addiction Treatment;”
- 30 • Policy H-95.944, “Third-Party Payer Policies on Opioid Use Disorder Pharmacotherapy;”
- 31 • Policy D-95.955, “Improving Access to Post-Acute Medical Care for Patients with Substance Use
32 Disorder (SUD);” and
- 33 • Policy D-95.972, “Expanding Access to Buprenorphine for the Treatment of Opioid Use
34 Disorder.”
35

36 It bears repeating that the Board of Trustees strongly supports the provision of MOUD to occur within a
37 medically supervised and physician-led environment. We also recognize that given the innumerable
38 barriers to such care, combined with the clear benefits of increasing access to buprenorphine, calling for
39 decriminalization of non-prescribed buprenorphine for personal use is necessary to help reduce harms,
40 including overdose and death.
41

42 AMA policy already supports efforts to increase access to a broad range of harm reduction initiatives:
43

44 Our AMA will advocate for and encourage state and county medical societies to advocate
45 for harm reduction policies that provide civil and criminal immunity for the possession,
46 distribution, and use of “drug paraphernalia” designed for harm reduction from drug use,
47 including but not limited to drug contamination testing and injection drug preparation,
48 use, and disposal supplies. (Policy D-95.987, “Prevention of Drug-Related Overdose”)
49

50 It is reasonable to conclude, therefore, that this policy helps inform AMA support for SSPs, public

1 availability of sharps disposal units, and other areas. For example, AMA support for SSPs can be found
2 here:

3
4 . . . encourages the extensive application of needle and syringe exchange and distribution
5 programs and the modification of restrictive laws and regulations concerning the sale and
6 possession of needles and syringes to maximize the availability of sterile syringes and
7 needles, while ensuring continued reimbursement for medically necessary needles and
8 syringes. strongly supports the ability of physicians to prescribe syringes and needles to
9 patients who inject drugs in conjunction with addiction counseling to help prevent the
10 transmission of contagious diseases. (Policy H-95.954, “The Reduction of Medical and
11 Public Health Consequences of Drug Use”)
12

13 Finally, as discussed above, the evidence base for SSPs has been demonstrated. In contrast, the evidence
14 base in support of safer smoking supplies has not. The Board, therefore, urges increased research as it
15 relates to the latter.
16

17 RECOMMENDATIONS

18

19 The Board of Trustees recommends that the following new policy be adopted in lieu of Resolution 204,
20 and that the remainder of the report be filed.
21

- 22 1. That the American Medical Association (AMA) support efforts to decriminalize the possession
23 of non-prescribed buprenorphine for personal use by individuals who lack access to a physician
24 for the treatment of opioid use disorder; (New HOD Policy)
- 25 2. That the AMA oppose the concept, promotion, or practice of “safe smoking” with respect to
26 inhalation of tobacco, cannabis or any illicit substance; (New HOD Policy)
- 27 3. That the AMA encourage additional study whether “safer smoking supplies” may be a potential
28 harm reduction measure to reduce harms from the nation’s overdose and death epidemic; and
29 (New HOD Policy)
- 30 4. That the AMA reaffirm Policy D-95.987, “Prevention of Drug-Related Overdose.” (Reaffirm
31 AMA Policy)

Fiscal Note: Less than \$500.

REFERENCES

- ¹ Controlled Substances—Alphabetical Order. U.S. Drug Enforcement Administration. Available at https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
- ² Medications to Treat Opioid Use Disorder Research Report. NIDA. December 2, 2021. Available at <https://nida.nih.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview>
- ³ Hagedorn H, Kenny M, Gordon AJ, Ackland PE, Noorbaloochi S, Yu W, Harris AHS. Advancing pharmacological treatments for opioid use disorder (ADaPT-ODU): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. *Addict Sci Clin Pract.* 2018 Dec 13;13(1):25. doi: 10.1186/s13722-018-0127-z. PMID: 30545409; PMCID: PMC6293521. Available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293521/>
- ⁴ Buprenorphine. U.S. Substance Abuse and Mental Health Services Administration. Last Updated January 30, 2024. <https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/buprenorphine>
- ⁵ “Removing prior authorization for MAT results in more patient care.” American Medical Association. February 5, 2020. Available at <https://www.ama-assn.org/practice-management/prior-authorization/removing-prior-authorization-mat-results-more-patient-care>
- ⁶ “AMA statement on HHS decision to remove barriers for opioid treatment.” Patrice A. Harris, MD, MA. January 14, 2021. Available at <https://www.ama-assn.org/press-center/press-releases/ama-statement-hhs-decision-remove-barriers-opioid-treatment>
- ⁷ “Why DEA’s latest move on telehealth could be a lifesaver.” American Medical Association. November 1, 2023. Available at <https://www.ama-assn.org/practice-management/digital/why-dea-s-latest-move-telehealth-could-be-lifesaver>
- ⁸ “Add flexibility on buprenorphine Rx for opioid use disorder.” American Medical Association. January 31, 2024. Available at <https://www.ama-assn.org/delivering-care/overdose-epidemic/add-flexibility-buprenorphine-rx-opioid-use-disorder>
- ⁹ Total dispensed prescriptions to treat opioid use disorder. IQVIA Xponent limited to retail pharmacy dispensed prescriptions; USC 78340 (drug dependency), which includes molecules buprenorphine (except where indicated for pain management in USC 02200), buprenorphine/naloxone, naltrexone. Available at <https://end-overdose-epidemic.org/wp-content/uploads/2023/11/AMA-2023-overdose-report-IQVIA-data-buprenorphine-FINAL.pdf>
- ¹⁰ SAMHSA Announces National Survey on Drug Use and Health (NSDUH) Results Detailing Mental Illness and Substance Use Levels in 2021. U.S. Substance Use and Mental Health Services Administration. January 4, 2023. Available at <https://www.hhs.gov/about/news/2023/01/04/samhsa-announces-national-survey-drug-use-health-results-detailing-mental-illness-substance-use-levels-2021.html>
- ¹¹ One Pill Can Kill. U.S. Drug Enforcement Administration. Available at <https://www.dea.gov/onepill>
- ¹² Fentanyl Facts. U.S. Centers for Disease Control and Prevention. Last Reviewed: September 6, 2023. Available at <https://www.cdc.gov/stopoverdose/fentanyl/index.html>
- ¹³ Reid MC, Oliphant-Wells T, Moreno C, Ketchum J, Fitzpatrick T, McMahan VM, Glick SN. High levels of interest in access to free safer smoking equipment to reduce injection frequency among people who inject drugs in Seattle, Washington. *Drug Alcohol Depend Rep.* 2023 May 2;7:100163. doi: 10.1016/j.dadr.2023.100163. PMID: 37214756; PMCID: PMC10193167.
- ¹⁴ Singh S, Banta-Green C, Kingston S. Distribution of Safer Drug Smoking Supplies as a Public Health Strategy. Seattle, WA: Addictions, Drug & Alcohol Institute, University of Washington, January 2022. <https://adai.uw.edu/SaferSmoking-Brief-2022>
- ¹⁵ Corey S. Davis, J.D., M.S.P.H., and Derek H. Carr, J.D. Repealing State Drug-Paraphernalia Laws — The Need for Federal Leadership. October 13, 2022. *N Engl J Med* 2022; 387:1344-1346. DOI: 10.1056/NEJMp2207866.
- ¹⁶ 21 U.S.C. 863 - Drug paraphernalia. <https://www.govinfo.gov/content/pkg/USCODE-2022-title21/pdf/USCODE-2022-title21-chap13-subchapl-partD-sec863.pdf>
- ¹⁷ Drug Paraphernalia: Summary of State Laws. Legislative Analysis and Public Policy Association. April 2022. Available at <https://legislativeanalysis.org/wp-content/uploads/2022/09/Drug-Paraphernalia-Summary-of-State-Laws-FINAL.pdf>
- ¹⁸ Drug Paraphernalia: Summary of State Laws. Legislative Analysis and Public Policy Association. April 2022. Available at <https://legislativeanalysis.org/wp-content/uploads/2022/09/Drug-Paraphernalia-Summary-of-State-Laws-FINAL.pdf>

- ¹⁹ See, for example, 21 U.S.C. §844. Penalties for simple possession. Available at <https://www.govinfo.gov/content/pkg/USCODE-2011-title21/html/USCODE-2011-title21-chap13-subchapI-partD-sec844.htm>
- ²⁰ NIDA. 2021, April 13. What is the treatment need versus the diversion risk for opioid use disorder treatment?. Retrieved from <https://nida.nih.gov/publications/research-reports/medications-to-treat-opioid-addiction/what-treatment-need-versus-diversion-risk-opioid-use-disorder-treatment> on 2024, February 28
- ²¹ Tanz LJ, Jones CM, Davis NL, et al. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic. *JAMA Netw Open*. 2023;6(1):e2251856. doi:10.1001/jamanetworkopen.2022.51856
- ²² Dong H, Stringfellow EJ, Russell WA, Jalali MS. Racial and Ethnic Disparities in Buprenorphine Treatment Duration in the US. *JAMA Psychiatry*. 2023;80(1):93–95. doi:10.1001/jamapsychiatry.2022.3673
- ²³ “Vermont becomes first state to legalize possession of buprenorphine.” VT Digger. June 3, 2021. Available at <https://vtdigger.org/2021/06/03/vermont-becomes-first-state-to-legalize-limited-possession-of-buprenorphine/>
- ²⁴ House Bill 222. An Act relating to reducing overdoses. Enacted May 25, 2023. Available at <https://legislature.vermont.gov/Documents/2024/Docs/ACTS/ACT022/ACT022%20As%20Enacted.pdf>
- ²⁵ S. 0065 Substitute A. Uniform Controlled Substances Act. Enacted July 7, 2021. Available at <http://webserver.rilin.state.ri.us/BillText/BillText21/SenateText21/S0065A.pdf>
- ²⁶ Ballot Measure 110. Secretary of State. Oregon. Available at <https://sos.oregon.gov/admin/Documents/irr/2020/044text.pdf>
- ²⁷ Percent of Class E Violation Offenses by Substance. Oregon Judicial Department. January 31, 2024. Available at <https://www.courts.oregon.gov/about/Documents/BM110Statistics.pdf>
- ²⁸ Del Pozo B, Atkins D, Andraka-Christou B, Wightman R, Clark MH, Huynh P, Ray B. Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021. *Drug Alcohol Depend Rep*. 2023 Mar;6:100131. doi: 10.1016/j.dadr.2023.100131. Epub 2023 Jan 4. PMID: 36777895; PMCID: PMC9910498.
- ²⁹ Samples, et al. Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries. *American Journal of Preventive Medicine*. March 10, 2023. DOI: <https://doi.org/10.1016/j.amepre.2023.01.037>
- ³⁰ Tanz LJ, Jones CM, Davis NL, et al. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic. *JAMA Netw Open*. 2023;6(1):e2251856. doi:10.1001/jamanetworkopen.2022.51856
- ³¹ Messinger et al. Against Our Instincts: Decriminalization of Buprenorphine. *Journal of the American Board of Family Medicine*. March-April 2022. Vol. 35 No. 2. Available at <https://www.jabfm.org/content/jabfp/35/2/394.full.pdf>
- ³² Bradley H, Hall EW, Asher A, Furukawa NW, Jones CM, Shealey J, Buchacz K, Handanagic S, Crepaz N, Rosenberg ES. Estimated Number of People Who Inject Drugs in the United States. *Clin Infect Dis*. 2023 Jan 6;76(1):96-102. doi: 10.1093/cid/ciac543. PMID: 35791261; PMCID: PMC10202436.
- ³³ Kidd SE, Grey JA, Torrone EA, Weinstock HS. Increased Methamphetamine, Injection Drug, and Heroin Use Among Women and Heterosexual Men with Primary and Secondary Syphilis — United States, 2013–2017. *MMWR Morb Mortal Wkly Rep* 2019;68:144–148. <https://www.cdc.gov/mmwr/volumes/68/wr/mm6806a4.htm>
- ³⁴ Cornford C, Close H. The physical health of people who inject drugs: complexities, challenges, and continuity. *Br J Gen Pract*. 2016 Jun;66(647):286-7. doi: 10.3399/bjgp16X685333. PMID: 27231287; PMCID: PMC4871283.
- ³⁵ Reid MC, Oliphant-Wells T, Moreno C, Ketchum J, Fitzpatrick T, McMahan VM, Glick SN. High levels of interest in access to free safer smoking equipment to reduce injection frequency among people who inject drugs in Seattle, Washington. *Drug Alcohol Depend Rep*. 2023 May 2;7:100163. doi: 10.1016/j.dadr.2023.100163. PMID: 37214756; PMCID: PMC10193167.
- ³⁶ Tapper A, Ahern C, Graveline-Long Z, Newberger NG, Hughto JMW. The utilization and delivery of safer smoking practices and services: a narrative synthesis of the literature. *Harm Reduct J*. 2023 Oct 27;20(1):160. doi: 10.1186/s12954-023-00875-x. PMID: 37891658; PMCID: PMC10612300.
- ³⁷ Kral AH, Lambdin BH, Browne EN, Wenger LD, Bluthenthal RN, Zibbell JE, Davidson PJ. Transition from injecting opioids to smoking fentanyl in San Francisco, California. *Drug Alcohol Depend*. 2021 Oct 1;227:109003. doi: 10.1016/j.drugalcdep.2021.109003. Epub 2021 Aug 27. PMID: 34482046; PMCID: PMC10790652.
- ³⁸ “Once feared, illicit fentanyl is now a drug of choice for many opioid users.” NBC News. August 7, 2022. Available at <https://www.nbcnews.com/health/health-news/feared-illicit-fentanyl-now-drug-choice-many-opioids-users-rcna40418>

³⁹ Can You Smoke Fentanyl? Effects of Smoking & Inhaling, Bicycle Health. October 15, 2023.

<https://www.bicyclehealth.com/opioid-education/fentanyl/smoking-inhaling-dangers>

⁴⁰ See, for example, AMA letters available at <https://searchlf.ama-assn.org/letter/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2F2021-7-9-Letter-to-LaBelle-re-ONDCP-2022-Strategy-v2.pdf>, <https://searchlf.ama-assn.org/letter/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2Ffcts.zip%2FAMA-letter-supporting-NE-LB1325-FINAL.pdf>, and <https://searchlf.ama-assn.org/letter/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2Fltrf.zip%2F2023-1-25-Letter-Supporting-SD-Drug-Testing-Eq-Final.pdf>

REPORT OF THE BOARD OF TRUSTEES

B of T Report 19-A-24

Subject: Attorneys’ Retention of Confidential Medical Records and Controlled Medical Expert’s Tax Returns After Case Adjudication (Resolution 240-A-23)

Presented by: Willie Underwood, III, MD, MSc, MPH, Chair

Referred to: Reference Committee B

1 INTRODUCTION

2
3 Resolution 240-A-23, introduced by the Illinois State Medical Society, consisted of the following
4 proposals:

5
6 RESOLVED, That our American Medical Association advocate that attorney requests for
7 controlled medical expert personal tax returns should be limited to 1099-MISC forms
8 (miscellaneous income) and that entire personal tax returns (including spouse’s) should not be
9 forced by the court to be disclosed (Directive to Take Action); and be it further

10
11 RESOLVED, That our AMA advocate through legislative or other relevant means the proper
12 destruction by attorneys of medical records (as suggested by *Haage v. Zavala*, 2021 IL
13 125918)¹ and medical expert’s personal tax returns within sixty days of the close of the case.
14 (Directive to Take Action).

15
16 FIRST RESOLVED

17
18 In cases requiring physicians as medical expert witnesses, their testimony is critical to the
19 resolution of the case. They provide an invaluable service. At the same time, it is the right of the
20 opposing party’s attorney to request discovery that allows the attorney to cross-examine the witness
21 to show potential bias. *See United States v. Abel*, 469 U.S. 45, 49-52 (1984). This discovery often
22 involves the expert’s financial history. Still, discovery must be balanced with the expert’s privacy
23 rights and the burden imposed. *See Grant v. Rancour*, 157 N.E.3d 1083, 1094-95 (Ill. 2020).
24 (“[W]hile cross-examination is permissible to show bias, partisanship, or financial interest, there is
25 a point at which such inquiries trample on the legitimate bounds of cross-examination and unduly
26 harass or unnecessarily invade the privacy of the witness.”).

27
28 There is no general rule or universal leaning that courts take when it comes to an expert’s personal
29 tax returns. Personal tax returns may be relevant to show an expert’s potential biases – how often
30 they have testified, how much they have earned for that testimony, what sources are paying for that
31 testimony, etc. Courts decide whether personal tax returns should be allowable discovery on a case-

¹ The form of citation quoted in the First Resolved refers to an Illinois-specific publication, one that might not be available to those outside of Illinois. For ease of reference and accessibility, the Board will use the citation of the case as published in the North Eastern Reporter, a widely available publication. The citation is *Haage v. Zavala*, 183 N.E.3d 830 (Ill. 2021).

1 by-case basis, depending on the specific facts of the case. *See, e.g., Olson v. State Farm Fire &*
2 *Cas. Co.*, No. C14-0786RSM, 2015 WL 753501, at *3 (W.D. Wash. Feb. 23, 2015) (“there is no
3 need for the expert to have to produce his or her tax returns, if the party seeking the discovery has
4 accurate information regarding the percentage of income earned as an expert”); *but see Noffke v.*
5 *Perez*, 178 P.3d 1141, 1150 (Alaska 2008) (“trial court determined that the income tax returns were
6 relevant and that production of the returns would help clarify any stake the witness might have in
7 the outcome of the case”). As with most discovery disputes, the resolution is within the court’s
8 discretion. “Courts must use their discretion to oversee the process and ensure that it is fair to both
9 sides.” *Grant*, 157 N.E.3d at 1095.

10
11 With this background, the Board agrees that seeking a medical expert’s entire personal income tax
12 returns is, in most instances, overly broad and unnecessarily invades the expert’s privacy. The
13 Board also agrees that limiting personal tax return discovery of a medical expert to miscellaneous
14 income (1099-MISC forms) strikes a reasonable balance between allowing the probing for
15 potential bias and protecting the expert’s privacy and burdens. Miscellaneous income discovery
16 would encompass the income that is received from serving as an expert, and the source of that
17 income. In most cases, this should shed sufficient light on potential bias.

18
19 This position is also in line with current AMA policy, which states, “(c) The AMA supports the
20 right to cross examine physician expert witnesses on the following issues: (i) the amount of
21 compensation received for the expert’s consultation and testimony; (ii) the frequency of the
22 physician’s expert witness activities; (iii) the proportion of the physician’s professional time
23 devoted to and income derived from such activities; and (iv) the frequency with which he or she
24 testified for either plaintiffs or defendants.” *Expert Witness Testimony*, H-265.994.

25
26 On the other hand, the Board believes the phrase “and that entire personal tax returns (including
27 spouse’s) should not be forced by the court to be disclosed” should be removed from the First
28 Resolved. It would be an overreach for the AMA to tell courts how to use their discretion in
29 managing discovery, which as discussed, varies on a case-by-case basis. In any event, the first part
30 of the Resolved makes this latter part largely unnecessary. Advocating for the limitation of tax
31 return discovery to miscellaneous income means that the discovery of entire personal tax returns is
32 generally unnecessary and inappropriate. Along those lines, we suggest that the word “usually” be
33 inserted between “should” and “be.”

34
35 As such, the Board believes the First Resolved should be rewritten as follows:

36
37 RESOLVED, That our American Medical Association advocate that attorneys’ discovery
38 requests for the personal tax returns of a medical expert for the opposing party should usually
39 be limited to 1099-MISC forms (miscellaneous income).

40
41 SECOND RESOLVED

42
43 The Second Resolved likely lumps together two different categories of documents: 1) client
44 medical records, and 2) tax returns of medical experts. The first category is personal health
45 information (“PHI”), likely protected under the Health Insurance Portability and Accountability
46 Act of 1996 (“HIPAA”). The second category is financial information that has nothing to do with
47 HIPAA. Yet the Second Resolved advocates for the destruction of both types of documents within
48 60 days of the conclusion of a case, using *Haage v. Zavala*, 183 N.E.3d 830 (Ill. 2021) as an
49 example.

50

1 In *Haage*, a personal injury matter, the trial court issued HIPAA qualified protective orders
2 (“QPOs”) expressly requiring the destruction of PHI within 60 days after the conclusion of the
3 litigation. The insurance company objected to the QPOs, arguing that the orders prevented insurers
4 from performing functions related to fraud detection and deterrence. The appellate court disagreed
5 and enforced the QPOs, finding that no law or regulations required the insurance company to use or
6 disclose plaintiffs’ PHI after the conclusion of the litigation. *See Haage*, 183 N.E.3d at 853.

7
8 Thus, *Haage* may be relevant to the return or destruction of PHI under a HIPAA QPO, but it is
9 irrelevant to the return or destruction of an expert’s tax return information. Thus, the Second
10 Resolved does not need to mention *Haage*.

11
12 Regarding the return of client records, the American Bar Association’s (“ABA”) Rules of
13 Professional Conduct state: “Upon termination of representation, a lawyer shall take steps to the
14 extent reasonably practicable to protect a client’s interests, such as . . . surrendering papers and
15 property to which the client is entitled[.] The lawyer may retain papers relating to the client to the
16 extent permitted by other law.” ABA Rule 1.6(d). The ABA rules do not address exactly *when*
17 attorneys are to return or destroy their client’s records.

18
19 As a general matter, the Board agrees with the intent of the Second Resolved – that certain
20 documents contain clients’ or experts’ sensitive and confidential information, and it is logical that
21 those individuals do not want that sensitive information used or available for longer than absolutely
22 necessary. Sixty days after the conclusion of litigation also seems like a reasonable time period for
23 the return or destruction of those documents. At the same time, the Board notes that reaching this
24 goal will likely be an uphill battle, as it would likely entail specific changes to the ABA’s Model
25 Rules of Professional Conduct, and could require changes to state and federal laws. Nonetheless,
26 advocating for this goal seems like a worthwhile effort.

27
28 As such, the Board believes the Second Resolved should be rewritten as follows:

29
30 RESOLVED, That our AMA support through legislative or other relevant means the proper
31 return or destruction of client medical records and medical expert’s personal tax returns by
32 attorneys within sixty days of the conclusion of the litigation.

33
34 RECOMMENDATION

35
36 The Board of Trustees recommends that the following be adopted in lieu of Resolution 240-A-23
37 and the remainder of this report be filed:

- 38
39 1. That our American Medical Association advocate that attorneys’ discovery requests for the
40 personal tax returns of a medical expert for the opposing party should usually be limited to
41 1099-MISC forms (miscellaneous income) (New HOD Policy); and
42
43 2. RESOLVED, That our AMA support through legislative or other relevant means the
44 proper return or destruction of client medical records and medical expert’s personal tax
45 returns by attorneys within sixty days of the conclusion of the litigation (New HOD
46 Policy).

Fiscal Note: TBD

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 202
(A-24)

Introduced by: American Association of Clinical Urologists

Subject: Use of Artificial Intelligence and Advanced Technology by Third Party Payors
to Deny Health Insurance Claims

Referred to: Reference Committee B

- 1 Whereas, insurers use of Artificial Intelligence (AI) and advanced technology to analyze Health
2 Insurance Claims is very frequent; and
3
4 Whereas, Humana, Cigna and UnitedHealthcare are facing class actions from consumers and
5 their estates for allegedly deploying advanced technology to deny claims; and
6
7 Whereas, health plans use of AI or algorithm software managed by firms such as naviHealth
8 and CareCentrix assist in coverage decisions; and
9
10 Whereas, insurers are using AI and algorithms to improve their bottom line under the guise of
11 delivering better service to their policy holders; and
12
13 Whereas, doctors, diagnostic companies and others are not able to deliver appropriate medical
14 care when insurance coverage is arbitrarily denied; and

15 Whereas, President Biden signed an executive order to establish AI standards in October 2023
16 which includes the responsible use of AI in Healthcare. This also requires the Department of
17 Health and Human Services (HHS) to set up a safety program to take in reports of harm or
18 unsafe health practices involving AI; and

19 Whereas, the HHS office of the National Coordinator for Health Information Technology issued
20 a rule in December 2023 requiring more transparency around AI; and

21 Whereas, the Center for Medicare and Medicaid Services (CMS) finalized rules requiring
22 Medicare Advantage Plans in 2024 to ensure they are making medical necessity determinations
23 based on the circumstances of a specific individual rather than an algorithm or software that
24 does not account for individual circumstances. Additionally, coverage denials based on medical
25 necessity determinations must be reviewed by a physician or other health care professional;
26 therefore be it

27 **RESOLVED**, that our American Medical Association adopt as policy that Commercial third-party
28 payors, Medicare, Medicaid, Workers Compensation, Medicare Advantage and other health
29 plans ensure they are making medical necessity determinations based on the circumstances of
30 the specific patient rather than by using an algorithm, software, or Artificial Intelligence (AI) that
31 does not account for an individual's circumstances (New HOD Policy); and be it further

- 1 RESOLVED, that our AMA adopt as policy that coverage denials based on a medical necessity
- 2 determination must be reviewed by a physician in the same specialty or by another appropriate
- 3 health care professional for non-physician health care providers. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 3/11/2024

REFERENCES

1. Lopez I., Pugh T. "AI Lawsuits Against Insurers Signal Wave of Health Litigation", news.bloomberglaw.com, Feb 1, 2024, 5:05 AM EST.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 203
(A-24)

Introduced by: Florida

Subject: Medicaid Patient Accountability

Referred to: Reference Committee B

- 1 Whereas, most Medicaid managed care plans assign patients who do not select their own
2 primary care physician (PCP) randomly to a physician of the plan's choosing; and
3
4 Whereas, despite their best efforts, physicians at times are unable to persuade these Medicaid
5 patients to come into the office for wellness visits, immunization updates, or their childhood
6 check-up visit; and
7
8 Whereas, parents in many states have the ability to opt out of vaccines and other treatments for
9 pediatric patients through state approved religious or medical exemptions; and
10
11 Whereas, physicians are responsible for their assigned patients completing visits to record
12 Healthcare Effectiveness Data and Information Set (HEDIS) measures; and
13
14 Whereas, physicians may be given bonuses/incentives or be penalized based on their HEDIS
15 star rating score; therefore be it
16
17 RESOLVED, that our American Medical Association advocate that physicians' Healthcare
18 Effectiveness Data and Information Set and other quality scores and ratings not be affected by
19 non-compliant patients or patients whose parents exercise state exemptions from
20 recommended treatment. (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/3/2024

Relevant AMA Policy

Retroactive Assignment of Patients by Managed Care Entities H-285.947

Our AMA opposes the practice of "retroactive or late assignment" of patients by managed care entities, noting that "retroactive or last assignment" includes: (a) the practice of failing to require enrollees in a capitated plan to select a responsible physician(s) at the time of enrollment; (b) the practice of failing to inform the responsible physician(s) of the enrollment of the patient and the assignment of responsibility until the patient has sought care; and (c) the practice of failing to pay the responsible physician the capitated rate until after the patient has sought care.

Sub. Res. 719, A-97Reaffirmation I-01Modified: CMS Rep. 7, A-11Reaffirmation: A-19

Physician Payment Reform H-390.849

1. Our AMA will advocate for the development and adoption of physician payment reforms that adhere to the following principles:

- a) promote improved patient access to high-quality, cost-effective care;
- b) be designed with input from the physician community;
- c) ensure that physicians have an appropriate level of decision-making authority over bonus or shared-savings distributions;
- d) not require budget neutrality within Medicare Part B;
- e) be based on payment rates that are sufficient to cover the full cost of sustainable medical practice;
- f) ensure reasonable implementation timeframes, with adequate support available to assist physicians with the implementation process;
- g) make participation options available for varying practice sizes, patient mixes, specialties, and locales;
- h) use adequate risk adjustment methodologies;
- i) incorporate incentives large enough to merit additional investments by physicians;
- j) provide patients with information and incentives to encourage appropriate utilization of medical care, including the use of preventive services and self-management protocols;
- k) provide a mechanism to ensure that budget baselines are reevaluated at regular intervals and are reflective of trends in service utilization;
- l) attribution processes should emphasize voluntary agreements between patients and physicians, minimize the use of algorithms or formulas, provide attribution information to physicians in a timely manner, and include formal mechanisms to allow physicians to verify and correct attribution data as necessary; and
- m) include ongoing evaluation processes to monitor the success of the reforms in achieving the goals of improving patient care and increasing the value of health care services.

2. Our AMA opposes bundling of payments in ways that limit medically necessary care, including institutional post-acute care, or otherwise interfere with a physician's ability to provide high quality care to patients.

3. Our AMA supports payment methodologies that redistribute Medicare payments among providers based on outcomes (including functional improvements, if appropriate), quality and risk-adjustment measures only if measures are scientifically valid, reliable, and consistent with national medical specialty society- developed clinical guidelines/standards.

4. Our AMA will continue to monitor health care delivery and physician payment reform activities and provide resources to help physicians understand and participate in these initiatives.

5. Our AMA supports the development of a public-private partnership for the purpose of validating statistical models used for risk adjustment.

Policy Timeline

CMS Rep. 6, A-09Reaffirmation A-10Appended: Res. 829, I-10Appended: CMS Rep. 1, A-11Appended: CMS Rep. 4, A-11Reaffirmed in lieu of Res. 119, A-12

Reaffirmed in lieu of Res. 122, A-12Modified: CMS Rep. 6, A-13Reaffirmation I-15Reaffirmation: A-16Reaffirmed in lieu of: Res. 712, A-17

Reaffirmed: BOT Action in response to referred for decision: Res. 237, I-17 Reaffirmation: A-19

Reaffirmed: BOT Action in response to referred for decision Res. 111, A-19 Reaffirmed: BOT Action in response to referred for decision Res. 132, A-19

Reaffirmed: Res. 212, I-21 Reaffirmed: Res. 240, A-22 Reaffirmation: A-22 Modified: CMS Rep. 04, A-23 Reaffirmed: Res. 214, A-23 Reaffirmation: A-23

Work of the Task Force on the Release of Physician Data H-406.991

Principles for the Public Release and Accurate Use of Physician Data

The AMA encourages the use of physician data to benefit both patients and physicians and to improve the quality of patient care and the efficient use of resources in the delivery of health care services. The AMA supports this use of physician data when it is used in conjunction with program(s) designed to improve or maintain the quality of, and access to, medical care for all patients and is used to provide accurate physician performance assessments in concert with the following Principles:

1. Patient Privacy Safeguards

- All entities involved in the collection, use and release of claims data comply with the HIPAA Privacy and Security Rules (H-315.972, H-315.973, H-315.983, H-315.984, H-315.989, H-450.947).
- Disclosures made without patient authorization are generally limited to claims data, as that is generally the only information necessary to accomplish the intended purpose of the task (H-315.973, H-315.975, H-315.983).

2. Data Accuracy and Security Safeguards

- Effective safeguards are established to protect against the dissemination of inconsistent, incomplete, invalid or inaccurate physician-specific medical practice data (H-406.996, H-450.947, H-450.961).
- Reliable administrative, technical, and physical safeguards provide security to prevent the unauthorized use or disclosure of patient or physician-specific health care data and physician profiles (H-406.996, H-450.947, H-450.961).
- Physician-specific medical practice data, and all analyses, proceedings, records and minutes from quality review activities are not subject to discovery or admittance into evidence in any judicial or administrative proceeding without the physician's consent (H-406.996, H-450.947, H-450.961).

3. Transparency Requirements

- When data are collected and analyzed for the purpose of creating physician profiles, the methodologies used to create the profiles and report the results are developed in conjunction with relevant physician organizations and practicing physicians and are disclosed in sufficient detail to allow each physician or medical group to re-analyze the validity of the reported results prior to more general disclosure (H-315.973, H-406.993, H-406.994, H-406.998, H-450.947, H-450.961).
- The limitations of the data sources used to create physician profiles are clearly identified and acknowledged in terms understandable to consumers (H-406.994, H-450.947).
- The capabilities and limitations of the methodologies and reporting systems applied to the data to profile and rank physicians are publicly revealed in understandable terms to consumers (H-315.973, H-406.994, H-406.997, H-450.947, H-450.961).
- Case-matched, risk-adjusted resource use data are provided to physicians to assist them in determining their relative utilization of resources in providing care to their patients (H-285.931).

4. Review and Appeal Requirements

- Physicians are provided with an adequate and timely opportunity to review, respond and appeal the results derived from the analysis of physician-specific medical practice data to ensure accuracy prior to their use, publication or release (H-315.973, H-406.996, H-406.998, H-450.941, H-450.947, H-450.961).
- When the physician and the rater cannot reach agreement, physician comments are appended to the report at the physician's request (H-450.947).

5. Physician Profiling Requirements

- The data and methodologies used in profiling physicians, including the use of representative and statistically valid sample sizes, statistically valid risk-adjustment methodologies and statistically valid attribution rules produce verifiably accurate results that reflect the quality and cost of care provided by the physicians (H-406.994, H-406.997, H-450.947, H-450.961).
- Data reporting programs only use accurate and balanced data sources to create physician profiles and do not use these profiles to create tiered or narrow network programs that are used to steer patients towards certain physicians primarily on cost of care factors (H-450.951).

- When a single set of claims data includes a sample of patients that are skewed or not representative of the physicians' entire patient population, multiple sources of claims data are used.
- Physician efficiency of care ratings use physician data for services, procedures, tests and prescriptions that are based on physicians' patient utilization of resources so that the focus is on comparative physicians' patient utilization and not on the actual charges for services.
- Physician-profiling programs may rank individual physician members of a medical group but do not use those individual rankings for placement in a network or for reimbursement purposes.

6. Quality Measurement Requirements

- The data are used to profile physicians based on quality of care provided - never on utilization of resources alone -- and the degree to which profiling is based on utilization of resources is clearly identified (H-450.947).
- Data are measured against evidence-based quality of care measures, created by physicians across appropriate specialties, such as the Physician Consortium for Performance Improvement. (H-406.994, H-406.998, H-450.947, H-450.961).
- These evidence-based measures are endorsed by the National Quality Forum (NQF) and/or the AQA and HQA, when available. When unavailable, scientifically valid measures developed in conjunction with appropriate medical specialty societies and practicing physicians are used to evaluate the data.

7. Patient Satisfaction Measurement Requirements

- Until the relationship between patient satisfaction and other outcomes is better understood, data collected on patient satisfaction is best used by physicians to better meet patient needs particularly as they relate to favorable patient outcomes and other criteria of high quality care (H-450.982).
- Because of the difficulty in determining whether responses to patient satisfaction surveys are a result of the performance of a physician or physician office, or the result of the demands or restrictions of health insurers or other factors out of the control of the physician, the use of patient satisfaction data is not appropriate for incentive or tiering mechanisms.
- As in physician profiling programs, it is important that programs that publicly rate physicians on patient satisfaction notify physicians of their rating and provide a chance for the physician to appeal that rating prior to its publication.

Policy Timeline

BOT Rep. 18, A-09Reaffirmation A-10Reaffirmed: BOT action in response to referred for decision Res. 709, A-10, Res. 710, A-10, Res. 711, A-10 and BOT Rep. 17, A-10

Reaffirmation I-10Reaffirmed in lieu of Res. 808, I-10Reaffirmed in lieu of Res. 824, I-10Reaffirmation A-11Reaffirmed: BOT Rep. 17, A-13Reaffirmed: Res. 806, I-13

Reaffirmation: A-19

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 204
(A-24)

Introduced by: Florida
Subject: Staffing Ratios in the Emergency Department
Referred to: Reference Committee B

1 Whereas, the Emergency Department is the medical safety net for the nation and provides care
2 to vulnerable patients who may not otherwise have access to primary or specialty medical care;
3 and
4
5 Whereas, in many states, physicians are the only health professionals authorized to practice
6 medicine in the Emergency Department without limitation; and
7
8 Whereas, every patient presenting to an Emergency Department should be under the direct,
9 real-time care of a licensed physician, including the on-site and real-time supervision of non-
10 physician practitioners (NPPs); and
11
12 Whereas, state laws vary on the number of nurse practitioners and physician assistants that a
13 physician can supervise, with some states having no limits at all; and
14
15 Whereas, a 2022 NBER paper using data from the VA shows that nurse practitioners working
16 without supervision in the Emergency Department resulted in increased lengths of stay,
17 increased costs, increased 30-day re-admissions, and increased mortality rates among the
18 higher acuity patients. Nursing literature also supports that NPs should not be working
19 unsupervised in the ED; and
20
21 Whereas, in an increasing number of states, most Emergency Physicians are employed by
22 corporate staffing groups with private equity backing seeking to maximize profit through
23 understaffing physicians and replacing them with non-physician practitioners (NPPs); and
24
25 Whereas, the staffing ratio of NPPs to physicians at any given time in the Emergency
26 Department determines whether a physician has time to adequately supervise and see the
27 patients being cared for by the NPPs; therefore be it
28
29 RESOLVED, that our American Medical Association seek federal legislation or regulation
30 prohibiting staffing ratios that do not allow for proper supervision of NPPs in the Emergency
31 Department (Directive to Take Action); and be it further
32
33 RESOLVED, that our AMA seek federal legislation or regulation that would require all
34 Emergency Departments to be staffed 24-7 by a qualified physician. (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/9/2024

References:

1. Chan, D. and Chen, Y. The Productivity of Professions: Evidence from the Emergency Department, National Bureau of Economic Research, Working Paper 30608, Oct 2022. <https://www.nber.org/papers/w30608>
2. Proffitt Lavin, R PhD FNP-BC FAAN, et al. Analysis of Nurse Practitioners' Educational Preparation, Credentialing, and Scope of Practice in U.S. Emergency Departments. Journal of Nursing Regulation, Vol 12, Issue 4, P50-62, Jan 01, 2022. [https://www.journalofnursingregulation.com/article/S2155-8256\(22\)00010-2/fulltext](https://www.journalofnursingregulation.com/article/S2155-8256(22)00010-2/fulltext)
3. Updated Position Statement on Non-Physician Practitioners. AAEM - American Academy of Emergency Medicine. Accessed April 12, 2023. <https://www.aaem.org/resources/statements/position/updated-advanced-practice-providers>
4. American Academy of Emergency Medicine (AAEM) paper on guidelines for safe patients per hour and NPP supervision limits...in process

Relevant AMA Policy

Promoting Supervision of Emergency Care Services in Emergency Departments by Physicians D-35.976

Our AMA will advocate for the establishment and enforcement of legislation and/or regulations that ensure only physicians supervise the provision of emergency care services in an emergency department. [Res. 218, A-23]

Principles for Strengthening the Physician-Hospital Relationship H-225.957

The following twelve principles are AMA policy:

PRINCIPLES FOR STRENGTHENING THE PHYSICIAN-HOSPITAL RELATIONSHIP

1. The organized medical staff and the hospital governing body are responsible for the provision of quality care, providing a safe environment for patients, staff and visitors, and working continuously to improve patient care and outcomes, with the primary responsibility for the quality of care rendered and for patient safety vested with the organized medical staff. These activities depend on mutual accountability, interdependence, and responsibility of the organized medical staff and the hospital governing body for the proper performance of their respective obligations.
2. The organized medical staff, a self-governing organization of professionals, possessing special expertise, knowledge and training, discharges certain inherent professional responsibilities by virtue of its authority to regulate the professional practice and standards of its members, and assumes primary responsibility for many functions, including but not limited to: the determination of organized medical staff membership; performance of credentialing, privileging and other peer review; and timely oversight of clinical quality and patient safety.
3. The leaders of the organized medical staff, with input from the hospital governing body and senior hospital managers, develop goals to address the healthcare needs of the community and are involved in hospital strategic planning as described in the medical staff bylaws.
4. Ongoing, timely and effective communication, by and between the hospital governing body and the organized medical staff, is critical to a constructive working relationship between the organized medical staff and the hospital governing body.
5. The organized medical staff bylaws are a binding, mutually enforceable agreement between the organized medical staff and the hospital governing body. The organized medical staff and hospital bylaws, rules and regulations should be aligned, current with all applicable law and accreditation body requirements and not conflict with one another. The hospital bylaws, policies and other governing documents do not conflict with the organized medical staff bylaws, rules, regulations and policies, nor with the organized medical staff's autonomy and authority to self govern, as that authority is set forth in the governing documents of the organized medical staff. The organized medical staff, and the hospital governing body/administration, shall, respectively, comply with the bylaws, rules, regulations, policies and procedures of one another. Neither party is authorized to, nor shall unilaterally amend the bylaws, rules, regulations, policies or procedures of the other.
6. The organized medical staff has inherent rights of self governance, which include but are not limited to:

- a) Initiating, developing and adopting organized medical staff bylaws, rules and regulations, and amendments thereto, subject to the approval of the hospital governing body, which approval shall not be unreasonably withheld. The organized medical staff bylaws shall be adopted or amended only by a vote of the voting membership of the medical staff.
- b) Identifying in the medical staff bylaws those categories of medical staff members that have voting rights.
- c) Identifying the indications for automatic or summary suspension, or termination or reduction of privileges or membership in the organized medical staff bylaws, restricting the use of summary suspension strictly for patient safety and never for purposes of punishment, retaliation or strategic advantage in a peer review matter. No summary suspension, termination or reduction of privileges can be imposed without organized medical staff action as authorized in the medical staff bylaws and under the law.
- d) Identifying a fair hearing and appeals process, including that hearing committees shall be composed of peers, and identifying the composition of an impartial appeals committee. These processes, contained within the organized medical staff bylaws, are adopted by the organized medical staff and approved by the hospital governing board, which approval cannot be unreasonably withheld nor unilaterally amended or altered by the hospital governing board or administration. The voting members of the organized medical staff decide any proposed changes.
- e) Establishing within the medical staff bylaws: 1) the qualifications for holding office, 2) the procedures for electing and removing its organized medical staff officers and all organized medical staff members elected to serve as voting members of the Medical Executive Committee, and 3) the qualifications for election and/or appointment to committees, department and other leadership positions.
- f) Assessing and maintaining sole control over the access and use of organized medical staff dues and assessments, and utilizing organized medical staff funds as appropriate for the purposes of the organized medical staff.
- g) Retaining and being represented by legal counsel at the option and expense of the organized medical staff.
- h) Establishing in the organized medical staff bylaws, the structure of the organized medical staff, the duties and prerogatives of organized medical staff categories, and criteria and standards for organized medical staff membership application, reapplication credentialing and criteria and processing for privileging. The standards and criteria for membership, credentialing and privileging shall be based only on quality of care criteria related to clinical qualifications and professional responsibilities, and not on economic credentialing, conflicts of interest or other non-clinical credentialing factors.
- i) Establishing in the organized medical staff bylaws, rules and regulations, clinical criteria and standards to oversee and manage quality assurance, utilization review and other organized medical staff activities, and engaging in all activities necessary and proper to implement those bylaw provisions including, but not limited to, periodic meetings of the organized medical staff and its committees and departments and review and analysis of patient medical records.
- j) The right to define and delegate clearly specific authority to an elected Medical Executive Committee to act on behalf of the organized medical staff. In addition, the organized medical staff defines indications and mechanisms for delegation of authority to the Medical Executive Committee and the removal of this authority. These matters are specified in the organized medical staff bylaws.
- k) Identifying within the organized medical staff bylaws a process for election and removal of elected Medical Executive Committee members.
- l) Defining within the organized medical staff bylaws the election process and the qualifications, roles and responsibilities of clinical department chairs. The Medical Executive Committee must appoint any clinical chair that is not otherwise elected by the vote of the general medical staff.
- m) Enforcing the organized medical staff bylaws, regulations and policies and procedures.
- n) Establishing in medical staff bylaws, medical staff involvement in contracting relationships, including exclusive contracting, medical directorships and all hospital-based physician contracts, that affect the functioning of the medical staff.

7. Organized medical staff bylaws are a binding, mutually enforceable agreement between the organized medical staff and the hospital governing body, as well as between those two entities and the individual members of the organized medical staff.
8. The self-governing organized medical staff determines the resources and financial support it requires to effectively discharge its responsibilities. The organized medical staff works with the hospital governing board to develop a budget to satisfy those requirements and related administrative activities, which the hospital shall fund, based upon the financial resources available to the hospital.
9. The organized medical staff has elected appropriate medical staff member representation to attend hospital governing board meetings, with rights of voice and vote, to ensure appropriate organized medical staff input into hospital governance. These members should be elected only after full disclosure to the medical staff of any personal and financial interests that may have a bearing on their representation of the medical staff at such meetings. The members of the organized medical staff define the process of election and removal of these representatives.
10. Individual members of the organized medical staff, if they meet the established criteria that are applicable to hospital governing body members, are eligible for full membership on the hospital governing body. Conflict of interest policies developed for members of the organized medical staff who serve on the hospital's governing body are to apply equally to all individuals serving on the hospital governing body.
11. Well-defined disclosure and conflict of interest policies are developed by the organized medical staff which relate exclusively to their functions as officers of the organized medical staff, as members and chairs of any medical staff committee, as chairs of departments and services, and as members who participate in conducting peer review or who serve in any other positions of leadership of the medical staff.
12. Areas of dispute and concern, arising between the organized medical staff and the hospital governing body, are addressed by well-defined processes in which the organized medical staff and hospital governing body are equally represented. These processes are determined by agreement between the organized medical staff and the hospital governing body. [Res. 828, I-07 Reaffirmed in lieu of Res. 730, A-09 Modified: Res. 820, I-09 Reaffirmed: Res. 725, A-10 Reaffirmation A-12 Reaffirmed: CMS Rep. 6, I-13 Reaffirmed: CMS Rep. 5, A-21]

Supervision and Proctoring by Facility Medical Staff H-375.967

Our AMA advocates that the conduct of medical staff supervision be included in medical staff bylaws and be guided by the following principles:

- (1) Physicians serving as medical staff supervisors should be indemnified at the facility's expense from malpractice claims and other litigation arising out of the supervision function.
- (2) Physicians being supervised should be indemnified at the facility's expense for any damages that might occur as a result of implementing interventions recommended by medical staff supervisors.
- (3) AMA principles of peer review as found in Policies H-320.968 [2,d], H-285.998 [5], and H-320.982 [2c,d] should be adhered to in the conduct of medical staff supervision.
- (4) The medical staff member serving as supervisor should be determined through a formal process by the department chair or medical staff executive committee.
- (5) The scope of the medical staff supervision should be limited to the provision of services that have been restricted, are clearly questionable, or are under question, as determined by the department chair or medical staff executive committee.
- (6) The duration of the medical staff supervision should be limited to the amount of time necessary to adequately assess the degree of clinical competence in the area of skill being assessed.
- (7) Medical staff supervision should include a sufficient volume of procedures or admissions for meaningful assessment.
- (8) Medical staff supervisors should provide periodic performance reports on each patient to the appropriate designated medical staff committee. The reports should be transcribed or transcribed by the medical staff office to assure confidentiality. The confidentiality of medical staff supervision reports must be strictly maintained.
- (9) Physicians whose performance is supervised should have access to the performance reports submitted by medical staff supervisors and should be given the opportunity to comment on the contents of the reports. [CMS Rep. 3, A-99 Reaffirmed: CLRPD Rep. 1, A-09 Reaffirmed: CMS Rep. 01, A-19]

Medical Staff Development Plans H-225.961

All hospitals/health systems incorporate the following principles for the development of medical staff development plans: (a) The medical staff and hospital/health system leaders have a mutual responsibility to: cooperate and work together to meet the overall health and medical needs of the community and preserve quality patient care; acknowledge the constraints imposed on the two by limited financial resources; recognize the need to preserve the hospital/health system's economic viability; and respect the autonomy, practice prerogatives, and professional responsibilities of physicians. (b) The medical staff and its elected leaders must be involved in the hospital/health system's leadership function, including: the process to develop a mission that is reflected in the long-range, strategic, and operational plans; service design; resource allocation; and organizational policies. (c) Medical staffs must ensure that quality patient care is not harmed by economic motivations. (d) The medical staff should review and approve and make recommendations to the governing body prior to any decision being made to close the medical staff and/or a clinical department. (e) The best interests of patients should be the predominant consideration in granting staff membership and clinical privileges. (f) The medical staff must be responsible for professional/quality criteria related to appointment/reappointment to the medical staff and granting/renewing clinical privileges. The professional/quality criteria should be based on objective standards and the standards should be disclosed. (g) The medical staff should be consulted in establishing and implementing institutional/community criteria. Institutional/community criteria should not be used inappropriately to prevent a particular practitioner or group of practitioners from gaining access to staff membership. (h) Staff privileges for physicians should be based on training, experience, demonstrated competence, and adherence to medical staff bylaws. No aspect of medical staff membership or particular clinical privileges shall be denied on the basis of sex, race, age, creed, color, national origin, religion, disability, ethnic origin sexual orientation, gender identity or physical or mental impairment that does not pose a threat to the quality of patient care. (i) Physician profiling must be adjusted to recognize case mix, severity of illness, age of patients and other aspects of the physician's practice that may account for higher or lower than expected costs. Profiles of physicians must be made available to the physicians at regular intervals. [BOT Rep. 14, A-98Modified: BOT Rep. 11, A-07Reaffirmation A-10Modified: CMS Rep. 01, A-20]

Credentialing and the Quality of Care H-225.971

It is the policy of the AMA: (1) that the hospital medical staff be recognized within the hospital as the entity with the overall responsibility for the quality of medical care; (2) that hospital medical staff bylaws reaffirm The Joint Commission standard that medical staffs have "overall responsibility for the quality of the professional services provided by individuals with clinical privileges"; (3) that each hospital's quality assurance, quality improvement, and other quality-related activities be coordinated with the hospital medical staff's overall responsibility for quality of medical care; (4) that the hospital governing body, management, and medical staff should jointly establish the purpose, duties, and responsibilities of the hospital administrative personnel involved in quality assurance and other quality-related activities; establish the qualifications for these positions; and provide a mechanism for medical staff participation in the selection, evaluation, and credentialing of these individuals; (5) that the hospital administrative personnel performing quality assurance and other quality activities related to patient care report to and be accountable to the medical staff committee responsible for quality improvement activities; (6) that the purpose, duties, responsibilities, and reporting relationships of the hospital administrative personnel performing quality assurance and other quality-related activities be included in the medical staff and hospital corporate bylaws; (7) that the general processes and policies related to patient care and used in a hospital quality assurance system and other quality-related activities should be developed, approved, and controlled by the hospital medical staff; and (8) that any physician hired or retained by a hospital to be involved solely in medical staff quality of care issues be credentialed by the medical staff prior to employment in the hospital. [BOT Rep. T, I-92Reaffirmed: CMS Rep. 10, A-03Modified: CMS Rep. 4, A-13 Reaffirmed: CMS Rep. 5, A-21]

On-Call Physicians H-130.948

Our AMA:

- (1) strongly encourages physicians and hospitals to work collaboratively to develop solutions based on adequate compensation or other appropriate incentives as the preferred method of ensuring on-call coverage and will monitor and oppose any state legislative or regulatory efforts mandating emergency room on-call coverage as a requirement for medical staff privileges and state licensure that are not supported by the state medical association;
- (2) advocates that physician on-call coverage for emergency departments be guided by the following principles:
 - (a) The hospital and physicians should jointly share the responsibility for the provision of care of emergency department patients.
 - (b) Every hospital that provides emergency services should maintain policies to ensure appropriate on-call coverage of the emergency department by medical staff specialists that are available for consultation and treatment of patients.
 - (c) The organization and function of on-call services should be determined through hospital policy and medical staff by-laws, and include methods for monitoring and assuring appropriate on-call performance.
 - (d) Physicians should be provided adequate compensation for being available and providing on-call and emergency services.
 - (e) Hospital medical staff by-laws and emergency department policies regarding on-call physicians' responsibilities must be consistent with Emergency Medical Treatment and Active Labor Act (EMTALA) requirements.
 - (f) Medical staffs should determine and adopt protocols for appropriate, fair, and responsible medical staff on-call coverage.
 - (g) Hospitals with specialized emergency care capabilities need to have a means to ensure medical staff responsibility for patient transfer acceptance and care.
 - (h) Hospitals that lack the staff to provide on-call coverage for a particular specialty should have a plan that specifies how such care will be obtained.
 - (i) The decision to operate or close an emergency department should be made jointly by the hospital and medical staff;
- (3) supports the enforcement of existing laws and regulations that require physicians under contract with health plans to be adequately compensated for emergency services provided to the health plans' enrollees; and
- (4) supports the enactment of legislation that would require health plans to adequately compensate out-of-plan physicians for emergency services provided to the health plans' enrollees or be subject to significant fines similar to the civil monetary penalties that can be imposed on hospitals and physicians for violation of EMTALA. [CMS Rep. 3, I-99 Reaffirmation A-00Modified: Sub. Res. 217, I-00 Reaffirmation I-01Reaffirmation A-07Appended and Reaffirmed: CMS Rep. 1, I-09 Modified: Res. 818, I-17]

Professional Nurse Staffing in Hospitals H-360.986

- The AMA: (1) encourages medical and nursing staffs in each facility to closely monitor the quality of medical care to help guide hospital administrations toward the best use of resources for patients;
- (2) encourages medical and nursing staffs to work together to develop and implement in-service education programs and promote compliance with established or pending guidelines for unlicensed assistive personnel and technicians that will help assure the highest and safest standards of patient care;
 - (3) encourages medical and nursing staffs to use identification mechanisms, e.g. badges, that provide the name, credentials, and/or title of the physicians, nurses, allied health personnel, and unlicensed assistive personnel in facilities to enable patients to easily note the level of personnel providing their care;
 - (4) encourages medical and nursing staffs to develop, promote, and implement educational guidelines for the training of all unlicensed personnel working in critical care units, according to the needs at each facility; and
 - (5) encourages medical and nursing staffs to work with hospital administrations to assure that patient care and safety are not compromised when a hospital's environment and staffing are restructured. [BOT Rep. 11, I-96Reaffirmed: CMS Rep. 8, A-06Reaffirmed: CMS Rep. 01, A-16]

Supervision of Non-Physician Practitioners by Physicians D-35.978

Our AMA will advocate: (1) to ensure physicians on staff receive written notification when their license is being used to document supervision of non-physician practitioners; (2) that physician supervision should be explicitly defined and mutually agreed upon; (3) for advanced notice and disclosure to the physician before they are hired or as soon as practicably known by provider organizations and institutions that anticipate physician supervision of non-physician practitioners as a condition for physician employment; (4) that organizations, institutions, and medical staffs that have physicians who participate in supervisory duties for non-physician practitioners have processes and procedures in place that have been developed with appropriate clinical physician input; and (5) that physicians be able to report professional concerns about care provided by the non-physician practitioners to the appropriate leadership with protections against retaliation. [Res. 017, I-22]

Emergency Department Boarding and Crowding H-130.940

Our AMA:

1. congratulates the American College of Emergency Physicians for developing and promulgating solutions to the problem of emergency department boarding and crowding;
2. supports collaboration between organized medical staff and emergency department staff to reduce emergency department boarding and crowding;
3. supports dissemination of best practices in reducing emergency department boarding and crowding;
4. continues to encourage entities engaged in measuring emergency department performance (e.g., payers, licensing bodies, health systems) to use evidence-based, clinical performance measures that enable clinical quality improvement and capture variation such as those developed by the profession through the Physician Consortium for Performance Improvement;
5. continues to support physician and hospital use and reporting of emergency medicine performance measures developed by the Physician Consortium for Performance Improvement; and
6. continues to support the harmonization of individual physician, team-based, and facility emergency medicine performance metrics so there is consistency in evaluation, methodology, and limited burden associated with measurement. [CMS Rep. 3, A-09Reaffirmed: CMS Rep. 01, A-19Reaffirmed: BOT Rep. 16, A-19]

Managed Care Organizations' Use of Physicians to Provide Second Opinions to Physicians Providing Emergency Services H-285.950

The AMA adopts the following principles to guide the use by managed care plans of physicians employed or contracted with to specifically provide second opinions to physicians providing emergency services. The AMA encourages managed care plans to follow these guidelines when employing or contracting with physicians to provide second opinions to physicians providing emergency services.

- (1) All managed care plans shall disclose to their enrollees and prospective enrollees any plan requirements or the existence of contractual arrangements whereby physicians are required to provide second opinions to physicians providing emergency services regarding the care provided to patients presenting at emergency departments or facilities.
- (2) The required use of physicians to provide second opinions to physicians providing emergency services regarding the care provided to patients presenting at emergency departments or facilities shall not impede the immediate diagnosis and therapy of acute cardiac, trauma, and other critical patient situations for which delay may result in death or an increase in severity of illness.
- (3) Any physician with a contractual arrangement to provide second opinions to physicians providing emergency services regarding the care provided to patients presenting at emergency departments or facilities shall be licensed to practice medicine and actively practicing emergency medicine in the same state in which the second opinion is provided.
- (4) Any physician with a contractual arrangement to provide second opinions to physicians providing emergency services regarding the care provided to patients presenting at emergency departments or facilities shall have active staff privileges in any facility in which the second opinion is provided.
- (5) To the degree possible, patients presenting at an emergency department or facility should be involved in the decisions regarding the treatment, referral, and follow-up care for their condition.

(6) In the event of disagreements over second opinions, final decisions regarding the treatment, referral, and follow-up care provided to patients presenting at emergency departments or facilities shall be made by the attending emergency physician or other appropriate physicians on staff at the facility. [CMS Rep. 1, I-96Reaffirmed: CMS Rep. 8, A-06Reaffirmed: CMS Rep. 01, A-16]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 205
(A-24)

Introduced by: Medical Student Section, American Association of Public Health Physicians

Subject: Medical-Legal Partnerships & Legal Aid Services

Referred to: Reference Committee B

Whereas, medical-legal partnerships (MLPs) address social determinants of health relating to civil law, such as family violence, child support and custody, workplace conditions, employment conflicts, financial exploitation, post-incarceration rehabilitation, housing, utility shutoffs, disability access, debt relief, and veteran benefits, by integrating lawyers in clinical settings team to meet patient's legal needs¹⁻⁶; and

Whereas, 70% of low-income households experience civil legal problems, with 40% experiencing at least 5, 20% experiencing at least 10, and the average low-income individual managing 2 to 3 legal issues at a time⁷⁻⁸; and

Whereas, unmet civil legal needs may lead to or exacerbate both physical and mental illness, as seen with inadequate housing, eviction, and even threat of eviction being connected to anxiety, depression, bodily injury, asthma, and respiratory infection⁹⁻¹¹; and

Whereas, MLPs demonstrate success in access to retroactive benefits, improved asthma control and neonatal preventive care use, and decreased length of hospitalization, readmission rates, and emergency department visits⁷; and

Whereas, while MLPs are found at only 26% of medical schools, studies indicate that MLPs can help educate physicians and medical students on screening for social determinants and legal needs, addressing issues impacting health through legal advocacy, and referring patients to reliable legal resources^{1,12-15}; and

Whereas, civil legal aid often includes free or low-cost direct legal services by lawyers as well as legal education to help low- and middle-income people navigate social systems¹⁶; and

Whereas, the high cost of civil legal aid is a significant barrier to access, with low-income Americans reporting only seek aid for 1 out of 4 civil legal problems and receiving inadequate legal aid for 92% of their needs^{8,17}; and

Whereas, civil legal aid services in the US are chronically underfunded, turning away an average of 50% of eligible individuals who seek services due to inadequate funds¹⁶; and

Whereas, the Association of American Medical Colleges and the American Bar Association both conduct initiatives relating to MLPs, including creation of models and directories¹⁸⁻¹⁹; therefore be it

RESOLVED, that our American Medical Association support the establishment and funding of medical-legal partnerships and civil legal aid services to meet patients' legal needs. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 03/28/2024

REFERENCES

1. Regenstein M, Trott J, Williamson A, Theiss J. Addressing Social Determinants Of Health Through Medical-Legal Partnerships. *Health Affairs*. 2018;37(3):378-385. doi:10.1377/hlthaff.2017.1264
2. Cloud DH, Bassett MT, Graves J, Fullilove RE, Brinkley-Rubinstein L. Documenting and addressing the health impacts of carceral systems. *Am J Public Health*. 2020;110(suppl 1) S5–S5.
3. Swope CB, Hernández D. Housing as a determinant of health equity: a conceptual model. *Soc Sci Med*. 2019;243:112571.
4. Gong, G., Phillips, S. G., Hudson, C., Curti, D., & Phillips, B. U. Higher US rural mortality rates linked to socioeconomic status, physician shortages, and lack of health insurance. *Health Affairs*, 2019; 38(12), 2003-2010.
5. Keith-Jennings B, Llobrera J, Dean S. Links of the Supplemental Nutrition Assistance Program with food insecurity, poverty, and health: evidence and potential. *Am J Public Health*. 2019;109(12):1636–1640.
6. Girard, V. et al. The Academic Medical-Legal Partnership. September 26, 2022.
7. Mead, Allee. Bringing Law and Medicine Together to Help Rural Patients. Rural Health Information Hub. Last accessed September 22, 2022. <https://www.ruralhealthinfo.org/rural-monitor/medical-legal-partnerships>
8. 2022 Justice Gap Study, Legal Services Corporation. Last accessed August 31, 2022. <https://justicegap.isc.gov/resource/executive-summary>
9. Jassar, Sunam. Access to Justice as a Social Determinant of Health: The Basis for Reducing Health Disparity and Advancing Health Equity of Marginalized Communities, *Windsor Yearbook of Access to Justice* 37 (2021), <https://wyai.uwindsor.ca/index.php/wyai/article/view/7283>
10. Cannon, Yael. Unmet Legal Needs as Health Injustice. *University of Richmond Law Review*, Vol. 56, pp. 801-877 (2022). <https://scholarship.law.georgetown.edu/facpub/2452>
11. Making Justice Equal, Center for American Progress (Dec. 8, 2016). <https://www.americanprogress.org/article/making-justice-equal>
12. Girard, V. W., Moore, E. S., Kessler, L. P., Perry, D., & Cannon, Y. An Interprofessional Approach to Teaching Advocacy Skills: Lessons from an Academic Medical–Legal Partnership. *Journal of Legal Medicine*, 2020; 40(2), 265-278.
13. Pettignano, R., Bliss, L., McLaren, S., & Caley, S. Interprofessional medical–legal education of medical students: assessing the benefits for addressing social determinants of health. *Academic Medicine*, 2017; 92(9), 1254-1258.
14. Coleman, R., Dunn, C., & McDonald, D. Medical Legal Partnerships: A Novel Way to Help Address Health-harming Legal Needs and Social Determinants of Health in Pediatric Patients with Asthma. *The Florida Pediatrician*, 2022; 41(1).
15. John, J. et al. Efficacy of Medical Legal Partnerships to Address Health Harming Legal Needs: A Systematic Review of Experimental Studies in the Field. 2022. <https://doi.org/10.21203/rs.3.rs-1625222/v1>
16. U.S. Department of Justice, Civil Legal Aid 1010. Last accessed September 22, 2022. <https://www.justice.gov/atj/civil-legal-aid-101>
17. Emery G. Lee, Law Without Lawyers: Access to Civil Justice and the Cost of Legal Services, *University of Miami Law Review* 69:499 (April 2015). <https://lawreview.law.miami.edu/wp-content/uploads/2015/04/Lee.pdf>.
18. AAMC releases three tools to help MLPs measure their impact on health and health equity. National Center for Medical-Legal Partnership, Milken Institute School of Public Health, The George Washington University. Published September 26, 2019. <https://medical-legalpartnership.org/aamc-evaluation-tools>
19. Medical-Legal Partnerships. American Bar Association. https://www.americanbar.org/groups/health_law/interest_groups/educational_outreach/medical-legal-partnerships-

RELEVANT AMA POLICY

H-165.822 Health Plan Initiatives Addressing Social Determinants of Health

Our AMA:

1. recognizing that social determinants of health encompass more than health care, encourages new and continued partnerships among all levels of government, the private sector, philanthropic organizations, and community- and faith-based organizations to address non-medical, yet critical health needs and the underlying social determinants of health;
2. supports continued efforts by public and private health plans to address social determinants of health in health insurance benefit designs;
3. encourages public and private health plans to examine implicit bias and the role of racism and social determinants of health, including through such mechanisms as professional development and other training;
4. supports mechanisms, including the establishment of incentives, to improve the acquisition of data related to social determinants of health, while minimizing burdens on patients and physicians;
5. supports research to determine how best to integrate and finance non-medical services as part of health insurance benefit design, and the impact of covering non-medical benefits on health care and societal costs; and
6. encourages coverage pilots to test the impacts of addressing certain non-medical, yet critical health needs, for which sufficient data and evidence are not available, on health outcomes and health care costs. [CMS Rep. 7, I-20Reaffirmed: CMS Rep. 5, I-21Reaffirmed: CMS Rep. 5, A-22]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 206
(A-24)

Introduced by: Medical Student Section

Subject: Indian Health Service Youth Regional Treatment Centers

Referred to: Reference Committee B

1 Whereas, nearly 13% of AI/AN youth ages 12-24 experienced a depressive episode or related
2 mental illness in 2018, and an estimated 20% require treatment due to early alcohol use¹⁻²; and
3

4 Whereas, the Indian Health Service (IHS) uses Youth Regional Treatment Centers (YRTCs) for
5 acute behavioral healthcare for AI/AN adolescents, but national capacity only meets 4% of the
6 need²⁻³; and
7

8 Whereas, YRTCs help adolescents develop independent living skills, provide schooling attuned
9 to individual needs, create post-discharge sobriety plans, and coordinate prison diversion
10 programs⁴⁻⁵; and
11

12 Whereas, while 61% of arrested AI/AN youth are eligible for YRTC diversion programs, only
13 14% ultimately receive care at YRTCs²; and
14

15 Whereas, the IHS, in consultation with Tribal leaders and key parties, has voiced concerns
16 regarding AI/AN youth traveling across state lines to seek care at non-IHS treatment centers⁶;
17 and
18

19 Whereas, non-IHS treatment centers are not equipped to address the complex effects of
20 intergenerational trauma, systematic discrimination, and displacement on AI/AN youth mental
21 health⁷⁻⁹; therefore be it
22

23 RESOLVED, that our American Medical Association support the expansion of Indian Health
24 Service Youth Regional Treatment Centers, recognizing them as a model for culturally-rooted,
25 evidence-based behavioral health treatment, and prompt referral of eligible AI/AN youth to Youth
26 Regional Treatment Centers (YRTCs) for community-directed care. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 4/5/2024

REFERENCES

1. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (2019). *National Survey on Drug Use and Health 2019* (NSDUH-2019-DS0001). Retrieved from <https://datafiles.samhsa.gov/>
2. Paschane DM, James TD, Kinlacheeny. American Indian and Alaska Native Youth Treatment Aftercare. Indian Health Service, U.S. Department of Health and Human Services. 2022.
3. 25 U.S.C. § 1665g (2020). Retrieved from <https://law.justia.com/codes/us/2020/title-25/chapter-18/subchapter-v-a/part-a/sec-1665g/>
4. IHS. Youth Regional Treatment Centers. <https://www.ihs.gov/yrtc/>
5. Greene, C, Espinosa, M. Caring for Native Youth with Substance Use Disorders. Retrieved from https://www.resourcebasket.org/wp-content/uploads/2019/01/caring_for_native_youth_with_substance_use_disorders.pdf

6. IHS. IHS Holds Grand Opening for New Youth Regional Treatment Center in California. 2022. <https://www.ihs.gov/newsroom/pressreleases/2022-press-releases/ihs-holds-grand-opening-for-new-youth-regional-treatment-center-in-california/>
7. Woods C, Kim B, Calvert D, Aronowitz T. The development and pandemic-related adaptation of a resilience program for native middle-school youth: A case study. *Public Health Nurs.* 2023;40(2):298-305. doi:10.1111/phn.13154
8. Daily RS, Vana G, Andrade JKL, Pruett J. Evaluating Native Youth: Issues and Considerations in Clinical Evaluation and Treatment. *Child Adolesc Psychiatr Clin N Am.* 2022;31(4):779-788. doi:10.1016/j.chc.2022.06.008
9. Dixon AL, Yabiku ST, Okamoto SK, Tann SS, Marsiglia FF, Kulis S, Burke AM. The efficacy of a multicultural prevention intervention among urban American Indian youth in the southwest U.S. *J Prim Prev.* 2007 Nov;28(6):547-68. doi: 10.1007/s10935-007-0114-8. Epub 2007 Dec 6. PMID: 18058235; PMCID: PMC3042736.

RELEVANT AMA POLICY

H-160.963 Community-Based Treatment Centers

Our AMA supports the use of community-based treatment centers for substance use disorders, mental health disorders and developmental disabilities. [BOT Rep. F, I-91; Reaffirmed: Sunset Report, I-01; Modified: CSAPH Rep. 1, A-11; Modified: CSAPH Rep. 1, A-21]

D-350.988 American Indian / Alaska Native Adolescent Suicide

Our AMA will: 1) provide active testimony in Congress for suicide prevention and intervention resources to be directed towards American Indian/Alaska Native communities; 2) encourage significant funding to be allocated to research the causes, prevention, and intervention regarding American Indian/Alaska Native adolescent suicide and make these findings widely available; and 3) lobby the Senate Committee on Indian Affairs on the important issue of American Indian/Alaska Native adolescent suicide. [Sub Res. 404, A-11; Reaffirmed: BOT Rep. 7, A-21]

H-345.974 Culturally, Linguistically Competent Mental Health Care and Outreach for At-Risk Communities

Our AMA supports adequate attention and funds being directed towards culturally and linguistically competent mental health direct services for the diverse, multi-ethnic communities at greatest risk, and encourages greater cultural and linguistic-competent outreach to ethnic communities including partnerships with ethnic community organizations, health care advocates, and respected media outlets. [Res. 917, I-13; Reaffirmed: Res. 426, A-16]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 207
(A-24)

Introduced by: Medical Student Section

Subject: Biosimilar Use Rates and Prevention of Pharmacy Benefit Manager Abuse

Referred to: Reference Committee B

- 1 Whereas, biologics account for only 2% of prescriptions but 40% of US pharmaceutical
2 spending and 90% of the net pharmaceutical spending growth over the past decade¹⁻⁶; and
3
4 Whereas, biologics are often significantly more expensive than small-molecule drugs, costing on
5 average \$10,000 to \$40,000 per patient annually with some prices up to \$500,000¹⁻⁶; and
6
7 Whereas, biosimilars exhibit no clinically meaningful differences in safety, purity, and potency
8 compared to their corresponding “brand-name” (originator, or reference product) biologic⁷; and
9
10 Whereas, the US has only approved 50% of the biosimilars approved in other industrialized
11 nations, with an average uptake rate of 20% compared to over 80%⁸⁻¹⁶; and
12
13 Whereas, average US price decreases due to biosimilar entry are only 15 to 40% compared to
14 70% in other industrialized nations⁸⁻¹⁶; and
15
16 Whereas, other industrialized nations improve biosimilar uptake through lucrative financial
17 incentives for physicians to maintain robust reimbursement while saving on medication costs,
18 including rewards for biosimilar usage targets and shared savings programs¹⁷⁻²³; and
19
20 Whereas, “brand-name” biologics manufacturers have blocked biosimilar uptake in the US via
21 long-term exclusivity agreements with pharmacy benefit managers (PBMs) for preferential
22 coverage in insurance plans, such as Johnson & Johnson with Remicade (infliximab) and
23 AbbVie with Humira (adalimumab)²⁴⁻²⁵; and
24
25 Whereas, biologics manufacturers’ efforts to prevent biosimilar coverage by insurers interfere
26 with physician’s prescriptive authority, conflict with analogous AMA policy supporting physicians’
27 right to prescribe generic drugs, and maintain exorbitant pharmaceutical costs; and
28
29 Whereas, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have the
30 authority to investigate and block exclusive distribution clauses as antitrust violations, and AMA
31 advocacy can help ensure that PBM exclusivity agreements are an antitrust priority²⁵⁻²⁷;
32 therefore be it
33
34 RESOLVED, that our American Medical Association support economic incentives to increase
35 physician use of less expensive biosimilars instead of their reference biologics (New HOD
36 Policy); and be it further
37
38 RESOLVED, that our AMA encourage the Federal Trade Commission (FTC) and Department of
39 Justice (DOJ) Antitrust Division to closely scrutinize long-term exclusive contracts signed

- 1 between biologics originators and PBMs to ensure they do not impede biosimilar development
- 2 and uptake. (New HOD Policy)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/5/2024

REFERENCES

1. Medicare Payment Advisory Commission, "Prescription Drugs." *Health Care Spending and the Medicare Program: Data Book*, July 2021. https://www.medpac.gov/wp-content/uploads/2021/10/July2021_MedPAC_DataBook_Sec10_SEC.pdf.
2. Tichy EM, Hoffman JM, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2022. *Am J Health Syst Pharm*. 2022;79(14):1158-1172. doi:10.1093/ajhp/zxac102
3. IQVIA Institute for Human Data and Science, Biosimilars in the United States 2020-2024: Competition, Savings and Sustainability (September 29, 2020), <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-theunited-states-2020-2024>.
4. Mulchachy et al. Projected US Savings From Biosimilars, 2021-2025. 2022. *Am J Manag Care*. 2022;28(7):329-335.
5. Roy, A. Biologic Medicines: The Biggest Driver of Rising Drug Prices. *Forbes*, <https://www.forbes.com/sites/theapothecary/2019/03/08/biologic-medicines-the-biggest-driver-of-rising-drug-prices/?sh=72e153a118b0>. March 8, 2019, Accessed August 28, 2022.
6. Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Medicare Part B Drugs: Trends in Spending and Utilization, 2006-2017, (ASPE, November 2020), <https://aspe.hhs.gov/system/files/pdf/264416/Part-B-Drugs-Trends-Issue-Brief.pdf>.
7. FDA. Biological Product Innovation and Competition Act. <https://www.fda.gov/drugs/biosimilars/biological-product-innovation-and-competition#:~:text=The%20Biologics%20Price%20Competition%20and,safe%20and%20effective%20biological%20products>.
8. Michael S. Reilly and Philip J. Schneider. "Policy Recommendations for a Sustainable Biosimilars Market: Lessons from Europe" *Generics and Biosimilars Initiative Journal* 9, no. 2 (February 2020): 76–83. <https://doi.org/10.5639/gabij.2020.0902.013>.
9. Uptake of Biosimilars in Different Countries Varies," *Generics and Biosimilars Initiative*, August 11, 2019. <https://www.gabionline.net/Reports/Uptake-of-biosimilars-in-different-countries-varies>
10. "Humira Biosimilars Available at up to 80 Percent Discount in Europe: AbbVie," Reuters, November 2, 2018, <https://www.reuters.com/article/us-abbvie-results-humira-idUSKCN1N71NZ>.
11. IQVIA Institute for Human Data and Science, Biosimilars in the United States 2020-2024: Competition, Savings and Sustainability (September 29, 2020), <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-theunited-states-2020-2024>.
12. San-Juan-Rodriguez et al. 2019. Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition. *JAMA Netw Open*. 2019;2(12):e1917379.
13. Benjamin Yu. 2016. Greater Potential Cost Savings With Biosimilar Use. *Am J Manag Care*. 2016;22(5):378
14. Mulchachy et al. Projected US Savings From Biosimilars, 2021-2025. 2022. *Am J Manag Care*. 2022;28(7):329-335.
15. Kay J. The Dawn of the Biosimilars in the Management of IMiDs: Understanding and Integrating Biosimilar Data into Informed Collaborative Care. Presented at: IAS 2018; April 27-29, 2018; Boston.
16. Scott Morton et al. 2018. The Impact of the Entry of Biosimilars: Evidence from Europe. *Review of Industrial Organization*. <https://link.springer.com/article/10.1007/s11151-018-9630-3#Sec14>
17. Evelien Moorkens et al., "Policies for Biosimilar Uptake in Europe: An overview," *PLoS ONE* 12, no. 12 (December 28, 2017), <https://doi.org/10.1371/journal.pone.0190147>.
18. Sabine Vogler et al., *Medicines reimbursement policies in Europe*, World Health Organization (WHO), 2018, <http://www.euro.who.int/en/health-topics/Health-systems/health-technologies-and-medicines/publications/2018/medicines-reimbursement-policies-in-europe>
19. Etienne Nedellec, "France National Health Strategy and Biosimilar Pilot Sharing Scheme" (Presentation, DIA Biosimilars Conference 2020, October 7, 2020).
20. Evelien Moorkens Eet et al., "Learnings from Regional Market Dynamics of Originator and Biosimilar Infiximab and Etanercept in Germany," *Pharmaceuticals* 13(10):324, (October 2020), doi: 10.3390/ph13100324.
21. Alex Brill, Shared Savings Demonstration for Biosimilars in Medicare: An Opportunity to Promote Biologic Drug Competition, Matrix Global Advisors (MGA), May 2020, http://getmga.com/wpcontent/uploads/2020/05/Biosimilar_Shared_Savings.pdf.
22. Cécile Rémuzat et al., "Supply-Side and Demand-Side Policies for Biosimilars: An Overview in 10 European Member States." *Journal of Market Access & Health Policy* 5, no. 1 (April 28, 2017), <https://doi.org/10.1080/20016689.2017.1307315>
23. "CMA Warns Businesses After Ending Remicade Investigation", GOV.UK, March, 2019, <https://www.gov.uk/government/news/cma-warns-businesses-after-ending-remicade-investigation>
24. Michael A. Carrier. 2017. High Prices & No Excuses: 6 Anticompetitive Games (Presentation Slides). Testimony for FTC Workshop on "Understanding Competition in Prescription Drug Markets".
25. Herman B. As Humira biosimilars take over the market, CVS has created a new ploy: the drug 'rebate credit.' *STAT+*. Published March 18, 2024. <https://www.statnews.com/2024/03/18/humira-pbms-cvs-caremark-rebate-credits>
26. Joseph Farrell. 2006. Exclusive Dealing: Substance and Process. Testimony for the DOJ. <https://www.justice.gov/atr/exclusive-dealing-substance-and-process>
27. US Department of Justice. 2008. Competition and Monopoly: Single-Firm Conduct Under Section 2 of the Sherman Act, Chapter 8. <https://www.justice.gov/archives/atr/competition-and-monopoly-single-firm-conduct-under-section-2-sherman-act-chapter-8>
28. Lina Khan. 2022. Statement of Chair Lina M. Khan Regarding 6(b) Study of Pharmacy Benefit Managers https://www.ftc.gov/system/files/ftc_gov/pdf/Statement-Khan-6b-Study-Pharmacy-Benefit-Managers.pdf

RELEVANT AMA POLICY

H-125.980 Abbreviated Pathway for Biosimilar Approval

Our AMA supports FDA implementation of the Biologics Price Competition and Innovation Act of 2009 in a manner that 1) places appropriate emphasis on promoting patient access, protecting patient safety, and preserving market competition and innovation; 2) includes planning by the FDA and the allocation of sufficient resources to ensure that physicians understand the distinctions between biosimilar products that are considered highly similar, and those that are deemed interchangeable. Focused educational activities must precede and accompany the entry of biosimilars into the U.S. market, both for physicians and patients; and 3) includes compiling and maintaining an official compendium of biosimilar products, biologic reference products, and their related interchangeable biosimilars as they are developed and approved for marketing by the FDA.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 208
(A-24)

Introduced by: Medical Student Section and American College of Physicians

Subject: Improving Supplemental Nutrition Programs

Referred to: Reference Committee B

1 Whereas, food insecurity is a public health crisis, especially among American Indian and Alaska
2 Native (AI/AN) persons, who were relocated and gave up 98% of their lands and ability to survive
3 under coercion and threats of violence by state and federal actors^{3,4}; and
4

5 Whereas, the burden of chronic diseases such as obesity and diabetes on AI/AN communities is
6 directly attributable to settler colonialism and interruption of AI/AN knowledge systems^{5,6}; and
7

8 Whereas, AI/AN persons experience food insecurity at twice the rate of whites, with 25% being
9 consistently food insecure⁴; and
10

11 Whereas, climate change uniquely affects AI/AN communities, including disproportionate
12 exposure of Alaska Native Villages to marine foods polluted by plastic and poor nutritional
13 offerings with significant price markups at grocery and convenience stores⁷; and
14

15 Whereas, US nutrition programs for AI/AN persons, including the Food Distribution Program on
16 Indian Reservations (FDPIR) and the recently launched Indian Health Service (IHS) Produce
17 Prescription Pilot Program, differ from other nutrition programs by including staple foods and
18 ingredients commonly used in pre-contact AI/AN societies and food systems⁸⁻⁹; and
19

20 Whereas, federally-recognized AI/AN Tribes and Villages without a reservation or land base and
21 the 2.8 million AI/AN persons in urban areas (greater than the population on Tribal lands) are all
22 ineligible for federal nutrition assistance programs for AI/AN persons⁸⁻¹³; and
23

24 Whereas, AI/AN persons in urban areas were 1.4 times as likely to experience food insecurity as
25 other AI/AN persons, with rates exacerbated by COVID^{4,14}; and
26

27 Whereas, the reduction of AI/AN food insecurity (by increasing AI/AN food choices, availability,
28 and household purchasing power and intervening preventively via early education and farm-to-
29 school programs) can decrease risk of gestational diabetes, sleep apnea, and metabolic
30 syndrome, promote AI/AN self-determination and self-governance, and improve AI/AN youth
31 health behavior¹⁵⁻¹⁸; therefore be it
32

33 RESOLVED, that our American Medical Association support regulatory and legal reforms to
34 extend multieligibility for USDA Food Assistance to enrolled members of federally-recognized
35 American Indian and Alaska Native Tribes and Villages to all federal feeding programs, such as,
36 but not limited to, Supplemental Nutrition Assistance Program (SNAP) and Food Distribution
37 Program on Indian Reservations (FDPIR). (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 4/19/2024

REFERENCES

1. United States Department of Agriculture: Food and Nutrition Service. SNAP Eligibility. U.S. Department of Agriculture; 2021. <https://www.fns.usda.gov/snap/recipient/eligibility>.
2. United States Department of Agriculture: Food and Nutrition Service. WIC Eligibility Requirements. U.S. Department of Agriculture; 2023. <https://www.fns.usda.gov/wic/wic-eligibility-requirements>.
3. Farrell J, Burow PB, McConnell K, Bayham J, Whyte K, and Koss G. Effects of land dispossession and forced migration on Indigenous peoples in North America. *Science*. 2021;374(6567). Doi: 10.1126/science.abe4943.
4. Jernigan VBB, Huyser KR, Valdes J, and Simonds VW. Food Insecurity among American Indians and Alaska Natives: A National Profile using the Current Population Survey - Food Security Supplement. *J Hunger Environ Nutr*. 2017;12(1):1-10. doi: 10.1080/19320248.2016.1227750
5. McKinley CE, Jernigan VBB. "I don't remember any of us ... having diabetes or cancer": How historical oppression undermines indigenous foodways, health, and wellness. *Food Foodways*. 2023;31(1):43-65. doi:10.1080/07409710.2023.2172795
6. National Education Policy Center. What is Tribal Crit? NEPC Newsletter November 26, 2020.
7. Aker A, Ayotte P, Caron-Beaudoin É, De Silva A, Ricard S, Lemire M. Associations between dietary profiles and perfluoroalkyl acids in Inuit youth and adults. *Sci Total Environ*. 2023;857(Pt 3):159557. doi:10.1016/j.scitotenv.2022.159557
8. United States Department of Agriculture: Food and Nutrition Service. Food Distribution Program on Indian Reservations. U.S. Department of Agriculture; 2023. <https://www.fns.usda.gov/fdpir/food-distribution-program-indian-reservations>.
9. United States Department of Health and Human Services: Indian Health Service. Produce Prescription Programs. U.S. Department of Health and Human Services; 2023. <https://www.ihs.gov/nutrition/produce-prescription-programs/>.
10. National Congress of American Indians. Trust Land. NCAI; 2023. <https://www.ncai.org/policy-issues/land-natural-resources/trust-land>.
11. National Conference of State Legislatures. State Recognition of American Indian Tribes. NCSL; 2016. <https://www.ncsl.org/quad-caucus/state-recognition-of-american-indian-tribes>.
12. Urban Indian Health Commission. Invisible Tribes: Urban Indians and Their Health in a Changing World. Urban Indian Health Commission; 2007. <https://www2.census.gov/cac/nac/meetings/2015-10-13/invisible-tribes.pdf>.
13. National Council on Aging. American Indians and Alaska Natives: Key Demographics and Characteristics. National Council on Aging; 2023. <https://www.ncoa.org/article/american-indians-and-alaska-natives-key-demographics-and-characteristics>.
14. Maudrie TL, Nguyen CJ, Jernigan VBB, et al. Impacts of COVID-19 on a Food Security Study with the Baltimore Native Community. *Am Indian Alsk Native Ment Health Res*. 2022;29(2):8-31. doi:10.5820/aian.2902.2022.8
15. Stotz SA, Hebert LE, Charron-Prochownik D, et al. Relationship between food insecurity and a gestational diabetes risk reduction intervention: outcomes among American Indian and Alaska Native adolescent and young adult females [published online ahead of print, 2023 Jun 24]. *Transl Behav Med*. 2023;:ibad029. doi:10.1093/tbm/ibad029
16. Dong L, D'Amico EJ, Dickerson DL, et al. Food insecurity, sleep, and cardiometabolic risks in urban American Indian/Alaska Native youth. *Sleep Health*. 2023;9(1):4-10. doi:10.1016/j.sleh.2022.10.003
17. Brockington M, Beale D, Gaupholm J, et al. Identifying Barriers and Pathways Linking Fish and Seafood to Food Security in Inuit Nunangat: A Scoping Review. *Int J Environ Res Public Health*. 2023;20(3):2629. Published 2023 Feb 1. doi:10.3390/ijerph20032629
18. Taniguchi T, Haslam A, Sun W, Sisk M, Hayman J, Jernigan VBB. Impact of a Farm-to-School Nutrition and Gardening Intervention for Native American Families from the FRESH Study: A Randomized Wait-List Controlled Trial. *Nutrients*. 2022;14(13):2601. Published 2022 Jun 23. doi:10.3390/nu14132601

RELEVANT AMA Policy

H-150.925 Food Environments and Challenges Accessing Healthy Food

Our AMA (1) encourages the U.S. Department of Agriculture and appropriate stakeholders to study the national prevalence, impact, and solutions to challenges accessing healthy affordable food, including, but not limited to, food environments like food mirages, food swamps, and food deserts; (2) recognizes that food access inequalities are a major contributor to health inequities, disproportionately affecting marginalized communities and people of color; (3) supports policy promoting community-based initiatives that empower resident businesses, create economic opportunities, and support sustainable local food supply chains to increase access to affordable healthy food; and (4) will advocate for CMS and other relevant agencies to develop, test, and then implement evidence-based innovative models to address food insecurity, such as food delivery and transportation services to supermarkets, food banks and pantries, and local farmers markets for healthy food options. [Res. 921, I-18; Modified: Res. 417, A-21; Appended: Res. 117, A-22]

H-150.937 Improvements to Supplemental Nutrition Programs

1. Our AMA supports: (a) improvements to the Supplemental Nutrition Assistance Program (SNAP) and Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) that are designed to promote adequate nutrient intake and reduce food insecurity and obesity; (b) efforts to decrease the price gap between calorie-dense, nutrition-poor foods and naturally nutrition-dense foods to improve health in economically disadvantaged populations by encouraging the expansion, through increased funds and increased enrollment, of existing programs that seek to improve nutrition and reduce obesity, such as the Farmer's Market Nutrition Program as a part of the Women, Infants, and Children program; and (c) the novel application of the Farmer's Market Nutrition Program to existing programs such as the Supplemental Nutrition Assistance Program (SNAP), and apply program models that incentivize the consumption of naturally nutrition-dense foods in wider food distribution venues than solely farmer's markets as part of the Women, Infants, and Children program.

2. Our AMA will request that the federal government support SNAP initiatives to (a) incentivize healthful foods and disincentivize or eliminate unhealthy foods and (b) harmonize SNAP food offerings with those of WIC.

3. Our AMA will actively lobby Congress to preserve and protect the Supplemental Nutrition Assistance Program through the reauthorization of the 2018 Farm Bill in order for Americans to live healthy and productive lives. [Res. 414, A-10; Reaffirmation A-12; Reaffirmation A-13; Appended: CSAPH Rep. 1, I-13; Reaffirmation A-14; Reaffirmation I-14; Reaffirmation A-15; Appended: Res. 407, A-17; Appended: Res. 233, A-18; Reaffirmed: Res. 259, A-23]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 209
(A-24)

Introduced by: Medical Student Section

Subject: Native American Voting Rights

Referred to: Reference Committee B

1 Whereas, our American Medical Association “acknowledges voting is a social determinant of
2 health and significantly contributes to the analyses of other social determinants of health as a
3 key metric”; and be it further
4

5 Whereas, the Association of American Medical Colleges (AAMC) supports medical schools and
6 teaching hospitals facilitating nonpartisan voter registration efforts¹; and
7

8 Whereas, health facilities’ nonpartisan voter registration efforts demonstrate improved civic
9 engagement and are protected by the National Voter Registration Act and IRS code²⁻⁵; and
10

11 Whereas, 1.2 million Native Americans (34%) are not registered to vote due to vast differences
12 in experiences and opportunities, especially for voters on reservations who experience
13 discrimination and unique challenges with voter identification laws (e.g., no addresses on
14 reservations, inability to use tribal-federal membership cards)⁶⁻¹¹; and
15

16 Whereas, the distinct political and dual citizenship status of Native Americans as members of
17 sovereign Tribal nations underscores the importance of their voter participation, as federal and
18 state elected officials are responsible for working with their Tribal governments to enact laws
19 governing Tribal authority and treaty rights⁸; and
20

21 Whereas, as Native Americans comprise over 10% of the electorate in many states, Congress
22 has repeatedly introduced the Native American Voting Rights Act, which would in part establish
23 a Native American voting task force grant program to increase turnout⁸; and
24

25 Whereas, President Biden’s Executive Order on Promoting Access to Voting strongly
26 encourages federal agencies, including Veterans Health Administration (VHA) and Indian Health
27 Service sites to seek designation as voter registration sites¹²; and
28

29 Whereas, other federal health and social programs such as the VHA, Medicaid, and SNAP/WIC
30 offer voter registration services, and the Health Resources and Services Administration even
31 offers guidance for Federally Qualified Health Centers to organize such efforts^{3,13-14}; and
32

33 Whereas, civic engagement efforts are limited at Indian Health Service, Tribal, and Urban Indian
34 Health Programs, which are crucial interfaces with Native American patients and Tribal
35 governments¹⁵⁻¹⁶; therefore be it
36

37 RESOLVED, that our American Medical Association support Indian Health Service, Tribal, and
38 Urban Indian Health Programs becoming designated voter registration sites to promote
39 nonpartisan civic engagement among the American Indian and Alaska Native population. (New
40 HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 4/19/2024

REFERENCES

1. Fact Sheet for Nonpartisan Voter Registration at Health Care Institutions. AAMC. Accessed May 14, 2023. <https://www.aamc.org/advocacy-policy/voterregistration>
2. The National Voter Registration Act Of 1993 (NVRA). US Department of Justice. Published online July 20, 2022. <https://www.justice.gov/crt/national-voter-registration-act-1993-nvra>
3. Tang OY, Wong KE, Ganguli R, et al. Emergency Absentee Voting for Hospitalized Patients and Voting During COVID-19: A 50-State Study. *West J Emerg Med.* 2021;22(4):1000-1009. Published 2021 Jul 15. doi:10.5811/westjem.2021.4.50884
4. Lickiss S, Lowery L, Triemstra JD. Voter Registration and Engagement in an Adolescent and Young Adult Primary Care Clinic. *J Adolesc Health.* 2020;66(6):747-749. doi:10.1016/j.jadohealth.2019.11.316
5. Chamberlain C, Jaime H, Wohler D. Emergency Patient Voting Initiative in a Community Hospital During a Global Pandemic:: Lessons and a Call-to-Action for Expanded Voter Access. *Dela J Public Health.* 2021;7(1):76-77. Published 2021 Jan 21. doi:10.32481/djph.2021.01.015
6. Tucker J, De Leon J, McCool D. Obstacles at Every Turn: Barriers to Political Participation Faced by Native Americans. Native American Rights Fund. Published online September 16, 2020. https://vote.narf.org/wp-content/uploads/2020/06/obstacles_at_every_turn.pdf
7. Indian Health Service Voter Registration. National Congress of American Indians. Published online 2020. <https://vote.narf.org/wp-content/uploads/2022/09/ihs-vote-explanation.pdf>
8. Luján BR. Native American Voting Rights Act of 2021.; 2021 <https://www.congress.gov/bill/117th-congress/senate-bill/2702/text?=&f=1&q=%7B%22search%22%3A%22native+american+voting+rights%22%7D>
9. Friel, K., Pablo, E. How Voter Suppression Laws Target Native Americans. Brennan Center. Published May 23, 2022. Last Accessed September 17, 2023. <https://www.brennancenter.org/our-work/research-reports/how-voter-suppression-laws-target-native-americans>
10. Ferguson-Bohnee, P. How the Native American Vote Continues to be Suppressed. American Bar Association. Published February 9, 2020. Last Accessed September 17, 2023. https://www.americanbar.org/groups/crsj/publications/human_rights_magazine_home/voting-rights/how-the-native-american-vote-continues-to-be-suppressed/
11. Thomas-Lundborg, A., Alvernaz, L. This Law Makes Voting Nearly Impossible for Native Americans in Montana. American Civil Liberties Union. Published March 12, 2020. Last Accessed September 17, 2023. <https://www.aclu.org/news/voting-rights/this-law-makes-voting-nearly-impossible-for-native-americans-in-montana>
12. Biden J. Executive Order on Promoting Access to Voting. The White House. Published online March 7, 2021. <https://www.whitehouse.gov/briefing-room/presidential-actions/2021/03/07/executive-order-on-promoting-access-to-voting>
13. VA promotes greater access to voter information to Veterans and families. Veterans Affairs. Published online March 24, 2022. <https://news.va.gov/press-room/va-promotes-greater-access-to-voter-information-to-veterans-and-families>
14. Hess D. Using Medicaid Automatic Voter Registration to Address Persistent Voter Registration Problems: Helping the National Voter Registration Act Achieve its Potential. Institute for Responsive Government. Published online June 23, 2023. <https://responsivegoverning.org/research/using-medicare-automatic-voter-registration-to-address-persistent-voter-registration-problems-helping-the-national-voter-registration-act-achieve-its-potential>
15. Title I | Office of Direct Service and Contracting Tribes. Title I | Office of Direct Service and Contracting Tribes. Office of Direct Service and Contracting Tribes. Current as of 2023. <https://www.ihs.gov/odsct/title1/>
16. Martin A, Raja A, Meese H. Health care-based voter registration: a new kind of healing. *International Journal of Emergency Medicine.* Published online April 30, 2021. doi:<https://doi.org/10.1186/s12245-021-00351-y>

RELEVANT AMA Policy

Support for Safe and Equitable Access to Voting H-440.805

1. Our AMA supports measures to facilitate safe and equitable access to voting as a harm-reduction strategy to safeguard public health and mitigate unnecessary risk of infectious disease transmission by measures including but not limited to: (a) extending polling hours; (b) increasing the number of polling locations; (c) extending early voting periods; (d) mail-in ballot postage that is free or prepaid by the government; (e) adequate resourcing of the United States Postal Service and election operational procedures; (f) improved access to drop off locations for mail-in or early ballots; and (g) use of a P.O. box for voter registration.
2. Our AMA opposes requirements for voters to stipulate a reason in order to receive a ballot by mail and other constraints for eligible voters to vote-by-mail.
3. Our AMA: (a) acknowledges voting is a social determinant of health and significantly contributes to the analyses of other social determinants of health as a key metric; (b) recognizes that gerrymandering which disenfranchises individuals/communities limits access to health care, including but not limited to the expansion of comprehensive medical insurance coverage, and negatively impacts health outcomes; and (c) will collaborate with appropriate stakeholders and provide resources to firmly establish a relationship between voter participation and health outcomes. [Res. 18, I-21; Appended: Res. 422, A-22]

AMERICAN MEDICAL ASSOCIATION HOOUSE OF DELEGATES

Resolution: 210
(A-24)

Introduced by: Oregon, American College of Physicians

Subject: Support for Physicians Pursuing Collective Bargaining and Unionization

Referred to: Reference Committee B

1 Whereas, the American Medical Association (AMA) supports the right of physicians to engage in
2 collective bargaining, and it is AMA policy to work for expansion of the numbers of physicians
3 eligible for that right under federal law; and
4

5 Whereas, while AMA policy supports expanding rights for physicians rights and abilities to
6 collectively bargain, the last study of this policy area last occurred pre-pandemic as the
7 paradigm shift of physician as employee continues to expand, particularly for younger
8 generations of physicians who would be more likely to leverage and seek unionization; and
9

10 Whereas, the AMA points out that bargaining units composed entirely of physicians are
11 presumed appropriate, a recommendation that makes sense in recognition of physicians' unique
12 skills and ethical and professional obligations; and
13

14 Whereas, in 1999 the AMA provided financial support for the establishment of a national labor
15 organization - Physicians for Responsible Negotiation (PRN) - under the National Labor
16 Relations Board (NLRA) to support the development and operation of local physician
17 negotiating units as an option for employed physicians and physicians in-training, but ultimately
18 withdrew support in 2004 as few physicians signed up; and
19

20 Whereas, the numbers of physicians who are union members is estimated to have grown
21 significantly since then with a 26% increase from 2014 to 2019 when 67,673 physicians were
22 members of a union; and
23

24 Whereas, the percentage of physicians now employed by hospitals, health systems, or
25 corporate entities has increased significant, most recently reported up to 73.9% as of January,
26 2022 (up from 47.4% in 2018), and the number of physician practices acquired by hospitals and
27 corporate entities between 2019-2022 also accelerated during the pandemic; and
28

29 Whereas, dominant hospitals, healthcare systems, and other corporate entities employing
30 physicians may present limited alternatives to physicians working in a market largely controlled
31 by their employer or where covenants-not-to-compete may further contribute to the employer's
32 bargaining advantage; and
33

34 Whereas, the transition from independent professional physician workforce to employed
35 physician workforce fundamentally alters the dynamics between hospitals, health systems,
36 corporate entities and physicians, with a risk of negatively affecting the conditions of care
37 delivery and quality of care provided; and

1 Whereas, the corporatization of medicine, including involvement of private equity in healthcare,
2 raises questions about incentive alignment, costs, and downstream effects on patients; and
3

4 Whereas, recent years have seen an increase in physician burnout, which accelerated during
5 the COVID-19 pandemic, directly related to time spent on electronic health record
6 documentation, bureaucratic administrative tasks, and moral injury related to an incongruence
7 between what physicians care about and what they are incentivized to do by the health care
8 system; and
9

10 Whereas, physicians face a dominant power when negotiating with hospital employers and may
11 not have countervailing influence without collective bargaining; and
12

13 Whereas, collective bargaining is an effective tool for protecting patient care safety standards,
14 improving work conditions, ensuring pay and job security, and a providing a process for
15 grievances; and
16

17 Whereas, the National Labor Relations Board determined in 2022 that employed physicians are
18 not in a supervisory role and are therefore eligible to unionize; and
19

20 Whereas, interest in exploring collective bargaining for residents and practicing physician
21 groups has increased in some parts of the country including in Oregon, likely driven by
22 dynamics seen in the profession's shift to "employed status" for the majority of physicians;
23 therefore be it
24

25 RESOLVED, that our American Medical Association convenes an updated study of
26 opportunities for the AMA or physician associations to support physicians initiating a collective
27 bargaining process, including but not limited to unionization. (Directive to Take Action)
28

Fiscal Note: \$43,308; Consult experts and coordinate with medical societies to identify and
communicate ways to aid physicians in collective bargaining efforts.

Received: 4/5/2024

REFERENCES

1. <https://www.ama-assn.org/system/files/advocacy-issue-brief-physician-unions.pdf>
2. AMA analysis shows most physicians work outside of private practice | American Medical Association
3. https://www.physiciansadvocacyinstitute.org/Portals/0/assets/docs/PAI-Research/PAI%20Avalere%20Physician%20Employment%20Trends%20Study%202019-21%20Final.pdf?ver=ksWkjKXB_yZflmFdXlvGq%3d%3d
4. <https://www.ama-assn.org/system/files/2019-07/prp-fewer-owners-benchmark-survey-2018.pdf>
5. https://jamanetwork.com/journals/jama/fullarticle/2799930?guestaccesskey=4b40dae9-69a2-4ec1-b2db-b5f235c67122&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=etoc&utm_term=122722
6. <https://acpinternist.org/archives/2022/03/3-cs-corporatization-consolidation-commodification.htm>
7. <https://www.healthaffairs.org/doi/10.1377/hlthaff.2020.01535>
8. [https://www.mayoclinicproceedings.org/article/S0025-6196\(22\)00515-8/fulltext](https://www.mayoclinicproceedings.org/article/S0025-6196(22)00515-8/fulltext)
9. <https://academic.oup.com/jamia/article/26/2/106/5230918>
10. https://www.medscape.com/slideshow/2022-lifestyle-burnout-6014664?icd=login_success_email_match_norm#1
11. <https://www.acpjournals.org/doi/10.7326/M16-0961>
12. <https://nap.nationalacademies.org/catalog/25521/taking-action-against-clinician-burnout-a-systems-approach-to-professional>
13. <https://www.jdsupra.com/legalnews/following-the-doctor-s-orders-nlr-7925443/>
14. <https://www.nytimes.com/2016/01/10/business/doctors-unionize-to-resist-the-medical-machine.html>
15. <https://www.nytimes.com/2023/06/15/magazine/doctors-moral-crises.html?smid=nytcore-ios-share&referringSource=articleShare>
16. <https://www.medpagetoday.com/special-reports/features/104210>

RELEVANT AMA POLICY

Collective Bargaining for Physicians H-385.946

The AMA will seek means to remove restrictions for physicians to form collective bargaining units in order to negotiate reasonable payments for medical services and to compete in the current managed care environment; and will include the drafting of appropriate legislation.

Citation: Res. 239, A-97Reaffirmation I-98Reaffirmation A-01Reaffirmation A-05Reaffirmation A-06Reaffirmation A-08Reaffirmation I-10

Physician Collective Bargaining H-385.976

Our AMA's present view on the issue of physician collective negotiation is as follows: (1) There is more that physicians can do within existing antitrust laws to enhance their collective bargaining ability, and medical associations can play an active role in that bargaining. Education and instruction of physicians is a critical need. The AMA supports taking a leadership role in this process through an expanded program of assistance to independent and employed physicians.

(2) Our AMA supports continued intervention in the courts and meetings with the Justice Department and FTC to enhance their understanding of the unique nature of medical practice and to seek interpretations of the antitrust laws which reflect that unique nature.

(3) Our AMA supports continued advocacy for changes in the application of federal labor laws to expand the number of physicians who can bargain collectively.

(4) Our AMA vigorously opposes any legislation that would further restrict the freedom of physicians to independently contract with Medicare patients.

(5) Our AMA supports obtaining for the profession the ability to fully negotiate with the government about important issues involving reimbursement and patient care.

Citation: BOT Rep. P, I-88; Modified: Sunset Report, I-98; Reaffirmation A-00; Reaffirmation I-00; Reaffirmation A-01; Reaffirmation I-03; Reaffirmation A-04; Reaffirmed in lieu of Res. 105, A-04; Reaffirmation A-05; Reaffirmation A-06; Reaffirmation A-08; Reaffirmed: BOT Rep. 17, A-09; Reaffirmation I-10; Reaffirmed: Sub. Res. 222, I-10; Reaffirmed: Res. 215, A-11; Reaffirmed: BOT action in response to referred for decision Res. 201, I-12; Reaffirmed: Res. 206, A-19;

Employee Associations and Collective Bargaining for Physicians D-383.981

Our AMA will study and report back on physician unionization in the United States.

Citation: Res. 601, I-14; Reaffirmed: Res. 206, A-19

Investigation into Residents, Fellows and Physician Unions D-383.977

Our AMA will study the risks and benefits of collective bargaining for physicians and physicians-in-training in today's health care environment. Citation: Res. 606, A-19

Physicians' Ability to Negotiate and Undergo Practice Consolidation H-383.988

Our AMA will: (1) pursue the elimination of or physician exemption from anti-trust provisions that serve as a barrier to negotiating adequate physician payment; (2) work to establish tools to enable physicians to consolidate in a manner to insure a viable governance structure and equitable distribution of equity, as well as pursuing the elimination of anti-trust provisions that inhibited collective bargaining; and (3) find and improve business models for physicians to improve their ability to maintain a viable economic environment to support community access to high quality comprehensive healthcare. Citation: Res. 229, A-12; Reaffirmed: Res. 206, A-19

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 211
(A-24)

Introduced by: Organized Medical Staff Section

Subject: Deceptive Hospital Badging 2.0

Referred to: Reference Committee B

1 Whereas, the public is wholly unaware of the false labeling for care personnel in the hospital,
2 with the increasing introduction of lesser trained people appearing to be equivalent caregivers;
3 and
4
5 Whereas, the most recent addition to this group of non-physicians are certified registered nurse
6 anesthetists (CRNAs), increasingly replacing anesthesiologists; and
7
8 Whereas, this has crept into the cardiac suites of our operating rooms with increasing fallout as
9 surgeons are being tasked with assuming responsibility and therefore enhanced liability for
10 these non-physician personnel; and
11
12 Whereas, anesthesia was also overing perfusion, which will now fall to surgeons who may not
13 be up to speed to perform these additional tasks; and
14
15 Whereas, this is unquestionably a quality of care issue as well as safety related, along with a
16 public relations, cost, and billing problem; and
17
18 Whereas, we were able to correct the previous deception at our hospital with a push by the
19 organized medical staff taking action, along with the support of the AMA; therefore be it
20
21 RESOLVED, that our American Medical Association promote and prioritize public awareness of
22 the difference and importance of having the proper level of training and clear identification and
23 labeling of caregivers as that relates to quality and safety of healthcare (Directive to Take
24 Action); and be it further
25
26 RESOLVED, that our AMA work with state and county medical societies to highlight to
27 physicians the growing practice of creating false equivalencies between physicians and non-
28 physicians in the healthcare team and encourage action in local institutions to assure the quality
29 and safety of patient care. (Directive to Take Action)
30

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/17/2024

RELEVANT AMA POLICY

Clarification of the Title "Doctor" in the Hospital Environment D-405.991

1. Our AMA Commissioners will, for the purpose of patient safety, request that The Joint Commission develop and implement standards for an identification system for all hospital facility staff who have direct contact with patients which would require that an identification badge be worn which indicates the individual's name and credentials as appropriate (i.e., MD, DO, RN, LPN, DC, DPM, DDS, etc), to differentiate between those who have achieved a Doctorate, and those with other types of credentials.
2. Our AMA Commissioners will, for the purpose of patient safety, request that The Joint Commission develop and implement new standards that require anyone in a hospital environment who has direct contact with a patient who presents himself or herself to the patient as a "doctor," and who is not a "physician" according to the AMA definition (H-405.969, ?that a physician is an individual who has received a "Doctor of Medicine" or a "Doctor of Osteopathic Medicine" degree or an equivalent degree following successful completion of a prescribed course of study from a school of medicine or osteopathic medicine?) must specifically and simultaneously declare themselves a "non-physician" and define the nature of their doctorate degree.
3. Our AMA will request the American Osteopathic Association (AOA) to (1) expand their standards to include proper identification of all medical staff and hospital personnel with their applicable credential (i.e., MD, DO, RN, LPN, DC, DPM, DDS, etc), and (2) Require anyone in a hospital environment who has direct contact with a patient presenting himself or herself to the patient as a "doctor", who is not a "Physician" according to the AMA definition (AMA Policy H-405.969 .. that a physician is an individual who has received a "Doctor of Medicine" or a "Doctor of Osteopathic Medicine" degree or an equivalent degree following successful completion of a prescribed course of study from a school of medicine or osteopathic medicine) must specifically and simultaneously declare themselves a "non-physician" and define the nature of their doctorate degree.

Citation: Res. 846, I-08; Modified: BOT Rep. 9, I-09; Reaffirmed: CCB/CLRPD Rep. 01, A-23

Need to Expose and Counter Nurse Doctoral Programs (NDP) Misrepresentation D-35.992

Our AMA will: (1) work jointly with state attorneys general to identify and prosecute those individuals who misrepresent themselves as physicians to their patients and mislead program applicants as to their future scope of practice; (2) pursue all other appropriate legislative, regulatory and legal actions through the Scope of Practice Partnership, as well as actions within hospital staff organizations, to counter misrepresentation by nurse doctoral programs and their students and graduates, particularly in clinical settings; and (3) work with all appropriate entities to ensure that all persons engaged in patient contact be clearly identified either verbally, or by name badge or similar identifier, with regard to their professional licensure in order that patients are aware of the professional educational background of that person.

Citation: Res. 211, A-06; Reaffirmed: BOT Rep. 6, A-16

Professional Nurse Staffing in Hospitals H-360.986

The AMA: (1) encourages medical and nursing staffs in each facility to closely monitor the quality of medical care to help guide hospital administrations toward the best use of resources for patients; (2) encourages medical and nursing staffs to work together to develop and implement in-service education programs and promote compliance with established or pending guidelines for unlicensed assistive personnel and technicians that will help assure the highest and safest standards of patient care; (3) encourages medical and nursing staffs to use identification mechanisms, e.g. badges, that provide the name, credentials, and/or title of the physicians, nurses, allied health personnel, and unlicensed assistive personnel in facilities to enable patients to easily note the level of personnel providing their care; (4) encourages medical and nursing staffs to develop, promote, and implement educational guidelines for the training of all unlicensed personnel working in critical care units, according to the needs at each facility; and

(5) encourages medical and nursing staffs to work with hospital administrations to assure that patient care and safety are not compromised when a hospital's environment and staffing are restructured.

Citation: BOT Rep. 11, I-96; Reaffirmed: CMS Rep. 8, A-06; Reaffirmed: CMS Rep. 01, A-16

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 212
(A-24)

Introduced by: Organized Medical Staff Section

Subject: Advocacy Education Towards a Sustainable Medical Care System

Referred to: Reference Committee B

1 Whereas, extensive AMA policy and actions address the education of medical students and
2 physicians on advocacy techniques and their involvement in AMA advocacy efforts; and
3

4 Whereas, our AMA believes that “better-informed and more active citizens will result in better
5 legislators, better government, and better health care” (AMA Policy G-640.020); and
6

7 Whereas, the AMA currently facilitates some patient education and engagement in advocacy
8 efforts via is Patient Action Network (PAN); and
9

10 Whereas, greater involvement of the public in AMA advocacy efforts potentially could make the
11 AMA more effective in its advocacy on behalf of patients and the profession; and
12

13 Whereas, any attempt to engage the public must consider the potential difficulties that can arise
14 from blending the perspectives of physicians and patients; therefore be it
15

16 RESOLVED, that our American Medical Association explore innovative opportunities for
17 engaging the public in advocacy on behalf of an improved healthcare environment. (Directive to
18 Take Action)
19

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/17/2024

RELEVANT AMA POLICY

Medical Student, Resident and Fellow Legislative Awareness H-295.953

1. The AMA strongly encourages the state medical associations to work in conjunction with medical schools to implement programs to educate medical students concerning legislative issues facing physicians and medical students.
2. Our AMA will advocate that political science classes which facilitate understanding of the legislative process be offered as an elective option in the medical school curriculum.
3. Our AMA will establish health policy and advocacy elective rotations based in Washington, DC for medical students, residents, and fellows.
4. Our AMA will support and encourage institutional, state, and specialty organizations to offer health policy and advocacy opportunities for medical students, residents, and fellows.

Improving Medical Student, Resident/Fellow and Academic Physician Engagement in Organized Medicine and Legislative Advocacy G-615.103

Our AMA will: (1) study the participation of academic and teaching physicians, residents, fellows, and medical students in organized medicine and legislative advocacy; (2) study the participation of community-based faculty members of medical schools and graduate medical education programs in organized medicine and legislative advocacy; (3) identify successful, innovative and best practices to engage academic physicians (including community-based physicians), residents/fellows, and medical students in organized medicine and legislative advocacy; and (4) study mechanisms to mitigate costs incurred by medical students, residents and fellows who participate at national, in person AMA conferences.

Political Action Committees and Contributions G-640.020

Our AMA: (1) believes that better-informed and more active citizens will result in better legislators, better government, and better health care; (2) encourages AMA members to participate personally in the campaign of their choice and strongly supports physician/family leadership in the campaign process; (3) opposes legislative initiatives that improperly limit individual and collective participation in the democratic process; (4) supports AMPAC's policy to adhere to a no Rigid Litmus Test policy in its assessment and support of political candidates; (5) encourages AMPAC to continue to consider the legislative agenda of our AMA and the recommendations of state medical PACs in its decisions; (6) urges members of the House to reaffirm their commitment to the growth of AMPAC and the state medical PACs; (7) will continue to work through its constituent societies to achieve a 100 percent rate of contribution to AMPAC by members; (8) calls upon all candidates for public office to refuse contributions from tobacco companies and their subsidiaries; and (9) calls upon all candidates for public office to refuse contributions from any organization that opposes evidence-based public health measures to reduce firearm violence.

Physician Health Policy Opportunity G-640.035

Our AMA encourages and supports efforts to educate interested medical students, residents, fellows, and practicing physicians about health policy and assist them in starting or transitioning to careers that involve health policy.

Our AMA: (a) recognizes, encourages, and supports the primary health policy training found in the physician specialties of Public Health / General Preventive Medicine, Occupational and Environmental Medicine, and Aerospace Medicine; (b) will significantly increase its collaborative efforts with the National Academy of Medicine (NAM) to make physicians aware of existing health policy training opportunities and help them to apply for and participate in them; (c) will engage with alumni of health policy training programs and joint degree programs and provide opportunities for them to share their health policy experiences with medical students, residents, fellows, and practicing physicians; (d) will include health policy content in its educational resources for members; (e) will work with the Office of the U.S. Surgeon General to disseminate information to medical students, residents, fellows, and practicing physicians about opportunities to join the Commissioned Corps of the U.S. Public Health Service; and (f) will consider options for funding a 1-year educational training program for practicing physicians who wish to transition from clinical practice to employment within the health policy sector.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 213
(A-24)

Introduced by: Private Practice Physicians Section

Subject: Access to Covered Benefits with an Out of Network Ordering Physician

Referred to: Reference Committee B

1 Whereas, physicians have not had inflationary increases like other service providers have for
2 decades in the Medicare program; and

3
4 Whereas, physicians' ability to continue to serve patients independent of hospital systems,
5 private equity, vertically and/or horizontally consolidated systems has narrowed under current
6 reimbursement settings⁶; and

7
8 Whereas, between 2019 and 2020, 48,400 physicians left independent practice according to a
9 2021 Physicians Advocacy Institute study¹; and

10
11 Whereas, as a result there is a growing number of private practice physicians using the Direct
12 Primary Care (DPC) model not accepting insurance or otherwise treating patients in models that
13 are not in-network with health maintenance organizations (HMOs), Medicare Advantage, or
14 other health plans^{2,3}; and

15
16 Whereas, there are 2,060 direct primary care practices spanning 48 states⁴; and

17
18 Whereas, patients with catastrophic insurance plans with high deductibles are well-served by
19 having access to direct primary care physicians⁵; and

20
21 Whereas, physicians who care for patients under the direct primary care model or other out-of-
22 network models are not compensated by insurers for physician services rendered to patients
23 with these plans; and

24
25 Whereas, many of the patients served in direct primary care or out-of-network models have
26 HMOs, Medicare Advantage or other health plans for their primary insurance while using a
27 direct-pay physician for their medical care; and

28
29 Whereas, these health plans often will not cover laboratory studies, radiology studies, referral or
30 even prescription medications when ordered by one of these out-of-network physicians; and

31
32 Whereas, non-coverage of valid orders for health plan benefits for the insured leads to delays in
33 case, increased cost to patients and redundancy and inefficiency in the healthcare system;
34 therefore be it

35
36 RESOLVED, that our American Medical Association develop model legislation to protect
37 patients in direct primary care plans and non-network plans thus furthering the ability of direct
38 primary care physicians and other out-of-network physicians to provide covered services,
39 including imaging, laboratory testing, referrals, medications, and other medically-necessary

1 services for patients under their commercial insurance, even if it is an HMO or point of service
2 plan (Directive to Take Action); and be it further

3
4 RESOLVED, that our AMA develop resources, tool kits, education, and internal experts to
5 support direct primary care and other out-of-network models. (Directive to Take Action)
6

Fiscal Note: Resolved 1, Modest - between \$1,000 - \$5,000. Resolved 2, \$22,980. Develop a comprehensive portfolio of education, experts, and toolkits

Received: 4/17/2024

REFERENCES

1. Physicians Advocacy Group, Covid 19's Impact on Physician Practices and Physician Employment 2019-2020- Prepared by Avalere Health June 2021 tma.tips/PAIStudy2021.
2. Cobra KL. Direct primary care may be the link to the "fourth aim" of healthcare. Medical Economics. Published July 11, 2018. Accessed January 12, 2021. <https://www.medicaleconomics.com/view/direct-primary-care-may-be-link-fourth-aim-healthcare>
3. AM J Lifestyle Med, 2021 Sept-Oct 15(5):557-562.
4. Mapper.dpcfrontier.com
5. Direct Primary Care: Update and Roadmap for Patient Centered Reforms. The Heritage Foundation Backgrounder No. 3635. June 28, 2021.
6. State of Maine Department of Professional and Financial Regulation, Bureau of Insurance, Bulletin 434 Referrals by Out of Network Direct Primary Care Providers, June 7, 2019
7. Health Services Research 2020 Aug;55(4) 491-495.

RELEVANT AMA POLICY

Direct Primary Care H-385.912

1. Our AMA supports: (a) inclusion of Direct Primary Care as a qualified medical expense by the Internal Revenue Service; and (b) efforts to ensure that patients in Direct Primary Care practices have access to specialty care, including efforts to oppose payer policies that prevent referrals to in-network specialists.
2. AMA policy is that the use of a health savings account (HSA) to access direct primary care providers and/or to receive care from a direct primary care medical home constitutes a bona fide medical expense, and that particular sections of the IRS code related to qualified medical expenses should be amended to recognize the use of HSA funds for direct primary care and direct primary care medical home models as a qualified medical expense.
3. Our AMA will seek federal legislation or regulation, as necessary, to amend appropriate sections of the IRS code to specify that direct primary care access or direct primary care medical homes are not health "plans" and that the use of HSA funds to pay for direct primary care provider services in such settings constitutes a qualified medical expense, enabling patients to use HSAs to help pay for Direct Primary Care and to enter DPC periodic-fee agreements without IRS interference or penalty.

Citation: Res. 103; A-16; Appended: Res. 246, A-18; Reaffirmed: A-18; Reaffirmed: I-18; Appended: Res. 102, A-19

Subacute Care Standards for Physicians H-160.945

AMA guidelines for physicians' responsibilities in subacute care include:

- (1) Physicians are responsible to their patients for delivery of care in all subacute care settings, 24 hours a day, 7 days a week.
- (2) Patients who might benefit from subacute care should be admitted to and discharged under the orders of the physician who is responsible for the continuous medical management needed to meet the patient's needs and safety and maintaining quality of care.
- (3) Physicians are responsible for coordinating care for their patients with other physicians including medical directors, primary care physicians, and appropriate specialists, to optimize the quality of care in subacute settings.
- (4) Physicians are responsible for supervision and coordination of the medical care for their patients and providing leadership for all other health care providers in subacute care.
- (5) Physicians should guide procedures for their patients performed within integrated practices and direct other health care providers, consistent with federal and state regulations.

(6) Physicians are responsible for: (a) Fulfilling their roles and identifying the medical skills needed to deliver care in subacute facilities and for creating and developing continuing medical education to meet the special needs of patients in subacute care. (b) Identifying and appropriately utilizing subacute care facilities in their communities. (c) Oversight of physician credentialing in subacute settings (d) Promoting medical staff organization and by-laws that may be needed to support peer evaluations. (e) Planning care of their patients with acute and chronic conditions in subacute care, as well as pursuing efforts to restore and maintain functions for quality of life.

(7) Subacute units and/or programs need physician medical directors to assure quality of medical care, provide peer group liaisons, and coordinate and supervise patients and families input and needs.

(8) Physicians provide a plan of care for medically necessary visits after completing an initial assessment within 24 hours of admission that identifies the medical services expected during subacute care.

(9) Attending physicians should: (a) make an on-site visit to review the interdisciplinary care plan within seventy two hours of admission. (b) Determine the number of medically necessary follow up visits; these may occur daily but never less often than weekly. (c) Document active involvement of physicians in interdisciplinary care and all major components of the patient care plan including completing a progress note for each patient visit.

(10) Physicians should implement these guidelines through organized medical staff by-laws in subacute settings to assure quality patient care.

Citation: BOT Rep. 21, I-95; Reaffirmed: CMS Rep. 7, A-05; Reaffirmed: CMS Rep. 1, A-15

Out-of-Network Care H-285.904

1. Our AMA adopts the following principles related to unanticipated out-of-network care:

A. Patients must not be financially penalized for receiving unanticipated care from an out-of-network provider.

B. Insurers must meet appropriate network adequacy standards that include adequate patient access to care, including access to hospital-based physician specialties. State regulators should enforce such standards through active regulation of health insurance company plans.

C. Insurers must be transparent and proactive in informing enrollees about all deductibles, copayments and other out-of-pocket costs that enrollees may incur.

D. Prior to scheduled procedures, insurers must provide enrollees with reasonable and timely access to in-network physicians.

E. Patients who are seeking emergency care should be protected under the "prudent layperson" legal standard as established in state and federal law, without regard to prior authorization or retrospective denial for services after emergency care is rendered.

F. Out-of-network payments must not be based on a contrived percentage of the Medicare rate or rates determined by the insurance company.

G. Minimum coverage standards for unanticipated out-of-network services should be identified. Minimum coverage standards should pay out-of-network providers at the usual and customary out-of-network charges for services, with the definition of usual and customary based upon a percentile of all out-of-network charges for the particular health care service performed by a provider in the same or similar specialty and provided in the same geographical area as reported by a benchmarking database. Such a benchmarking database must be independently recognized and verifiable, completely transparent, independent of the control of either payers or providers and maintained by a non-profit organization. The non-profit organization shall not be affiliated with an insurer, a municipal cooperative health benefit plan or health management organization.

H. Independent Dispute Resolution (IDR) should be allowed in all circumstances as an option or alternative to come to payment resolution between insurers and physicians.

2. Our AMA will advocate for the principles delineated in Policy H-285.904 for all health plans, including ERISA plans.

3. Our AMA will advocate that any legislation addressing surprise out of network medical bills use an independent, non-conflicted database of commercial charges.

Citation: Res. 108, A-17; Reaffirmed: A-19; Appended: Res. 104, A-18; Reaffirmed in lieu of: Res. 225, A-18; Reaffirmed: A-19; Reaffirmed: Res. 210, A-19; Appended Res. 211, A-19; Reaffirmed: CMS Rep. 5, A-21; Modified: Res. 236, A-22

Out-of-Network Care D-285.962

Our AMA will develop model state legislation addressing the coverage of and payment for unanticipated out-of-network care.

Citation: Res. 108, A-17

Physician Penalties for Out-of-Network Services H-180.952

Our AMA vehemently opposes any penalties implemented by insurance companies against physicians when patients independently choose to obtain out-of-network services.

Citation: Res. 702, A-07; Reaffirmed: CMS Rep. 01, A-17

Out of Network Restrictions of Physicians H-285.907

Our American Medical Association opposes the denial of payment for a medically necessary prescription of a drug or service covered by the policy based solely on the network participation of the duly licensed physician ordering it.

Citation: Res. 126, A-15

Out of Network Coverage Denials for Physician Prescriptions and Ordered Services D-285.963

Our American Medical Association will pursue regulation or legislation to prohibit any insurer from writing individual or group policies which deny or unreasonably delay coverage of medically necessary prescription drugs or services based on network distinctions of the licensed health care provider ordering the drug or service.

Citation: Res. 119, A-15

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 214
(A-24)

Introduced by: Medical Student Section

Subject: Support for Paid Sick Leave

Referred to: Reference Committee B

1 Whereas, sick leave can be used by employees to recover from illness, attend medical
2 appointments, care for sick relatives, and seek assistance for domestic violence, and access
3 disproportionately impacts women who take on caregiver responsibilities¹⁻⁴; and
4

5 Whereas, all but 10 countries feasibly fund paid sick leave via governments and/or employers,
6 but the US' Family and Medical Leave Act (FMLA) only ensures unpaid leave⁵⁻⁷; and
7

8 Whereas, 75% of voters support a national paid leave policy, but currently 25% of private sector
9 workers do not receive paid sick leave, including 62% of those in the lowest income decile, 45%
10 of those in the lowest income quartile, 54% of Latine workers, 47% of Indigenous workers, and
11 38% of Black workers⁸⁻¹¹; and
12

13 Whereas, multiple studies demonstrate that paid sick leave increases primary care use and
14 reduces occupational injuries and infectious spread, with one estimating over \$1 billion in
15 annual savings from over 1 million prevented ED visits¹²⁻²²; and
16

17 Whereas, paid sick leave is guaranteed in 15 states including DC, 4 counties, and 17 cities, with
18 early adopters showing sustainable success for over a decade^{2,23-24}; and
19

20 Whereas, the Healthy Families Act would guarantee paid sick leave and is currently being
21 considered in both the House and Senate²⁵; therefore be it
22

23 RESOLVED, that our American Medical Association amend Policy H-440.823, "Paid Sick
24 Leave," as follows:
25

26 Paid Sick Leave H-440.823

27 Our AMA: (1) recognizes the public health benefits of paid sick
28 leave and other discretionary paid time off; (2) supports employer
29 policies that allow employees to accrue paid time off and to use
30 such time to care for themselves or a family member; ~~and~~ (3)
31 supports employer policies that provide employees with paid sick
32 days to use to care for themselves or a family member where
33 providing paid leave is overly burdensome; and (4) advocates for
34 federal and state policies that guarantee employee access to
35 protected paid sick leave. (Modify Current HOD Policy)
36

Fiscal Note: Minimal - less than \$1,000

Received: 4/5/2024

REFERENCES

1. Understanding the difference between paid sick days & paid family and medical leave. National Partnership for Women & Families [web]. Published November 2022. Accessed August 27, 2023. <https://nationalpartnership.org/report/paid-sick-days-family-medical-leave>
2. Paid leave in the U.S. Kaiser Family Foundation. Published December 17, 2021. Accessed August 27, 2023. <https://www.kff.org/womens-health-policy/fact-sheet/paid-leave-in-u-s>
3. California paid sick leave: frequently asked questions. State of California Department of Industrial Relations. Updated March 29, 2017. Accessed August 27, 2023. https://www.dir.ca.gov/dlse/paid_sick_leave.htm
4. Ranji U, Long M, and Salganicoff A. Coronavirus puts a spotlight on paid leave policies. Kaiser Family Foundation. Published December 14, 2020. Accessed August 27, 2023. <https://www.kff.org/coronavirus-covid-19/issue-brief/coronavirus-puts-a-spotlight-on-paid-leave-policies>
5. The Family and Medical Leave Act of 1993, as amended. U.S. Department of Labor. Accessed August 27, 2023. <https://www.dol.gov/agencies/whd/fmla/law>
6. Heymann J and Sprague A. Why adopting a national paid sick leave law is critical to health and to reducing racial and socioeconomic disparities—long past due. *JAMA Health Forum*. May 6, 2021;2(5):e210514. doi: 10.1001/jamahealthforum.2021.0514
7. Raub A, Chung P, Batra P, Earle A, Bose B, Jou J, Chorny NDG, Wong E, Franken D, and Heymann J. Paid leave for personal illness: a detailed look at approaches across OECD countries. *WORLD Policy Analysis Center*. Published 2018. Accessed August 27, 2023. https://www.worldpolicycenter.org/sites/default/files/WORLD%20Report%20-%20Personal%20Medical%20Leave%20OECD%20Country%20Approaches_0.pdf
8. Paid sick leave benefits factsheet. U.S. Bureau of Labor Statistics. Updated January 12, 2021. Accessed August 27, 2023. <https://www.bls.gov/ebs/factsheets/paid-sick-leave.htm>
9. Higher paid workers more likely than lower paid workers to have paid leave benefits in 2022. U.S. Bureau of Labor Statistics, *The Economics Daily*. Published February 15, 2023. Accessed August 27, 2023. <https://www.bls.gov/opub/ted/2023/higher-paid-workers-more-likely-than-lower-paid-workers-to-have-paid-leave-benefits-in-2022.htm>
10. Xia J, Hayes J, Gault B, and Nguyen H. Paid sick days access and usage rates vary by race/ethnicity, occupation, and earnings. *Institute for Women's Policy Research*. Published February 2016. Accessed August 27, 2023. <https://iwpr.org/wp-content/uploads/2020/08/B356-paid-sick-days.pdf>
11. New polling confirms strong, broad support for paid family and medical leave. National Partnership for Women & Families. Published April 2020. Accessed August 27, 2023. <https://nationalpartnership.org/wp-content/uploads/2023/02/new-polling-paid-family-and-medical-leave.pdf>
12. Ranji U, Long M, and Salganicoff A. Coronavirus puts a spotlight on paid leave policies. Kaiser Family Foundation. Published December 14, 2020. Accessed August 27, 2023. <https://www.kff.org/coronavirus-covid-19/issue-brief/coronavirus-puts-a-spotlight-on-paid-leave-policies>
13. Pichler S, Wen K, and Ziebarth NR. COVID-19 emergency sick leave has helped flatten the curve in the United States. *Health Affairs*. October 15, 2020; 39 (12). doi: 10.1377/hlthaff.2020.00863
14. Pichler S and Ziebarth N. The pros and cons of sick pay schemes: Testing for contagious presenteeism and noncontagious absenteeism behavior. *Journal of Public Economics*. 2017;156:14-33. doi: 10.1016/j.jpubeco.2017.07.003
15. Stearns J and White C. Can paid sick leave mandates reduce leave-taking? *Labour Economics*. 2018;51:227-246. doi: 10.1016/j.labeco.2018.01.002
16. Callison K, Pesko MF, Phillips S, and Sosa JA. Cancer screening after the adoption of paid-sick-leave mandates. *N Engl J Med*. March 2, 2023; 388(9):824-832. doi: 10.1056/NEJMsa2209197
17. Ko H and Glied SA. Associations between a New York City paid sick leave mandate and health care utilization among Medicaid beneficiaries in New York City and New York State. *JAMA Health Forum*. 2021;2(5):e210342. doi: 10.1001/jamahealthforum.2021.0342
18. DeRigne L, Stoddard-Dare, Collins C, and Quinn L. Paid sick leave and preventive health care service use among US working adults. *Preventive Medicine*. June 2017;99:58-62. doi: 10.1016/j.yjmed.2017.01.020
19. Hegland TA and Berdahl TA. High job flexibility and paid sick leave increase health care access and use among US workers. *Health Affairs*. June 2022;41(6):873-882. doi: 10.1377/hlthaff.2021.01876
20. Miller K, Williams C, and Yi Y. Paid sick days and health: cost savings from reduced emergency department visits. *Institute for Women's Policy Research*. Published November 2011. Accessed August 27, 2023. <https://iwpr.org/wp-content/uploads/2022/10/IWPR-Miller-et-al-2011-PSD-and-emergency-hospital-visits.pdf>
21. Ma Y, Johnston KJ, Yu H, Wharam JF, and Wen H. State mandatory paid sick leave associated with a decline in emergency department use in the US, 2011-19. *Health Affairs*. August 2022;41(8):1169-1175. doi: 10.1377/hlthaff.2022.00098
22. Asfaw A, Pana-Cryan R, and Rosa R. Paid sick leave and nonfatal occupational injuries. *Am J Public Health*. September 2012;102(9):e59-e64. doi: 10.2105/AJPH.2011.300482
23. Paid sick leave. National Conference of State Legislatures. Updated July 21, 2020. Accessed August 27, 2023. <https://www.ncsl.org/labor-and-employment/paid-sick-leave>
24. Current paid sick days laws fact sheet. National Partnership for Women & Families. Published June 2023. Accessed August 27, 2023. <https://nationalpartnership.org/wp-content/uploads/2023/02/current-paid-sick-days-laws.pdf>
25. The Healthy Families Act Fact Sheet. National Partnership for Women & Families. Published November 2023. Accessed March 15, 2024. <https://nationalpartnership.org/wp-content/uploads/2023/02/the-healthy-families-act-fact-sheet.pdf>

RELEVANT AMA POLICY**H-420.979 AMA Statement on Family, Medical, and Safe Leave**

Our AMA supports policies that provide employees with reasonable job security and continued availability of health plan benefits in the event leave by an employee becomes necessary due to documented medical conditions. Such policies should provide for reasonable periods of paid or unpaid:

1) Medical leave for the employee, including pregnancy, abortion, and stillbirth; 2) Maternity leave for the employee-mother; 3) Leave if medically appropriate to care for a member of the employee's immediate family, i.e., a spouse or children; 4) Leave for adoption or for foster care leading to adoption; and 5) Safe leave provisions for those experiencing any instances of violence, including but not limited to intimate partner violence, sexual violence or coercion, and stalking.

Such periods of leave may differ with respect to each of the foregoing classifications and may vary with reasonable categories of employers. Such policies should encourage voluntary programs by employers and may provide for appropriate legislation (with or without financial assistance from government). Any legislative proposals will be reviewed through the Association's normal legislative process for appropriateness, taking into consideration all elements therein, including classifications of employees and employers, reasons for the leave, periods of leave recognized (whether paid or unpaid), obligations on return from leave, and other factors involved in order to achieve reasonable objectives recognizing the legitimate needs of employees and employers.

Our AMA recognizes the positive impact of paid safe leave on public health outcomes and supports legislation that offers safe leave.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 215
(A-24)

Introduced by: Medical Student Section

Subject: American Indian and Alaska Native Language Revitalization and Elder Care

Referred to: Reference Committee B

- 1 Whereas, American Indian and Alaska Native (AI/AN) elders ages 65 and over are expected to
2 increase from 13% of the AI/AN population in 2012 to 20% by 2030¹; and
3
- 4 Whereas, AI/AN elders are considered essential to community identity, as extended family and
5 clanship leaders are valued as protectors, mentors, teachers, and intergenerational transmitters
6 of cultural knowledge, a well-recognized protective health factor for AI/AN youth²⁻⁵; and
7
- 8 Whereas, AI/AN elders experience significant health and socioeconomic disparities including
9 the lowest life expectancy of all racial/ethnic groups in the US, a 25% uninsured rate, and a 25%
10 rate of having at least one documented disability¹; and
11
- 12 Whereas, a study in Canada of AI/AN elders found that Indigenous-led health service
13 partnerships improve holistic health outcomes, as well as access to care, prevention uptake and
14 adherence to care plans for First Nations⁶; and
15
- 16 Whereas, a survey with southwestern Tribal Nations found that AI/AN elders consistently shared
17 themes of healthcare insecurity due to failed systems and IHS underfunding⁷; and
18
- 19 Whereas, while AI/AN elders receive primary care through the IHS, underfunding and
20 understaffing has forced IHS to rely on non-IHS facilities for more specialized elder care,
21 including hospice and respite care, forcing AI/AN elders to navigate unknown health systems
22 not respective of their cultural values and traditions⁸; and
23
- 24 Whereas, despite the well-documented comorbidities AI/AN people carry into elderhood, AI/AN
25 elders are less likely to create end-of-life care plans compared to non-Hispanic Whites and
26 remain one of the least studied populations regarding their use of advance care planning⁷⁻⁹; and
27
- 28 Whereas, terminally ill AI/AN elders are less likely to receive hospice and palliative care than
29 other racial/ethnic groups, with fewer than a third receiving these services compared to over
30 45% of the non-Hispanic white population¹⁰; and
31
- 32 Whereas, according to data collected by the Mayo Clinic Spirit of Eagles program, Tribal Health
33 Directors reported pain management, advanced care planning, hospice contracts, care for the
34 dying, and bereavement support as their most pressing needs, with 60% reporting limited
35 access to end-of-life care¹¹; and
36
- 37 Whereas, by 2060, the number of AI/AN elders with memory loss is expected to increase by
38 400%, requiring additional resources for the IHS to provide dementia services¹²; and

1 Whereas, language and cultural barriers severely restrict AI/AN elder access to federal and
2 state programs, such as Social Security, Medicare, and Medicaid¹³⁻¹⁴; and
3

4 Whereas, over 20% of AI/AN elders mostly speak their native language, and in several counties
5 on the Navajo Nation, over 40% speak their native language as their primary language¹⁵; and
6

7 Whereas, the National Indian Council on Aging considers Native languages as key for improving
8 health and social services and well-being for AI/AN elders¹⁶; and
9

10 Whereas, the White House Office of Science and Technology Policy (OSTP) has directed the
11 Department of Health and Human Services, Centers for Medicare and Medicaid Services, IHS,
12 and other federal agencies to value and prioritize Indigenous knowledge, including languages
13 and knowledge holders, in federal grantmaking and other funding opportunities¹⁷; and
14

15 Whereas, the Biden-Harris Administration's 2024 budget request for Indian Affairs programs
16 makes significant investments in Tribal native language revitalization¹⁸; therefore be it
17

18 RESOLVED, that our American Medical Association recognize that access to language
19 concordant services for AI/AN patients will require targeted investment as Indigenous languages
20 in North America are threatened due to a complex history of removal and assimilation by state
21 and federal actors (New HOD Policy); and be it further
22

23 RESOLVED, that our AMA support federal-tribal funding opportunities for American Indian and
24 Alaska Native language revitalization efforts, especially those that increase health information
25 resources and access to language-concordant health care services for American Indian and
26 Alaska Native elders living on or near tribal lands (New HOD Policy); and be it further
27

28 RESOLVED, that our AMA collaborate with stakeholders, including but not limited to the
29 National Indian Council on Aging and Association of American Indian Physicians, to identify best
30 practices for AI/AN elder care to ensure this group is provided culturally-competent healthcare
31 outside of the umbrella of the Indian Health Service. (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/5/2024

REFERENCES

1. Sinnett GM. The state of tribal elders. NICOA. June 2, 2022. Accessed August 26, 2023. <https://www.nicoa.org/the-state-of-tribal-elders/>.
2. Elders. National Congress of the American Indian. Accessed August 26, 2023. <https://www.ncai.org/policy-issues/education-health-human-services/elders>
3. Whitewater S, Reinschmidt KM, Kahn C, Attakai A, Teufel-Shone NI. Flexible Roles for American Indian Elders in Community-Based Participatory Research. *Prev Chronic Dis*. 2016;13:E72. Published 2016 Jun 2. doi:10.5888/pcd13.150575
4. Henson M, Sabo S, Trujillo A, Teufel-Shone N. Identifying Protective Factors to Promote Health in American Indian and Alaska Native Adolescents: A Literature Review. *J Prim Prev*. 2017;38(1-2):5-26. doi:10.1007/s10935-016-0455-2
5. Dellinger M, Poupart AE. Lessons Native American Culture Can Teach Us About Resilience During Pandemics and Health Care Crises. *WMJ*. 2021;120(S1):S80-S84.
6. Lindsay Allen, Andrew Hatala, Sabina Ijaz, Elder David Courchene and Elder Burma Bushie CMAJ March 02, 2020 192 (9) E208-E216; DOI: <https://doi.org/10.1503/cmaj.190728>
7. Jaramillo ET, Willging CE. Producing insecurity: Healthcare access, health insurance, and wellbeing among American Indian elders. *Soc Sci Med*. 2021;268:113384. doi:10.1016/j.socscimed.2020.113384
8. Haozous EA, Jaramillo ET, Willging CE. Getting to Know: American Indian Elder Health Seeking in an Under-funded Healthcare System. *SSM Qual Res Health*. 2021;1:100009. doi:10.1016/j.ssmqr.2021.100009
9. Kwak J, Cho Y, Lee Y, Noh H, Roh S. Advance Care Planning Among American Indians. *Innov Aging*. 2018;2(Suppl 1):189-190. Published 2018 Nov 11. doi:10.1093/geroni/igy023.695
10. Jervis LL, Cox DW. End-of-Life Services in Tribal Communities. *Innov Aging*. 2019;3(Suppl 1):S667-S668. Published 2019 Nov 8. doi:10.1093/geroni/igz038.2469
11. Isaacson MJ, Lynch AR. Culturally Relevant Palliative and End-of-Life Care for U.S. Indigenous Populations: An Integrative Review. *Journal of Transcultural Nursing*. 2018;29(2):180-191. doi:10.1177/1043659617720980

12. Dementia Models of Care Grantees. Indian Health Service. Accessed August 26, 2023. [Dementia Models of Care Grantees | Grantees and Awardees \(ihs.gov\)](https://www.ihs.gov/grantees-and-awardees/)
13. Mangla A, Agarwal N. Clinical Practice Issues in American Indians and Alaska Natives. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK570601/>
14. B. M.-. *Elders*. National Congress of American Indians. Retrieved September 9, 2023, from <https://www.ncai.org/policy-issues/education-health-human-services/elders>
15. *Navajo & Apache Counties Puma*, AZ. Data USA. Retrieved September 9, 2023, from <https://datausa.io/profile/geo/navajo-apache-counties-puma-az>
16. Sawyer, K., Matter, M., Biggar, A., & Vanderburg, J. (2022, Nov 9). *Effective effort to revive native languages*. ASA Generations. Retrieved September 9, 2023, from <https://generations.asaging.org/effective-effort-revive-native-languages>
17. Prabhakar, A., & Mallory, B. (2022, November 30). *White House releases first-of-a-kind Indigenous Knowledge Guidance for federal agencies*. The White House. Retrieved September 9, 2023, from <https://www.whitehouse.gov/ostp/news-updates/2022/12/01/white-house-releases-first-of-a-kind-indigenous-knowledge-guidance-for-federal-agencies/>
18. Statement by assistant secretary for Indian affairs Bryan Newland on the president's fiscal year 2024 budget. U.S. Department of the Interior Bureau of Indian Affairs. March 9, 2023. Accessed September 17, 2023. <https://www.bia.gov/news/statement-assistant-secretary-indian-affairs-bryan-newland-presidents-fiscal-year-2024-budget>

RELEVANT AMA POLICY

H-295.897 Enhancing the Cultural Competence of Physicians

1. Our AMA continues to inform medical schools and residency program directors about activities and resources related to assisting physicians in providing culturally competent care to patients throughout their life span and encourage them to include the topic of culturally effective health care in their curricula.
2. Our AMA continues to support research into the need for and effectiveness of training in cultural competence and cultural humility, using existing mechanisms such as the annual medical education surveys.
3. Our AMA will assist physicians in obtaining information about and/or training in culturally effective health care through dissemination of currently available resources from the AMA and other relevant organizations.
4. Our AMA encourages training opportunities for students and residents, as members of the physician-led team, to learn cultural competency from community health workers, when this exposure can be integrated into existing rotation and service assignments.
5. Our AMA supports initiatives for medical schools to incorporate diversity in their Standardized Patient programs as a means of combining knowledge of health disparities and practice of cultural competence with clinical skills.
6. Our AMA will encourage the inclusion of peer-facilitated intergroup dialogue in medical education programs nationwide.
7. Our AMA supports the development of national standards for cultural humility training in the medical school curricula.

[CME Rep. 5, A-98; Reaffirmed: Res. 221, A-07; Reaffirmation A-11; Appended: Res. 304, I-16; Modified: CME Rep. 01, A-17; Appended: Res. 320, A-17; Reaffirmed: CMS Rep. 02, I-17; Appended: Res. 315, A-18; Modified: Res. 322, A-22]

H-350.976 Improving Health Care of American Indians

Our AMA recommends that: (1) All individuals, special interest groups, and levels of government recognize the American Indian people as full citizens of the U.S., entitled to the same equal rights and privileges as other U.S. citizens.

- (2) The federal government provide sufficient funds to support needed health services for American Indians.
- (3) State and local governments give special attention to the health and health-related needs of nonreservation American Indians in an effort to improve their quality of life.
- (4) American Indian religions and cultural beliefs be recognized and respected by those responsible for planning and providing services in Indian health programs.
- (5) Our AMA recognize the "medicine man" as an integral and culturally necessary individual in delivering health care to American Indians.
- (6) Strong emphasis be given to mental health programs for American Indians in an effort to reduce the high incidence of alcoholism, homicide, suicide, and accidents.
- (7) A team approach drawing from traditional health providers supplemented by psychiatric social workers, health aides, visiting nurses, and health educators be utilized in solving these problems.

(8) Our AMA continue its liaison with the Indian Health Service and the National Indian Health Board and establish a liaison with the Association of American Indian Physicians.

(9) State and county medical associations establish liaisons with intertribal health councils in those states where American Indians reside.

(10) Our AMA supports and encourages further development and use of innovative delivery systems and staffing configurations to meet American Indian health needs but opposes overemphasis on research for the sake of research, particularly if needed federal funds are diverted from direct services for American Indians.

(11) Our AMA strongly supports those bills before Congressional committees that aim to improve the health of and health-related services provided to American Indians and further recommends that members of appropriate AMA councils and committees provide testimony in favor of effective legislation and proposed regulations.

[CLRPD Rep. 3, I-98; Reaffirmed: Res. 221, A-07; Reaffirmation A-12; Reaffirmed: Res. 233, A-13; Reaffirmed: BOT Rep. 09, A-23]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 216
(A-24)

Introduced by: American College of Legal Medicine

Subject: The AMA Supports H.R. 7225, the Bipartisan “Administrative Law Judges Competitive Service Restoration Act”

Referred to: Reference Committee B

- 1 Whereas, Medicare and Medicaid beneficiaries and providers must appeal their
2 coverage and payment disputes to the Health and Human Services Administrative Law
3 Judges (ALJs); and
4
- 5 Whereas, from 1946 until 2018, attorney candidates who wanted to become federal
6 ALJs were required:
- 7 a. to pass an examination on administrative law given by the U.S. Department of
8 Personnel Management, and only the top three scoring candidates were
9 offered positions as federal ALJs; and
 - 10 b. to have at least seven years of experience in an area of law relevant to
11 administrative proceedings; and
 - 12 c. to prove they had the ability to write clear and understandable decisions
13 following an administrative proceeding; and
14
- 15 Whereas, following the Supreme Court decision in *Lucia v. SEC*¹, Executive Order
16 (E.O.) 13,843 was signed²; and
17
- 18 Whereas, E.O. 13,843 removed federal ALJs from the competitive civil service; and
19
- 20 Whereas, the only current requirements for a new federal ALJ are a license to practice
21 law somewhere in the United States and an appointment made by a temporary,
22 politically appointed agency head; and
23
- 24 Whereas, E.O. 13,843 politicized the federal ALJ service, potentially resulting in the
25 appointment of questionably competent ALJs³; and
26
- 27 Whereas, Medicare and Medicaid coverage and payment disputes are more likely to be
28 correctly decided by informed, competent, and truly neutral ALJs; and
29
- 30 Whereas, the bipartisan “Administrative Law Judges Competitive Service Restoration
31 Act,” H.R.7225, was introduced on February 4, 2024, by Congressman Gerry Connolly
32 (D-VA-11) and is co-sponsored by Congressman Brian Fitzpatrick (R-PA-1) and
33 Congressman Michael Lawler (R-NY-17) and is endorsed by the American College of
34 Legal Medicine (ACLM), the Association of Administrative Law Judges (AALJ), and the

1 International Federation of Professional and Technical Engineers (IFPTE); therefore be
2 it
3
4 RESOLVED, that our American Medical Association support H.R. 7225, the bipartisan
5 “Administrative Law Judges Competitive Service Restoration Act” that supports the
6 merit-based process for the selection of all Medicare/Medicaid Administrative Law
7 Judges. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 4/21/2024

REFERENCES

1. 138 S. Ct. 2044 (2018)
2. <https://www.federalregister.gov/documents/2018/07/13/2018-15202/excepting-administrative-law-judges-from-the-competitive-service>.
3. <https://www.govexec.com/oversight/2018/07/judges-union-supreme-court-decision-excuse-politicize-aljs/149773/>

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 217
(A-24)

Introduced by: American Society for Reproductive Medicine, American College of
Obstetricians and Gynecologists

Subject: Protecting Access to IVF Treatment

Referred to: Reference Committee B

1 Whereas, on Friday 2/16/24, the Alabama Supreme Court¹ ruled that

2 (a) “an embryo created through in vitro fertilization (IVF) is a child protected by
3 Alabama’s wrongful death act and the Alabama Constitution;” and that

4 (b) “a human frozen embryo is a ‘child’ which is an unborn or recently born [child];” and
5 that

6 (c) “the Constitution ... commands the judge to ... upholding the sanctity of unborn life,
7 including unborn life that exists outside the womb;” and that

8 (d) “the Court would not create an exception in the statute for these IVF embryo children
9 just because they were located outside the womb;” and

10
11 Whereas, in current IVF practice in the United States, over half of embryo transfers will *not*
12 result in live birth, as many embryos after transfer will either (a) not result in a pregnancy, or (b)
13 result in a miscarriage, or (c) result in a non-viable ectopic or molar pregnancy; and

14
15 Whereas, cryopreserved embryos also do *not* have a 100% thaw-survival rate, and a small
16 percentage of embryos will not survive freeze-thaw; such that if embryos in the IVF lab have the
17 same legal status as children, then an embryology laboratory that fails to have a 100% thaw-
18 survival rate may also have some potential liability; and

19
20 Whereas, not all IVF patients (a) can afford the long-term storage fees to cryopreserve embryos
21 for future use or (b) wish to donate those embryos; and

22
23 Whereas, defining all embryos as “children” promotes the dangerous notion that all embryos
24 should somehow be transferred in an IVF cycle (instead of cryopreserving extra embryos of
25 adequate quality), which could potentially increase the rate of dangerous higher-order multiple
26 gestation pregnancies (triplets, quadruplets, etc); and

27
28 Whereas, defining all embryos as “children” may promote the dangerous and misguided notion
29 that an ectopic pregnancy could somehow be safely implanted into the uterus (as is erroneously
30 reported on various “Personhood” websites⁹); and

31
32 Whereas, the American Society for Reproductive Medicine (ASRM) Position Statement on
33 Personhood Measures states that

- 34 - “The ASRM is strongly opposed to measures granting constitutional rights or protections
35 and “personhood” status to fertilized reproductive tissues.
36 - In a growing number of states, vaguely worded and often misleading measures are...
37 defining when life begins and granting legal “personhood” status to embryos at varying
38 stages of development.

- 39 - ..., these broadly worded measures will have significant effects on a number of medical
40 treatments available to women of reproductive age.
41 o Personhood measures would make illegal some commonly used birth control
42 methods.
43 o Personhood measures would make illegal a physician's ability to provide
44 medically appropriate care to women experiencing life-threatening complications
45 due to a tubal pregnancy.
46 o Personhood measures would consign infertility patients to less effective, less
47 safe treatments for their disease.
48 o Personhood measures would unduly restrict infertile patients' right to make
49 decisions about their own medical treatments, including determining the fate of
50 any embryos created as part of the IVF process.
51 - ASRM will oppose any personhood measure;" and
52

53 Whereas, partly in response to a movement to allow the establishment of college savings
54 accounts for undelivered pregnancies; our AMA established policy H-140.835 which states that:
55 "our AMA opposes any policies that interfere with the patient-physician relationship by
56 giving probate, inheritance, a social security number, or other legal rights to
57 an undelivered pregnancy, or imposing legislative barriers to medical decision-making by
58 changes in tax codes or in definitions of beneficiaries." therefore, be it
59

60 RESOLVED, that our American Medical Association oppose any legislation or ballot measures
61 that could criminalize in-vitro fertilization (New HOD Policy); and be it further
62

63 RESOLVED, that our AMA work with other interested organizations to oppose any legislation or
64 ballot measures or court rulings that equate gametes (oocytes and sperm) or embryos with
65 children (New HOD Policy); and be it further
66

67 RESOLVED, that our AMA report back at A-25, on the status of, and AMA's activities
68 surrounding, ballot measures, court rulings, and legislation that equate embryos with children.
69 (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/23/2024

REFERENCES

1. AP news on "Alabama's IVF embryo ruling explained. And what's next?" at <https://apnews.com/article/alabama-frozen-embryos-ivf-storage-questions-1adbc349e0f99851973a609e360c242c>; posted 2/22/24, accessed 3/14/24
2. "Personhood" amendment fails by 3-1 margin. Denver Post 11/3/10 at http://www.denverpost.com/headlines/ci_16506253
3. Mississippi's "Personhood Amendment" fails at the polls. CBS News 11/8/11 at http://www.cbsnews.com/8301-250_162-57321126/mississippi-personhood-amendment-fails-at-polls/
4. Virginia House of Delegates, House Bill No 1 at <http://lis.virginia.gov/cgi-bin/legp604.exe?121+ful+HB1+pdf>
5. 'Personhood' bill killed for this year by Virginia Senate. Washington Post 2/23/12 at http://www.washingtonpost.com/blogs/virginia-politics/post/personhood-bill-killed-for-this-year-by-virginiasenate/2012/02/23/gIQAYxvBWR_blog.html
6. Anti-abortion "personhood" bill clears Oklahoma senate. Reuters 12/1/12 at <http://www.reuters.com/article/2012/02/16/us-oklahoma-personhood-idUSTRE81F0ES20120216>
7. "Mississippi 'Personhood' law could cause legal mayhem, experts warn. Huffington post 11/7/11 at http://www.huffingtonpost.com/2011/11/07/mississippi-personhood-la_n_1079710.html
8. "Successful Ectopic Pregnancies" by Bill Fortenberry on www.personhoodinitiative.com, at <<http://www.personhoodinitiative.com/successful-ectopic-pregnancies.html>>, accessed 3/14/24
9. American Society for Reproductive Medicine (ASRM) Position Statement on Personhood Measures, at <<https://www.asrm.org/advocacy-and-policy/media-and-public-affairs/asrm-position-statement-on-personhood-measures/>>, accessed 3/14/24
10. Letterie G, Fox D. Legal personhood and frozen embryos: implications for fertility patients and providers in post-Roe America. J Law Biosci. 2023 May 19;10(1):lsad006. doi: 10.1093/jlb/lsad006. PMID: 37220567; PMCID: PMC10200124.

11. Jones HW. The ethics of in vitro fertilization--1982. *Fertil Steril.* 1982 Feb;37(2):146-9. doi: 10.1016/s0015-0282(16)46030-9. PMID: 11643718.

RELEVANT AMA POLICY

D-5.999 “Preserving Access to Reproductive Health Services”

Our AMA: (1) recognizes that healthcare, including reproductive health services like contraception and abortion, is a human right; (2) opposes limitations on access to evidence-based reproductive health services, including fertility treatments, contraception, and abortion; (3) will work with interested state medical societies and medical specialty societies to vigorously advocate for broad, equitable access to reproductive health services, including fertility treatments, fertility preservation, contraception, and abortion; (4) supports shared decision-making between patients and their physicians regarding reproductive healthcare; (5) opposes any effort to undermine the basic medical principle that clinical assessments, such as viability of the pregnancy and safety of the pregnant person, are determinations to be made only by healthcare professionals with their patients; (6) opposes the imposition of criminal and civil penalties or other retaliatory efforts, including adverse medical licensing actions and the termination of medical liability coverage or clinical privileges against patients, patient advocates, physicians, other healthcare workers, and health systems for receiving, assisting in, referring patients to, or providing reproductive health services; (7) will advocate for legal protections for patients who cross state lines to receive reproductive health services, including contraception and abortion, or who receive medications for contraception and abortion from across state lines, and legal protections for those that provide, support, or refer patients to these services; and (8) will advocate for legal protections for medical students and physicians who cross state lines to receive education in or deliver reproductive health services, including contraception and abortion.

(Res 028, A-22; Reaffirmed: Res 224, I-22; Modified: BOT Rep. 4, I-22; Appended: Res 317, I-22; Reaffirmation: A-23, Appended: Res 711, A-23)

G-605.009 “Establishing a Task Force to Preserve the Patient-Physician Relationship when Evidence-Based Appropriate Care is Banned or Restricted”

1. Our AMA will convene a task force of appropriate AMA councils and interested state and medical specialty societies, in conjunction with the AMA Center for Health Equity, and in consultation with relevant organizations, practices, government bodies, and impacted communities for the purpose of preserving the patient-physician relationship.

2. This task force, which will serve at the direction of our AMA Board of Trustees, will inform the Board to help guide organized medicine’s response to bans and restrictions on abortion, prepare for widespread criminalization of other evidence-based care, implement relevant AMA policies, and identify and create implementation-focused practice and advocacy resources on issues including but not limited to:

- a. Health equity impact, including monitoring and evaluating the consequences of abortion bans and restrictions for public health and the physician workforce and including making actionable recommendations to mitigate harm, with a focus on the disproportionate impact on under-resourced, marginalized, and minoritized communities;
- b. Practice management, including developing recommendations and educational materials for addressing reimbursement, uncompensated care, interstate licensure, and provision of care, including telehealth and care provided across state lines;
- c. Training, including collaborating with interested medical schools, residency and fellowship programs, academic centers, and clinicians to mitigate radically diminished training opportunities;
- d. Privacy protections, including best practice support for maintaining medical records privacy and confidentiality, including under HIPAA, for strengthening physician, patient, and clinic security measures, and countering law enforcement reporting requirements;
- e. Patient triage and care coordination, including identifying and publicizing resources for physicians and patients to connect with referrals, practical support, and legal assistance;
- f. Coordinating implementation of pertinent AMA policies, including any actions to protect against civil, criminal, and professional liability and retaliation, including criminalizing and penalizing physicians for referring patients to the care they need; and
- g. Anticipation and preparation, including assessing information and resource gaps and creating a blueprint for preventing or mitigating bans on other appropriate health care, such as gender

affirming care, contraceptive care, sterilization, infertility care, and management of ectopic pregnancy and spontaneous pregnancy loss and pregnancy complications.

3. Our American Medical Association will appoint an ad hoc committee or task force, composed of physicians from specialties who routinely provide gender-affirming care, payers, community advocates, and state Medicaid directors and/or insurance commissioners, to identify issues with physician payment and reimbursement for gender-affirming care and recommend solutions to address these barriers to care.

(Res 621, A-22; Appended: Res 816, I-23)

H-160.954 Criminalization of Medical Judgment

(1) Our AMA continues to take all reasonable and necessary steps to insure that medical decision-making exercised in good faith, does not become a violation of criminal law. (2) Henceforth our AMA opposes any future legislation which gives the federal government the responsibility to define appropriate medical practice and regulate such practice through the use of criminal penalties.

(Sub. Res. 223, I-93; Reaffirmed: Res. 227, I-98; Reaffirmed: Res. 237, A-99; Reaffirmed and Appended: Sub. Res. 215, I-99; Reaffirmation A-09; Reaffirmed: CEJA Rep. 8, A-09)

H-160.946 The Criminalization of Health Care Decision-making

The AMA opposes the attempted criminalization of health care decision-making especially as represented by the current trend toward criminalization of malpractice; it interferes with appropriate decision making and is a disservice to the American public; and will develop model state legislation properly defining criminal conduct and prohibiting the criminalization of health care decision-making, including cases involving allegations of medical malpractice, and implement an appropriate action plan for all components of the Federation to educate opinion leaders, elected officials and the media regarding the detrimental effects on health care resulting from the criminalization of health care decision-making.

(Sub. Res. 202, A-95; Reaffirmed: Res. 227, I-98; Reaffirmed: BOT Rep. 2, A-07; Reaffirmation A-09)

D-160.999 Opposition to Criminalizing Health Care Decisions

Our AMA will educate physicians regarding the continuing threat posed by the criminalization of healthcare decision-making and the existence of our model legislation "An Act to Prohibit the Criminalization of Healthcare Decision-Making."

(Res. 228, I-98; Reaffirmed: BOT Rep. 5, A-08)

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 218
(A-24)

Introduced by: Michigan
Subject: Designation of Descendants of Enslaved Africans in America
Referred To: Reference Committee B

1 Whereas, the designation of African American and Black has been expanded to include any
2 person who immigrated from Africa or Caribbean countries and obtained American citizenship at
3 any point in recent history; and
4
5 Whereas, since 2003 the United States Supreme Court, ruled the definition of "Black" included
6 every person who identifies as Black on a census form including people who check the box for
7 Black and any other racial or ethnic category such as white, Asian, and Hispanic or Latino, which
8 the federal government considers to be an ethnicity that can be of any race; and
9
10 Whereas, anyone Black or White who was born in Africa, immigrated to the United States, and
11 legally becomes an American citizen is considered an African American (i.e., Elon Musk); and
12
13 Whereas, the number of immigrants entering the United States legally rose from 3.3 million in the
14 1960s to a record 7.3 million in the 1980s; and during the 1990s, some 900,000 Black immigrants
15 came from the Caribbean; another 400,000 came from Africa; still many others came from Europe,
16 Pacific Rim, Arab and Asian countries; and
17
18 Whereas, today, nearly one in ten Black Americans is an immigrant or the child of an immigrant in
19 the United States; and
20
21 Whereas, the "Intelligent" survey found 34 percent of white students who applied to colleges and
22 universities falsely claimed they were a racial minority on their application; 81 percent of students
23 who faked minority status did so to improve their chances of getting accepted and 50 percent did it
24 to get minority-focused financial aid; and
25
26 Whereas, the "Intelligent" survey found that 3 in 4, or 77 percent, of white applicants who faked
27 minority status on their applications were accepted to those colleges; and
28
29 Whereas, Descendants of Enslaved Africans in America are the only people in U.S. history
30 classified as nonhuman and property, to undergo chattel slavery, and to be deemed by the U.S.
31 constitution 3/5 of a human, according to the 13th, 14th, and 15th amendments; and
32
33 Whereas, the Descendants of Enslaved Africans in America are the only people for whom it was
34 illegal to attend school or learn how to read and write in the United States; and
35
36 Whereas, it is important to disaggregate data to make sure everyone is recognized and that the
37 data influencing policies, programs, and solutions is accurate; therefore be it
38
39 RESOLVED, that our American Medical Association work with appropriate organizations including,
40 but not limited to, the Association of American Medical Colleges to adopt and define the term
41 Descendants of Enslaved Africans in America and separate it from the generic terms African
42 American and Black in glossaries and on medical school applications. (Directive to Take Action)

Fiscal Note: Moderate - between \$5,000 - \$10,000

Received: 4/23/2024

REFERENCES

Bibliography: Evidence of Non-African Americans Claiming to be African Americans for personal gain:

1. American Medical Association. New AMA policy recognizes racism as a public health threat. American Medical Association. November 16, 2020. Accessed January 16, 2023. <https://www.ama-assn.org/press-center/press-releases/new-ama-policy-recognizes-racism-public-health-threat>.
2. Vijay Chokal-Ingam. Why I faked being black for med school. New York Post. April 12, 2015, 5:05am. Viewed February 6, 2023
3. Leah Asmelash. A White professor says she has been pretending to be Black for her entire professional career. CNN. Updated 11:59 AM EDT, Fri September 4, 2020
4. Colleen Flaherty. More White Lies. Jessica Krug resigns from George Washington as a graduate student from her alma mater also admits to being dishonest about racial identity. Inside Higher Ed. September 10, 2020
5. Colleen Flaherty. Feeling the Need to Defend Your Credentials Why did Elizabeth Warren divulge her genetic test results, which show she is in fact part Native American, while simultaneously insisting that she's always been evaluated professionally as a white person? Inside Higher Ed. October 16, 2018
6. Colleen Flaherty. Passing in the Classroom. Academics weigh in on the curious case of Rachel Dolezal, a white woman who allegedly passed as a black instructor of African-American studies for five years. Inside Higher Ed. June 15, 2015
7. Scott Jaschik. Professor Answers Charges of Faking Cherokee Status. Inside Higher Ed. July 13, 2015
8. Wanda Thompson. How White Women On Instagram Are Profiting Off Black Women. Blackfishing. Paper Magazine. 14 November 2018. Internet February 6, 2023
9. Cambridge Advanced Learner's Dictionary & Thesaurus Â© Cambridge University Press. Cultural Appropriation: the act of taking or using things from a culture that is not your own, especially without showing that you understand or respect this culture.
10. Maha Ikram Cherid. "Ain't Got Enough Money to Pay Me Respect": Blackfishing, Cultural Appropriation, and the Commodification of Blackness. Maha Ikram Cherid https://orcid.org/0000-0002-2768-4698_maha_cherid@mail.mcgill.caView all authors and affiliations Volume 21, Issue 5 <https://doi.org/10.1177/15327086211029357> Internet February 6, 2023

Evidence of the invention of Race as a Matter of Politics and Not Science

1. Barzun, J (1965). Race: A Study in superstition. NY:Harper
2. Ben-Jochanan, Y. (1972). Cultural genocide in the black and African studies curriculum. NY: Alkebu-Lan Books
3. Benedict, R. (1959). Race: Science and Politics. NY: Viking
4. Biddis, M.D. (1970). Father of racist ideology: The social and political thought of Count Gobineau. NY: Weinriht and Talley
5. Chase, A. (1977). The Legacy of Malthus: The social costs of the new scientific racism. NY: Alfred A. Knopf
6. Gregory, D. (1971). No more Lies: The myth and reality of American history. NY: Harper and Row
7. Gossett, T. F. (1973). Race: The history of an idea in America. NY: Schoken
8. Hodges, J. L., Struckmann, D. K. and Trost, L. D. (1975). Cultural bases of racism and group oppression: An examination of traditional "Western" concepts, values and institutional structures which support racism, sexism and elitism Berkeley: Two Riders Press, Berkeley, CA 94704
9. Montagu, A. (1974) Man's most dangerous myth: The fallacy of race. NY
10. Stoddard, L (1971). The rising tide of color against white world supremacy. Westport, Connecticut: Negro University Press. (First published 1920)
11. Weinreich, M. (1946). Hitler's professors: The part of scholarship in Germany's crimes against the Jewish people. NY: Yiddish Scientific Institute-YIVO 12. Wobogo, V. (1976). Diop's two cradle theory and the origin of white racism. Black books Bulletin, 4(4), pp. 20-37

Definition of African American(s)

1. African Americans are an ethnic group consisting of Americans with partial or total ancestry from sub-Saharan Africa. The term "African American" generally denotes descendants of enslaved Africans who are from the United States (Ref)
2. The glossary that is available on the AAMC FACTS website, as well as the FACTS tables that display the full race/ethnicity response options does not include DOESAA: FACTS Glossary: <https://www.aamc.org/data-reports/students-residents/interactive-data/facts-glossary> Example FACTS Table with response options: <https://www.aamc.org/media/6046/download?attachment>
3. AAMC DATA FACTS TABLE 12-A of the freshman class acceptees for medical schools in the United States in 2021: 456 African Americans, who are not distinguished as immigrant or non-immigrant; 203 individuals indicating more than 1 Black or African American response, which implies an immigrant status or admixture; 33 "other Black or African American" which implies immigrant status.

RELEVANT AMA POLICY

Racism as a Public Health Threat H-65.952

1. Our AMA acknowledges that, although the primary drivers of racial health inequity are systemic and structural racism, racism and unconscious bias within medical research and health care delivery have caused and continue to cause harm to marginalized communities and society as a whole.
2. Our AMA recognizes racism, in its systemic, cultural, interpersonal, and other forms, as a serious threat to public health, to the advancement of health equity, and a barrier to appropriate medical care.

3. Our AMA encourages the development, implementation, and evaluation of undergraduate, graduate, and continuing medical education programs and curricula that engender greater understanding of: (a) the causes, influences, and effects of systemic, cultural, institutional, and interpersonal racism; and (b) how to prevent and ameliorate the health effects of racism.

4. Our AMA: (a) supports the development of policy to combat racism and its effects; and (b) encourages governmental agencies and nongovernmental organizations to increase funding for research into the epidemiology of risks and damages related to racism and how to prevent or repair them.

5. Our AMA will work to prevent and combat the influences of racism and bias in innovative health technologies.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 219
(A-24)

Introduced by: American College of Obstetricians and Gynecologists

Subject: Bundling for Maternity Care Services

Referred to: Reference Committee B

1 Whereas, maternal mortality in the US continues to rise, up from 861 deaths in 2020 to 1,205
2 deaths in 2021¹; and
3
4 Whereas, rates of severe maternal morbidity (SMM) continues to climb and of particular
5 significance, the increasing gap in SMM between the national average (88.2/10,000 in 2020)
6 and among Black mothers (139.0/10,000)²; and
7
8 Whereas, access to maternity care continues to decline, with 35.6 percent of counties classified
9 as “maternity care deserts” and only 45.4 percent of counties classified as having “full access”
10 to maternity care and 56 counties losing obstetric providers³; and
11
12 Whereas, state Medicaid programs and private commercial plans are developing Alternative
13 Payment Models and that inappropriately bundle community and wrap-around services under
14 the physician payment^{4,5}; and
15
16 Whereas, insurers are not recognizing separate billing for services such as immediate
17 postpartum long-acting reversible contraception, care coordination, transfers during labor,
18 increased time in delivery, screening, counseling and treatment for health-related social needs
19 or co-morbid conditions that increase pregnancy risk, postpartum care, and many other
20 services^{6,7}; and
21
22 Whereas, the American Medical Association opposes the incorrect use of CPT by insurers and
23 others (Improper Use of AMA-CPT by Carriers/Software Programs (H-70.954); and
24
25 Whereas, the AMA has several policies that call for advocacy to third party payers for
26 inappropriate bundling of services (D-70.983, H-70.983); and
27
28 Whereas, the AMA CPT instructions for use of the maternity global codes includes “services
29 normally provided in uncomplicated maternity cases include antepartum care, delivery, and
30 postpartum care” and that services for high-risk pregnancies and hospital stays more than 24
31 hours before delivery should be reported separately; therefore be it
32
33 RESOLVED, that our American Medical Association advocates for the separate payment of
34 services not accounted for in the valuation of the maternity global codes and opposes the
35 inappropriate bundling of related services. (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/23/2024

REFERENCES

1. Hoyert DL. Maternal mortality rates in the United States, 2021. NCHS Health E-Stats. 2023. DOI: <https://dx.doi.org/10.15620/cdc.124678>.
2. Hirai, A. Severe Maternal Morbidity: Trends and Disparities. Health Resources & Services Administration. Presentation to Advisory Committee on Infant and Maternal Mortality. March 20, 2023. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/infant-mortality/meetings/hirai-severe-maternal-morbidity.pdf>.
3. Brigrance, C., Lucas R., Jones, E., Davis, A., Oinuma, M., Mishkin, K. and Henderson, Z. (2022). Nowhere to Go: Maternity Care Deserts Across the U.S. (Report No. 3). March of Dimes. <https://www.marchofdimes.org/research/maternity-care-deserts-report.aspx>.
4. Centers for Medicare & Medicaid Services. Transforming Maternal Health (TMaH) Model. Available at: <https://portal.ct.gov/DSS/Health-And-Home-Care/HUSKY-Maternity-Bundle>.
5. Connecticut Department of Social Services. HUSKY Maternity Bundle. Available at: <https://portal.ct.gov/DSS/Health-And-Home-Care/HUSKY-Maternity-Bundle>.
6. Guiahi M. Immediate Postpartum Long-Acting Reversible Contraception: An Effective and Underutilized Strategy. *JAMA Netw Open*. 2022;5(10):e2238098. doi:10.1001/jamanetworkopen.2022.38098.
7. Geissler K, Ranchoff BL, Cooper MI, Attanasio LB. Association of Insurance Status With Provision of Recommended Services During Comprehensive Postpartum Visits. *JAMA Netw Open*. 2020 Nov 2;3(11):e2025095. doi: 10.1001/jamanetworkopen.2020.25095. PMID: 33170263; PMCID: PMC7656283.

RELEVANT AMA POLICY

H-70.954 Improper Use of AMA-CPT by Carriers/Software Programs

Our AMA: (1) continues to seek endorsement of Current Procedural Terminology (CPT) as the national coding standard for physician services; in collaboration with state and specialty societies, will urge the Secretary of HHS and CMS and all other payers to adopt CPT as the single uniform coding standard for physician services in all practice settings; and will oppose the incorrect use of CPT by insurers and others, taking necessary actions to insure compliance with licensing agreements, which include provisions for termination of the agreement;

(2) will work with the American Academy of Pediatrics and other specialty societies to support state and federal legislation requiring insurers to follow the coding as defined in the Current Procedural Terminology Manual and interpreted by the CPT Assistant for all contracts in both the public and private sectors, as long as the CPT process is simple, user friendly, and does not undergo frequent changes; and

(3) seeks legislation and/or regulation to ensure that all insurance companies and group payers recognize all published CPT codes including modifiers.

D-70.983 Inappropriate Bundling of Medical Services by Third Party Payers

Our AMA will: (1) continue to promote its Private Sector Advocacy activities and initiatives associated with the collection of information on third party payer modifier acceptance and inappropriate bundling practices;

(2) use the data collected as part of its Private Sector Advocacy information clearinghouse to work, in a legally appropriate manner, with interested state medical associations and national medical specialty societies to identify and address inappropriate third party payer coding and reimbursement practices, including inappropriate bundling of services, rejection of CPT modifiers, and denial and delay of payment;

(3) continue to monitor the class action lawsuits of state medical associations, and provide supportive legal and technical resources, as appropriate;

4) develop model state legislation to prohibit third party payers from bundling services inappropriately by encompassing individually coded services under other separately coded services unless specifically addressed in CPT guidelines, or unless a physician has been specifically advised of such bundling practices at the time of entering into a contractual agreement with the physician;

(5) urge state medical associations to advocate the introduction and enactment of AMA model state legislation on claims bundling by their state legislatures; and.

(6) highlight its Private Sector Advocacy document on bundling and downcoding, the related section of the AMA Model Managed Care Contract, and its advocacy initiatives on its web site and other communications measures to assure that physicians are aware of the AMA's advocacy on this issue.

H-70.937 Bundling and Downcoding of CPT Codes

Our AMA: (1) vigorously opposes the practice of unilateral, arbitrary recoding and/or bundling by all payers;

(2) makes it a priority to establish national standards for the appropriate use of CPT codes, guidelines, and modifiers and to advocate the adoption of these standards;

(3) formulates a national policy for intervention with carriers or payers who use unreasonable business practices to unilaterally recode or inappropriately bundle physician services, and support legislation to accomplish this; and

(4) along with medical specialty societies, calls on its members to identify to our AMA specific CPT code bundling problems by payers in their area and that our AMA develop a mechanism for assisting our members in dealing with these problems with payers.

H-70.949 Bundling of Codes for Physician Services

Our AMA: (1) advocates and will take steps to ensure that public and private payers do not bundle services inappropriately by encompassing individually coded services under other separately coded services unless specifically addressed in CPT guidelines; and (2) will enhance and fully coordinate its activities to prevent the inappropriate bundling of CPT codes (and other coding systems for supplies, injections, etc) used for payment by both public and private payers.

H-70.962 Changes in the Bundling of Medical Services by Managed Care Plans

Our AMA will introduce or support legislation or regulation that would require that managed care plans be monitored and prohibited from the arbitrary and inappropriate bundling of services to reduce payment to participating physicians; and that the medically indicated patient services such as consultations and diagnostic procedures provided by physicians on the same day be paid on a separate basis in conformity with the AMA Current Procedural Terminology (CPT) coding policy and not inappropriately bundled as they currently are by managed care plans.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 220
(A-24)

Introduced by: California

Subject: Restorative Justice for the Treatment of Substance Use Disorders

Referred to: Reference Committee B

1 Whereas, Restorative Justice (RJ) is a correctional model featuring relationship building,
2 rehabilitation, and community empowerment. Examples of Restorative Justice models include
3 Restorative Community Conferencing (RCC) and Drug Treatment Courts, which have reduced
4 recidivism, cut costs (one RCC estimates a cost savings of \$18,500 per case per year), and
5 promoted familial connectedness, particularly among people of color; and
6

7 Whereas, police brutality, racist sentencing practices, and implicit biases that created health
8 inequities have contributed to the US having the highest incarceration rate in the world, with one
9 in three black men currently incarcerated; and
10

11 Whereas, the “war on drugs” prioritized punishment over treatment for non-violent drug
12 offenses, leading to an eight-fold increase in incarceration to 400,000 people by 1997. The Anti-
13 Drug Abuse Act diverted \$1.7 billion away from education, drug treatment, and research
14 towards law enforcement and now the U.S. spends \$12 billion annually on the war on drugs;
15 and
16

17 Whereas, during the crack cocaine epidemic of the mid 1980s where there were an estimated
18 1.6 million users, the black community was devastated because of an inequitable response by
19 law enforcement and mass incarceration due to racist sentencing practices, such as unequal
20 mandatory minimum sentences for crack cocaine - as 80% of crack users were black (due to its
21 affordability) as compared to more expensive powdered cocaine used preferentially by white
22 users; and
23

24 Whereas, injected powdered cocaine delivers a fast, intense high similar to crack, and has been
25 found to have the highest risk of overdose and death; and
26

27 Whereas, the U.S. Sentencing Commission reported in 1995 that 52% of all crack users were
28 white and 38% were black. However, only 4.1% of those sentenced for crack offenses were
29 White and 88% were Black. Prisoners have a higher rate of suicide, self harm, violence, HIV,
30 and other infectious diseases and public health experts recommend that substance abuse
31 impacts are best addressed through community resources such as family counseling, and
32 mental health programs; and
33

34 Whereas, black patients are less likely to receive pain medication and decreasing opiate
35 prescriptions increases the use of fentanyl and heroin. Conversely, increasing services such as
36 medication-assisted addiction treatment, needle exchange, naloxone availability, and
37 psychosocial treatment improve outcomes; and
38

39 Whereas, the U.S. Office of National Drug Control Policy estimated that in 1996, 3.6 million
40 people required medical treatment for their addiction, but only one million were receiving

1 treatment because 19% of the \$13.5 billion budget was dedicated to drug treatment as
2 compared to 58% for criminal justice and thus, the crack cocaine epidemic caused a multitude
3 of negative health outcomes including a four-fold increase in emergency room visits, as well as
4 a significant increase in Sexually Transmitted Diseases; and
5

6 Whereas, some minor steps in line with “Restorative Justice” have been taken, such as The Fair
7 Sentencing Act of 2010 and The First Step Act of 2018 which applied the Fair Sentencing Act
8 retroactively, and reduced the sentencing disparity from 100:1 to 18:1; and
9

10 Whereas, by contrast, the opioid epidemic, which has predominantly affected white individuals,
11 has been combatted using a “Disease Model” featuring a reduction in stigmatizing language, the
12 expenditure of \$59 million by the U.S. Department of Justice for community health interventions,
13 and sentencing individuals to rehabilitation as opposed to incarceration; and
14

15 Whereas, in 2019 alone, the Centers for Disease Control and Prevention (CDC) granted \$475
16 million for opioid overdose prevention and has (1) funded research to identify effective
17 strategies for combating the epidemic, (2) worked with health departments and community-
18 based organizations to implement evidence-based prevention strategies, (3) created an
19 evidence-based “CDC Guideline for Prescribing Opioids for Chronic Pain” and implemented
20 quality-improvement measures, (4) created the “Rx Awareness” campaign to educate users on
21 the risks of opioid use, and (5) partnered with first responders, including police, with an
22 emphasis on saving lives through naloxone administration rather than incarceration; and
23 Whereas, approaches, such as the CDC models for the opioid epidemic, are examples of the
24 application of the Restorative Justice model and can be applied retroactively to those negatively
25 impacted by the crack cocaine epidemic; therefore be it
26

27 RESOLVED, that our American Medical Association (1) continues to support the right of
28 incarcerated individuals to receive appropriate care for substance use disorders, (2) supports
29 providing incentives for incarcerated individuals to overcome substance use disorders, such as
30 participation in treatment as a condition for early release, and (3) supports providing access to
31 social services and family therapy during and after incarceration (New HOD Policy); and be it
32 further
33

34 RESOLVED, that our AMA (1) recognizes that criminalization of substance use
35 disproportionately impacts minoritized and disadvantaged communities due to structural racism
36 and implicit bias, (2) acknowledges inequitable sentencing structures, such as towards crack
37 cocaine versus opioids, have contributed to unjust imprisonments, and (3) supports implicit bias
38 and antiracism training for medical professionals working in correctional facilities. (New HOD
39 Policy)
40

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/23/2024

RELEVANT AMA POLICY

H-95.931 AMA Support for Justice Reinvestment Initiatives

Our American Medical Association supports justice reinvestment initiatives aimed at improving risk assessment tools for screening and assessing individuals for substance use disorders and mental health issues, expanding jail diversion and jail alternative programs, and increasing access to reentry and treatment programs. [Reaffirmed: CSAPH Rep. 4, I-23, Res. 205, A-16.]

H-430.986 Health Care While Incarcerated

1. Our American Medical Association advocates for adequate payment to health care providers, including primary care and mental health, and addiction treatment professionals, to encourage improved access to comprehensive physical and behavioral health care services to juveniles and adults throughout the incarceration process from intake to re-entry into the community.
2. Our AMA advocates and requires a smooth transition including partnerships and information sharing between correctional systems, community health systems and state insurance programs to provide access to a continuum of health care services for juveniles and adults in the correctional system, including correctional settings having sufficient resources to assist incarcerated persons' timely access to mental health, drug and residential rehabilitation facilities upon release.
3. Our AMA encourages state Medicaid agencies to accept and process Medicaid applications from juveniles and adults who are incarcerated.
4. Our AMA encourages state Medicaid agencies to work with their local departments of corrections, prisons, and jails to assist incarcerated juveniles and adults who may not have been enrolled in Medicaid at the time of their incarceration to apply and receive an eligibility determination for Medicaid.
5. Our AMA advocates for states to suspend rather than terminate Medicaid eligibility of juveniles and adults upon intake into the criminal legal system and throughout the incarceration process, and to reinstate coverage when the individual transitions back into the community.
6. Our AMA advocates for Congress to repeal the "inmate exclusion" of the 1965 Social Security Act that bars the use of federal Medicaid matching funds from covering healthcare services in jails and prisons.
7. Our AMA advocates for Congress and the Centers for Medicare & Medicaid Services (CMS) to revise the Medicare statute and rescind related regulations that prevent payment for medical care furnished to a Medicare beneficiary who is incarcerated or in custody at the time the services are delivered.
8. Our AMA advocates for necessary programs and staff training to address the distinctive health care needs of women and adolescent females who are incarcerated, including gynecological care and obstetrics care for individuals who are pregnant or postpartum.
9. Our AMA will collaborate with state medical societies, relevant medical specialty societies, and federal regulators to emphasize the importance of hygiene and health literacy information sessions, as well as information sessions on the science of addiction, evidence-based addiction treatment including medications, and related stigma reduction, for both individuals who are incarcerated and staff in correctional facilities.
10. Our AMA supports:
 - a. linkage of those incarcerated to community clinics upon release in order to accelerate access to comprehensive health care, including mental health and substance use disorder services, and improve health outcomes among this vulnerable patient population, as well as adequate funding;
 - b. the collaboration of correctional health workers and community health care providers for those transitioning from a correctional institution to the community;
 - c. the provision of longitudinal care from state supported social workers, to perform foundational check-ins that not only assess mental health but also develop lifestyle plans with newly released people; and
 - d. collaboration with community-based organizations and integrated models of care that support formerly incarcerated people with regard to their health care, safety, and social determinant of health needs, including employment, education, and housing.

11. Our AMA advocates for the continuation of federal funding for health insurance benefits, including Medicaid, Medicare, and the Children's Health Insurance Program, for otherwise eligible individuals in pre-trial detention.
12. Our AMA advocates for the prohibition of the use of co-payments to access healthcare services in correctional facilities.
13. Our AMA encourages the following qualifications for the Director and Assistant Director of the Health Services Division within the Federal Bureau of Prisons:
 - a. MD or DO, or an international equivalent degree with at least five years of clinical experience at a Bureau of Prisons medical facility or a community clinical setting;
 - b. knowledge of health disparities among Black, American Indian and Alaska Native, and people of color, including the pathophysiological basis of the disease process and the social determinants of health that affect disparities; and
 - c. knowledge of the health disparities among individuals who are involved with the criminal justice system.
14. Our AMA will collaborate with interested parties to promote the highest quality of health care and oversight for those who are involved in the criminal justice system by advocating for health administrators and executive staff to possess credentials and experience comparable to individuals in the community in similar professional roles

[Appended: Res. 429, A-23; Appended: Res. 244, A-23; Modified: Res. 127, A-22; Reaffirmed: Res. 229, A-21; Modified: Res. 503, A-21; Modified: Res. 216, I-19; Appended: Res 420, A-19; Appended: Res. 417, A-19; CMS Rep. 02, I-16.]

H-430.997 Standards of Care for Inmates of Correctional Facilities

Our AMA believes that correctional and detention facilities should provide medical, psychiatric, and substance use disorder care that meets prevailing community standards, including appropriate referrals for ongoing care upon release from the correctional facility in order to prevent recidivism.
[Modified: CSAPH Rep. 1, A-22; Reaffirmation: I-12; Modified in lieu of Res. 502, A-12; Reaffirmation I-09; Reaffirmed: CEJA Rep. 8, A-09; Amended: Res. 416, I-99; Reaffirmed by CLRPD Rep. 3 – I-94; Res 60, A-84.]

H-95.922 Substance Use and Substance Use Disorders

Our AMA: (1) will continue to seek and participate in partnerships designed to foster awareness and to promote screening, diagnosis, and appropriate treatment of substance misuse and substance use disorders;

(2) will renew efforts to: (a) have substance use disorders addressed across the continuum of medical education; (b) provide tools to assist physicians in screening, diagnosing, intervening, and/or referring patients with substance use disorders so that they have access to treatment; (c) develop partnerships with other organizations to promote national policies to prevent and treat these illnesses, particularly in adolescents and young adults; and (d) assist physicians in becoming valuable resources for the general public, in order to reduce the stigma and enhance knowledge about substance use disorders and to communicate the fact that substance use disorder is a treatable disease; and

(3) will support appropriate federal and state legislation that would enhance the prevention, diagnosis, and treatment of substance use disorders.

[Reaffirmed: CSAPH Rep. 01, A-23; Reaffirmed: BOT Rep. 14, I-20; CSAPH Rep. 01, A-18]

H-95.975 Substance Use Disorders as a Public Health Hazard

Our AMA: (1) recognizes that substance use disorders are a major public health problem in the United States today and that its solution requires a multifaceted approach;

(2) declares substance use disorders are a public health priority;

(3) supports taking a positive stance as the leader in matters concerning substance use disorders, including addiction;

(4) supports studying innovative approaches to the elimination of substance use disorders and their resultant street crime, including approaches which have been used in other nations; and
(5) opposes the manufacture, distribution, and sale of substances created by chemical alteration of illicit substances, herbal remedies, and over-the-counter drugs with the intent of circumventing laws prohibiting possession or use of such substances.

[Reaffirmed: CSAPH Rep. 01, A-19; Modified and Reaffirmed: CSAPH Rep. 1, A-09; Reaffirmed: CSAPH Rep. 1, A-09; Reaffirmed: Sunset Rep., I-99; Appended: Sub. Res. 401; Res. 7, I-89.]

D-95.962 Enhanced Funding for and Access to Outpatient Addiction Rehabilitation

Our AMA will advocate for: (1) the expansion of federal grants in support of treatment for a substance use disorder to states that are conditioned on that state's adoption of law and/or regulation that prohibit drug courts, recovery homes, sober houses, correctional settings, and other similar programs from denying entry or ongoing care if a patient is receiving medication for an opioid use disorder or other chronic medical condition; and (2) sustained funding to states in support of evidence-based treatment for patients with a substance use disorder and/or co-occurring mental disorder, such as that put forward by the American Society of Addiction Medicine, American Academy of Addiction Psychiatry, American Psychiatric Association, American Academy of Child and Adolescent Psychiatry and other professional medical organizations. [BOT Rep. 14, I-20]

H-430.987 Medications for Opioid Use Disorder in Correctional Facilities

1. Our AMA endorses: (a) the medical treatment model of employing medications for opioid use disorder (OUD) as the standard of care for persons with OUD who are incarcerated; and (b) medications for persons with OUD who are incarcerated, an endorsement in collaboration with relevant organizations including but not limited to the American Society of Addiction Medicine and the American Academy of Addiction Psychiatry.

2. Our AMA advocates for legislation, standards, policies and funding that require correctional facilities to increase access to evidence-based treatment of OUD, including initiation and continuation of medications for OUD, in conjunction with psychosocial treatment when desired by the person with OUD, in correctional facilities within the United States and that this apply to all individuals who are incarcerated, including individuals who are pregnant, postpartum, or parenting.

3. Our AMA advocates for legislation, standards, policies, and funding that require correctional facilities within the United States to work in ongoing collaboration with addiction treatment physician-led teams, case managers, social workers, and pharmacies in the communities where patients, including individuals who are pregnant, postpartum, or parenting, are released to offer post-incarceration treatment plans for OUD, including education, medication for addiction treatment and counseling, and medication for preventing overdose deaths, including naloxone (or any other medication that is approved by the United States Food and Drug Administration for the treatment of an opioid overdose), and help ensure post-incarceration medical coverage and accessibility to mental health and substance use disorder treatments, that include medication and behavioral health and social supports for addiction treatment.

4. Our AMA advocates for all correctional facilities to use a validated screening tool to identify opioid withdrawal and take steps to determine potential need for treatment for OUD and opioid withdrawal syndrome for all persons upon entry.

[Modified: Res. 503, A-21; Appended: Res. 223, I-17; Reaffirmed: CSAPH Rep. 1, A-15; Res. 443, A-05.]

D-405.970 Racism - A Threat to Public Health

Our American Medical Association advocates for the creation of an International Classification of Diseases (ICD) code for patients presenting with conditions related to experiencing racism (including systemic racism and unconscious bias), a code that will provide physicians with a tool to document the clinical impact of racism, and capture the data needed to help provide more effective patient care.

[Modified: Res. 503, A-21; Appended: Res. 223, I-17; Reaffirmed: CSAPH Rep. 1, A-15; Res. 443, A-05]

H-65.952 Racism as a Public Health Threat

1. Our AMA acknowledges that, although the primary drivers of racial health inequity are systemic and structural racism, racism and unconscious bias within medical research and health care delivery have caused and continue to cause harm to marginalized communities and society as a whole.

2. Our AMA recognizes racism, in its systemic, cultural, interpersonal, and other forms, as a serious threat to public health, to the advancement of health equity, and a barrier to appropriate medical care.

3. Our AMA encourages the development, implementation, and evaluation of undergraduate, graduate, and continuing medical education programs and curricula that engender greater understanding of: (a) the causes, influences, and effects of systemic, cultural, institutional, and interpersonal racism; and (b) how to prevent and ameliorate the health effects of racism.
4. Our AMA: (a) supports the development of policy to combat racism and its effects; and (b) encourages governmental agencies and nongovernmental organizations to increase funding for research into the epidemiology of risks and damages related to racism and how to prevent or repair them.
5. Our AMA will work to prevent and combat the influences of racism and bias in innovative health technologies.

[Modified: Speakers Rep., A-22; Reaffirmed: Res. 013, A-22; Res. 5, I-20]

H-65.943 Redressing the Harms of Misusing Race in Medicine

1. Our American Medical Association recognizes the exacerbation of health and economic inequities due to race-based algorithms as a manifestation of racism within the medical field.
2. Our AMA will revise the AMA Guides to the Evaluation of Permanent Impairment, in accordance with existing AMA policy on race as a social construct and national standards of care, to modify recommendations that perpetuate racial essentialism or race-based medicine.
3. Our AMA advocates for and promotes racism-conscious, reparative, community engaged interventions at the health system, organized medical society, local, and federal levels which seek to identify, evaluate, and address the health, economic, and other consequences of structural racism in medicine.

[Modified: Speakers Rep., A-22, Reaffirmed: Res. 013, A-22, Res. 5, I-20.]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 221
(A-24)

Introduced by: California

Subject: Reforming Medicare Part B Drug Reimbursement to Promote Patient
Affordability and Physician Practice Sustainability

Referred to: Reference Committee B

1 Whereas, the skyrocketing cost of drugs is a key driver of U.S. healthcare costs; In 2021,
2 Medicare spent \$215B and \$33B on Part D and Part B drugs respectively, with Part B clinically-
3 administered drugs costs rising at an average rate of 9.2% annually from 2008-2021;^{1,2} and
4

5 Whereas, Medicare Part B reimburses for Part B drugs under the “Buy and Bill” method, in
6 which healthcare systems or physicians purchase, stock, maintain inventory for and administer
7 drugs, and are reimbursed at an amount equal to the Average Sales Price (ASP) of the drug
8 plus 6% of the ASP;^{3,4} and
9

10 Whereas, multiple factors contribute to the high cost of Part B drugs, including longer patent
11 exclusivity periods, lack of market competition and generic alternatives, and historical prohibition
12 of Medicare in negotiating drug prices; and
13

14 Whereas, the “Buy and Bill” reimbursement structure which ties reimbursement directly to drug
15 prices disincentivizes healthcare systems or physicians to choose the lowest-cost drugs;⁵ and
16

17 Whereas, Part B drugs have high levels of patient cost-sharing, as patients are charged a
18 coinsurance of 20% of the cost of the drug rather than a fixed copay;⁶ and
19

20 Whereas, more than half of patients with a chronic illness are in medical debt, and 25% of
21 cancer patients experience eviction, home foreclosure or bankruptcy;⁷ and
22

23 Whereas, The Inflation Reduction Act authorized Medicare to begin drug price negotiations for
24 Part B drugs in 2026, with these prices taking effect in 2028;⁸ and
25

26 Whereas, while lower drug prices will undoubtedly improve affordability for patients, as noted in
27 an AMA Letter to CMS in 2018⁹, tying reimbursement to the ASP over time as prices drop “may
28 no longer be sufficient to cover the administrative costs to the practice”, threatening practice
29 viability and therefore patient access to care; and
30

31 Whereas, ASP-based Medicare reimbursement for physicians has a six-month lag period,
32 contributing to the financial vulnerability of small/medium-sized physician practices, practices in
33 rural and/or underserved areas, and practices serving a significant proportion of Medicare
34 patients;¹⁰ and
35

36 Whereas, While the administration of Part B drugs is most prevalent in the fields of oncology,
37 rheumatology, ophthalmology, dermatology and gastroenterology, this issue affects all
38 physicians serving Medicare patients, as the anticipated billions saved annually through drug
39 price negotiations could be reappropriated towards improving physician reimbursement across-
40 the-board; therefore be it

- 1 RESOLVED, that our American Medical Association support the creation of a new
2 reimbursement model for Part B drugs that 1) Disentangles reimbursement from the drug price,
3 or any weighted market average of the drug price, by reimbursing physicians for the actual cost
4 of the drug, and 2) Ensures adequate compensation for the cost of acquisition, inventory,
5 storage, and administration of clinically-administered drugs that is based on physician costs, not
6 a percent of the drug price (New HOD Policy); and be it further
7
8 RESOLVED, that our AMA maintain the principles that any revised Part B reimbursement
9 models should promote practice viability, especially for small physician practices, practices in
10 rural and/or underserved areas, and practices with a significant proportion of Medicare patients,
11 to promote continued treatment access for patients. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 4/23/2024

REFERENCES

1. A Small Number of Drugs Account for a Large Share of Medicare Part D Spending. Kaiser Family Foundation. Jul 12, 2023 <https://www.kff.org/medicare/press-release/10-prescription-drugs-accounted-for-48-billion-in-medicare-part-d-spending-in-2021-or-more-than-one-fifth-of-part-d-spending-that-year/#:~:text=In%202021%2C%20Part%20D%20covered.manufacturers%20to%20pharmacy%20benefit%20managers>
2. Medicare Payment Advisory Commission, "Prescription Drugs." *Health Care Spending and the Medicare Program: Data Book*, July 2021. https://www.medpac.gov/wp-content/uploads/2021/10/July2021_MedPAC_DataBook_Sec10_SEC.pdf.
3. Ginsburg P, Lieberman SM. Medicare payment for physician-administered (Part B) drugs. Brookings. Published February 10, 2021. Accessed March 21, 2022. <https://www.brookings.edu/blog/usc-brookings-schaeffer-on-health-policy/2021/02/10/medicare-payment-for-physician-administered-part-b-drugs/>
4. Ginsburg P, Brandt C, Lieberman SM. The use of vendors in Medicare Part B drug payment. Brookings. Published August 2, 2019. Accessed March 21, 2022. <https://www.brookings.edu/blog/usc-brookings-schaeffer-on-health-policy/2019/08/02/the-use-of-vendors-in-medicare-part-b-drug-payment/>
5. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on Ensuring Patient Access to Affordable Drug Therapies; Nass SJ, Madhavan G, Augustine NR, editors. *Making Medicines Affordable: A National Imperative*. Washington (DC): National Academies Press (US); 2017:3/73-124. Accessed April 16, 2024.3, Factors Influencing Affordability. <https://www.ncbi.nlm.nih.gov/books/NBK493090>
6. Medicare Part B Drugs: Cost Implications for Beneficiaries in Traditional Medicare and Medicare Advantage. Kaiser Family Foundation. Mar 15, 2022 <https://www.kff.org/medicare/issue-brief/medicare-part-b-drugs-cost-implications-for-beneficiaries-in-traditional-medicare-and-medicare-advantage/>
7. In America, Cancer Patients Endure Debt on Top of Disease. Kaiser Health News. July 9, 2022 <https://kffhealthnews.org/news/article/in-america-cancer-patients-endure-debt-on-top-of-disease/>
8. Medicare Part B Drugs: Trends in Spending and Utilization, 2008-2021. Assistant Secretary for Planning and Evaluation Issue Brief. June 9, 2023 <https://aspe.hhs.gov/sites/default/files/documents/fb7f647e32d57ce4672320b61a0a1443/aspe-medicare-part-b-drug-pricing.pdf>
9. AMA Letter: Advance Notice of Proposed Rulemaking: Medicare Program; International Pricing Index Model for Medicare Part B Drugs. December 20, 2018 <https://searchlf.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2F2018-12-20-Letter-to-Verma-re-Comments-on-IPI-Model-ANPRM.pdf>
10. Polite B, Conti RM, Ward JC. Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist. *Am Soc Clin Oncol Educ Book*. 2015;e75-e80. doi:10.14694/EdBook_AM.2015.35.e75

RELEVANT AMA POLICY

H-330.888 Exempt Physician-Administered Drugs from Medicare Sequestration

Our AMA supports passage of federal legislation 1) exempting payments for biologics and other drugs provided under Medicare Part B from sequestration cuts, and 2) reimbursing providers for reductions in payments for biologics and other drugs furnished under Medicare Part B on or after April 1, 2013. [Reaffirmed: Res. 212, I-21; Reaffirmation A-15; Res. 235, A-13]

D-330.960 Cuts in Medicare Outpatient Infusion Services

1. Our AMA will actively support efforts to seek legislation to ensure that Medicare payments for drugs fully cover the physician's acquisition, inventory and carrying cost and that Medicare payments for drug administration and related services are adequate to ensure continued patient access to outpatient infusion services.

2. Our AMA will continue strong advocacy efforts working with relevant national medical specialty societies to ensure adequate physician payment for Part B drugs and patient access to biologic and pharmacologic agents.

[Reaffirmation: I-18; Reaffirmed: CMS Rep. 10, A-16; Reaffirmation A-15; Reaffirmed and Modified: CMS Rep. 3, I-08; Res. 926, I-03]

D-330.904 Opposition to the CMS Medicare Part B Drug Payment Model

1. Our AMA will request that the Centers for Medicare & Medicaid Services (CMS) withdraw the proposed Part B Drug Payment Model.

2. Our AMA will support and actively work to advance Congressional action to block the proposed Part B Drug Payment Model if CMS proceeds with the proposal.

3. Our AMA will advocate against policies that are likely to undermine access to the best course of treatment for individual patients and oppose demonstration programs that could lead to lower quality of care and do not contain mechanisms for safeguarding patients.

4. Our AMA will advocate for ensuring that CMS solicits and takes into consideration feedback from patients, physicians, advocates, or other stakeholders in a way that allows for meaningful input on any Medicare coverage or reimbursement policy that impacts patient access to medical therapies, including policies on coverage and reimbursement.

[Res. 241, A-16]

H-110.983 Medicare Part B Competitive Acquisition Program (CAP)

Our AMA will advocate that any revised Medicare Part B Competitive Acquisition Program meet the following standards to improve the value of the program by lowering the cost of drugs without undermining quality of care:

(1) it must be genuinely voluntary and not penalize practices that choose not to participate;

(2) it should provide supplemental payments to reimburse for costs associated with special handling and storage for Part B drugs;

(3) it must not reduce reimbursement for services related to provision/administration of Part B drugs, and reimbursement should be indexed to an appropriate healthcare inflation rate;

(4) it should permit flexibility such as allowing for variation in orders that may occur on the day of treatment, and allow for the use of CAP-acquired drugs at multiple office locations;

(5) it should allow practices to choose from multiple vendors to ensure competition, and should also ensure that vendors meet appropriate safety and quality standards;

(6) it should include robust and comprehensive patient protections which include preventing delays in treatment, helping patients find assistance or alternative payment arrangements if they cannot meet the cost-sharing responsibility, and vendors should bear the risk of non-payment of patient copayments in a way that does not penalize the physician;

(7) it should not allow vendors to restrict patient access using utilization management policies such as step therapy; and

(8) it should not force disruption of current systems which have evolved to ensure patient access to necessary medications.

[Reaffirmed: CMS Rep. 4, A-22; Reaffirmed: CMS Rep. 4, I-19; Res. 216, I-18]

H-110.987 Pharmaceutical Costs

1. Our AMA encourages Federal Trade Commission (FTC) actions to limit anticompetitive behavior by pharmaceutical companies attempting to reduce competition from generic manufacturers through manipulation of patent protections and abuse of regulatory exclusivity incentives.

2. Our AMA encourages Congress, the FTC and the Department of Health and Human Services to monitor and evaluate the utilization and impact of controlled distribution channels for prescription pharmaceuticals on patient access and market competition.

3. Our AMA will monitor the impact of mergers and acquisitions in the pharmaceutical industry.

4. Our AMA will continue to monitor and support an appropriate balance between incentives based on appropriate safeguards for innovation on the one hand and efforts to reduce regulatory and statutory barriers to competition as part of the patent system.
 5. Our AMA encourages prescription drug price and cost transparency among pharmaceutical companies, pharmacy benefit managers and health insurance companies.
 6. Our AMA supports legislation to require generic drug manufacturers to pay an additional rebate to state Medicaid programs if the price of a generic drug rises faster than inflation.
 7. Our AMA supports legislation to shorten the exclusivity period for biologics.
 8. Our AMA will convene a task force of appropriate AMA Councils, state medical societies and national medical specialty societies to develop principles to guide advocacy and grassroots efforts aimed at addressing pharmaceutical costs and improving patient access and adherence to medically necessary prescription drug regimens.
 9. Our AMA will generate an advocacy campaign to engage physicians and patients in local and national advocacy initiatives that bring attention to the rising price of prescription drugs and help to put forward solutions to make prescription drugs more affordable for all patients.
 10. Our AMA supports: (a) drug price transparency legislation that requires pharmaceutical manufacturers to provide public notice before increasing the price of any drug (generic, brand, or specialty) by 10% or more each year or per course of treatment and provide justification for the price increase; (b) legislation that authorizes the Attorney General and/or the Federal Trade Commission to take legal action to address price gouging by pharmaceutical manufacturers and increase access to affordable drugs for patients; and (c) the expedited review of generic drug applications and prioritizing review of such applications when there is a drug shortage, no available comparable generic drug, or a price increase of 10% or more each year or per course of treatment.
 11. Our AMA advocates for policies that prohibit price gouging on prescription medications when there are no justifiable factors or data to support the price increase.
 12. Our AMA will provide assistance upon request to state medical associations in support of state legislative and regulatory efforts addressing drug price and cost transparency.
 13. Our AMA supports legislation to shorten the exclusivity period for FDA pharmaceutical products where manufacturers engage in anti-competitive behaviors or unwarranted price escalations.
 14. Our AMA supports legislation that limits Medicare annual drug price increases to the rate of inflation.
- [Reaffirmed: Res. 801, I-23; Reaffirmed in lieu of: Res. 810, I-22; Appended: Res. 113, I-21; Reaffirmed: Res. 105, A-19; Appended: BOT Rep. 14, A-19; Appended: CMS Rep. 07, A-18; Reaffirmed: BOT Rep. 14, A-18; Appended: Alt. Res. 806, I-17; Modified: Speakers Rep. 01, A-17; Reaffirmed in lieu of Res. 107, A-17; Appended: Res. 201 A-17; Reaffirmed in lieu of: Res. 817, I-16; CMS Rep. 2, I-15]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 222
(A-24)

Introduced by: Resident and Fellow Section

Subject: Studying Avenues for Parity in Mental Health & Substance Use Coverage

Referred to: Reference Committee B

1 Whereas, the Mental Health Parity Act passed in 1996 and was the first law to impose any sort
2 of parity between mental and physical health care, with an imposition on the annual or lifetime
3 dollar limits on mental health benefits being any less favorable than those imposed on
4 medical/surgical benefits¹; and

5
6 Whereas, the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act
7 of 2008 took this concept further by preventing group health plans and health insurance insurers
8 from imposing less favorable benefit limitations for mental health or substance use disorder
9 benefits than on medical/surgical benefits¹; and

10
11 Whereas, prior to and since the inception of these federal laws, our AMA has been advocating
12 for parity in insurance benefits for those receiving mental health and substance use care (H-
13 185.974, H-168.888); and

14
15 Whereas, despite violations being found in every investigation of insurance companies, as well
16 as multiple AMA policies supporting parity and calling for compliance with parity laws (D-
17 180.998, H-185.916, H-185.974), parity still does not exist and health plans are not remotely
18 close to following parity laws regarding mental health/substance use benefits^{2,3}; and

19
20 Whereas, both the 2022 DOL/HHS/IRS Report to Congress & July 2023 MHPAEA Comparative
21 Analysis Report to Congress showed widespread violations and repeated failure of health plans
22 to provide sufficient, accurate information to regulators to perform the comparative analyses
23 required by law^{2,3}; and

24
25 Whereas, a 2023 Robert Wood Johnson Foundation Report found that cost-sharing was
26 decreased for mental health when compared to primary care visits, such that 17% of plans
27 required that a deductible be satisfied for mental health visits but not primary care visits, and
28 that despite reporting these deficits year after year, they remain unchanged^{4,5}; and

29
30 Whereas, in Georgia, 24 health plans provided no information to the state Department of
31 Insurance (DOI) to perform its statutorily-required comparative analyses and of the 28 plans that
32 did submit information, none submitted sufficient information for the DOI to perform the
33 comparative analyses⁶; and

34
35 Whereas, lack of compliance occurs at both the federal and the state level, without significant
36 consequences including continuing to allow insurer participation in state-delivered insurance
37 plans⁶; therefore be it

38
39 RESOLVED, that our American Medical Association study potential penalties to insurers for not
40 complying with mental health and substance use parity laws. (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/24/2024

REFERENCES:

1. The Mental Health Parity and Addiction Equity Act (MHPAEA). CMS.gov. September 6, 2023. Accessed September 25, 2023. <https://www.cms.gov/marketplace/private-health-insurance/mental-health-parity-addiction-equity>.
2. Realizing Parity, Reducing Stigma, and Raising Awareness: Increasing Access to Mental Health and Substance Use Disorder Coverage. 2022 MHPAEA Report to Congress. 2AD. Accessed September 25, 2023. <https://www.dol.gov/sites/dolgov/files/EBSA/laws-and-regulations/laws/mental-health-parity/report-to-congress-2022-realizing-parity-reducing-stigma-and-raising-awareness.pdf>.
3. 2023 MHPAEA Comparative Analysis Report to Congress. 2AD. Accessed September 25, 2023. <https://www.dol.gov/sites/dolgov/files/EBSA/laws-and-regulations/laws/mental-health-parity/report-to-congress-2023-mhpaea-comparative-analysis.pdf>
4. Hempstead K. Cost-sharing for mental health services and primary care in the individual and small group markets. is it always the same? RWJF. October 17, 2022. Accessed September 25, 2023. <https://www.rwjf.org/en/insights/our-research/2022/10/marketplace-pulse-cost-sharing-for-mental-health-services-and-primary-care-in-the-individual-and-small-group-markets.html>.
5. Hempstead K. Differences in cost-sharing for mental health and primary care services persist. RWJF. August 24, 2023. Accessed September 25, 2023. <https://www.rwjf.org/en/insights/our-research/2023/08/marketplace-pulse-differences-in-cost-sharing-for-mental-health-and-primary-care-services-persist.html>.
6. Jordan Sieder J. Georgia insurance companies flout mental health parity reporting requirements. State Affairs. September 8, 2023. Accessed September 25, 2023. <https://stateaffairs.com/georgia/healthcare/georgia-insurance-companies-flout-mental-health-parity-reporting-requirements/>.

RELEVANT AMA POLICY:

Expanding Parity Protections and Coverage of Mental Health and Substance Use Disorder Care H-185.916

Our AMA supports requirements of all health insurance plans to implement a compliance program to demonstrate compliance with state and federal mental health parity laws. [Res. 216, I-22]

Parity for Mental Health and Substance Use Disorders in Health Insurance Programs H-185.974

1. Our AMA supports parity of coverage for mental, health, and substance use disorders.
2. Our AMA supports federal legislation, standards, policies, and funding that enforce and expand the parity and non-discrimination protections of the Paul Wellstone and Peter Domenici Mental Health Parity and Addiction Equity Act of 2008 to Medicare (Parts A, B, C and D).
3. Our AMA supports federal legislation, standards, policies, and funding that require Medicare coverage (Parts A, B, C, and D) of all levels of mental health and substance use disorder care, consistent with nationally recognized medical professional organization level of care criteria for mental health or substance use disorders. [Res. 212, A-96, Reaffirmation A-97, Reaffirmed: Res. 215, I-98, Reaffirmation A-99, Reaffirmed: BOT Action in response to referred for decision Res. 612, I-99, Reaffirmation A-00, Reaffirmed: CMS Rep. 9, A-01, Reaffirmation A-02, Reaffirmation I-03, Modified: CMS Rep. 2, A-08, Reaffirmed: CMS Rep. 5, I-12, Reaffirmed in lieu of Res. 804, I-13, Reaffirmation A-15, Modified: Res. 113, A-16, Modified: Res. 216, I-22]

Insurance Parity for Mental Health and Psychiatry D-180.998

Our AMA in conjunction with the American Psychiatric Association and other interested organizations will develop model state legislation for the use of state medical associations and specialty societies to promote legislative changes assuring parity for the coverage of mental illness, alcoholism, and substance abuse. [Res. 215, I-98, Reaffirmation I-03, Reaffirmed in lieu of Res. 910, I-06, Reaffirmation A-15]

Maintaining Mental Health Services by States H-345.975

Our AMA:

1. supports maintaining essential mental health services at the state level, to include maintaining state inpatient and outpatient mental hospitals, community mental health centers, addiction treatment centers, and other state-supported psychiatric services;
2. supports state responsibility to develop programs that rapidly identify and refer individuals with

significant mental illness for treatment, to avoid repeated psychiatric hospitalizations and repeated interactions with the law, primarily as a result of untreated mental conditions;

3. supports increased funding for state Mobile Crisis Teams to locate and treat homeless individuals with mental illness;

4. supports enforcement of the Mental Health Parity Act at the federal and state level; and

5. will take these resolves into consideration when developing policy on essential benefit services.

[Res. 116, A-12, Reaffirmation A-15, Reaffirmed: Res. 414, A-22]

Evaluating Health System Reform Proposals H-165.888

1. Our AMA will continue its efforts to ensure that health system reform proposals adhere to the following principles:

A. Physicians maintain primary ethical responsibility to advocate for their patients' interests and needs.

B. Unfair concentration of market power of payers is detrimental to patients and physicians, if patient freedom of choice or physician ability to select mode of practice is limited or denied. Single-payer systems clearly fall within such a definition and, consequently, should continue to be opposed by the AMA. Reform proposals should balance fairly the market power between payers and physicians or be opposed.

C. All health system reform proposals should include a valid estimate of implementation cost, based on all health care expenditures to be included in the reform; and supports the concept that all health system reform proposals should identify specifically what means of funding (including employer-mandated funding, general taxation, payroll or value-added taxation) will be used to pay for the reform proposal and what the impact will be.

D. All physicians participating in managed care plans and medical delivery systems must be able without threat of punitive action to comment on and present their positions on the plan's policies and procedures for medical review, quality assurance, grievance procedures, credentialing criteria, and other financial and administrative matters, including physician representation on the governing board and key committees of the plan.

E. Any national legislation for health system reform should include sufficient and continuing financial support for inner-city and rural hospitals, community health centers, clinics, special programs for special populations and other essential public health facilities that serve underserved populations that otherwise lack the financial means to pay for their health care.

F. Health system reform proposals and ultimate legislation should result in adequate resources to enable medical schools and residency programs to produce an adequate supply and appropriate generalist/specialist mix of physicians to deliver patient care in a reformed health care system.

G. All civilian federal government employees, including Congress and the Administration, should be covered by any health care delivery system passed by Congress and signed by the President.

H. True health reform is impossible without true tort reform.

2. Our AMA supports health care reform that meets the needs of all Americans including people with injuries, congenital or acquired disabilities, and chronic conditions, and as such values function and its improvement as key outcomes to be specifically included in national health care reform legislation.

3. Our AMA supports health care reform that meets the needs of all Americans including people with mental illness and substance use / addiction disorders and will advocate for the inclusion of full parity for the treatment of mental illness and substance use / addiction disorders in all national health care reform legislation.

4. Our AMA supports health system reform alternatives that are consistent with AMA principles of pluralism, freedom of choice, freedom of practice, and universal access for patients.

[Res. 118, I-91, Res. 102, I-92, BOT Rep. NN, I-92, BOT Rep. S, A-93, Reaffirmed: Res. 135, A-93, Reaffirmed: BOT Reps. 25 and 40, I-93, Reaffirmed in lieu of Res. 714, I-93, Res. 130, I-93, Res. 316, I-93, Sub. Res. 718, I-93, Reaffirmed: CMS Rep. 5, I-93, Res. 124, A-94, Reaffirmed by BOT Rep. 1- I-94, CEJA Rep. 3, A-95, Reaffirmed: BOT Rep. 34, I-95, Reaffirmation A-00, Reaffirmation A-01, Reaffirmed: CMS Rep. 10, A-03, Reaffirmed: CME Rep. 2, A-03, Reaffirmed and Modified: CMS Rep. 5, A-04, Reaffirmed with change in title: CEJA Rep. 2, A-05, Consolidated: CMS Rep. 7, I-05, Reaffirmation I-07, Reaffirmed in lieu of Res. 113, A-08, Reaffirmation A-09, Res. 101, A-09, Sub. Res. 110, A-09, Res. 123, A-09, Reaffirmed in lieu of Res. 120, A-12, Reaffirmation: A-17]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 223
(A-24)

Introduced by: American Academy of Pediatrics, American College of Obstetricians and Gynecologists

Subject: Increase in Children's Hospital Graduate Medical Education Funding

Referred to: Reference Committee B

1 Whereas, the Children's Hospitals Graduate Medical Education (CHGME) program has been a
2 vital component of supporting pediatric residency training programs in the United States since
3 its inception in the 1990s^{1,4} and was established to address the unique funding challenges faced
4 by children's hospitals in providing quality graduate medical education, recognizing the
5 importance of specialized pediatric training^{1,3} for pediatricians and other specialties who care for
6 children; and
7

8 Whereas, since the 1990s, the funding for the CHGME program has not kept pace with the
9 evolving needs of pediatric residency programs, leading to a widening gap between the funding
10 provided and the increasing demands on pediatric healthcare^{2,3,6-7}; and
11

12 Whereas, the lack of adequate adjustments to CHGME funding over the years has created
13 financial strains on children's hospitals and pediatric residency programs, limiting their ability to
14 expand training capacities and adequately respond to the growing healthcare needs of
15 children^{4,7}; and
16

17 Whereas, investing in pediatric medical education contributes to the overall improvement of
18 child health outcomes and strengthens the healthcare system as a whole⁵; and
19

20 Whereas, the American Medical Association has a longstanding commitment to advocating for
21 policies that enhance medical education and improve the healthcare workforce; therefore be it
22

23 RESOLVED, that our American Medical Association collaborate with other relevant medical
24 organizations to support and advocate for increased funding for the Children's Hospitals
25 Graduate Medical Education program, recognizing the vital role it plays in shaping the future of
26 pediatric healthcare in the United States. (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/23/2024

REFERENCES

1. Catherine G. Coughlin, Kenneth A. Michelson, Amy J. DeLong, Amanda M. Stewart; Federal Funding for Children's Hospitals: Challenges and Critical Shortages for Pediatric Care. *Pediatrics* October 2023; 152 (4): e2023061714. 10.1542/peds.2023-061714
2. COMMITTEE ON PEDIATRIC WORKFORCE, Mary Ellen Rimsza, Andrew J. Hotaling, Harold K. Simon, Mary E. Keown, James P. Marcin, William B. Moskowitz; Financing Graduate Medical Education to Meet the Needs of Children and the Future Pediatrician Workforce. *Pediatrics* April 2016; 137 (4): e20160211. 10.1542/peds.2016-0211
3. Association of American Medical Colleges. Proportion of charity care provided at COH, other teaching, and non-teaching hospitals, 2012. Updated 2014.

4. Chandra A, Khullar D, Wilensky GR. The economics of graduate medical education. *N Engl J Med.* 2014;370(25):2357–2360 [PubMed]
5. Cushing AM, Bucholz EM, Chien AT, Rauch DA, Michelson KA. Availability of Pediatric Inpatient Services in the United States. *Pediatrics.* 2021 Jul;148(1):e2020041723. doi: 10.1542/peds.2020-041723. Epub 2021 Jun 14. PMID: 34127553; PMCID: PMC8642812.
6. VonAchen P, Gaur D, Wickremasinghe W, Hall M, Goodman DM, Agrawal R, Berry JG. Assessment of Underpayment for Inpatient Care at Children's Hospitals. *JAMA Pediatr.* 2021 Sep 1;175(9):972-974. doi: 10.1001/jamapediatrics.2021.1133. PMID: 34047755; PMCID: PMC8424474.
7. Dobson DaVanzo & Associates. Comparative analysis of GME funding programs for children's hospitals and general acute care teaching hospitals. Available at: https://www.childrenshospitals.org/-/media/files/public-policy/chgme_workforce/reports/chgme_dobson_davanzo_report_032422.pdf. Accessed February 2, 2022

RELEVANT AMA POLICY

Increasing Coverage for Children H-165.877

Our AMA: (1) supports appropriate legislation that will provide health coverage for the greatest number of children, adolescents, and pregnant women; (2) recognizes incremental levels of coverage for different groups of the uninsured, consistent with finite resources, as a necessary interim step toward universal access; (3) places particular emphasis on advocating policies and proposals designed to expand the extent of health expense coverage protection for presently uninsured children and recommends that the funding for this coverage should preferably be used to allow these children, by their parents or legal guardians, to select private insurance rather than being placed in Medicaid programs; (4) supports, and encourages state medical associations to support, a requirement by all states that all insurers in that jurisdiction make available for purchase individual and group health expense coverage solely for children up to age 18; (5) encourages state medical associations to support study by their states of the need to extend coverage under such children's policies to the age of 23; (6) seeks to have introduced or support federal legislation prohibiting employers from conditioning their provision of group coverage including children on the availability of individual coverage for this age group for direct purchase by families; (7) advocates that, in order to be eligible for any federal or state premium subsidies or assistance, the private children's coverage offered in each state should be no less than the benefits provided under Medicaid in that state and allow states flexibility in the basic benefits package; (8) advocates that state and/or federal legislative proposals to provide premium assistance for private children's coverage provide for an appropriately graduated subsidy of premium costs for insurance benefits; (9) supports an increase in the federal and/or state sales tax on tobacco products, with the increased revenue earmarked for an income-related premium subsidy for purchase of private children's coverage; (10) advocates consideration by Congress, and encourage consideration by states, of other sources of financing premium subsidies for children's private coverage; (11) supports and encourages state medical associations and local medical societies to support, the use of school districts as one possible risk pooling mechanism for purchase of children's health insurance coverage, with inclusion of children from birth through school age in the insured group; (12) supports and encourages state medical associations to support, study by states of the actuarial feasibility of requiring pure community rating in the geographic areas or insurance markets in which policies are made available for children; and (13) encourages state medical associations, county medical societies, hospitals, emergency departments, clinics and individual physicians to assist in identifying and encouraging enrollment in Medicaid of the estimated three million children currently eligible for but not covered under this program.

The Preservation, Stability and Expansion of Full Funding for Graduate Medical Education D-305.967

1. Our AMA will actively collaborate with appropriate stakeholder organizations, (including Association of American Medical Colleges, American Hospital Association, state medical societies, medical specialty societies/associations) to advocate for the preservation, stability and expansion of full funding for the direct and indirect costs of graduate medical education (GME) positions from all existing sources (e.g. Medicare, Medicaid, Veterans Administration, CDC and others).
2. Our AMA will actively advocate for the stable provision of matching federal funds for state Medicaid programs that fund GME positions.
3. Our AMA will actively seek congressional action to remove the caps on Medicare funding of GME positions for resident physicians that were imposed by the Balanced Budget Amendment of 1997 (BBA-1997).

4. Our AMA will strenuously advocate for increasing the number of GME positions to address the future physician workforce needs of the nation.
5. Our AMA will oppose efforts to move federal funding of GME positions to the annual appropriations process that is subject to instability and uncertainty.
6. Our AMA will oppose regulatory and legislative efforts that reduce funding for GME from the full scope of resident educational activities that are designated by residency programs for accreditation and the board certification of their graduates (e.g. didactic teaching, community service, off-site ambulatory rotations, etc.).
7. Our AMA will actively explore additional sources of GME funding and their potential impact on the quality of residency training and on patient care.
8. Our AMA will vigorously advocate for the continued and expanded contribution by all payers for health care (including the federal government, the states, and local and private sources) to fund both the direct and indirect costs of GME.
9. Our AMA will work, in collaboration with other stakeholders, to improve the awareness of the general public that GME is a public good that provides essential services as part of the training process and serves as a necessary component of physician preparation to provide patient care that is safe, effective and of high quality.
10. Our AMA staff and governance will continuously monitor federal, state and private proposals for health care reform for their potential impact on the preservation, stability and expansion of full funding for the direct and indirect costs of GME.
11. Our AMA: (a) recognizes that funding for and distribution of positions for GME are in crisis in the United States and that meaningful and comprehensive reform is urgently needed; (b) will immediately work with Congress to expand medical residencies in a balanced fashion based on expected specialty needs throughout our nation to produce a geographically distributed and appropriately sized physician workforce; and to make increasing support and funding for GME programs and residencies a top priority of the AMA in its national political agenda; and (c) will continue to work closely with the Accreditation Council for Graduate Medical Education, Association of American Medical Colleges, American Osteopathic Association, and other key stakeholders to raise awareness among policymakers and the public about the importance of expanded GME funding to meet the nation's current and anticipated medical workforce needs.
12. Our AMA will collaborate with other organizations to explore evidence-based approaches to quality and accountability in residency education to support enhanced funding of GME.
13. Our AMA will continue to strongly advocate that Congress fund additional graduate medical education (GME) positions for the most critical workforce needs, especially considering the current and worsening maldistribution of physicians.
14. Our AMA will advocate that the Centers for Medicare and Medicaid Services allow for rural and other underserved rotations in Accreditation Council for Graduate Medical Education (ACGME)-accredited residency programs, in disciplines of particular local/regional need, to occur in the offices of physicians who meet the qualifications for adjunct faculty of the residency program's sponsoring institution.
15. Our AMA encourages the ACGME to reduce barriers to rural and other underserved community experiences for graduate medical education programs that choose to provide such training, by adjusting as needed its program requirements, such as continuity requirements or limitations on time spent away from the primary residency site.
16. Our AMA encourages the ACGME and the American Osteopathic Association (AOA) to continue to develop and disseminate innovative methods of training physicians efficiently that foster the skills and inclinations to practice in a health care system that rewards team-based care and social accountability.
17. Our AMA will work with interested state and national medical specialty societies and other appropriate stakeholders to share and support legislation to increase GME funding, enabling a state to accomplish one or more of the following: (a) train more physicians to meet state and regional workforce needs; (b) train physicians who will practice in physician shortage/underserved areas; or (c) train physicians in undersupplied specialties and subspecialties in the state/region.
18. Our AMA supports the ongoing efforts by states to identify and address changing physician workforce needs within the GME landscape and continue to broadly advocate for innovative pilot programs that will increase the number of positions and create enhanced accountability of GME programs for quality outcomes.
19. Our AMA will continue to work with stakeholders such as Association of American Medical Colleges (AAMC), ACGME, AOA, American Academy of Family Physicians, American College of Physicians, and

other specialty organizations to analyze the changing landscape of future physician workforce needs as well as the number and variety of GME positions necessary to provide that workforce.

20. Our AMA will explore innovative funding models for incremental increases in funded residency positions related to quality of resident education and provision of patient care as evaluated by appropriate medical education organizations such as the Accreditation Council for Graduate Medical Education.

21. Our AMA will utilize its resources to share its content expertise with policymakers and the public to ensure greater awareness of the significant societal value of graduate medical education (GME) in terms of patient care, particularly for underserved and at-risk populations, as well as global health, research and education.

22. Our AMA will advocate for the appropriation of Congressional funding in support of the National Healthcare Workforce Commission, established under section 5101 of the Affordable Care Act, to provide data and healthcare workforce policy and advice to the nation and provide data that support the value of GME to the nation.

23. Our AMA supports recommendations to increase the accountability for and transparency of GME funding and continue to monitor data and peer-reviewed studies that contribute to further assess the value of GME.

24. Our AMA will explore various models of all-payer funding for GME, especially as the Institute of Medicine (now a program unit of the National Academy of Medicine) did not examine those options in its 2014 report on GME governance and financing.

25. Our AMA encourages organizations with successful existing models to publicize and share strategies, outcomes and costs.

26. Our AMA encourages insurance payers and foundations to enter into partnerships with state and local agencies as well as academic medical centers and community hospitals seeking to expand GME.

27. Our AMA will develop, along with other interested stakeholders, a national campaign to educate the public on the definition and importance of graduate medical education, student debt and the state of the medical profession today and in the future.

28. Our AMA will collaborate with other stakeholder organizations to evaluate and work to establish consensus regarding the appropriate economic value of resident and fellow services.

29. Our AMA will monitor ongoing pilots and demonstration projects, and explore the feasibility of broader implementation of proposals that show promise as alternative means for funding physician education and training while providing appropriate compensation for residents and fellows.

30. Our AMA will monitor the status of the House Energy and Commerce Committee's response to public comments solicited regarding the 2014 IOM report, Graduate Medical Education That Meets the Nation's Health Needs, as well as results of ongoing studies, including that requested of the GAO, in order to formulate new advocacy strategy for GME funding, and will report back to the House of Delegates regularly on important changes in the landscape of GME funding.

31. Our AMA will advocate to the Centers for Medicare & Medicaid Services to adopt the concept of "Cap-Flexibility" and allow new and current Graduate Medical Education teaching institutions to extend their cap-building window for up to an additional five years beyond the current window (for a total of up to ten years), giving priority to new residency programs in underserved areas and/or economically depressed areas.

32. Our AMA will: (a) encourage all existing and planned allopathic and osteopathic medical schools to thoroughly research match statistics and other career placement metrics when developing career guidance plans; (b) strongly advocate for and work with legislators, private sector partnerships, and existing and planned osteopathic and allopathic medical schools to create and fund graduate medical education (GME) programs that can accommodate the equivalent number of additional medical school graduates consistent with the workforce needs of our nation; and (c) encourage the Liaison Committee on Medical Education (LCME), the Commission on Osteopathic College Accreditation (COCA), and other accrediting bodies, as part of accreditation of allopathic and osteopathic medical schools, to prospectively and retrospectively monitor medical school graduates' rates of placement into GME as well as GME completion.

33. Our AMA encourages the Secretary of the U.S. Department of Health and Human Services to coordinate with federal agencies that fund GME training to identify and collect information needed to effectively evaluate how hospitals, health systems, and health centers with residency programs are utilizing these financial resources to meet the nation's health care workforce needs. This includes information on payment amounts by the type of training programs supported, resident training costs and revenue generation, output or outcomes related to health workforce planning (i.e., percentage of primary

care residents that went on to practice in rural or medically underserved areas), and measures related to resident competency and educational quality offered by GME training programs.

34. Our AMA will publicize best practice examples of state-funded Graduate Medical Education positions and develop model state legislation where appropriate.

Securing Funding for Graduate Medical Education H-310.917

Our American Medical Association: (1) continues to be vigilant while monitoring pending legislation that may change the financing of medical services (health system reform) and advocate for expanded and broad-based funding for graduate medical education (from federal, state, and commercial entities); (2) continues to advocate for graduate medical education funding that reflects the physician workforce needs of the nation; (3) encourages all funders of GME to adhere to the Accreditation Council for Graduate Medical Education's requirements on restrictive covenants and its principles guiding the relationship between GME, industry and other funding sources, as well as the AMA's Opinion 8.061, and other AMA policy that protects residents and fellows from exploitation, including physicians training in non-ACGME-accredited programs; and (4) encourages entities planning to expand or start GME programs to develop a clear statement of the benefits of their GME activities to facilitate potential funding from appropriate sources given the goals of their programs.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 224
(A-24)

Introduced by: Medical Student Section

Subject: Antidiscrimination Protections for LGBTQ+ Youth in Foster Care

Referred to: Reference Committee B

- 1 Whereas, 30% of youth in foster care are LGBTQ+, triple the rate of those not in care¹⁻⁴; and
2
3 Whereas, in the foster care system, LGBTQ+ identifying youth encounter unique and significant
4 threats associated with their identity including rejection, harassment, violence, and discrimination
5 from social workers, foster parents, residential staff, and peers in addition to poorer health
6 outcomes compared to their non-LGBTQ+ counterparts including worse physical, mental, and
7 sexual health alongside higher prevalence of trauma, substance use, survival sex, sexual
8 victimization, and unintended pregnancy¹⁻¹⁹; and
9
10 Whereas, studies demonstrate LGBTQ+ youth are twice as likely to enter foster care, more likely
11 to spend longer time in care, be removed from placements due to hostility based on LGBTQ+
12 identity, and to age out of care without adequate preparation for higher education, employment,
13 and housing^{6,7,20-26}; and
14
15 Whereas, in 2016, the United States Children’s Bureau confidentially collected data on foster
16 youth’s sexual orientation as well as family conflicts related to a child’s gender identity, sexual
17 orientation, and or gender expression, demonstrating the ability of the system to obtain
18 demographic information confidentially to improve the system for LGBTQ+ youth²⁷; and
19
20 Whereas, in 2020, the United States Children’s Bureau eliminated requirements for collection of
21 demographics on sexual orientation in the Foster Care Analysis and Reporting System, which
22 limited child welfare agencies’ ability to analyze LGBTQ+ youth in foster care and increase
23 programs, laws, and funds protecting LGBTQ+ foster youth²⁷⁻³⁰; and
24
25 Whereas, social care professionals at religiously-affiliated foster care facilities in the United States
26 were found to propagate negative stereotypes about same-sex relationships³¹; and
27
28 Whereas, in recent years, New Jersey child welfare officials successfully recruited and licensed
29 120 new foster homes that affirm and support LGBTQ+ youth, demonstrating through local
30 LGBTQ+ community organization, home studies, and training sessions that child services can
31 successfully recruit inclusive families for the foster care system³²; and
32
33 Whereas, the Children’s Bureau and Child Welfare League of America provide fact sheets and
34 brochures with passive guidance on supporting LGBTQ+ youth in foster care as an accessible
35 and feasible means of improving care for LGBTQ+ youth³³⁻³⁸; and
36
37 Whereas, implementation of the *RISE Care Coordination Team Program* in Los Angeles helped
38 LGBTQ+ youth in the Los Angeles foster care system feel supported in their identities and
39 demonstrated an accessible model by which other programs can support LGBTQ+ youth³⁹; and

1 Whereas, the Civil Rights Act of 1964 does not protect against discrimination of LGBTQ+
2 individuals in federally-funded programs, including adoption and foster care, with recent attempts
3 to expand nondiscrimination protections failing to pass⁴⁰⁻⁴⁶; and
4

5 Whereas, the lack of inclusive protections for LGBTQ+ individuals in federal legislation, such as
6 the Civil Rights Act of 1964, the Fair Housing Act, and the Affordable Care Act, has enabled rule
7 changes and proposals that permit discrimination against LGBTQ+ individuals⁴⁷⁻⁴⁹; and
8

9 Whereas, only 28 states and the District of Columbia have specific laws and policies in place to
10 protect LGBTQ+ foster youth from discrimination based on both sexual orientation and gender
11 identity, six other states include sexual orientation but not gender identity as a protected class in
12 child welfare, and some states have no protections at all^{21,33,50}; and
13

14 Whereas, only four states had regulatory guidance regarding placement of transgender youth in
15 out-of-home care in alignment with gender identity as of 2016, and child welfare agency officials
16 from three states reported placing transgender youth in gender-segregated residential facilities
17 by their sex assigned at birth rather than their gender identity^{32,51}; and
18

19 Whereas, the relationship between LGBTQ+ protections and availability of foster families is
20 unclear, but court cases in states challenging those protections are pending^{52,53}; and
21

22 Whereas, because youth may begin to identify as LGBTQ+ after being placed with a family not
23 supportive of those identities, screening for unsupportive families is necessary to reduce harm
24 toward LGBTQ+ youth⁵⁴⁻⁵⁶; and
25

26 Whereas, though AMA policies H-60.910 and H-160.991 separately address the healthcare needs
27 of youth in foster care and of LGBTQ+ individuals, the AMA has only written one letter to the
28 Department of Housing and Urban Development opposing the removal of protections for housing
29 allocation based on gender identity⁵⁷; therefore be it
30

31 RESOLVED, that our American Medical Association collaborate with state medical societies and
32 other appropriate stakeholders to support policies on the federal and state levels that establish
33 nondiscrimination protections within the foster care system on the basis of sexual orientation and
34 gender identity (New HOD Policy); and be it further
35

36 RESOLVED, that our AMA support efforts by the Department of Health and Human Services and
37 other appropriate stakeholders to establish a reporting mechanism for the collection of
38 anonymized and aggregated sexual orientation and gender identity data in the Foster Care
39 Analysis and Reporting System only when strong privacy protections exist (New HOD Policy);
40 and be it further
41

42 RESOLVED, that our AMA encourage child welfare agencies to implement practices, policies,
43 and regulations that: (a) provide training to child welfare professionals, social workers, and foster
44 caregivers on how to establish safe, stable, and affirming care placements for LGBTQ+ youth; (b)
45 adopt programs to prevent and reduce violence against LGBTQ+ youth in foster care; (c) improve
46 recruitment of foster families that are affirming of LGBTQ+ youth; and (d) allow gender diverse
47 youth to be placed in residential foster homes that are willing to accept their gender identity.
48 (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 4/24/2024

REFERENCES

1. Baams L, Wilson BDM, Russell ST. LGBTQ Youth in Unstable Housing and Foster Care. *Pediatrics*. 2019;143(3):e20174211. doi:10.1542/peds.2017-4211
2. Grooms J. No Home and No Acceptance: Exploring the Intersectionality of Sexual/Gender Identities (LGBTQ) and Race in the Foster Care System. *The Review of Black Political Economy*. 2020;47(2):177-193. doi:10.1177/0034644620911381
3. The Cuyahoga Youth Count: A Report on LGBTQ+ Youth Experience in Foster Care, 2021. Accessed March 6, 2023 from: <https://theinstitute.umaryland.edu/media/ssw/institute/Cuyahoga-Youth-Count.6.8.1.pdf>
4. Dettlaff AJ, Washburn M, Carr LC, Vogel AN. Lesbian, gay, and bisexual (LGB) youth within in welfare: Prevalence, risk and outcomes. *Child Abuse Negl*. 2018;80:183-193. doi:10.1016/j.chiabu.2018.03.009
5. Wilson BD, Cooper K, Kastanis A, Nezhad S. Sexual and Gender Minority Youth in Foster Care: Assessing Disproportionality and Disparities in Los Angeles. Published online August 1, 2014. Accessed March 5, 2023 from: <https://escholarship.org/uc/item/6mg3n153>
6. Schaub J, Stander WJ, Montgomery P. LGBTQ+ Young People's Health and Well-being Experiences in Out-of-home Social Care: A scoping review. *Child Youth Serv Rev*. 2022;143:106682. doi:10.1016/j.chilyouth.2022.106682
7. Dank M, Yu L, Yahner J, et al. Surviving the Streets of New York: Experiences of LGBTQ Youth, YMSM, and YWSW Engaged in Survival Sex, Urban Institute, 2015. Accessed March 6, 2023 from: <https://www.urban.org/sites/default/files/publication/42186/2000119-Surviving-the-Streets-of-New-York.pdf>
8. 2022 National Survey on LGBTQ Youth Mental Health. The Trevor Project. Published 2022. Accessed March 5, 2023. <https://www.thetrevorproject.org/survey-2022/>
9. Information Memorandum: Lesbian, Gay, Bisexual, Transgender and Questioning Youth in Foster Care, April 2011. Accessed March 6, 2023 from: <https://www.acf.hhs.gov/sites/default/files/documents/cb/im1103.pdf>
10. Craig-Oldsen H, Craig JA, Morton T. Issues of Shared Parenting of LGBTQ Children and Youth in Foster Care: Preparing Foster Parents for New Roles. *Child Welfare*. 2006;85(2):267-280.
11. Feinstein R, Greenblatt A, Hass L, Kohn S, Rana J. Justice for All? A Report on Lesbian, Gay, Bisexual and Transgendered Youth in the New York Juvenile Justice System.; 2001. Accessed March 5, 2023. <https://eric.ed.gov/?id=ED471676>
12. Clements JA, Rosenwald M. Foster Parents' Perspectives on LGB Youth in the Child Welfare System. *J Gay Lesbian Soc Serv*. 2007;19(1):57-69. doi:10.1300/J041v19n01_04
13. Gallegos A, Roller White C, Ryan C, O'Brien K, Pecora PJ, Thomas P. Exploring the Experiences of Lesbian, Gay, Bisexual, and Questioning Adolescents in Foster Care. *J Fam Soc Work*. 2011;14(3):226-236. doi:10.1080/10522158.2011.571547
14. Rosenwald M. A Glimpse Within: An Exploratory Study of Child Welfare Agencies' Practices With LGBTQ Youth. *J Gay Lesbian Soc Serv*. 2009;21(4):343-356. doi:10.1080/10538720802498124
15. Sullivan C, Sommer S, Moff J. Youth in the Margins: A Report on the Unmet Needs of Lesbian, Gay, Bisexual, and Transgender Adolescents in Foster Care. Lambda Legal Defense and Education Fund; 2001. Accessed March 6, 2023 from: <https://www.lambdalegal.org/publications/youth-in-the-margins>
16. Wilber S, Reyes C, Marksamer J. The model standards project: creating inclusive systems for LGBT youth in out-of-home care. *Child Welfare*. 2006;85(2):133-149.
17. Woronoff R, Estrada R. Regional listening forums: an examination of the methodologies used by the child welfare league of America and lambda legal to highlight the experiences of LGBTQ youth in care. *Child Welfare*. 2006;85(2):341-360.
18. Scannapieco M, Painter KR, Blau G. A comparison of LGBTQ youth and heterosexual youth in the child welfare system: Mental health and substance abuse occurrence and outcomes. *Child Youth Serv Rev*. 2018;91:39-46. doi:10.1016/j.chilyouth.2018.05.016
19. Brandon-Friedman RA, Pierce B, Wahler E, Thigpen J, Fortenberry JD. Sexual identity development and sexual well-being: Differences between sexual minority and non-sexual minority former foster youth. *Child Youth Serv Rev*. 2020;117:105294. doi:10.1016/j.chilyouth.2020.105294
20. Poirier JM, Wilkie S, Sepulveda K, Uruchima T. Jim Casey Youth Opportunities Initiative: Experiences and Outcomes of Youth who are LGBTQ. *Child Welfare*. 2018;96(1):1-26.
21. Child welfare nondiscrimination laws. Movement Advancement Project. Accessed September 21, 2023. https://www.lgbtmap.org/equality-maps/foster_and_adoption_laws.
22. Jacobs J, Freundlich M. Achieving permanency for LGBTQ youth. *Child Welfare*. 2006;85(2):299-316.
23. Mallon GP, Aledort N, Ferrera M. There's no place like home: achieving safety, permanency, and well-being for lesbian and gay adolescents in out-of-home care settings. *Child Welfare*. 2002;81(2):407-439.
24. Capous-Desyllas M, Mountz S. Using Photovoice Methodology to Illuminate the Experiences of LGBTQ Former Foster Youth. *Child Youth Serv*. 2019;40(3):267-307. doi:10.1080/0145935X.2019.1583099
25. Erney R, Weber K. Not all Children are Straight and White: Strategies for Serving Youth of Color in Out-of-Home care who Identify as LGBTQ. *Child Welfare*. 2018;96(2):151-177.
26. Mountz S, Capous-Desyllas M. Exploring the families of origin of LGBTQ former foster youth and their trajectories throughout care. *Children and Youth Services Review*. 2020;109:104622. doi:10.1016/j.chilyouth.2019.104622
27. Adoption and Foster Care Analysis and Reporting System. Federal Register. Published December 14, 2016. Accessed March 6, 2023 from: <https://www.federalregister.gov/documents/2016/12/14/2016-29366/adoption-and-foster-care-analysis-and-reporting-system>
28. Adoption and Foster Care Analysis and Reporting System. Federal Register. Published May 12, 2020. Accessed March 6, 2023 from: <https://www.federalregister.gov/documents/2020/05/12/2020-09817/adoption-and-foster-care-analysis-and-reporting-system>
29. Woods JB. The Regulatory Erasure of LGBTQ+ Foster Youth. *The Regulatory Review*. Published June 22, 2021. Accessed March 6, 2023 from: <https://www.theregview.org/2021/06/22/woods-regulatory-erasure-lgbtq-youth/>
30. Greeno E, Matarese M, Weeks A. Attitudes, beliefs, and behaviors of child welfare workers toward LGBTQ youth. *J Public Child Welf*. 2022;16(5):555-574. doi:10.1080/15548732.2021.1940415
31. Bermea AM, Rueda HA, Toews ML. Queerness and Dating Violence Among Adolescent Mothers in Foster Care. *Affilia*. 2018;33(2):164-176. doi:10.1177/0886109917737880

32. Foster Care: Further Assistance from HHS Would be Helpful in Supporting Youth's LGBTQ+ Identities and Religious Beliefs. Us. Government Accountability Office. Published April 2022. Accessed September 21, 2023. <https://www.gao.gov/assets/gao-22-104688.pdf>
33. Child Welfare. Lambda Legal. Accessed March 5, 2023 from: <https://www.lambdalegal.org/map/child-welfare>
34. Desano A. Youth and Family Services - RISE. Published April 2, 2019. Accessed March 5, 2023 from: <https://rise.lalgbtcenter.org/youth-and-family-services/>
35. REACHING HIGHER: A Curriculum for Foster/Adoptive Parents and Kinship Caregivers Caring for LGBTQ Youth. Accessed March 6, 2023 from: <http://www.nccwe.org/downloads/LGBTQ-FosterParentFacilitatorGuide.pdf>
36. Training, Consultation & Program Development. San Francisco State University | Family Acceptance Project. Accessed March 5, 2023 from: <https://familyproject.sfsu.edu/training>
37. Paul JC. Exploring support for LGBTQ youth transitioning from foster care to emerging adulthood. *Child Youth Serv Rev.* 2020;119:105481. doi:10.1016/j.chldyouth.2020.105481
38. RECOMMENDED PRACTICES: PRACTICES To Promote the Safety and Well-Being of Lesbian, Gay, Bisexual, Transgender and Questioning (LGBTQ) Youth and Youth at Risk of or Living with HIV in Child Welfare Settings, 2012. Accessed March 6, 2023 from: <https://www.lambdalegal.org/sites/default/files/publications/downloads/recommended-practices-youth.pdf>
39. Phillips L, Parrish L, Khavar V, Rodriguez E, Islas A. 2016 RISE Project Care Coordination Team Program Manual, 2016. Accessed March 6, 2023 from: <https://files.lalgbtcenter.org/pdf/rise/Los-Angeles-LGBT-Center-RISE-Care-Coordination-Services-Program-Manual.pdf>
40. Title VI, Civil Rights Act of 1964. U.S. Department of Labor: Office of the Assistant Secretary for Administration & Management. Accessed March 5, 2023 from: <http://www.dol.gov/agencies/oasam/regulatory/statutes/title-vi-civil-rights-act-of-1964>
41. Civil Rights Requirements- A. Title VI of the Civil Rights Act of 1964, 42 U.S.C. 2000d et seq. ("Title VI"). HHS.gov. Published July 26, 2013. Accessed March 5, 2023 from: <https://www.hhs.gov/civil-rights/for-individuals/special-topics/needy-families/civil-rights-requirements/index.html>
42. Greenberg MH, Lopez R, Samuels J. Title VI Child Welfare Guidance. Published online October 19, 2016. Accessed March 6, 2023 from: <https://www.justice.gov/crt/title-vi-child-welfare-guidance>
43. Cicilline D. H.R.5 - Equality Act. *Congress.gov*. Published March 17, 2021. Accessed March 5, 2023 from: <https://www.congress.gov/bill/117th-congress/house-bill/5>
44. Merkley J. S.393 - Equality Act. *Congress.gov*. Published February 23, 2021. Accessed March 5, 2023 from: <http://www.congress.gov/>
45. Cicilline D. H.R. 5 (117th): Equality Act. *GovTrack.us*. Published March 2, 2021. Accessed March 5, 2023 from: <https://www.govtrack.us/congress/bills/117/hr5>
46. Gillibrand K. S.1791 - Every Child Deserves a Family Act. *Congress.gov*. Published June 11, 2019. Accessed March 5, 2023 from: <https://www.congress.gov/bill/116th-congress/senate-bill/1791>
47. Nondiscrimination in Health and Health Education Programs or Activities, Delegation of Authority. *Fed Regist.* 2020;85(119). Accessed March 5, 2023 from: <https://www.govinfo.gov/content/pkg/FR-2020-06-19/pdf/2020-11758.pdf>
48. Battle S, Wheeler II TE. Dear Colleague Letter. Published online February 22, 2017. Accessed March 6, 2023 from: <https://www2.ed.gov/about/offices/list/ocr/letters/colleague-201702-title-ix.pdf>
49. Carson. Letter to Chairwoman Maxine Waters and Congresswoman Jennifer Wexton. Published online July 13, 2020. Accessed March 6, 2023 from: https://wexton.house.gov/uploadedfiles/hud_response_to_waters-wexton_6.29.20_letter.pdf
50. Remlin C, Cook MC, Erney R. SAFE HAVENS: Closing the Gap Between Recommended Practice and Reality for Transgender and Gender-Expansive Youth in Out-of-Home Care, April 2017. Accessed March 6, 2023 from: https://www.lambdalegal.org/sites/default/files/publications/downloads/tgnc-policy-report_2017_final-web_05-02-17.pdf
51. Erney R. 50 State Survey: Licensing regulations in Child Welfare, Juvenile Justice and systems serving runaway and homeless youth relating to sexual orientation, gender identity and gender expression, 2016. Accessed March 6, 2023 from: <https://cssp.org/wp-content/uploads/2019/01/50-State-Survey-Licensing-regulations-in-Child-Welfare-Juvenile-Justice.pdf>
52. *Burke v. Walsh*. U.S. District Court for the District of Massachusetts. Case 1:23-cv-11798. Filed August 8, 2023. Accessed September 21, 2023. <https://becketnewsite.s3.amazonaws.com/20230808154524/Burke-Complaint-and-Exhibits.pdf>.
53. *Bates v. Pakseresht et al.* U.S. District Court for the District of Oregon. Case 2:2023cv00474. Filed April 3, 2023. Accessed September 21, 2023. <https://dockets.justia.com/docket/oregon/ordce/2:2023cv00474/172578>
54. Livingston NA, Flentje A, Brennan J, Mereish EH, Reed O, Cochran BN. Real-time associations between discrimination and anxious and depressed mood among sexual and gender minorities: The moderating effects of lifetime victimization and identity concealment. *Psychol Sex Orientat Gend Divers.* 2020;7(2):132-141. doi:10.1037/sgd0000371
55. Reisner SL, White Hughto JM, Gamarel KE, Keuroghlian AS, Mizock L, Pachankis JE. Discriminatory experiences associated with posttraumatic stress disorder symptoms among transgender adults. *J Couns Psychol.* 2016;63(5):509-519. doi:10.1037/cou0000143
56. Valentine SE, Livingston NA, Salomaa AC, Shipherd JC. Trauma, Discrimination and PTSD Among LGBTQ+ People. U.S. Department of Veteran Affairs, National Center for PTSD. Accessed September 21, 2023. https://www.ptsd.va.gov/professional/treat/specific/trauma_discrimination_lgbtq.asp.
57. Madara JL. Re: Making Admission or Placement Determinations Based on Sex in Facilities Under Community Planning and Development Housing Programs (Docket No. FR—6152—P—01). Published online September 22, 2020. Accessed March 6, 2023 from: <https://searchf.ama-assn.org/letter/documentDownload?uri=%2Funstructured%2Fbinary%2Fletter%2FLETTERS%2F2020-9-22-Letter-to-Carson-on-HUD-NPRM-re-Single-Sex-Housing-Facilities.pdf>

RELEVANT AMA Policy

Addressing Healthcare Needs of Children in Foster Care, H-60.910

Our AMA advocates for comprehensive and evidence-based care that addresses the specific health care needs of children in foster care. [Res. 907, I-17]

Health Care Needs of Lesbian, Gay, Bisexual, Transgender and Queer Populations, H-160.991

1. Our AMA: (a) believes that the physician's nonjudgmental recognition of patients' sexual orientations, sexual behaviors, and gender identities enhances the ability to render optimal patient care in health as well as in illness. In the case of lesbian, gay, bisexual, transgender, queer/questioning, and other (LGBTQ) patients, this recognition is especially important to address the specific health care needs of people who are or may be LGBTQ; (b) is committed to taking a leadership role in: (i) educating physicians on the current state of research in and knowledge of LGBTQ Health and the need to elicit relevant gender and sexuality information from our patients; these efforts should start in medical school, but must also be a part of continuing medical education; (ii) educating physicians to recognize the physical and psychological needs of LGBTQ patients; (iii) encouraging the development of educational programs in LGBTQ Health; (iv) encouraging physicians to seek out local or national experts in the health care needs of LGBTQ people so that all physicians will achieve a better understanding of the medical needs of these populations; and (v) working with LGBTQ communities to offer physicians the opportunity to better understand the medical needs of LGBTQ patients; and (c) opposes, the use of "reparative" or "conversion" therapy for sexual orientation or gender identity.

2. Our AMA will collaborate with our partner organizations to educate physicians regarding: (i) the need for sexual and gender minority individuals to undergo regular cancer and sexually transmitted infection screenings based on anatomy due to their comparable or elevated risk for these conditions; and (ii) the need for comprehensive screening for sexually transmitted diseases in men who have sex with men; (iii) appropriate safe sex techniques to avoid the risk for sexually transmitted diseases; and (iv) that individuals who identify as a sexual and/or gender minority (lesbian, gay, bisexual, transgender, queer/questioning individuals) experience intimate partner violence, and how sexual and gender minorities present with intimate partner violence differs from their cisgender, heterosexual peers and may have unique complicating factors.

3. Our AMA will continue to work alongside our partner organizations, including GLMA, to increase physician competency on LGBTQ health issues.

4. Our AMA will continue to explore opportunities to collaborate with other organizations, focusing on issues of mutual concern in order to provide the most comprehensive and up-to-date education and information to enable the provision of high quality and culturally competent care to LGBTQ people. [CSA Rep. C, I-81; Reaffirmed: CLRPD Rep. F, I-91; CSA Rep. 8, I-94; Appended: Res. 506, A-00; Modified and Reaffirmed: Res. 501, A-07; Modified: CSAPH Rep. 9, A-08; Reaffirmation A-12; Modified: Res. 08, A-16; Modified: Res. 903, I-17; Modified: Res. 904, I-17; Res. 16, A-18; Reaffirmed: CSAPH Rep. 01, I-18]

Reducing Suicide Risk Among Lesbian, Gay, Bisexual, Transgender, and Questioning Youth Through Collaboration with Allied Organizations, H-60.927

Our AMA will partner with public and private organizations dedicated to public health and public policy to reduce lesbian, gay, bisexual, transgender, and questioning (LGBTQ) youth suicide and improve health among LGBTQ youth. [Res. 402, A-12; Reaffirmed: CSAPH Rep. 1, A-22]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 225
(A-24)

Introduced by: Medical Student Section

Subject: Humanitarian Efforts to Resettle Refugees

Referred to: Reference Committee B

1 Whereas, “refugee” is defined in the Immigration and Nationality Act as an individual
2 experiencing persecution or a well-founded fear of persecution on account of their race, religion,
3 nationality, membership in a particular social group, or political opinion¹⁻³; and
4

5 Whereas, refugees in the US undergo an extensive and complex admission process involving
6 evaluation and referral by UNHCR (the UN’s refugee agency) to the US State Department’s
7 Refugee Admissions Program (USRAP), and are a distinct population from asylum seekers or
8 migrants crossing at the US’ southern border, who follow a completely separate process¹; and
9

10 Whereas, the US consistently admits fewer refugees than its cap, leading to 5,000 to 40,000
11 unallocated refugees⁴; and
12

13 Whereas, 29 million refugees are estimated in 2023, including 14 million children⁵⁻⁶; and
14

15 Whereas, over a 20-year period, refugees in the US ages 18 to 45 pay on average \$21,000-
16 \$43,707 more in taxes than they receive in benefits⁷⁻¹⁰; and
17

18 Whereas, refugees in general contribute \$21 billion in taxes annually, including to Social
19 Security and Medicare, offsetting the costs our aging population¹³; and
20

21 Whereas, analyses from Ohio, Michigan, and Minnesota demonstrate how refugees produce
22 billions of dollars in economic activity annually and create thousands of jobs^{9,11}; and
23

24 Whereas, 77% of refugees are working age, as opposed to the 39.7% of the US-born population
25 and male refugees participate in the labor force at higher rates than US males^{7,12,14}; and
26

27 Whereas, under 3% of refugees return to their country of origin, and 84% of long-term refugees
28 make the US their home by taking steps to become citizens^{6,10,15}; and
29

30 Whereas, when annual refugee admissions decreased 86% between 2016-2020, the 295,000
31 person gap actually harmed the US economy by nearly \$10 billion annually⁸; and
32

33 Whereas, decreased resettlement caps and worsening backlogs delay family reunification and
34 leave people displaced for decades, remaining indefinitely in refugee camps¹⁶; and
35

36 Whereas, forced displacement and restrictions on refugee admissions result in distinct chronic
37 physical and mental phenomena and generational trauma¹⁶⁻¹⁸; therefore be it
38

39 RESOLVED, that our American Medical Association support increases and oppose decreases
40 to the annual refugee admissions cap in the United States. (New HOD Policy)
41

Fiscal Note: Minimal - less than \$1,000

Received: 4/24/2024

REFERENCES

1. Roy D, Klobucista C, McBride J. How Does the U.S. Refugee System Work? Council on Foreign Relations. Published March 11, 2024. Accessed March 15, 2024. <https://www.cfr.org/background/how-does-us-refugee-system-work-trump-biden-afghanistan>
2. 8 USC 1101: Definitions. Accessed March 5, 2023. <https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-prelim-title8-section1101&num=0&edition=prelim>
3. Refugee Admissions. United States Department of State. Accessed March 5, 2023. <https://www.state.gov/refugee-admissions>
4. Bruno A. Refugee Admissions and Resettlement Policy. Congr Res Serv Rep Congr. Published online August 8, 2013.
5. UNHCR. Global Appeal 2023. Accessed March 5, 2023. <https://reporting.unhcr.org/globalappeal2023/pdf>
6. Global Trends - Forced Displacement in 2018 - UNHCR. UNHCR Global Trends 2018. Accessed March 5, 2023. <https://www.unhcr.org/globaltrends2018>
7. Evans W, Fitzgerald D. The Economic and Social Outcomes of Refugees in the United States: Evidence from the ACS. National Bureau of Economic Research; 2017:w23498. doi:10.3386/w23498
8. Clemens MA. The Economic and Fiscal Effects on the United States from Reduced Numbers of Refugees and Asylum Seekers. Published online 2022.
9. National Immigration Forum. Immigrants as Economic Contributors: Refugees Are A Fiscal Success Story for America. <https://www.immigrationresearch.org/system/files/Economic-and-Fiscal-Impact-of-Refugees.pdf>
10. New American Economy. From Struggle to Resilience.; 2017. https://www.immigrationresearch.org/system/files/NAE_Struggle_to_Resilience.pdf
11. New American Economy. New Americans in Minneapolis: The Demographic and Economic Contributions of Immigrants and Refugees in the Area.
12. Immigrants Contribute Greatly to U.S. Economy, Despite Administration's "Public Charge" Rule Rationale Center on Budget and Policy Priorities. Published August 15, 2019. Accessed March 6, 2023. <https://www.cbpp.org/research/poverty-and-inequality/immigrants-contribute-greatly-to-us-economy-despite-administrations>
13. Schneider MJ. Introduction to Public Health. Jones & Bartlett Learning; 2020.
14. Capps R. The Integration Outcomes of U.S. Refugees. Migr Policy Inst.
15. Protecting the Nation From Foreign Terrorist Entry Into the United States. Federal Register. Published February 1, 2017. Accessed March 6, 2023. <https://www.federalregister.gov/documents/2017/02/01/2017-02281/protecting-the-nation-from-foreign-terrorist-entry-into-the-united-states>
16. Lorenz ML. U.S. Refugee Resettlement Is in Ruins-It Is Our Duty to Rebuild It. J Gen Intern Med. 2022;37(4):940-943. doi:10.1007/s11606-021-07373-5
17. Murray KE, Davidson GR, Schweitzer RD. Review of refugee mental health interventions following resettlement: best practices and recommendations. Am J Orthopsychiatry. 2010;80(4):576-585. doi:10.1111/j.1939-0025.2010.01062.x
18. Asylum in the United States. American Immigration Council. <https://www.americanimmigrationcouncil.org/research/asylum-united-states>. Published June 11, 2020. Accessed April 9, 2023.

RELEVANT AMA Policy

D-65.984 Humanitarian and Medical Aid Support to Ukraine

Our AMA will advocate for: (1) continuous support of organizations providing humanitarian missions and medical care to Ukrainian refugees in Ukraine, at the Polish-Ukrainian border, in nearby countries, and/or in the US; (2) an early implementation of mental health measures, including suicide prevention efforts, and address war-related trauma and post-traumatic stress disorder when dealing with Ukrainian refugees with special attention to vulnerable populations including but not limited to young children, mothers, pregnant women, and the elderly; and (3) educational measures to enhance the understanding of war-related trauma in war survivors and promote broad protective factors (e.g., financial, employment, housing, and food stability) that can improve adjustment and outcomes for war-affected people, particularly when applied to vulnerable categories of people. [Res. 017, A-22]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 226
(A-24)

Introduced by: Missouri

Subject: Protecting Access to IVF Treatment

Referred to: Reference Committee B

1 Whereas, on Friday, 2/16/24, the Alabama Supreme Court ruled that “an embryo created
2 through in vitro fertilization (IVF) is a child protected by Alabama’s wrongful death act and the
3 Alabama Constitution;” and that “a human frozen embryo is a ‘child’ which is an unborn or
4 recently born children;” and that “the Constitution ... commands the judge to ... upholding the
5 sanctity of unborn life, including unborn life that exists outside the womb;” and that “the Court
6 would not create an exception in the statute for these IVF embryo children just because they
7 were located outside the womb; and

8
9 Whereas, historically, multiple states have already rejected attempts through legislation,
10 constitutional amendments or ballot measures to establish and expand the definition of
11 personhood and associated rights:

12 1. In 2008 and 2010, Colorado voters rejected ballot measures, to give constitutional
13 rights to individuals “at the beginning of biological development;” and

14 2. In 2011, Mississippi considered Proposition 26: "Should the term ‘person’ be defined
15 to include every human being from the moment of fertilization, cloning, or the equivalent
16 thereof?" which was voted down; and

17 3. In 2012, the Virginia House of Delegates passed House Bill 1 that was subsequently
18 tabled by the state Senate until 2013, which if passed would “construe the word ‘person’ under
19 Virginia Law ... to include unborn children” and enact that “the life of each human being begins
20 at conception;” and

21 4. Similar “Personhood” bills have also been passed by a single legislative chamber in
22 North Dakota, Oklahoma, and Mississippi; and

23
24 Whereas, these “Personhood” bills and ballot measures define a person as being a legal
25 entity from the moment of conception, and thus define fertilized eggs and embryos, as persons
26 with constitutional rights; and

27
28 Whereas, giving constitutional rights to a fertilized oocyte or embryo would interfere with the
29 physician-patient relationship in the provision of in vitro fertilization (IVF) services; and

30
31 Whereas, in current IVF practice in the United States, over half of embryo transfers will *not*
32 result in live birth, as many embryos after transfer will either (a) not result in a pregnancy, (b)
33 result in a miscarriage, or (c) result in a non-viable ectopic or molar pregnancy; and

34
35 Whereas, cryopreserved embryos also do *not* have a 100% thaw-survival rate, and a small
36 percentage of embryos will not survive freeze-thaw; and if embryos in the IVF lab have the
37 same legal status as children, then an embryology laboratory that fails to have a 100% thaw-
38 survival rate may also have some potential liability; and

1 Whereas, not all IVF patients can afford the long-term storage fees to cryopreserve embryos for
2 future use or to donate those embryos to others; and
3

4 Whereas, defining all embryos as “children” promotes the dangerous notion that all embryos
5 should somehow be transferred in an IVF cycle (instead of cryopreserving extra embryos of
6 adequate quality), which could potentially increase the rate of dangerous higher-order multiple
7 gestation pregnancies (triplets, quadruplets, etc.); and
8

9 Whereas, defining all embryos as “children” may promote the dangerous and misguided notion
10 that an ectopic pregnancy could somehow be safely implanted into the uterus (as is erroneously
11 reported on various “Personhood” websites); and
12

13 Whereas, considering embryos to be “children” also raises potential legal complications, such
14 as how inheritance and probate laws would apply to embryos; and
15

16 Whereas, defining all embryos as “children” may promote the dangerous and misguided notion
17 that a molar pregnancy can somehow be “rescued” instead of being a potential cancer; and
18

19 Whereas, considering abandoned embryos to be “children” raises questions about whether
20 states would then be liable to provide support for cryopreserved embryos and long-term storage
21 costs, such as under Medicaid as if they were “wards” of the state; and
22

23 Whereas, giving “rights” to embryos in the IVF lab will potentially complicate the practice of IVF
24 by inappropriately pressuring physicians to transfer abnormally-growing and arrested embryos;
25 and
26

27 Whereas, the American Society for Reproductive Medicine (ASRM) Position Statement on
28 Personhood Measures states that:

29 1. The ASRM is strongly opposed to measures granting constitutional rights or
30 protections and “personhood” status to fertilized reproductive tissues.

31 2. In a growing number of states, vaguely worded and often misleading measures are
32 appearing either in legislation or as proposed constitutional amendments, defining when life
33 begins and granting legal “personhood” status to embryos at varying stages of development. If
34 approved, these measures will have profound consequences for women and their families.

35 3. ..., these broadly worded measures will have significant effects on a number of
36 medical treatments available to women of reproductive age.

37 a. Personhood measures would make illegal some commonly used birth control
38 methods.

39 b. Personhood measures would make illegal a physician's ability to provide medically
40 appropriate care to women experiencing life-threatening complications due to a tubal
41 pregnancy.

42 c. Personhood measures would consign infertility patients to less effective, less safe
43 treatments for their disease.

44 d. Personhood measures would unduly restrict infertile patients' right to make decisions
45 about their own medical treatments, including determining the fate of any embryos created as
46 part of the IVF process.

47 4. ASRM will oppose any personhood measure that is unclear, confusing, ambiguous, or
48 not based on sound scientific or medical knowledge, and which threatens the safety and
49 effective treatment of patients; therefore be it
50

51 RESOLVED, that our American Medical Association oppose any legislation that could
52 criminalize in-vitro fertilization (New HOD Policy); and be it further

1 RESOLVED, that our AMA work with other interested organizations to oppose Court rulings that
2 equate gametes (oocytes and sperm) or embryos with children. (Directive to Take Action)
3

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/16/2024

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 227
(A-24)

Introduced by: Missouri

Subject: Medicare Reimbursement for Telemedicine

Referred to: Reference Committee B

1 Whereas, during the COVID-19 pandemic, Medicare billing rules were revised to enable and
2 facilitate reimbursement to clinicians for services rendered by telemedicine links to their
3 patients; and
4

5 Whereas, these rules were adopted during the COVID-19 pandemic, and did not differentiate
6 reimbursement rates for office-based vs telemedicine-based patient care; and
7

8 Whereas, commercial insurers have generally adopted Medicare’s methodology for
9 reimbursement; and
10

11 Whereas, reimbursement for telemedicine services has had two salutatory effects: 1) greater
12 convenience for patients, and 2) decreased need to utilize petroleum-powered vehicles for
13 patients’ and doctors’ transit from their homes to physicians’ offices; and
14

15 Whereas, for mobility-challenged patients telemedicine links offer an increased level of
16 convenience; and
17

18 Whereas, American Medical Association Policy D-135.966, “Declaring Climate Change a Public
19 Health Crisis”, states that a goal for America’s health care sector is to decrease its greenhouse
20 gas emissions by 50% by 2030, and to achieve “carbon neutrality” by 2050; and
21

22 Whereas, under Medicare, through December 31, 2024, Medicare will reimburse physicians for
23 charges that accrue for the provision of medical care to patients via telehealth services; and
24

25 Whereas, the remission of the COVID pandemic has enabled much medical care to again be
26 provided in “brick and mortar” offices, which makes it imperative that reimbursement rates for
27 office-based care should be greater than reimbursement rates for telemedicine-based care, due
28 to the greater overhead expenses associated with office-based care; and
29

30 Whereas, to extend indefinitely the policy of reimbursement to physicians for services provided via
31 telemedicine links (at rates lower than provided for office-based care) would be salutatory toward
32 patient convenience and toward reducing the greenhouse gas emissions attributable to the
33 healthcare sector, a previously-established goal of our AMA via its Policy D-135.9661; therefore
34 be it
35

36 RESOLVED, that our American Medical Association support removal of the December 31, 2024
37 “sunset” date currently set for Medicare to cease reimbursement for services provided via
38 telemedicine, such that reimbursement of medical services provided by telemedicine be
39 continued indefinitely into the future, consistent with what would be determined by the Relative
40 Value Update Committee (“RUC”). (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 4/16/2024

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 228
(A-24)

Introduced by: Missouri
Subject: Waiver of Due Process Clauses
Referred to: Reference Committee B

1 Whereas, the right to and access to due process protections is a fundamental right enjoyed by all
2 employed Americans, unless specifically waived by the employee; and
3
4 Whereas, approximately half of all physicians are employed by employers that are not local,
5 physician-owned groups; and
6
7 Whereas, many employment agreements offered to such employed physicians contain “Waiver
8 of Due Process” clauses, which the non-physician employer has inserted to nullify the physician-
9 employee’s due process rights; and
10
11 Whereas, by working at the patient care interface, physicians are uniquely situated to detect
12 threats to patients’ health and well-being that have not been recognized or acknowledged by
13 members of hospitals’ administrations; and
14
15 Whereas, hospital administrators have occasionally retaliated against physicians who have
16 reported threats to patient or hospital worker safety in a manner that adversely impacts the
17 physician’s employment security, income stream and access to ongoing opportunities to provide
18 patient care, especially after within-organization reporting has failed to result in the employer
19 addressing or resolving those threats; and
20
21 Whereas, due process protections are thus essential for physicians, because they are duty-
22 bound to advocate for the best interest of patients and co-workers, without fear of adverse job
23 actions on the part of their employer; and
24
25 Whereas, federal legislation proposing to ban waiver of due process provisions in the
26 employment contracts of some physicians was introduced in the 116th Congress of the United
27 States of America, the “ER Hero and Patient Safety Act”, also known as HR 69102, a proposed
28 law that was not enacted; and
29
30 Whereas, the AMA House of Delegates adopted Resolution I-205-2022, advocating that our
31 AMA work for the abolition of waiver of due process clauses in physicians’ employment
32 agreements; and
33
34 Whereas, the AMA has since developed model state legislation on this topic, yet has not
35 developed model federal legislation regarding this matter as had been envisioned within the “ER
36 Hero and Patient Safety Act”; therefore be it
37
38 RESOLVED, that our American Medical Association advocate that waiver of due process
39 clauses be eliminated from all employment agreements between employed physicians and their
40 non-physician employers, and be declared unenforceable in physicians’ previously-executed

1 employment agreements between physicians and their non-physician employers that currently
2 exist (Directive to Take Action); and be it further

3

4 RESOLVED, that our AMA will engage in advocacy for adoption of such legislation at the
5 federal level. (Directive to Take Action)

6

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/16/2024

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 229
(A-24)

Introduced by: Illinois

Subject: Opposition to Legalization of Psilocybin

Referred to: Reference Committee B

1 Whereas, the effects of psilocybin, psilocin, baeocystin, norbaeocystin, and indole alkaloids
2 similar to LSD (d-lysergic acid) are primarily central (hallucinogenic) but there are some
3 peripheral effects, probably through the serotonin-norepinephrine pathways similar to
4 bufotenine; and

5
6 Whereas, according to the Drug Enforcement Administration (DEA), "The physical effects
7 include: nausea, vomiting, muscle weakness, and lack of coordination. The psychological
8 consequences of psilocybin use include hallucinations and an inability to discern fantasy from
9 reality. Panic reactions and a psychotic-like episode also may occur, particularly if a user
10 ingests a high dose." (<https://www.dea.gov/factsheets/psilocybin>); and

11
12 Whereas, mild to moderate effects of hallucinogenic mushrooms include dilated pupils
13 (develops in over 90% of cases), confusion, vertigo, drowsiness, nausea, vomiting, tachycardia,
14 and mild hypertension. Psychotropic effects include sense of exhilaration, hallucinations
15 including vivid bright colors and shapes, euphoria, distortion of sense of time, dysesthesias,
16 anxiety, perceptual distortions (may result in either a pleasant or apprehensive mood; "good" or
17 "bad" trip), and impaired judgement. Although hallucinations usually do not persist after 4 to 5
18 hours, prolonged hallucinations persisting for up to 4 days have rarely been reported. Flashback
19 phenomena have occurred from 2 weeks to 8 months after ingestion; and

20
21 Whereas, severe toxic physical effects include: muscular weakness, increased deep tendon
22 reflexes, fever (particularly in children), flushing (primarily face and upper trunk), tachycardia,
23 hypertension, ataxia, paresthesias, seizures (more common in children), rhabdomyolysis (very
24 rarely), renal failure, or cardiopulmonary arrest. Intravenous injection of mushroom extract can
25 cause fever, hypoxia, or mild methemoglobinemia. Severe psychotropic effects include: mood
26 alterations, acute psychosis, panic reactions, and powerful distortions of space and time; and

27
28 Whereas, psilocybin can induce complex changes at various levels of the brain which lead to
29 altered states of consciousness; and

30
31 Whereas, there is little correlation between the quantity ingested and clinical effects. One to four
32 large Psilocybes (10 to 30 grams fresh weight) may yield 5 to 15 mg of psilocybin, and produce
33 hallucinations. A dose of 12 mg or more of psilocybin can produce vivid hallucinations; and

34
35 Whereas, Psilocybin or it's related substances should not be used in any safety sensitive
36 position in that impairment is likely to occur; and

37
38 Whereas, quality control (for dose confirmation and contaminant detection) is difficult to obtain
39 for a fungal based product; and

- 1 Whereas, Psilocybin is not detected with usual toxicological screening methods and blood/urine
2 concentrations of the active ingredient (Psilocin or 4-hydroxy-dimethyltryptamine; 4-OH-DMT) is
3 not possible for the clinical application (requiring at least one-week turnaround from most
4 reference labs (<https://www.nmslabs.com/tests?test=psilocybin>); and
5
6 Whereas, therapeutic drug monitoring, dose titration to effects and prediction of toxic sequelae
7 is not possible with Psilocybin; therefore be it
8
9 RESOLVED, that our American Medical Association oppose any legislative efforts relatable to
10 legalization of Psilocybin/Psilocin or its related substances use. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 4/24/2024

References:

1. Tylš, Filip, Tomáš Páleníček, and Jiří Horáček. "Psilocybin—summary of knowledge and new perspectives." *European Neuropsychopharmacology* 24.3 (2014): 342-356.
2. Leikin, J. B., Krantz, A. J., Zell-Kanter, M., Barkin, R. L., & Hryhorczuk, D. O. (1989). Clinical features and management of intoxication due to hallucinogenic drugs. *Medical toxicology and adverse drug experience*, 4, 324-350.
3. Leikin, Jerrold B., and Frank P. Paloucek. "Poisoning and toxicology handbook." CRC Press (2008). Page 913
4. MUSHROOMS-HALLUCINOGENIC in: Merative™ Micromedex® POISINDEX® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: July 5, 2023).

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 230
(A-24)

Introduced by: American Academy of Dermatology, American Society for Dermatologic Surgery Association, American Contact Dermatitis Society and American College of Mohs Surgery

Subject: Protecting Patients from Inappropriate Dentist and Dental Hygienist Scope of Practice Expansion

Referred to: Reference Committee B

1 Whereas, procedures performed by any means, methods, devices, or instruments that can alter
2 or cause biologic change or damage the skin and subcutaneous tissue constitute the practice of
3 medicine and surgery; and
4

5 Whereas, there are increased legislative and regulatory efforts to allow dentists and dental
6 hygienists to administer neurotoxins and dermal fillers for therapeutic or cosmetic purposes
7 without physician supervision; and
8

9 Whereas, in order to ensure patient safety, administration of neurotoxins and dermal fillers
10 requires supervision by a trained physician, education, training, specific knowledge of facial
11 anatomy (particularly in the periocular region), and the ability to manage complications that may
12 arise; and
13

14 Whereas, the focus of dental education is on oral health, rather than the skin and facial tissue;
15 and
16

17 Whereas, dentists and dental hygienists are not required to demonstrate competency in
18 procedures that augment skin and soft tissues using products that can alter or damage such
19 living tissue; and
20

21 Whereas, the American Dental Association and the American Dental Hygienist Association are
22 silent on the issue of dentists and dental hygienists performing medical procedures related to
23 fillers and neurotoxins; and
24

25 Whereas, in 2023 the Food and Drug Administration (FDA) updated consumer guidance to state
26 that anyone considering a neurotoxin or dermal filler should consult with a licensed health care
27 provider who has experience in the fields of dermatology or plastic surgery, who is experienced
28 in injecting dermal fillers, who is knowledgeable about fillers, anatomy and managing
29 complications, and who knows the risks and benefits of treatment³; and
30

31 Whereas, preventing and treating adverse events of injectable fillers requires the development
32 of evidence-based clinical practice guidelines to support decision-making in daily practice and
33 knowledge of vascular anatomy is *crucial* for all filler injections⁴; and
34

35 Whereas, intravascular injection is possible at any location on the face, but certain locations
36 carry a higher risk of filler embolization, necrosis, visual abnormalities, blindness and stroke⁵;
37 and

1 Whereas, allowing dentists and dental hygienists to administer neurotoxins and dermal fillers for
2 therapeutic or cosmetic purposes jeopardizes patient safety and disregards what is considered
3 adequate and appropriate medical education and training; therefore be it
4

5 RESOLVED, that our American Medical Association advocacy efforts recognize the threat
6 posed to patient safety when dentists and dental hygienists are authorized to practice medicine
7 and administer procedures outside their level of education and training (New HOD Policy); and
8 be it further
9

10 RESOLVED, that our AMA actively oppose regulatory and legislative efforts authorizing dentists
11 and dental hygienists to practice outside their level of education and training. (Directive to Take
12 Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/24/2024

REFERENCES

1. General Dentistry. Retrieved from <http://www.ada.org/en/education-careers/careers-in-dentistry/general-dentistry>
2. Dental Hygienist Education and Training Requirements. Retrieved from <http://www.ada.org/en/education-careers/careers-in-dentistry/dental-team-careers/dental-hygienist/education-training-requirements-dental-hygienist>
3. Dermal filler Do's and Don'ts For Wrinkles, Lips and More. U.S. Food and Drug Administration. Retrieved from <https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049349.htm>
4. Jones D, Fitzgerald R, Cox S, Butterwick K, et al. Preventing and Treating Adverse Events of Injectable Fillers: Evidence-Based Recommendations From the American Society for Dermatologic Surgery Multidisciplinary Task Force. *Dermatol Surg* 2021;47:214-26.
5. Ibid.
6. Scope of Practice. ADHA. Retrieved from <https://www.adha.org/advocacy/scope-of-practice/>
7. Advocacy. American Dental Association. Retrieved from <https://www.ada.org/advocacy>

RELEVANT AMA POLICY

D-35.983 Addressing Safety and Regulation in Medical Spas

Our AMA will: (1) advocate for state regulation to ensure that cosmetic medical procedures, whether performed in medical spas or in more traditional medical settings, have the same safeguards as "medically necessary" procedures, including those which require appropriate training, supervision and oversight; (2) advocate that cosmetic medical procedures, such as botulinum toxin injections, dermal filler injections, and laser and intense pulsed light procedures, be considered the practice of medicine; (3) take steps to increase the public awareness about the dangers of those medical spas which do not adhere to patient safety standards by encouraging the creation of formal complaint procedures and accountability measures in order to increase transparency; and (4) continue to evaluate the evolving issues related to medical spas, in conjunction with interested state and medical specialty societies. (Res. 209, I-11; Reaffirmed: BOT Rep. 7, A-21)

D-160.995 Physician and Nonphysician Licensure and Scope of Practice

1. Our AMA will: (a) continue to support the activities of the Advocacy Resource Center in providing advice and assistance to specialty and state medical societies concerning scope of practice issues to include the collection, summarization and wide dissemination of data on the training and the scope of practice of physicians (MDs and DOs) and nonphysician groups and that our AMA make these issues a legislative/advocacy priority; (b) endorse current and future funding of research to identify the most cost effective, high-quality methods to deliver care to patients, including methods of multidisciplinary care; and (c) review and report to the House of Delegates on a periodic basis on such data that may become available in the future on the quality of care provided by physician and nonphysician groups.
2. Our AMA will: (a) continue to work with relevant stakeholders to recognize physician training and education and patient safety concerns, and produce advocacy tools and materials for state level advocates to use in scope of practice discussions with legislatures, including but not limited to infographics, interactive maps, scientific overviews, geographic comparisons, and educational experience; (b) advocate for the inclusion of non-physician scope of practice characteristics in various

analyses of practice location attributes and desirability; (c) advocate for the inclusion of scope of practice expansion into measurements of physician well-being; and (d) study the impact of scope of practice expansion on medical student choice of specialty.

3. Our AMA will consider all available legal, regulatory, and legislative options to oppose state board decisions that increase non-physician health care provider scope of practice beyond legislative statute or regulation. (CME Rep. 1, I-00; Reaffirmed: CME Rep. 2, A-10; Modified: CCB/CLRPD Rep. 2, A-14; Appended: Res. 251, A-18; Appended: Res. 222, I-19)

H-160.949 Practicing Medicine by Non-Physicians

Our AMA: (1) urges all people, including physicians and patients, to consider the consequences of any health care plan that places any patient care at risk by substitution of a non-physician in the diagnosis, treatment, education, direction and medical procedures where clear-cut documentation of assured quality has not been carried out, and where such alters the traditional pattern of practice in which the physician directs and supervises the care given;

(2) continues to work with constituent societies to educate the public regarding the differences in the scopes of practice and education of physicians and non-physician health care workers;

(3) continues to actively oppose legislation allowing non-physician groups to engage in the practice of medicine without physician (MD, DO) training or appropriate physician (MD, DO) supervision;

(4) continues to encourage state medical societies to oppose state legislation allowing non-physician groups to engage in the practice of medicine without physician (MD, DO) training or appropriate physician (MD, DO) supervision;

(5) through legislative and regulatory efforts, vigorously support and advocate for the requirement of appropriate physician supervision of non-physician clinical staff in all areas of medicine; and

(6) opposes special licensing pathways for "assistant physicians" (i.e., those who are not currently enrolled in an Accreditation Council for Graduate Medical Education training program or have not completed at least one year of accredited graduate medical education in the U.S). (Res. 317, I-94; Modified by Res. 501, A-97; Appended: Res. 321, I-98; Reaffirmation A-99; Appended: Res. 240, Reaffirmed: Res. 708 and Reaffirmation A-00; Reaffirmed: CME Rep. 1, I-00; Reaffirmed: CMS Rep. 6, A-10; Reaffirmed: Res. 208, I-10; Reaffirmed: Res. 224, A-11; Reaffirmed: BOT Rep. 9, I-11; Reaffirmed: Res. 107, A-14; Appended: Res. 324, A-14; Modified: CME Rep. 2, A-21)

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 231
(A-24)

Introduced by: American College of Medical Genetics and Genomics

Subject: Supporting the Establishment of Rare Disease Advisory Councils

Referred to: Reference Committee B

- 1 Whereas, a rare disease is defined as a disease or condition that impacts fewer than 200,000
2 people in the United States¹; and
3
4 Whereas, given the current estimate for the number of known rare diseases is more than
5 10,000, the rare disease population comprises of more than 30 million people in the United
6 States²; and
7
8 Whereas, the economic burden of rare diseases surpasses that of some of the most prevalent
9 chronic diseases in the United States³; and
10
11 Whereas, rare diseases are often chronic, progressive, and debilitating, and lead to significant
12 morbidity and mortality⁴; and
13
14 Whereas, rare disease patients continue to face hurdles with accessing new available
15 medications due to costs and payor policies, including prior authorizations and denials⁵; and
16
17 Whereas, patients with rare disorders face other unique challenges in healthcare including
18 limited access to specialists, the cost-sharing mechanism of prescriptions, insurance coverage
19 issues without a proper diagnosis, and more^{5,6}; and
20
21 Whereas, rare patients report significantly lower quality of life scores due to facing these hurdles
22 and experiencing a longer diagnostic journey than typical patients^{5,6}; and
23
24 Whereas, a Rare Disease Advisory Council (RDAC) is an advisory body that informs
25 policymakers on the issues relevant to the rare community and gives said community a stronger
26 voice⁷; and
27
28 Whereas, since 2015, Rare Disease Advisory Councils have been established in 27 states,
29 leaving many states without advocates for proper rights for rare patients⁷; and
30
31 Whereas, Rare Disease Advisory Councils have been actively working on state and federal
32 policies addressing barriers to obtaining proper care for patients with rare diseases such as
33 Medicaid eligibility, newborn screening processes, coverage of medical nutrition, out-of-pocket
34 prescription drug costs, reforming step therapy, and more⁸; and
35
36 Whereas, AMA Policy H 460.880 recognizes the under-treatment and under-diagnosis of
37 orphan diseases but fails to sufficiently include how to act on this recognition to actively support
38 rare disease patients and their families; therefore be it

1 RESOLVED, that our American Medical Association will support state legislation for the
2 establishment of Rare Disease Advisory Councils in each state (New HOD Policy).
3

Fiscal Note: Minimal - less than \$1,000

Received: 4/24/2024

REFERENCES

1. Orphan Drug Act. P.L. 97-414 (Jan 4, 1983). <https://www.congress.gov/bill/97th-congress/house-bill/5238/text>
2. Haendel M, Vasilevsky N, Unni D, et al. How many rare diseases are there?. *Nat Rev Drug Discov.* 2020;19(2):77-78. doi:10.1038/d41573-019-00180-y
3. Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. *Orphanet J Rare Dis.* 2022;17(1):163. doi:10.1186/s13023-022-02299-5
4. Gopal-Srivastava R, Kaufmann P. Facilitating Clinical Studies in Rare Diseases. *Adv Exp Med Biol.* 2017;1031:125-140. doi:10.1007/978-3-319-67144-4_6
5. Barriers to Rare Disease Diagnosis, Care and Treatment in the US: A 30-Year Comparative Analysis. National Organization for Rare Disorders; 2020. https://rarediseases.org/wp-content/uploads/2022/10/NRD-2088-Barriers-30-Yr-Survey-Report_FNL-2.pdf
6. Bogart K, Hemmesch A, Barnes E, et al. Healthcare access, satisfaction, and health-related quality of life among children and adults with rare diseases. *Orphanet Journal of Rare Diseases.* 2022;17(1):196. doi:10.1186/s13023-022-02343-4
7. Rare Disease Advisory Councils (RDAC). National Organization for Rare Disorders. https://rarediseases.org/wp-content/uploads/2023/07/NRD-2301-RDAC-Sell-Sheet_FNL-1.pdf. Updated 2023. Accessed April 9, 2024.
8. Rare Disease Advisory Councils - National Organization for Rare Disorders. Published April 15, 2022. Accessed August 20, 2023. <https://rarediseases.org/policy-issues/rare-disease-advisory-councils/>

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 232
(A-24)

Introduced by: Association for Clinical Oncology, American College of Rheumatology

Subject: Medicare Advantage Part B Drug Coverage

Referred to: Reference Committee B

1 Whereas, 66% of Medicare beneficiaries have been diagnosed with at least two chronic
2 diseases; and
3
4 Whereas, the majority of patients enrolled in traditional (fee-for-service) Medicare have
5 additional coverage that limits their financial exposure to the 20% coinsurance required for Part
6 B drugs and biologicals; and
7
8 Whereas, over half of all Medicare-eligible patients were enrolled in a Medicare Advantage (MA)
9 plan in 2023; and
10
11 Whereas, Medicare patients are increasingly choosing MA plans because many of those plans
12 have lower premiums and are more affordable for less affluent patients; and
13
14 Whereas, more MA plans are listing specialty drugs and biologicals as either non-covered
15 benefits or are covering only 80% of the cost of physician administered drugs and biologicals;
16 and
17
18 Whereas, patients enrolled in MA are prohibited from purchasing Medigap policies; and
19
20 Whereas, less affluent patients may not be able to afford the remaining 20% coinsurance for
21 essential drugs and biologicals required by most MA plans, potentially leading to disparities in
22 health outcomes; and
23
24 Whereas, prior to a chronic disease diagnosis, patients enrolling in MA can have no knowledge
25 of which expensive drugs and biologicals they may require and, further, that those drugs and
26 biologicals may be designated as non-covered by the plan or require a 20% coinsurance
27 payment; and
28
29 Whereas, when a patient enrolled in MA is diagnosed with a chronic disease where costly
30 physician-administered drugs and biologicals are necessary, they cannot revert to traditional
31 (fee-for-service) Medicare or purchase a Medigap policy; therefore be it
32
33 RESOLVED, that our American Medical Association will advocate with Congress, through the
34 appropriate oversight committees, and with the Centers for Medicare & Medicaid Services
35 (CMS) to require that Medicare Advantage (MA) plans cover physician-administered drugs and
36 biologicals in such a way that the patient out of pocket cost is the same or less than the amount
37 that a patient with traditional Medicare plus a Medigap plan would pay. (Directive to Take Action)

Fiscal Note: Moderate - between \$5,000 - \$10,000

Received: 4/24/2024

REFERENCES

1. Chronic Condition Data Warehouse, "Medicare Beneficiary Summary Files," 2018. <https://www2.cdwdata.org/documents/10280/19099065/b2-prevalence-current-year.jpg>
2. Ochieng N, Clerveau G, Cubanski J, & Neuman T. (2023). A snapshot of sources of coverage among Medicare beneficiaries. Kaiser Family Foundation. [https://www.kff.org/medicare/issue-brief/a-snapshot-of-sources-of-coverage-among-medicare-beneficiaries/#:~:text=PNG-,Medigap,12.5%20million%20beneficiaries\)%20in%202021](https://www.kff.org/medicare/issue-brief/a-snapshot-of-sources-of-coverage-among-medicare-beneficiaries/#:~:text=PNG-,Medigap,12.5%20million%20beneficiaries)%20in%202021)
3. Ochieng N, Biniek JF, Freed M, Damico A & Neuman T. (2023). Medicare Advantage in 2023: Enrollment update and key trends. Kaiser Family Foundation. <https://www.kff.org/medicare/issue-brief/medicare-advantage-in-2023-enrollment-update-and-key-trends/>
4. Neuman T, Freed M, & Biniek JF. (2024). 10 reasons why Medicare Advantage enrollment is growing and why it matters. Kaiser Family Foundation. <https://www.kff.org/medicare/issue-brief/10-reasons-why-medicare-advantage-enrollment-is-growing-and-why-it-matters/>
5. Centers for Medicare and Medicaid Services. Learn how Medigap works. US Department of Health and Human Services. <https://www.medicare.gov/health-drug-plans/medigap/basics/how-medigap-works#:~:text=When%20you%27re%20getting%20started,switching%20back%20to%20Original%20Medicare.>

RELEVANT AMA POLICY

Medicare Advantage Policies H-330.878

1. Our AMA supports that Medicare Advantage plans must provide enrollees with coverage for, at a minimum, all Part A and Part B original Medicare services, if the enrollee is entitled to benefits under both parts.
2. Our AMA will advocate: (a) for better enforcement of Medicare Advantage regulations to hold the Centers for Medicare & Medicaid Services (CMS) accountable for presenting transparency of minimum standards and to determine if those standards are being met for physicians and their patients; (b) that Medicare Advantage plans be required to post all components of Medicare covered and not covered in all plans across the US on their website along with the additional benefits provided; and (c) that CMS maintain a publicly available database of physicians in network under Medicare Advantage and the status of each of these physicians in regard to accepting new patients in a manner least burdensome to physicians.

Deemed Participation and Misleading Marketing by Medicare Advantage Private Fee for Service Plans D-330.930

Our AMA will continue its efforts to educate physicians and the general public on the implications of participating in programs offered under Medicare Advantage and educate physicians and the public about the lack of secondary coverage (Medigap policies) with Medicare Advantage plans and how this may affect enrollees.

Transparency of Costs to Patients for Their Prescription Medications Under Medicare Part D and Medicare Advantage Plans H-330.870

Our AMA will: (1) advocate for provision of transparent print and audio/video patient educational resources to patients and families in multiple languages from health care systems and from Medicare - directly accessible - by consumers and families, explaining clearly the different benefits, as well as the varied, programmatic and other out-of-pocket costs for their medications under Medicare, Medicare Supplemental and Medicare Advantage plans; (2) advocate for printed and audio/video patient educational resources regarding personal costs, changes in benefits and provider panels that may be incurred when switching (voluntarily or otherwise) between Medicare, Medical Supplemental and Medicare Advantage or other plans, including additional information regarding federal and state health insurance assistance programs that patients and consumers could access directly; and (3) advocate for increased funding for federal and state health insurance assistance programs and educate physicians, hospitals, and patients about the availability of and access to such programs.

Medicare Cost-Sharing D-330.951

Our AMA will urge the Centers for Medicare and Medicaid Services to require companies that participate in the Medicare Advantage program to provide enrollees and potential enrollees timely information in a comparable, standardized, and clearly-written format that details enrollment restrictions, as well as all coverage restrictions and beneficiary cost-sharing requirements for all services.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 233
(A-24)

Introduced by: Association for Clinical Oncology, American College of Rheumatology

Subject: Prohibiting Mandatory White Bagging

Referred to: Reference Committee B

- 1 Whereas, many health insurers and pharmacy benefit managers (PBMs) have adopted policies
2 that condition coverage of a clinician-administered drug, such as an IV infusion, on the drug
3 being dispensed from a PBM-affiliated mail order pharmacy; and
4
- 5 Whereas, this practice is commonly referred to as “white bagging”; and
6
- 7 Whereas, mandatory white bagging policies exclude payment for medically necessary drugs
8 from any health care provider that is not under common ownership with the insurer or PBM,
9 including in-network pharmacies; and
10
- 11 Whereas, drugs commonly subject to mandatory white bagging policies are often needed to
12 treat the most vulnerable patient populations with complex treatment plans who require efficient
13 and timely delivery of clinician-administered drugs for successful outcomes; and
14
- 15 Whereas, white bagging requires each individual patient-specific treatment dose to be shipped
16 in a separate parcel, via common carrier, to the administering provider, even if the administering
17 provider already has the drug in stock and available for administration; and
18
- 19 Whereas, shipments from specialty pharmacies can be delayed and are difficult for providers to
20 track; and
21
- 22 Whereas, if a patient’s clinical status changes from when the medication was ordered, the
23 adjusted medication must be re-ordered from the third-party pharmacy, which can result in
24 increases in canceled appointments, days to initiation of therapy, and frequency of past-due
25 administrations; and
26
- 27 Whereas, day-of treatment changes lead to drug waste when an unused portion of the drug
28 cannot be used for another patient, and practices and hospitals must then discard the unused
29 portion of highly toxic drugs according to state and federal safety standards, creating additional
30 administrative burden; and
31
- 32 Whereas, providers have no control over the shipping process, limiting their ability to prevent
33 improper storage or mishandling of white bagged drugs; and
34
- 35 Whereas, a 2023 analysis found that, on average, bagging increased oncology patients’ out-of-
36 pocket costs by \$180 per month, or \$2,160 per year; and
37
- 38 Whereas, since 2021, eight states have prohibited the use of payer-mandated white bagging;
39 therefore be it

1 RESOLVED, that our American Medical Association urge state and federal policymakers to
2 enact legislation to prohibit the mandatory use of white bagging (Directive to Take Action).
3

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/24/2024

REFERENCES

1. White Bagging Policy Brief. American Society of Clinical Oncology, 2024. <https://society.asco.org/sites/new-www.asco.org/files/content-files/2024-White-Bagging-Brief.pdf>
2. Komorny et. al, Payer site of care mandates with oncology medications: It's time to demand payer accountability on behalf of patients, American Journal of Health-System Pharmacy, 2023; zxad078, <https://doi.org/10.1093/ajhp/zxad078>
3. Shih YT, Xu Y, Yao JC. Financial Outcomes of "Bagging" Oncology Drugs Among Privately Insured Patients With Cancer. JAMA Netw Open. 2023;6(9):e2332643. doi:10.1001/jamanetworkopen.2023.32643
4. State of Play: White Bagging. American Society of Clinical Oncology. December 2023. <https://society.asco.org/news-initiatives/policy-news-analysis/state-play-white-bagging#:~:text=Arkansas%20and%20Louisiana%20became%20the,added%20guardrails%20around%20the%20practice>

RELEVANT AMA POLICY

Medication Brown Bagging H-100.951

1. Our AMA affirms that decisions to accept or refuse "brown bagged" (patient-acquired, physician-administered) pharmaceuticals be made only by physicians responsible for administering these medications.
2. Our AMA affirms that "brown bagged" pharmaceuticals be accepted for in-office or hospital administration only after the physician responsible for administering these medications determines that the individual patient, or his or her agent, is fully capable of safely handling and transporting the medication.
3. Our AMA will work with interested national medical specialty societies and state medical associations to oppose third party payer policies and legislative and regulatory actions that require patients to utilize "brown bagging" to ensure coverage of office-administered medications.
4. Our AMA will work with interested national medical specialty societies and state medical associations to oppose third party payer policies that reimburse office-administered drug costs at less than the provider's cost of acquiring the drug if the provider does not accept "brown bagging."

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 234
(A-24)

Introduced by: Association for Clinical Oncology, American Academy of Dermatology
Association, American College of Mohs Surgery, American Contact
Dermatitis Society, American College of Rheumatology

Subject: State Prescription Drug Affordability Boards - Study

Referred to: Reference Committee B

- 1 Whereas, in an effort to control high prescription drug costs, states are increasingly considering
2 prescription drug affordability boards (PDABs); and
3
4 Whereas, PDABs in Colorado, Maryland and Minnesota have the authority to set upper
5 payment limits (UPLs) for certain high-cost medications; and
6
7 Whereas, a UPL is the maximum reimbursement rate above which purchasers throughout the
8 state may not pay for prescription drug products; and
9
10 Whereas, Medicare pays most separately payable Part-B covered drugs and biologics at a rate
11 of the drug's average sales price plus 6%; and
12
13 Whereas, the 6% add-on payment for Medicare Part B drugs is intended to cover expenses
14 associated with administering drugs in-office, including storage and handling; and
15
16 Whereas, similar to the concept of an upper payment limit, the Inflation Reduction Act (IRA)
17 establishes a "maximum fair price" for a negotiated drug; and
18
19 Whereas, under the IRA, Medicare's payment to providers for Part B drugs with negotiated
20 prices will be at 106% of the maximum fair price; and
21
22 Whereas, reimbursement for physician administered drugs can be up to 125% of a drug's
23 average sales price in the private insurance market; and
24
25 Whereas, state PDAB legislation that includes UPL authority often lacks language that would
26 allow physicians to seek reimbursement for storage and handling of a physician-administered
27 drug subject to a UPL; therefore be it
28
29 RESOLVED, that our American Medical Association conduct a study to determine how upper
30 payment limits (UPLs) established by state prescription drug affordability boards (PDABs) will
31 impact reimbursement for physician-administered drugs and what impact state UPLs will have
32 on patient access to care (Directive to Take Action); and be it further
33
34 RESOLVED, that our AMA report the results of the study on UPLs to the House of Delegates at
35 A-25. (Directive to Take Action)
36

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 4/24/2024

REFERENCES

1. Comparison of State Prescription Drug Affordability Review Initiatives. National Academy for State Health Policy. January 2024. <https://nashp.org/comparison-of-state-prescription-drug-affordability-review-initiatives/>
2. Enacted Prescription Drug Affordability Boards 2019-2023. Aimed Alliance. January 2024. <https://aimedalliance.org/wp-content/uploads/2024/01/AA-PDAB-Enacted-Chart-Jan-2024.pdf>
3. Q&A on NASHP's Model Act to Reduce the Cost of Prescription Drugs. August 2022. <https://nashp.org/qa-on-nashps-model-act-to-reduce-the-cost-of-prescription-drugs/>
4. Cubanski et al. Explaining the Prescription Drug Provisions in the Inflation Reduction Act. KFF. January 2023. <https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/>

RELEVANT AMA POLICY

Reducing Prescription Drug Prices D-110.993

Our AMA will (1) continue to meet with the Pharmaceutical Research and Manufacturers of America to engage in effective dialogue that urges the pharmaceutical industry to exercise reasonable restraint in the pricing of drugs; and (2) encourage state medical associations and others that are interested in pharmaceutical bulk purchasing alliances, pharmaceutical assistance and drug discount programs, and other related pharmaceutical pricing legislation, to contact the National Conference of State Legislatures, which maintains a comprehensive database on all such programs and legislation.

Medicare Part B Competitive Acquisition Program (CAP) H-110.983

Our AMA will advocate that any revised Medicare Part B Competitive Acquisition Program meet the following standards to improve the value of the program by lowering the cost of drugs without undermining quality of care:

- (1) it must be genuinely voluntary and not penalize practices that choose not to participate;
- (2) it should provide supplemental payments to reimburse for costs associated with special handling and storage for Part B drugs;
- (3) it must not reduce reimbursement for services related to provision/administration of Part B drugs, and reimbursement should be indexed to an appropriate healthcare inflation rate;
- (4) it should permit flexibility such as allowing for variation in orders that may occur on the day of treatment, and allow for the use of CAP-acquired drugs at multiple office locations;
- (5) it should allow practices to choose from multiple vendors to ensure competition, and should also ensure that vendors meet appropriate safety and quality standards;
- (6) it should include robust and comprehensive patient protections which include preventing delays in treatment, helping patients find assistance or alternative payment arrangements if they cannot meet the cost-sharing responsibility, and vendors should bear the risk of non-payment of patient copayments in a way that does not penalize the physician;
- (7) it should not allow vendors to restrict patient access using utilization management policies such as step therapy; and
- (8) it should not force disruption of current systems which have evolved to ensure patient access to necessary medications.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 235
(A-24)

Introduced by: New Jersey

Subject: Establish a Cyber-Security Relief Fund

Referred to: Reference Committee B

- 1 Whereas, Cyber-attacks are becoming frequent and that they will continue to escalate and
2 become more complex; and
3
4 Whereas, the recent cyber-attack on “Optum” resulted in thousands of Physician payments to
5 be withheld for several weeks or months resulting in devastating consequences to the several
6 thousand families because of inability to meet the payroll of the physicians and their employees;
7 and
8
9 Whereas, the financial impact is global, affecting private practicing Physicians, Medical groups,
10 and healthcare systems; and
11
12 Whereas, United Healthcare’s full year 2023 earnings from operations were \$32.4 billion;
13 therefore be it
14
15 RESOLVED, that our American Medical Association, through appropriate channels, advocate
16 for a ‘Cyber Security Relief Fund” to be established by Congress (Directive to Take Action); and
17 be it further
18
19 RESOLVED, that the “Cyber Security Relief Fund” be funded through contributions from health
20 insurance companies and all payers - as a mandated requirement by each of the payer
21 (Directive to Take Action); and be it further
22
23 RESOLVED, that the “Cyber Security Relief Fund” only be utilized for ‘uninterrupted’ payments
24 to all providers- in a structured way, in the event of future cyber-attacks affecting payments.
25 (Directive to Take Action)

Fiscal Note: Moderate - between \$5,000 - \$10,000

Received: 5/3/2024

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 236
(A-24)

Introduced by: Delaware

Subject: Support of Physicians Pursuing Collective Bargaining and Unionization

Referred to: Reference Committee B

1 Whereas, the American Medical Association supports physicians' entitlement to engage in
2 collective bargaining, and it is AMA policy to advocate for broadening the scope of eligibility for
3 this right under federal law, thereby expanding the number of physicians eligible to join unions¹;
4 and

5
6 Whereas, the AMA highlights that bargaining units consisting solely of physicians are presumed
7 appropriate,¹ a recommendation that aligns with the acknowledgment of physicians' unique
8 skills, distinct expertise, and ethical and professional obligations; and

9
10 Whereas, in 1999 the AMA provided financial support for the establishment of a national labor
11 organization, the Physicians for Responsible Negotiation (PRN), under the National Labor
12 Relations Board (NLRB), an initiative aimed to support the development and operation of local
13 physician negotiating units as an option for employed physicians and physicians in-training, but
14 due to limited participation from physicians, the AMA withdrew this support in 2004¹; and

15
16 Whereas, since 2004, the number of physicians belonging to unions in the United States has
17 reportedly surged, with a notable 26% increase from 2014 to 2019 reaching a total of 67,673
18 physicians that were union members¹; and

19
20 Whereas, the percentage of physicians in the United States now employed by hospitals, health
21 systems, or corporate entities has seen a substantial rise, reaching 73.9% as of January 2022,
22 compared to 47.4% in 2018, and the acquisition of physician practices by hospitals and
23 corporate entities escalated between 2019-2022 during the pandemic^{2,3}; and

24
25 Whereas, the shift from a workforce of independent professional physicians to one composed of
26 employed physicians fundamentally alters the dynamics among hospitals, health systems,
27 corporate entities and physicians, with a risk of adversely affecting the conditions under which
28 care is delivered and quality of care provided,⁴ consequently altering the physician-patient
29 relationship; and

30
31 Whereas, major hospitals, health care systems, and other corporate entities that employ
32 physicians may restrict employment options available to these professionals in a market largely
33 influenced by their employer or where covenants not to compete may further contribute to an
34 employer's bargaining advantage¹; and

35
36 Whereas, the increasing corporatization of medicine, encompassing private equity involvement
37 in health care, raises concerns about alignment of incentives, costs, impacts on physician
38 wellness, and subsequent downstream effects on patients^{5,6}; and

1 Whereas, in recent years, there has been a rise in physician burnout, exacerbated by the
2 COVID-19 pandemic, primarily stemming from the excessive time dedicated to electronic health
3 record documentation, bureaucratic administrative duties, and moral distress arising from a
4 misalignment between physicians' values and the incentivized actions dictated by the health
5 care system⁷⁻¹¹; and
6

7 Whereas, as physicians increasingly transition to employment, there's a trend toward
8 standardization of work schedules, time of appointments, and other aspects of work conditions.
9 Studies indicate that burnout is directly impacted by a lack of control over work conditions and
10 that granting more autonomy can mitigate stress and burnout, and even reduce cardiovascular
11 risk¹²; and
12

13 Whereas, physicians encounter significant power differentials when negotiating with hospital
14 systems as employers and may lack sufficient influence without collective bargaining to
15 counterbalance the dynamic¹; and
16

17 Whereas, collective bargaining serves as an effective mechanism for safeguarding patient care
18 safety standards, enhancing work conditions, securing fair compensation and job stability, and
19 establishing a structured process for addressing grievances; and
20

21 Whereas, unionization is linked with enhanced wages and benefits, as well as diminished
22 disparities in compensation for minority groups¹³; and
23

24 Whereas, in 2022, the National Labor Relations Board concluded that employed physicians are
25 not in a supervisory role simply by virtue of their position in the organization and, therefore, may
26 be eligible to unionize¹⁴; and
27

28 Whereas, collective bargaining and unionization do not necessarily require resorting to strikes.
29 For example, first responder unions often utilize binding arbitration as an alternative tactic.
30 Other potential strategies may include work slowdowns, picketing, mass resignation,
31 whistleblowing to regulatory and accrediting bodies, boycotting administrative tasks, and
32 suspending billing activities, among other options; therefore be it
33

34 RESOLVED, that our American Medical Association investigate avenues for the AMA and other
35 physician associations to aid physicians in initiating and navigating collective bargaining efforts,
36 encompassing but not limited to unionization. (Directive to Take Action)
37

Fiscal Note: \$43,308: Consult experts and coordinate with medical societies to identify and
communicate ways to aid physicians in collective bargaining efforts.

Received: 5/3/2024

REFERENCES

1. American Medical Association. ARC Issue brief: Collective bargaining for physicians and physicians-in-training. Available at: <https://www.ama-assn.org/system/files/advocacy-issue-brief-physician-unions.pdf>. Accessed March 30, 2024.
2. Matthews, S. Physicians Advocacy Institute. Report: Supermajority of U.S. Physicians are Employed by Health Systems or Corporate Entities. Available at: <https://www.physiciansadvocacyinstitute.org/Portals/0/assets/docs/PAI-Research/2022%20Avalere%20Employment%20Release%20-%20FINAL.pdf?ver=Cy6aAKaFIM56SND598Xlvw%3d%3d>. Accessed March 30, 2024.
3. Kane, C. American Medical Association. Policy Research Perspectives. Updated on Physician Practice Arrangements: For the First Time, Fewer Physicians are Owners Than Employees. <https://www.ama-assn.org/system/files/2019-07/prp-fewer-owners-benchmark-survey-2018.pdf>. Accessed March 30, 2024.
4. Richman, BD, and Schulman KA. Restoring Physician Authority in an Era of Hospital Dominance. *Jama*. 2022;328(24):2400-2401. Doi.10.1001/jama.2022.23610. Accessed online at: <https://jamanetwork.com/journals/jama/fullarticle/2799930>.
5. Gooney, T. I.M. Matters from ACP. 3 C's: Corporatization, consolidation, commodification. Current trends in health care emphasize the importance of our continued advocacy efforts for our patients and our profession. <https://acpinternist.org/archives/2022/03/3-cs-corporatization-consolidation-commodification.htm>. Accessed March 30, 2024
6. Offodile AC, Cerullo M, Rauh-Hain JA, and Ho V. Private Equity Investments In Health Care: An Overview of Hospital and Health System Leveraged Buyouts, 2003-17. *Hlth Aff* 2021;40(5). DOI.10.1377/hlthaff.2020.01535. Accessed online at: <https://www.healthaffairs.org/doi/10.1377/hlthaff.2020.01535>.
7. Shanafelt TD, West CP, Dyrbye LN, Wang H, Carlasare LE, and Sinsky C. Changes in Burnout and Satisfaction with Work-Life Integration in Physicians during the First 2 Years of the COVID-19 Pandemic. *Mayo CP*. 2022;97(12):2248-2258. DOI: <https://doi.org/10.1016/j.mayocp.2022.09.002>.
8. Gardner RL, Cooper E, Haskell J, Harris DA, Poplay S, Kroth P, Linser L. Physician stress and burnout: the impact of health information technology. *Journal of American Medical Informatics Association*. 2019;26(2):106-114. DOI: <https://academic.oup.com/jamia/article/26/2/106/5230918>.
9. Kane, L. Medscape Internal Medicine. Physician Burnout & Depression Report 2022: Stress, Anxiety, and Anger. https://www.medscape.com/slideshow/2022-lifestyle-burnout-6014664?icd=login_success_email_match_norm#1. Accessed March 30, 2024.
10. Sinsky C, Colligan L, Li L, Prgomet M, Reynolds S, Goeders L, Westbrook J, Tutty M, Blike G. Allocation of Physician Time in Ambulatory Practice: A Time and Motion Study in 4 Specialties. *Annals of Int Med*. 2016;165(11):753-761. DOI: <https://doi.org/10.7326/M16-0961>.
11. National Academies of Sciences, Engineering, and Medicine. 2019. Taking Action Against Clinician Burnout: A Systems Approach to Professional Well-Being. Washington, DC: The National Academies Press. <https://doi.org/10.17226/25521>.
12. Linzer M, Levine R, Meltzer D, Poplau S, Warde C, West CP. 10 Bold Steps to Prevent Burnout in General Internal Medicine. *J Gen Intern Med* 2014;29:18-20. DOI: <https://doi.org/10.1007/s11606-013-2597-8>.
13. Ahmed AM, Kadakia K, Ahmed A, Shultz B, Li X. Trends in Labor Unionization Among US Health Care Workers, 2009-2021. *JAMA*. 2022;328(24):2404-2411. doi:10.1001/jama.2022.22790.
14. Mastrony M, Pariano C, Stanevich J. Following the Doctor's Orders: NLRB Decision Prescribes Union Election for Physicians. Available at: <https://www.jdsupra.com/legalnews/following-the-doctor-s-orders-nlr-7925443/>. Accessed March 30, 2024.

RELEVANT AMA POLICY

D-383.977 Investigation into Residents, Fellows, and Physician Unions

Our AMA will study the risks and benefits of collective bargaining for physicians and physicians-in-training in today's health care environment. [Res. 606, A-19]

D-383.988 Collective Bargaining and the Definition of Supervisors

Our AMA will support legislative efforts by other organizations and entities that would overturn the Supreme Court's ruling in *National Labor Relations Board v. Kentucky River Community Care, Inc., et al.* [BOT Action in response to referred for decision Res. 248, A-01; Modified: BOT Rep. 22, A-11; Reaffirmed: Res. 206, A-19]

Update:

2022: In Piedmont Health Services, Inc. and Piedmont Health Services Medical Providers United, Case No. 10-RC-286648, Region 10 of the National Labor Relations Board (Region) issued a Decision and Direction of Election (DDE) in which it held that physicians are not supervisors under the National Labor Relations Act (the Act) simply by virtue of their position in the healthcare institution.

This DDE is notable, as it confirms that physicians will not automatically be considered supervisors under the Act and may seek union representation. Indeed, Piedmont's physicians and providers ultimately voted in favor of union representation. Healthcare employers should consider reviewing their physicians' job descriptions and job duties to determine whether they potentially can be considered supervisors under the Act.

H-385.946 Collective Bargaining for Physicians

The AMA will seek means to remove restrictions for physicians to form collective bargaining units in order to negotiate reasonable payments for medical services and to compete in the current managed care environment; and will include the drafting of appropriate legislation. [Res. 239, A-97; Reaffirmation I-98; Reaffirmation A-01; Reaffirmation A-05; Reaffirmation A-06; Reaffirmation A-08; Reaffirmation I-10; Reaffirmed: Res. 206, A-19]

H-383.998 Resident Physicians, Unions and Organized Labor

Our AMA strongly advocates for the separation of academic issues from terms of employment in determining negotiable items for labor organizations representing resident physicians and that those organizations should adhere to the AMA's Principles of Medical Ethics which prohibits such organizations or any of its members from engaging in any strike by the withholding of essential medical services from patients. [CME Rep. 7, A-00; Reaffirmed: CME Rep. 2, A-10; Modified: Speakers Rep. 01, A-17; Reaffirmed: BOT Rep. 13, A-19]

H-385.976 Physician Collective Bargaining

Our AMA's present view on the issue of physician collective negotiation is as follows:

- (1) There is more that physicians can do within existing antitrust laws to enhance their collective bargaining ability, and medical associations can play an active role in that bargaining. Education and instruction of physicians is a critical need. The AMA supports taking a leadership role in this process through an expanded program of assistance to independent and employed physicians.
- (2) Our AMA supports continued intervention in the courts and meetings with the Justice Department and FTC to enhance their understanding of the unique nature of medical practice and to seek interpretations of the antitrust laws which reflect that unique nature.
- (3) Our AMA supports continued advocacy for changes in the application of federal labor laws to expand the number of physicians who can bargain collectively.
- (4) Our AMA vigorously opposes any legislation that would further restrict the freedom of physicians to independently contract with Medicare patients.
- (5) Our AMA supports obtaining for the profession the ability to fully negotiate with the government about important issues involving reimbursement and patient care.

[BOT Rep. P, I-88; Modified: Sunset Report, I-98; Reaffirmation A-00; Reaffirmation I-00; Reaffirmation A-01; Reaffirmation I-03; Reaffirmation A-04; Reaffirmed in lieu of Res. 105, A-04; Reaffirmation A-05; Reaffirmation A-06; Reaffirmation A-08; Reaffirmed: BOT Rep. 17, A-09; Reaffirmation I-10; Reaffirmed: Sub. Res. 222, I-10; Reaffirmed: Res. 215, A-11; Reaffirmed: BOT action in response to referred for decision Res. 201, I-12; Reaffirmed: Res. 206, A-19]

H-383.988 Physicians' Ability to Negotiate and Undergo Practice Consolidation

Our AMA will: (1) pursue the elimination of or physician exemption from anti-trust provisions that serve as a barrier to negotiating adequate physician payment; (2) work to establish tools to enable physicians to consolidate in a manner to insure a viable governance structure and equitable distribution of equity, as well as pursuing the elimination of anti-trust provisions that inhibited collective bargaining; and (3) find and improve business models for physicians to improve their ability to maintain a viable economic environment to support community access to high quality comprehensive healthcare. [Res. 229, A-12; Reaffirmed: Res. 206, A-19]

AMA Code of Medical Ethics

1.2.10 Political Action by Physicians

Like all Americans, physicians enjoy the right to advocate for change in law and policy, in the public arena, and within their institutions. Indeed, physicians have an ethical responsibility to seek change when they believe the requirements of law or policy are contrary to the best interests of patients. However, they have a responsibility to do so in ways that are not disruptive to patient care.

Physicians who participate in advocacy activities should:

- (a) Ensure that the health of patients is not jeopardized and that patient care is not compromised.
- (b) Avoid using disruptive means to press for reform. Strikes and other collection actions may reduce access to care, eliminate or delay needed care, and interfere with continuity of care and should not be used as a bargaining tactic. In rare circumstances, briefly limiting personal availability may be appropriate as a means of calling attention to the need for changes in patient care. Physicians should be aware that some actions may put them or their organizations at risk of violating antitrust laws or laws pertaining to medical licensure or malpractice.
- (c) Avoid forming workplace alliances, such as unions, with workers who do not share physicians primary and overriding commitment to patients.
- (d) Refrain from using undue influence or pressure colleagues to participate in advocacy activities and should not punish colleagues, overtly or covertly, for deciding not to participate.

[AMA Principles of Medical Ethics: I,III,VI](#)

The Opinions in this chapter are offered as ethics guidance for physicians and are not intended to establish standards of clinical practice or rules of law.

[Issued: 2016]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 237
(A-24)

Introduced by: American College of Preventive Medicine

Subject: Encouraging the Passage of the Preventive Health Savings Act (S.114)

Referred to: Reference Committee B

1 Whereas, the Congressional Budget Office (CBO) was established in 1974 to provide objective,
2 nonpartisan information to support the U.S. budget process and aid Congress in making
3 effective budget and economic policy¹; and
4

5 Whereas, the CBO is directed to estimate and project the cost of legislation approved by
6 Congressional committees for a specified period of time, usually 10 years²; and
7

8 Whereas, the CBO estimates the United States Federal Budget deficit will increase substantially
9 over the next 30 years³; and
10

11 Whereas, the CBO is evaluating the economic impact of legislation pertaining to roles of health
12 behaviors and preventive measures beyond the 10-year budget window in specific cases⁴; and
13

14 Whereas, the 118th House of Representatives has passed legislation in a bipartisan vote to
15 direct the CBO to expand the scoring window to estimate the budgetary effects of legislation
16 related to preventive health care services up to a 30-year period⁵; and
17

18 Whereas, expanding the CBO scoring window to estimate the budgetary effects over a 30-year
19 period of legislation related to preventive health care services would not significantly increase
20 the cost of generating economic estimates for legislation⁶; and
21

22 Whereas, the United States spends \$4.1 trillion in annual health care expenditure⁷; and
23

24 Whereas, 70% of the U.S. health care expenditure is spent on the management and treatment
25 of chronic disease⁷; and
26

27 Whereas, the American Medical Association encourages the CBO to more comprehensively
28 measure long-term budget deficit reductions and costs associated with legislation related to the
29 preventive health services⁸; therefore be it
30

31 RESOLVED, that our American Medical Association encourages continued advocacy to federal
32 and state legislatures of the importance of more accurately and effectively measuring the health
33 and economic impacts of investing in preventive health services to improve health and reduce
34 healthcare spending costs in the long term. (Directive to Take Action); and be it further
35

36 RESOLVED, that our AMA reaffirm the following policy: D-155.994, "Value-Based Decision
37 Making in the Health Care System" to encourage legislation and efforts to allow the
38 Congressional Budget Office to more effectively project long-term budget deficit reductions and
39 costs associated with legislation related to preventive health services. (Reaffirm HOD Policy)
40

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 5/8/2024

REFERENCES

1. 93rd Congress (1974). "H.R.7130 - Congressional Budget and Impoundment Control Act of 1974". Congress.gov, Library of Congress, <https://www.congress.gov/bill/93rd-congress/house-bill/7130/text>.
2. Congressional Budget Office (2024). "An Introduction to the Congressional Budget Office". CBO.gov, Congressional Budget Office, Accessed May 3, 2024. <https://www.cbo.gov/system/files/2024-01/59687-Intro-to-CBO.pdf>
3. Congressional Budget Office (2024). "The Long-Term Budget Outlook: 2024 to 2054". CBO.gov, Congressional Budget Office, Accessed May 3, 2024. <https://www.cbo.gov/publication/59711>
4. Swagel, P. (2024). "The Federal Budget and Health Care Policy". CBO.gov, Congressional Budget Office. Accessed May 3, 2024. <https://www.cbo.gov/system/files/2024-04/60224-FederalBudgetandHealthCare.pdf>
5. 118th Congress (2024). "H.R.766 - Dr. Michael C. Burgess Preventive Health Savings Act". Congress.gov, Library of Congress, Accessed May 3, 2024. <https://www.congress.gov/bill/118th-congress/house-bill/766>.
6. Pickford, M., Robillard, L., Chirico, C., Swagel, P (2024). "H.R. 766, Dr. Michael C. Burgess Preventive Health Savings Act Cost Estimate". CBO.gov, Congressional Budget Office. Accessed May 3, 2024. <https://www.cbo.gov/system/files/2024-02/hr766.pdf>
7. Centers for Disease Control and Prevention (2023). "Health and Economic Costs of Chronic Disease". CDC.gov, Accessed May 3, 2024. <https://www.cdc.gov/chronicdisease/about/costs/index.htm>
8. American Medical Association (2015). "Value-Based Decision-Making in the Health Care System D-155.994". PolicySearch.ama-assn.org, Accessed May 3, 2024. <https://policysearch.ama-assn.org/policyfinder/detail/congressional%20budget%20office?uri=%2FAMADoc%2Fdirectives.xml-0-289.xml>

RELEVANT AMA POLICY

Value-Based Decision-Making in the Health Care System D-155.994

1. Our AMA will advocate for third-party payers and purchasers to make cost data available to physicians in a useable form at the point of service and decision-making, including the cost of each alternate intervention, and the insurance coverage and cost-sharing requirements of the respective patient.
2. Our AMA encourages efforts by the Congressional Budget Office to more comprehensively measure the long-term as well as short-term budget deficit reductions and costs associated with legislation related to the prevention of health conditions and effects as a key step in improving and promoting value-based decision-making by Congress. [CMS Rep. 7, A-08; Reaffirmed in lieu of Res. 230, I-14; Reaffirmation I-15]

American Medical Association House of Delegates

Resolution: 238
(A-24)

Introduced by: New York

Subject: AMA Supports Efforts to Fund Overdose Prevention Sites

Referred to: Reference Committee B

1 Whereas, the federal “Defund Heroin Injections Centers of 2023” Act prohibits federal funding
2 for injection sites; and

3
4 Whereas, this Act states: No Federal funds may be used by any Federal agency to operate or
5 control, or to pay the salaries of officers and employees of such an agency to operate or control,
6 an injection center in violation of section 416 of the Controlled Substances Act (21 U.S.C. 856;
7 commonly referred to as the “Crack House Statute”); and

8
9 Whereas, OPS (Overdose Prevention Sites) have been shown to be effective at reducing
10 overdoses, refer patients for ongoing drug treatment, prevent communicable disease and
11 decrease health care costs; therefore be it

12
13 RESOLVED, that our American Medical Association support legislation or regulation that would
14 fund overdose prevention sites. (New HOD Policy)

Fiscal Note: Moderate - between \$5,000 - \$10,000

Received: 5/7/2024

REFERENCES

<https://www.congress.gov/117/bills/hr6741/BILLS-117hr6741ih.pdf>

American Medical Association House of Delegates

Resolution: 239
(A-24)

Introduced by: New York

Subject: Requiring stores that sell tobacco products to display NYS Quitline information

Referred to: Reference Committee B

1 Whereas, state laws already only allow only certain stores (not pharmacies) to sell to certain
2 persons (those over age 20) in certain locations (not near schools); and
3

4 Whereas, the states various Tobacco Control Programs allow Quitline phone number and
5 website which offers to persons who smoke the ability to get help with stopping by texting,
6 calling, or chatting; free nicotine patches, gum or lozenges, and other tools for cessation
7 assistance, therefore be it
8

9 RESVOLVED, that our American Medical Association seek federal legislation and/or regulation
10 requiring all stores licensed to sell tobacco or nicotine products to display easily visible
11 information about the CDC hotline 1-800-QUIT-NOW in multiple languages and/or the
12 information for the corresponding state or territory. (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000

Received: 5/8/2024

REFERENCES

<https://www.nysmokefree.com/>

https://www.health.ny.gov/prevention/tobacco_control/current_policies.htm

American Medical Association House of Delegates

Resolution: 240
(A-24)

Introduced by: New York
Subject: Expanding Visa Requirement Waivers for NY IMGs Working in Underserved Areas
Referred to: Reference Committee B

1 Whereas, the most common visa that international medical graduates (IMG) use to participate in
2 US graduate medical education programs is the J-1 visa¹; and
3
4 Whereas, the J-1 visa traditionally requires a mandatory two-year foreign residency after
5 completion of their graduate medical education , forcing many IMGs who may wish to begin
6 practice inside the US to undergo a long and painful transition out of the country before
7 reapplication under a new visa²; and
8
9 Whereas, the Conrad 30 waiver program is a federal exemption to the J-1 visa residency
10 requirement, which allows up to 30 IMGs per State under a J-1 visa to avoid the two-year
11 foreign residency requirement after graduation if they practice in a federally designated
12 medically underserved area or with a medically underserved population³; and
13
14 Whereas, some studies have suggested that US residency-trained IMG physicians may yield
15 superior patient outcomes relative to their US medical graduate peers⁶; and
16
17 Whereas, reapproval or expansion of the Conrad 30 waiver program is unlikely to meaningfully
18 harm the economic competitiveness of native New York physicians or physician practices due to
19 requirements that waiver recipients be employed by health systems that have been
20 unsuccessful in attracting US medical graduates to the same position⁹; and
21
22 Whereas, the Conrad State 30 and Physician Access Reauthorization Act would extend and
23 expand the Conrad 30 waiver exemption program, allowing for approximately ~50% additional
24 waivers to be granted on a per-year basis over the next decade¹¹; therefore be it
25
26 RESOLVED, that our American Medical Association supports reauthorization and expansion of
27 the Conrad-30 J-1 visa waiver program, including permitting reallocation of unused slots to
28 states that have already used the maximum number of waivers. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000

Received: 5/8/2024

REFERENCES

1. <https://www.ama-assn.org/education/international-medical-education/immigration-information-international-medical-graduates>
2. <https://internationalaffairs.uchicago.edu/twoyearreq>
3. <https://bhwh.hrsa.gov/workforce-shortage-areas/shortage-designation#maps>
4. <https://cbkimmigration.com/health-care-workers/conrad-flex-program/>
5. <https://www.graham-center.org/content/dam/rqc/documents/maps-data-tools/state-collections/workforce-projections/New%20York.pdf>
6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334519/#REF5>
7. <https://www.ruralhealthinfo.org/charts/5?state=NY>
8. <https://www.ruralhealthinfo.org/charts/7?state=NY>
9. <https://www.irvine-legal.com/irvine-articles/2019/10/21/conrad-30-overview-by-state-j-1-waivers-for-physicians>

10. <https://www.niskanencenter.org/the-bipartisan-immigration-policy-that-helps-rural-americans-get-access-to-local-physicians/>
11. <https://www.collins.senate.gov/newsroom/collins-klobuchar-rosen-tillis-introduce-bipartisan-legislation-to-build-healthcare-workforce-in-rural-and-medically-underserved-areas>
12. <https://stefanik.house.gov/2024/1/stefanik-helps-introduce-bill-to-address-doctor-shortage>

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 241
(A-24)

Introduced by: New York

Subject: Healthcare Cybersecurity Breaches

Referred to: Reference Committee B

1 Whereas, cybersecurity attacks by malicious criminals on Healthcare entities: Insurers, Health
2 systems and Medical Practices are becoming more and more common; and
3

4 Whereas, the recent 2024 attack on Change Healthcare website has crippled Healthcare
5 operations across multiple insurers and threatens the financial viability of thousands of practices
6 and healthcare systems; and
7

8 Whereas, the timely delivery of healthcare to millions of patients is jeopardized by healthcare
9 Cybercrime, thus jeopardizing the health and safety of New Yorkers and the US population as a
10 whole ; making Healthcare Cybercrimes especially heinous and deserving of more vigorous
11 punishment and prevention efforts than are currently in effect; therefore be it
12

13 RESOLVED, that our American Medical Association advocate for the development of an
14 adequately funded multidisciplinary task-force including representation of AMA, health insurers,
15 the FBI and other pertinent stakeholders to prevent future healthcare cyberattacks throughout
16 the country and to increase the apprehension of cybercriminals who prey on patients and
17 healthcare entities, and to recommend appropriate penalties for their crimes. (Directive to Take
18 Action)

Fiscal Note: Moderate - between \$5,000 - \$10,000

Received: 5/8/24

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 242
(A-24)

Introduced by: Minority Affairs Section

Subject: Cancer Care in Indian Health Services Facilities

Referred to: Reference Committee B

- 1 Whereas, cancer is the leading cause of death among American Indian and Alaska Native
2 (AI/AN) persons in the United States (US)^{1,2}; and
3
4 Whereas, AI/AN Tribes and Villages are sovereign governments that have unique needs and
5 challenges; and
6
7 Whereas, AI/AN patients, as dual citizens of their Tribal Nations and the US, are entitled to the
8 same rights and privileges of US citizens, including those relating to healthcare (H-350.976 and
9 H-350.977); and
10
11 Whereas, the Indian Health Service (IHS) was established by Article I, Section 8 of the
12 Constitution to provide adequate and timely healthcare, in honoring the government-to-
13 government relationship between the United States and these Tribal organizations^{3,4}; and
14
15 Whereas, federal IHS facilities do not offer on-site cancer care or provide payment for cancer
16 treatment, unlike other federal health programs like the VA, unless funds are available for
17 referral^{5,6}; and
18
19 Whereas, several Indian Health Service Areas do not have a single comprehensive cancer
20 care center, increasing the likelihood that AI/AN patients have to obtain care from other public
21 and private payors and shoulder out-of-pocket costs⁷; and
22
23 Whereas, funding limitations to the IHS primarily limit health care to direct ambulatory care
24 services, thus denying access to comprehensive, specialty healthcare services to their patients
25 (H-350.977); and
26
27 Whereas, many cancers, including liver, stomach, kidney, lung, melanoma, and colorectal
28 cancer have a significantly higher prevalence among AI/AN persons⁸; and
29
30 Whereas, for the ten most populated AI/AN reservations, the median travel distance to a
31 National Cancer Institute (NCI) cancer center is 186.5 miles (range 77.8 - 629 miles), and the
32 median travel time is 3.37 hours (range 1.32 - 10.42 hours), while 45.2% of the general US
33 population lives <1 hour from an NCI cancer center⁹; and
34
35 Whereas, 14% of the US population lives >2 hours from an NCI cancer center, with 37% of
36 these individuals being identified as AI/AN persons⁹; and
37
38 Whereas, a study analyzing the effects of distance on cancer treatment outcomes found that
39 patients who traveled 50 miles or 1+ hour in driving time were associated with a more advanced

1 disease at diagnosis, and patients in rural areas were found to be twice as likely to have
2 unstaged cancer and/or more advanced disease when compared to urban counterparts¹⁰; and

3
4 Whereas, counties with poor access to healthcare are known to have statistically lower cancer
5 screening rates and higher cancer-related mortality rates¹¹; and

6
7 Whereas, oncology patients not first seen at NCI-designated Comprehensive Cancer Care
8 Centers have worse outcomes, even when adjusting for sociodemographic and clinical factors¹²;
9 and

10
11 Whereas, it is unethical to deny appropriate and timely cancer care to American Indian and
12 Alaska Native patients; therefore be it

13
14 RESOLVED, that our American Medical Association actively advocate for the federal
15 government to continue enhancing and developing alternative pathways for American Indian
16 and Alaska Native patients to access the full spectrum of cancer care and cancer-directed
17 therapies outside of the established Indian Health Service system (Directive to Take Action);
18 and be it further

19
20 RESOLVED, that our AMA (a) support collaborative research efforts to better understand the
21 limitations of IHS cancer care, including barriers to access, disparities in treatment outcomes,
22 and areas for improvement and (b) encourage cancer linkage studies between the IHS and the
23 CDC to better evaluate regional cancer rates, outcomes, and potential treatment deficiencies
24 among American Indian and Alaska Native populations. (Directive to Take Action)

Fiscal Note: Moderate - between \$5,000 - \$10,000

Received: 5/4/2024

REFERENCES

1. Leading causes of death-non-Hispanic American Indian or Alaska native males - United States, 2017. Centers for Disease Control and Prevention. November 20, 2019. Accessed August 27, 2023. <https://www.cdc.gov/minorityhealth/lcod/men/2017/nonhispanic-native/index.htm>.
2. Leading causes of death – females – non-Hispanic American Indian or Alaska native – United States, 2018. Centers for Disease Control and Prevention. March 3, 2022. Accessed August 27, 2023. <https://www.cdc.gov/women/lcod/2018/nonhispanic-native/index.htm>.
3. Morton v. Mancari, 417 U.S. 535 (1974). Justia Law. Accessed August 27, 2023. <https://supreme.justia.com/cases/federal/us/417/535/>.
4. Indian Health Service (IHS). About IHS. Accessed August 27, 2023. <https://www.ihs.gov/aboutihs/>.
5. National Oncology Program. VA. Accessed August 27, 2023. <https://www.cancer.va.gov/>.
6. Chapter 3 - purchased/referred care: Part 2. The Indian Health Manual (IHM). Accessed August 27, 2023. <https://www.ihs.gov/ihtm/pc/part-2/chapter-3-purchased-referred-care/>.
7. Find an NCI-designated cancer center. National Cancer Institute. Accessed August 27, 2023. <https://www.cancer.gov/research/infrastructure/cancer-centers/find>.
8. Melkonian SC, Weir HK, Jim MA, Preikschat B, Haverkamp D, White MC. Incidence of and trends in the leading cancers with elevated incidence among American Indian and Alaska native populations, 2012–2016. OUP Academic. October 14, 2020. Accessed August 27, 2023. <https://academic.oup.com/aje/article/190/4/528/5922784?login=false>.
9. Onega T, Alford-Teaster J, Wang F. Population-based geographic access to parent and satellite National Cancer Institute Cancer Center Facilities. *Cancer*. 2017;123(17):3305-3311. doi:<https://doi.org/10.1002/cncr.30727>
10. Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L. Distance as a barrier to cancer diagnosis and treatment: Review of the literature. *The oncologist*. December 2015. Accessed August 27, 2023. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679078/>.
11. Belasco EJ, Gong G, Pence B, Wilkes E. The impact of Rural Health Care Accessibility on cancer-related behaviors and outcomes - applied health economics and health policy. SpringerLink. June 3, 2014. Accessed August 27, 2023.
12. Wolfson JA, Sun C-L, Wyatt LP, Hurria A, Bhatia S. Impact of care at comprehensive cancer centers on outcome: Results from a population-based study. *Cancer*. November 1, 2015. Accessed August 27, 2023. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892698/>.

RELEVANT AMA Policy

Improving Health Care of American Indians H-350.976

Our AMA recommends that: (1) All individuals, special interest groups, and levels of government recognize the American Indian people as full citizens of the U.S., entitled to the same equal rights and privileges as other U.S. citizens.

(2) The federal government provide sufficient funds to support needed health services for American Indians.

(3) State and local governments give special attention to the health and health-related needs of non-reservation American Indians in an effort to improve their quality of life.

(4) American Indian religions and cultural beliefs be recognized and respected by those responsible for planning and providing services in Indian health programs.

(5) Our AMA recognize the "medicine man" as an integral and culturally necessary individual in delivering health care to American Indians.

(6) Strong emphasis be given to mental health programs for American Indians in an effort to reduce the high incidence of alcoholism, homicide, suicide, and accidents.

(7) A team approach drawing from traditional health providers supplemented by psychiatric social workers, health aides, visiting nurses, and health educators be utilized in solving these problems.

(8) Our AMA continue its liaison with the Indian Health Service and the National Indian Health Board and establish a liaison with the Association of American Indian Physicians.

(9) State and county medical associations establish liaisons with intertribal health councils in those states where American Indians reside.

(10) Our AMA supports and encourages further development and use of innovative delivery systems and staffing configurations to meet American Indian health needs but opposes overemphasis on research for the sake of research, particularly if needed federal funds are diverted from direct services for American Indians.

(11) Our AMA strongly supports those bills before Congressional committees that aim to improve the health of and health-related services provided to American Indians and further recommends that members of appropriate AMA councils and committees provide testimony in favor of effective legislation and proposed regulations. [CLRPD Rep. 3, I-98; Reaffirmed: Res. 221, A-07; Reaffirmation A-12; Reaffirmed: Res. 233, A-13; Reaffirmed: BOT Rep. 09, A-23]

Cancer and Health Care Disparities Among Minority Women D-55.997

Our AMA encourages research and funding directed at addressing racial and ethnic disparities in minority women pertaining to cancer screening, diagnosis, and treatment. [Res. 509, A-08; Modified: CSAPH Rep. 01, A-18]

Clinical Preventive Services H-410.967

The AMA: (1) recommends the USPSTF guidelines to clinicians and medical educators as one resource for guiding the delivery of clinical preventive services. USPSTF recommendations should not be construed as AMA policy on screening procedures and should not take the place of clinical judgment and the need for individualizing care with patients; physicians should weigh the utility of individual recommendations within the context of their scope of practice and the situation presented by each clinical encounter; (2) will continue to encourage the adoption of practice guidelines as they are developed based on the best scientific evidence and methodology available; and (3) will continue to promote discussion, collaboration, and consensus among expert groups and medical specialty societies involved in preparation of practice guidelines. [CSA Rep. 1, A-97; Modified and Reaffirmed: CSAPH Rep. 3, A-07; Reaffirmed: Sub. Res. 517, A-12; Modified: CSAPH Rep. 1, A-22]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 243
(A-24)

Introduced by: Minority Affairs Section

Subject: Disaggregation of Demographic Data for Individuals of Federally Recognized Tribes

Referred to: Reference Committee B

1 Whereas, the Indian Health Service (IHS) is a health care system for federally recognized
2 American Indians and Alaska Natives in the United States;¹ and
3
4 Whereas, the Snyder Act of 1921 and the Indian Health Care Improvement Act (IHCIA) of 1976
5 recognized treaty obligations in codifying federal responsibility for Native American health in the
6 creation of the IHS; and
7
8 Whereas, the Supreme Court decision of Morton v. Mancari 417 U.S. 535 (1974) ruled that
9 members of federally recognized tribes possess a unique political status of quasi-sovereign
10 tribal entities; and
11
12 Whereas, the IHS currently delivers care to over 2.8 million American Indians and Alaska
13 Natives;² and
14
15 Whereas, eligibility for IHS services is strictly restricted to members of federally recognized
16 American Indian or Alaska Native tribes;³ and
17
18 Whereas, the Indian Health Service (IHS) Physician Scholarship program, as well as many
19 other Native scholarship programs, require applicants to be enrolled members of federally
20 recognized tribes;⁴ and
21
22 Whereas, the IHS has severe physician vacancy issues;⁵ and
23
24 Whereas, American Indians and Alaska Natives carry the lowest life expectancy (65.2 years old)
25 of all races;⁶ and
26
27 Whereas, American Indians and Alaska Natives have the least representation in the physician
28 workforce of any racial group per capita;⁷ and
29
30 Whereas, the American Medical Association and its partners, such as the Association of
31 American Medical Colleges (AAMC) and the Accreditation Council for Graduate Medical
32 Education (ACGME), currently do not collect demographic data on federally recognized tribal
33 members; and
34
35 Whereas, demographic data of federally recognized tribal members is a necessary first step
36 towards better aiding the Indian Health Service (IHS); therefore be it
37
38 RESOLVED, that our American Medical Association add “Enrolled Member of a Federally
39 Recognized Tribe” on all AMA demographic forms (Directive to Take Action); and be it further

1 RESOLVED, that our AMA advocate for the use of “Enrolled Member of a Federally Recognized
2 Tribe” as an additional category in all uses of demographic data including but not limited to
3 medical records, government data collection and research, and within medical education
4 (Directive to Take Action); and be it further

5
6 RESOLVED, that our AMA support the Association of American Medical Colleges (AAMC)
7 inclusion of “Enrolled Member of a Federally Recognized Tribe” on all AAMC demographic
8 forms (New HOD Policy); and be it further

9
10 RESOLVED, that our AMA advocate for the Accreditation Council for Graduate Medical
11 Education (ACGME) to include “Enrolled Member of a Federally Recognized Tribe” on all
12 ACGME demographic forms. (Directive to Take Action)

13
Fiscal Note: To Be Determined

Received: 5/24/2024

REFERENCES

1. About, Indian Health Service. U.S. Department of Health and Human Services. Accessed March 31, 2024. <https://www.ihs.gov/aboutihs/>
2. FY2024 Budget in Brief; US Department of Health and Human Services, pg. 33. <https://www.hhs.gov/sites/default/files/fy-2024-budget-in-brief.pdf>
3. Eligibility - Indian Health Service. U.S. Department of Health and Human Services. Accessed March 31, 2024. <https://www.ihs.gov/aboutihs/eligibility/>
4. IHS Scholarship Program. U.S. Department of Health and Human Services. Accessed March 31, 2024. <https://www.ihs.gov/scholarship/apply/>
5. Agency Faces Ongoing Challenges Filling Provider Vacancies. U.S. Government Accountability Office. Published August 2018. Accessed March 31, 2022. <https://www.gao.gov/assets/gao-18-580.pdf>
6. United States Life Tables 2021, National Vital Statistics Reports. National Center for Health Statistics. November 2023. <https://www.cdc.gov/nchs/data/nvsr/nvsr72/nvsr72-12.pdf>
7. Active Physicians who identified as American Indian or Alaska Native, 2021. Association of American Medical Colleges. Accessed March 31, 2024. <https://www.aamc.org/data-reports/workforce/data/active-physicians-american-indian-alaska-native-2021>

RELEVANT AMA POLICY

Disaggregation of Demographic Data for Individuals of Middle Eastern and North African (MENA) descent D-350.979

Our AMA will: (1) add “Middle Eastern/North African (MENA)” as a separate racial category on all AMA demographics forms; (2) advocate for the use of “Middle Eastern/North African (MENA)” as a separate race category in all uses of demographic data including but not limited to medical records, government data collection and research, and within medical education; and (3) study methods to further improve disaggregation of data by race which most accurately represent the diversity of our patients. [Res.19, I-21]

Disaggregation of Demographic Data Within Ethnic Groups H-350.954

1. Our AMA supports the disaggregation of demographic data regarding: (a) Asian-Americans and Pacific Islanders in order to reveal the within-group disparities that exist in health outcomes and representation in medicine; and (b) ethnic groups in order to reveal the within-group disparities that exist in health outcomes and representation in medicine.

2. Our AMA: (a) will advocate for restoration of webpages on the Asian American and Pacific Islander (AAPI) initiative (similar to those from prior administrations) that specifically address disaggregation of health outcomes related to AAPI data; (b) supports the disaggregation of data regarding AAPIs in order to reveal the AAPI ethnic subgroup disparities that exist in health outcomes; (c) supports the disaggregation of data regarding AAPIs in order to reveal the AAPI ethnic subgroup disparities that exist in representation in medicine, including but not limited to leadership positions in academic medicine; and (d) will report back at the 2020 Annual Meeting on the issue of disaggregation of data regarding AAPIs (and other ethnic subgroups) with regards to the ethnic subgroup disparities that exist in health outcomes and representation in medicine, including leadership positions in academic medicine. [Res. 001, I-17; Appended: Res. 403, A-19]

AMA Race/Ethnicity Data D-630.972

1. Our American Medical Association will continue to work with the Association of American Medical Colleges to collect race/ethnicity information through the student matriculation file and the GME census including automating the integration of this information into the Masterfile.
2. Our AMA will: (a) adopt racial and ethnic demographic data collection practices that allow self-identification of designation of one or more racial categories; (b) report demographic physician workforce data in categories of race and ethnicity whereby Latino, Hispanic, and other identified ethnicities are categories, irrespective of race; (c) adopt racial and ethnic physician workforce demographic data reporting practices that permit disaggregation of individuals who have chosen multiple categories of race so as to distinguish each category of individuals' demographics as alone or in combination with any other racial and ethnic category; and (d) collaborate with AAMC, ACGME, AACOM, AOA, NBME, NBOME, NRMP, FSBM, CMSS, ABMS, HRSA, OMB, NIH, ECFMG, and all other appropriate stakeholders, including minority physician organizations, and relevant federal agencies to develop standardized processes and identify strategies to improve the accurate collection, disclosure and reporting of racial and ethnic data across the medical education continuum and physician workforce. [BOT Rep. 24, I-06; Modified: CCB/CLRPD Rep. 3, A-12; Reaffirmed: CME Rep. 1, A-22; Appended: Res. 612, A-22]

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 244
(A-24)

Introduced by: Minority Affairs Section

Subject: Graduate Medical Education Opportunities for American Indian and Alaska Native Communities

Referred to: Reference Committee B

1 Whereas, the federal government has a unique government-to-government relationship with
2 574 federally recognized tribes based on Article I, Section 8 of the U.S. Constitution; and
3
4 Whereas, the federal government has committed itself to provide health care services to Tribal
5 nations under the enforceable federal Indian trust responsibility, a legal fiduciary obligation to
6 provide basic social, medical, and educational services for American Indians and Alaska
7 Natives (AI/ANs);¹ and
8
9 Whereas, AI/AN are disproportionately affected by many chronic conditions, including heart
10 disease, cancer, diabetes, stroke, and accidental injuries;² and
11
12 Whereas, AI/AN have the lowest life expectancy of any racial group (65.2 years), with AI/AN
13 communities experiencing a 6.6-year decline between 2019 and 2021;³ and
14
15 Whereas, the Indian Health Service (IHS) provides health care to over 2.8 million AI/AN through
16 IHS and Tribal Health Programs and Urban Indian Organizations, often referred to as the I/T/U
17 or the Indian Health system;⁴ and
18
19 Whereas, the IHS is chronically under-funded compared to other federal health care systems,
20 and the lack of funds has contributed to health disparities in Tribal communities;⁵ and
21
22 Whereas, the IHS is the only large federal health care system to lack formalized partnerships
23 with academic medical centers, unlike the Veterans Health Administration and the Military
24 Health System;⁶ and
25
26 Whereas, IHS and Tribal medical facilities often suffer from high physician staffing vacancy
27 rates, contributing to negative outcomes;⁷ and
28
29 Whereas, Congress mandated that IHS form workforce partnerships with teaching hospitals in
30 the Indian Health Care Improvement Act of 1976 but has failed to appropriate funds to that
31 effect;⁸ and
32
33 Whereas, the President of the United States in the FY 2023 and FY 2024 Budget Proposals to
34 Congress has recommended establishing and funding a Division of Graduate Medical Education
35 in the IHS that would be tasked with expanding and supporting graduate medical education
36 programs to create a pathway and an enhanced ecosystem for future physicians to address
37 longstanding vacancy issues at IHS;⁹ and

1 Whereas, the AMA reaffirmed its recommendation in 2023 to support efforts in Congress to
2 enable the IHS to meet its obligation to bring American Indian health up to the general
3 population level, and support efforts to establish closer ties with teaching centers to increase
4 both the available manpower and the level of professional expertise available in Tribal clinics;¹⁰
5 and
6

7 Whereas, the AMA also reaffirmed its commitment to advocate that the IHS establish an Office
8 of Academic Affiliations responsible for coordinating partnerships with LCME- and COCA-
9 accredited medical schools and ACGME-accredited residency programs, and encourage the
10 development of funding streams to promote rotations and learning opportunities at IHS, Tribal,
11 and Urban Indian Health Programs;¹¹ and
12

13 Whereas, the AMA reaffirmed its recommendation in 2023 that the federal government provide
14 sufficient funds to support needed health services for American Indians, and encourage further
15 development and use of innovative delivery systems and staffing configurations to meet
16 American Indian health needs;¹² and
17

18 Whereas, the AMA acknowledges the importance of graduate medical education in training the
19 next generation of physicians, reducing physician shortages, and benefiting communities;¹³ and
20

21 Whereas, the AMA reaffirmed in 2022 that it will strenuously advocate for increasing the number
22 of GME positions to address the future physician workforce needs of the nation;¹⁴ and
23

24 Whereas, the AMA also is committed to strongly advocate that Congress fund additional
25 graduate medical education positions for the most critical workforce needs;¹⁵ and
26

27 Whereas, the AMA is also committed to utilizing its resources to share its content expertise with
28 policymakers and the public to ensure greater awareness of the significant societal value of
29 graduate medical education in terms of patient care, particularly for underserved and at-risk
30 populations, as well as global health, research, and education;¹⁶ and
31

32 Whereas, the AMA included in its Recovery Plan for America's Physicians the need to expand
33 the number of residency training slots and remove caps to Medicare-funded positions;¹⁷
34 therefore be it
35

36 RESOLVED, that our American Medical Association supports policy and communication efforts
37 to (1) advance legislative and regulatory policies and actions that establish, authorize, fund, and
38 incentivize the creation of graduate medical education opportunities in IHS, Tribal-administered,
39 and urban Indian health organizations and facilities and (2) establish associated partnerships
40 with accredited medical schools and teaching hospitals (New HOD Policy); and be it further
41

42 RESOLVED, that our AMA supports collaboratively working with Tribal nations, Tribal
43 organizations, academic medical centers, policy professionals, medical schools, teaching
44 hospitals, coalition builders, and other stakeholders to advocate to Congress, The White House,
45 the Department of Health and Human Services, and other government entities to establish
46 dedicated graduate medical education funding and programs that benefit Tribal communities,
47 increase physician training sites, and reduce physician shortages, particularly among
48 underserved populations. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000)

Received: 5/8/2024

REFERENCES

1. "What is the federal Indian trust responsibility?" Bureau of Indian Affairs. U.S Department of the Interior.
2. "Disparities." Indian Health Service. US Department of Health and Human Services. See also "Infant Mortality and American Indians/Alaska Natives." Office of Minority Health. US Department of Health and Human Services.
3. Hill, L. and Artiga S. "What is Driving Widening Racial Disparities in Life Expectancy?" Kaiser Family Foundation. May 23, 2023. <https://www.kff.org/racial-equity-and-health-policy/issue-brief/what-is-driving-widening-racial-disparities-in-life-expectancy/>
4. FY2024 Budget in Brief; US Department of Health and Human Services, pg. 33
5. FY2024 Budget in Brief; US Department of Health and Human Services, pg. 33. See also Government Accountability Office Report: Indian Health Service: Spending Levels and Characteristics of IHS and Three Other Federal Health Care Programs
6. Tobey M, Ott A, Owen M. The Indian Health Service and the Need for Resources to Implement Graduate Medical Education Programs. JAMA. 2022;328(4):327. doi:10.1001/jama.2022.10359
7. <https://aspe.hhs.gov/sites/default/files/documents/1b5d32824c31e113a2df43170c45ac15/aspe-ihs-funding-disparities-report.pdf>
8. 25 USC Chapter 18 – Indian Health Care, §1616n – p. See Indian Health Care Improvement Act, Public Law 94-437. See also Tobey M, Ott A, Owen M. The Indian Health Service and the Need for Resources to Implement Graduate Medical Education Programs. JAMA. 2022;328(4):327. doi:10.1001/jama.2022.10359
9. FY 2024 Justification of Estimates for Appropriations Committees; Indian Health Service; US Department of Health and Human Services; pg. CJ-47.
10. American Medical Association Policy: Indian Health Service H-350.977
11. American Medical Association Policy: Indian Health Service H-350.977
12. American Medical Association Policy: Improving Health Care of American Indians H-350.976
13. "Save Graduate Medical Education." American Medical Association. <https://www.ama-assn.org/education/gme-funding/save-graduate-medical-education>
14. American Medical Association Directive: The Preservation, Stability and Expansion of Full Funding for Graduate Medical Education D-305.967
15. American Medical Association Directive: The Preservation, Stability and Expansion of Full Funding for Graduate Medical Education D-305.967
16. American Medical Association Directive: The Preservation, Stability and Expansion of Full Funding for Graduate Medical Education D-305.967
17. American Medical Association. "AMA Recovery Plan for America's Physicians." <https://www.ama-assn.org/amaone/ama-recovery-plan-america-s-physicians>. See also "AMA unveils Recovery Plan for America's Physicians." June 10, 2022. <https://www.ama-assn.org/press-center/press-releases/ama-unveils-recovery-plan-america-s-physicians>

RELEVANT AMA Policy

Indian Health Service H-350.977

The policy of the AMA is to support efforts in Congress to enable the Indian Health Service to meet its obligation to bring American Indian health up to the general population level. The AMA specifically recommends: (1) Indian Population: (a) In current education programs, and in the expansion of educational activities suggested below, special consideration be given to involving the American Indian and Alaska native population in training for the various health professions, in the expectation that such professionals, if provided with adequate professional resources, facilities, and income, will be more likely to serve the tribal areas permanently; (b) Exploration with American Indian leaders of the possibility of increased numbers of nonfederal American Indian health centers, under tribal sponsorship, to expand the American Indian role in its own health care; (c) Increased involvement of private practitioners and facilities in American Indian care, through such mechanisms as agreements with tribal leaders or Indian Health Service contracts, as well as normal private practice relationships; and (d) Improvement in transportation to make access to existing private care easier for the American Indian population.

(2) Federal Facilities: Based on the distribution of the eligible population, transportation facilities and roads, and the availability of alternative nonfederal resources, the AMA recommends that those Indian Health Service facilities currently necessary for American Indian care be identified and that an immediate construction and modernization program be initiated to bring these facilities up to current standards of practice and accreditation.

(3) Manpower: (a) Compensation for Indian Health Service physicians be increased to a level competitive with other Federal agencies and nongovernmental service; (b) Consideration should be given to increased compensation for service in remote areas; (c) In conjunction with improvement of Service facilities, efforts should be made to establish closer ties with teaching centers, thus increasing both the available manpower and the level of professional expertise available for consultation; (d) Allied health professional staffing of Service facilities should be maintained at a level appropriate to the special needs of the population served; (e) Continuing education opportunities should be provided for those health professionals serving these communities, and especially those in remote areas, and, increased peer contact, both to maintain the quality of care and to avert professional isolation; and (f) Consideration

should be given to a federal statement of policy supporting continuation of the Public Health Service to reduce the great uncertainty now felt by many career officers of the corps.

(4) Medical Societies: In those states where Indian Health Service facilities are located, and in counties containing or adjacent to Service facilities, that the appropriate medical societies should explore the possibility of increased formal liaison with local Indian Health Service physicians. Increased support from organized medicine for improvement of health care provided under their direction, including professional consultation and involvement in society activities should be pursued.

(5) Our AMA also support the removal of any requirement for competitive bidding in the Indian Health Service that compromises proper care for the American Indian population.

(6) Our AMA will advocate that the Indian Health Service (IHS) establish an Office of Academic Affiliations responsible for coordinating partnerships with LCME- and COCA-accredited medical schools and ACGME-accredited residency programs.

(7) Our AMA will encourage the development of funding streams to promote rotations and learning opportunities at Indian Health Service, Tribal, and Urban Indian Health Programs. [CLRPD Rep. 3, I-98; Reaffirmed: CLRPD Rep. 1, A-08; Reaffirmation A-12; Reaffirmed: Res. 233, A-13; Appended: Res. 305, A-23; Reaffirmed: BOT Rep. 09, A-23]

Improving Health Care of American Indians H-350.976

Our AMA recommends that: (1) All individuals, special interest groups, and levels of government recognize the American Indian people as full citizens of the U.S., entitled to the same equal rights and privileges as other U.S. citizens.

(2) The federal government provide sufficient funds to support needed health services for American Indians.

(3) State and local governments give special attention to the health and health-related needs of nonreservation American Indians in an effort to improve their quality of life.

(4) American Indian religions and cultural beliefs be recognized and respected by those responsible for planning and providing services in Indian health programs.

(5) Our AMA recognize the "medicine man" as an integral and culturally necessary individual in delivering health care to American Indians.

(6) Strong emphasis be given to mental health programs for American Indians in an effort to reduce the high incidence of alcoholism, homicide, suicide, and accidents.

(7) A team approach drawing from traditional health providers supplemented by psychiatric social workers, health aides, visiting nurses, and health educators be utilized in solving these problems.

(8) Our AMA continue its liaison with the Indian Health Service and the National Indian Health Board and establish a liaison with the Association of American Indian Physicians.

(9) State and county medical associations establish liaisons with intertribal health councils in those states where American Indians reside.

(10) Our AMA supports and encourages further development and use of innovative delivery systems and staffing configurations to meet American Indian health needs but opposes overemphasis on research for the sake of research, particularly if needed federal funds are diverted from direct services for American Indians.

(11) Our AMA strongly supports those bills before Congressional committees that aim to improve the health of and health-related services provided to American Indians and further recommends that members of appropriate AMA councils and committees provide testimony in favor of effective legislation and proposed regulations. [CLRPD Rep. 3, I-98; Reaffirmed: Res. 221, A-07; Reaffirmation A-12; Reaffirmed: Res. 233, A-13; Reaffirmed: BOT Rep. 09, A-23]